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ABSTRACT 
This thesis deals with the topic of head and neck cancer (HNC) follow-up from a health 
economics perspective. Despite recent advances in treating primary HNC, the long-term 
prognosis of these patients is still poor due to a high risk of cancer recurrence. Until 
now, there is no agreement about the best way of monitoring patients after the end of 
therapies. Moreover, patients’ preferences for alternative surveillance schemes are 
unknown. A multicentre randomized controlled trial comparing two follow-up strategies 
of different intensity is currently ongoing in Italy. This thesis aims at filling some of the 
literature “gaps” around HNC surveillance, using Italy as a case study. The first chapter 
introduces the topic. The second chapter is a systematic literature review and critical 
appraisal of economic evaluation studies of post-treatment follow-up programs in any 
cancer type. The third chapter is a systematic literature review and quality appraisal of 
studies reporting original health state utility values in HNC, with a focus on articles 
addressing the post-treatment phase. The fourth chapter maps the EuroQol 5-Dimension 
5-Level (EQ-5D-5L) utility values from two cancer-specific measures developed by the 
European Organization for Research and Treatment of Cancer (EORTC) by using a 
variety of regression techniques (linear, Tobit, mixture models) and several EQ-5D-5L 
country tariff sets; the developed functions are useful to inform future economic 
evaluations in HNC. The fifth chapter presents an exploratory model-based economic 
evaluation of the two follow-up strategies under investigation in the trial, where an 
intensive program of radiological assessments is compared to a symptom-driven 
surveillance; the cost analysis is conducted from a regional healthcare system 
perspective in Italy. Lastly, the sixth chapter presents a discrete choice experiment using 
best-worst scaling to elicit patients’ preferences during follow-up at the National Cancer 
Institute (Milan, Italy). 
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1 BACKGROUND AND AIMS 
1.1 Thesis’s overall purposes 
This thesis was conceived around the concept of ‘value’ in the follow-up of head and 
neck cancer (HNC) patients. Contrary to therapeutic strategies, post-treatment 
surveillance in HNC has not been deeply studied yet, nor have costs and outcomes been 
jointly evaluated in any health economic framework. This thesis work was conducted 
alongside an ongoing randomized controlled trial (RCT), which generated research 
questions and was the basis for multiple data collections. The trial is going to estimate 
the ‘value’, from a health economic perspective, of an intensive follow-up program of 
radiological assessments, as designed by the trial’s investigators, compared to 
symptom-driven surveillance as recommended by international guidelines.  
The thesis contributes in several ways to the clinical study and to current knowledge 
about post-treatment surveillance in HNC. First, using an exploratory modelling 
framework, the thesis provides the expected lifetime outcomes and costs arising from 
the two follow-up interventions investigated in the trial. Second, the thesis generates 
evidence on aspects not considered within the trial, such as patient’s preferences for 
features of follow-up programs in HNC, including the two under evaluation in the 
clinical study. Moreover, the thesis provides a systematic review of economic 
evaluation studies of follow-up programs in oncology to be compared with the 
modelling study’s results. Following a similar systematic approach, the thesis collects 
health state utility values (HSUVs) from the HNC literature, which are required to 
calculate quality-adjusted life year (QALY), the main outcome of the cost-effectiveness 
model. The review provides useful data especially for recurrent and palliative states, 
which are not considered in the ongoing RCT, since health-related quality of life 
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(HRQoL) questionnaires are not being administered after the patient’s relapse. Lastly, a 
statistical relationship between generic and HNC-specific HRQoL tools is established, 
using the most recent recommendations from the mapping literature.  
1.2 Head and neck cancer: basic facts  
HNC is the sixth most common cancer in the world with around 690,000 incident cases 
and 375,000 deaths reported in 2012 [1]. In the same year, there were 140,000 new 
diagnoses and 63,500 deaths in Europe [2]. Squamous cell carcinoma of the head and 
neck (SCCHN) is the predominant histological type concerning around 91% of all HNC 
cases. The remaining cancers are sarcomas (2%) and adenocarcinomas, melanomas, or 
not well specified tumours (7%) [2]. HNC includes a heterogeneous group of 
malignancies located in the upper respiratory and digestive tract with the most prevalent 
site being the oral cavity followed by the larynx and the pharynx. Alcohol and tobacco 
abuse are traditional etiological factors for the disease with a synergistic effect and are 
estimated to be responsible for at least 75% of all HNC cases [3]; additional risk factors 
for HNC development are poor dental hygiene, limited consumption of fruit and 
vegetables and genetic predisposition to cancer [2] [4].  
The incidence rate in Italy has recently been assessed at 16 per 100,000 [3], with 
considerable differences between men (30.2 per 100,000) and women (5.1 per 100,000) 
as recently estimated for the Sardinia region [4]. The risk of being diagnosed with HNC, 
indeed, is seven times higher in men [3] although an increasing trend in incidence in 
women only can be observed in recent decades [1] [4]. In 2010, the number of people 
living with HNC in Italy was equal to 111,520 (4.3% of the overall cancer survivors); of 
these, the proportions diagnosed more than 2, 5 and 10 years earlier were 84%, 67% and 
45%, respectively [3]. HNC prevalence was higher in Northern regions (≈230 per 
100,000 inhabitants) compared with Central (164 per 100,000) and Southern ones (154 
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per 100,000) and in people aged ≥75 years (783 per 100,000) compared to the overall 
population (199 per 100,000) (Table 1.1). No significant differences in survival have 
been shown by gender and geographical areas; the 5-year survival rate, indeed, stratified 
by gender, ranges between 54% in women living in Central Italy and 59% in those 
living in Northern regions [5]. The differences in HNC prevalence across Italy may be 
explained by different incidence rates [3] [6], likely due to higher consumption of 
alcoholic drinks in the North and in the Centre compared to the South [7]. There is no 
difference in the prevalence of smokers between the Northern and Southern regions, but 
the proportion of smokers is significantly higher in Central Italy [8]. 
Table 1.1 HNC prevalence (per 100,000) by age, gender, and geographical area in Italy 
(2010). 
  0-44 45-59 60-74 75+ All ages 
North-West 
Male 17 229 896 1808 372 
Female 13 77 197 298 101 
Total 15 151 520 839 231 
North-East 
Male 16 231 918 1756 354 
Female 13 79 220 315 103 
Total 15 155 551 843 225 
Centre 
Male 12 165 628 1381 263 
Female 15 65 121 241 72 
Total 13 114 362 684 164 
South and 
Islands 
Male 14 201 741 1346 250 
Female 12 73 128 235 65 
Total 13 135 417 670 154 
Italy 
Male 15 216 840 1625 318 
Female 13 76 180 283 88 
Total 14 145 490 783 199 
Source: AIRTUM [6]. 
The epidemiology of HNC is rapidly changing. Over the last decade, there has been a 
shift in the primary site distribution, with a steady increase in oropharyngeal and oral 
cavity cancers and a slight decline of cases in the larynx, hypopharynx, and 
nasopharynx [2] [9]. Indeed, an epidemic of oropharyngeal cancers (particularly those 
of lingual and palatine tonsils) caused by the Human Papilloma Virus (HPV) has 
recently emerged in younger age groups compared with other HNC types [10] [11] [12] 
[13] [14]. Therefore, the overall incidence has remained substantially stable over the 
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past 10 years despite declining smoking habits in Europe [2]. The great majority of 
HPV-related oropharyngeal cancer is due to the HPV16 serotype [4] [12] [15]. HPV-
positive patients are typically middle-age, non-smoking men with high socio-economic 
status and a history of exposure to multiple sexual partners; their prognosis is 
substantially better than for HPV-negative tobacco-related cancer patients treated 
similarly [9]. HNC also presents a marked socio-economic gradient in survival between 
affluent and deprived patients or geographical areas (e.g. Northern vs. Eastern Europe) 
[2]. 
In early stage SCCHN (about 20%) the standard clinical therapy is surgery and/or 
radiation therapy [13] [16], while another fifth diagnosed with metastatic disease can 
only aim at systemic chemotherapy [17] [18]. Most patients (around 60%) who present 
instead with locally advanced disease usually receive multimodality treatments 
including concurrent radiotherapy and chemotherapy with surgery, if indicated [17]. 
Despite aggressive multimodal therapy, the 5-year overall survival is 50%-60% [3] [11], 
mainly due to loco-regional or distant relapses occurring within few years after the end 
of primary treatments [10] [19]. Cancer recurrence is usually defined as the re-
emergence of the disease after a post-treatment six-month period of complete 
regression; the risk varies from 10% to 50% according to cancer site and stage [20]. 
Moreover, there is a lifetime risk of developing second primary tumours of around 3% 
per year [16] [21] [22] [23] and the most frequent localizations are head and neck, lung, 
and oesophagus [24].  
A few patients with loco-regional recurrences or second primaries can be salvaged by 
surgery or re-irradiation [16] [17]. In patients with resectable cancers and good health 
status, surgical salvage remains the best option for long-term disease-free and overall 
survival; however, in recent years, non-surgical therapies such as re-irradiation have 
also demonstrated significant improvements in loco-regional control [25]. There exist 
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different types of re-irradiation including conventional techniques, intensity modulated 
radiotherapy, and stereotactic body radiotherapy [26]. The overall survival of patients 
treated with re-irradiation at 2 years range from 30% to 67% according to the technique 
adopted and disease extent [23]. Early diagnosis of HNC relapse or second primary 
cancer allows these options to be implemented more frequently and with better 
outcomes. However, most patients with recurrent or metastatic disease only qualify for 
palliative treatment, comprising supportive care alone, or in addition to, single-agent 
chemotherapy or chemotherapy combined with biological agents [9] [17]. The 
administration of cetuximab plus 5-fluoracil and cisplatin is currently the standard of 
care in recurrent patients not amenable to surgery or re-irradiation [27]. Despite the 
choice of treatment, the prognosis is poor with a median survival that does not exceed 
10-12 months [10].  
1.3 Head and neck cancer: follow-up 
Post-treatment follow-up is a well-established service in oncology, due to the risk of 
relapse experienced by treated cancer patients. The primary objective of follow-up, 
indeed, is the early detection of loco-regional recurrences, metastases and second 
primaries that are likely to occur in the years following any primary treatment with 
curative intent [20] [28]. In HNC, follow-up visits should include a physical 
examination of the head and neck region, an assessment of vocal, breathing, and 
swallowing functions, and a pain evaluation [23]. As secondary aims, surveillance 
programs should manage treatment-related side effects and late complications, provide 
psychological and social support to patients and families, and discourage patients from 
dangerous habits that contributed to the development of the primary cancer [16] [28]. In 
HNC, dental care, nutritional counselling, speech, and swallowing rehabilitation are 
interventions routinely delivered during follow-up [23]. At population level, the follow-
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up aims at collecting data on the efficacy of the available cancer therapies and other 
clinical and epidemiological variables that are useful to improve the future provision of 
healthcare services in oncology [29]. 
Several modalities for monitoring patients treated for HNC have been proposed in 
clinical practice to fulfil the primary aims of follow-up [16] [20] [23]. Overall, the 
published guidelines are concordant in recommending a 5-year hospital-based program 
with frequency of visits decreasing over time (although the time interval between 
clinical appointments is controversial). From the 6th year onwards, follow-up visit is 
advised every year, especially for patients at high risk of second primaries [16] [20]; in 
some cases, the general practitioners conduct a minimal surveillance, with referral to the 
specialist doctors for doubtful cases. There are less homogeneous indications instead 
about the number and type of diagnostic tests to be prescribed during follow-up [29]. 
Overall, an imaging test should be administered between 2 and 6 months since the end 
of primary therapies to assess the treatment response and provide a benchmark for 
future evaluations. Subsequently, routine imaging is advisable for patients in whom 
there is a clinical suspicion of cancer relapse and/or clinical assessment and endoscopic 
visualization are not reliable or sufficient [16] [29]. Computed tomography (CT), 
magnetic resonance imaging (MRI), and 18-F-fluorodeoxyglucose positron emission 
tomography (18-F-FDG-PET, thereafter PET) are standard diagnostic techniques in 
HNC. CT is routinely used to assess initial response to treatment, MRI has the 
advantage of providing a better soft-tissue differentiation, while PET should be helpful 
in distinguishing tissue necrosis (following primary surgery or radiotherapy) from 
recurrent tumour [20]. PET is also recommended for restaging patients who are being 
considered for major salvage surgery [16]. Clinical guidelines do not usually provide 
specific indications regarding the best radiological technique to adopt during follow-up, 
although MRI and PET are usually preferred over CT in identifying early recurrences; 
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PET, however, is usually recommended as a “second level” examination due to its high 
costs [29].  
Since there are no standardized and universally accepted guidelines, the contents of 
follow-up in terms of frequency of clinical and radiological investigations are often at 
discretion of local centres in Italy [23] [30]. The main clinical guidelines to which 
Italian oncologists refer are summarized in Table 1.2. Among them, the National 
Comprehensive Cancer Network (NCCN) recommends a program of outpatient visits 
according to cancer subsite and a baseline radiological assessment within 6 months of 
the treatment ending; further imaging is recommended based on signs and symptoms 
over the course of follow-up. Similarly, the European Society for Medical Oncology 
(ESMO) suggests the adoption of clinical evaluations and imaging to monitor HNC 
survivors, but without specifying a timetable of visits; a baseline radiological 
assessment should be performed once after primary treatment, and subsequently, only 
when recurrence is suspected. The guidelines developed by Italian scientific 
associations are generally more intensive. Among them, the Italian Association of 
Oncology Radiotherapy (AIRO) prescribes imaging at fix time points over the 5-year 
period irrespective of the symptoms reported by the patient. Similarly, the Italian 
Hospital Otorhinolaryngologic Association (AOOI) suggests performing a yearly MRI 
or CT scan for high-risk patients and PET scans during the first two years (subsequently 
only for high-risk patients) [29]. More recently, a follow-up program proposal 
distinguishing between clinically evaluable and not evaluable primary tumours has been 
published by a research group in Italy [30]. Moreover, a chest CT or x-ray can be 
prescribed to heavy smokers (≥ 20 pack/years) or patients aged above 50, who are at 
increased risk of developing second lung primaries [3]. 
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Table 1.2 Frequency of clinical/endoscopic evaluations and radiological assessments according to the mostly adopted guidelines in Italy. 
 NCCN BAHNO AIOM AIRO AOOI 
 Clinical 
exam 
Imaging Clinical 
exam 
Imaging Clinical 
exam 
Imaging Clinical 
exam 
Imaging Clinical 
exam 
Imaging 
MRI/CT 
Imaging 
PET 
Year 1 1-3 months Once within 
6 months 
4-6 weeks  Once within 
3 months 
3 months Once within 
3 months 
1-2 months 6 months 1-3 months Once within 
6 months 
Once within 
4-6 months 
Year 2 2-6 months - 4-6 weeks - 3 months  2-3 months 6 months 2-4 months Only HR 6 months 
Year 3 4-8 months - 3 months - 3-6 months  4-6 months 6 months* 4-8 months Only HR Only HR 
Year 4 4-8 months - 6 months - 6 months  4-6 months 6 months* 4-8 
Months 
Only HR Only HR 
Year 5 4-8 months - 6 months - 6 months  4-6 months - 4-8 months Only HR  
Year 6 
onwards 
Annually - Annually - Annually  Annually - Annually Only HR  
NCCN: National Comprehensive Cancer Network; BAHNO: British Association of Head and Neck Oncologists; AIOM: Italian Association of Medical Oncology; AIRO: Italian Association of 
Oncology Radiotherapy; AOOI: Italian Hospital Otorhinolaryngologic Association; HR: high-risk. 
* Only nasopharynx 
Sources: [3] [20] [29]. 
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Best practice in HNC follow-up remains uncertain. The primary aim of a surveillance 
program is to achieve earlier detection of recurrent cancer compared to patient self-
identification through frequent clinical assessments at regular intervals. This task is 
justified by the high-risk of relapsing experienced by HNC patients. Early diagnosis is 
beneficial because it increases the opportunity for potentially salvageable treatment 
instead of palliative care. However, there are currently limited data regarding the 
survival benefits achievable by different follow-up programs [30] [31]. In particular, 
there is no RCT comparing a structured follow-up program with a patient self-referral 
policy in the literature [20] [29]. Some observational studies demonstrate a survival 
benefit in patients diagnosed at routine follow-up, compared to those who present 
spontaneously with symptoms. Conversely, other studies do not find any survival gains 
from detecting asymptomatic recurrences [23]. However, most clinical studies only 
report intermediate outcomes, i.e. the proportion of recurrences detected during 
scheduled appointments versus those identified thanks to symptoms referred by the 
patient, and dissenting conclusions are obtained across studies [29]. Additionally, the 
administration of intensive follow-up programs may encounter feasibility constraints, 
cause unnecessary discomfort to the patients, and have serious cost implications for 
healthcare systems [32]. In recent years, the oncological community has been arguing 
whether intensive follow-up assessments might pose a relevant economic burden 
without significant clinical benefits [23]. Therefore, a cost-effectiveness evaluation of 
alternative follow-up programs is recommended to avoid over-treatment and waste of 
scarce healthcare resources.  
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1.4 The HETeCo trial 
The first RCT comparing alternative follow-up strategies in HNC entitled: “Health and 
Economic Outcomes of Two Different Follow-Up Strategies in Effectively Cured 
Advanced Head and Neck Cancer (HETeCo)” started in Italy in 2014. Full details are 
available in the trial protocol (clinicaltrials.gov identifier NCT02262221) [33]. In brief, 
330 patients are being enrolled and followed-up for five years in several health centres 
across Italy and Switzerland. The centre leading the trial is the National Cancer Institute 
(NCI) located in Milan (Italy). Inclusion criteria are as follows: diagnosis of stage III-IV 
squamous HNC located in the oral cavity, oropharynx, hypopharynx, or larynx; if 
oropharyngeal cancer, HPV negative or HPV positive with a smoking history (i.e. more 
than 10 pack/years); radiotherapy (as a minimum) already administered as curative 
treatment or in post-operative setting; no evidence of disease for six months after 
treatment’s end; age ≥18 years. The patients enrolled in the study do not have to be 
potential candidates for salvage surgery, in case of recurrence or a second primary. 
Patients are excluded if they have a diagnosis of HNC in any site different from those 
reported in the inclusion criteria (e.g. nasopharynx, paranasal sinus, salivary glands, or 
unknown site), or a diagnosis of any other malignancies unless free of disease for at 
least five years or are unable to comply with the study requirements in the opinion of 
the investigators. Patients are randomized to symptom-driven surveillance (arm A) 
according to NCCN guidelines [34] or to more intensive follow-up (arm B), as 
described in Table 1.3. In both study groups, HRQoL questionnaires including the 
EuroQol five-dimensional five-level questionnaire (EQ-5D-5L) and the European 
Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life 
Questionnaire (QLQ-C30), supplemented with the HNC module (QLQ-H&N35), are 
administered to patients at every other visit in the first two years and then at each visit, 
until the patient is free of disease. The primary study objective is to evaluate the two-
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year cost-effectiveness of the two alternative follow-up programs. As secondary 
objectives, the trial aims to estimate the proportion of potentially salvageable loco-
regional recurrences or second primaries, the cause-specific survival, and the overall 
survival of relapsing patients in both arms.   
Table 1.3 5-year follow-up programs under evaluation in the HETeCo trial. 
Arm A (non-intensive follow-up) – NCCN 
guidelines 
Arm B (intensive follow-up) 
Outpatient visits every 2-3 months in the first 
two years, every 4-6 months in the last three 
years (according to cancer subsite) 
Outpatient visits every 2-3 months in the first 
two years, every 4-6 months in the last three 
years (according to cancer subsite) 
Physical and fibre optic endoscopic head and 
neck examination at each visit 
Physical and fibre optic endoscopic head and 
neck examination at each visit 
Laboratory tests (complete blood count, renal, 
hepatic, and thyroid function) performed once 
a year 
Laboratory tests (complete blood count, renal, 
hepatic, and thyroid function) performed once 
a year 
Loco-regional imaging (MRI/CT scan) 
performed once at the beginning of follow-up 
and then recommended only at the occurrence 
of new signs or symptoms 
Loco-regional imaging (MRI/CT scan) 
requested twice/year in the first two years and 
once/year in the third and fourth years 
Patients instructed how to recognize signs or 
symptoms of recurrence  
PET scan requested yearly in the first three 
years only in patients ≥ 50 years and with 
smoking history of ≥ 20 pack/years 
Patients contacted by a phone call between 
visits to monitor potential recurrence 
symptoms 
CT: computed tomography; MRI: magnetic resonance imaging; HETeCo: Health and Economic Outcomes of Two 
Different Follow Up Strategies in Effectively Cured Advanced Head and Neck Cancer; NCCN: National 
Comprehensive Cancer Network; PET: positron emission tomography. 
1.5 Measuring ‘value’ in oncology: the QALY approach 
The concept of ‘value’, traditionally defined as the health outcome achieved per unit of 
cost, has recently become a central topic in cancer care due to rising cancer costs in all 
developed countries. Specifically, value should be measured by costing the full range of 
products and services delivered over the full cycle of care to achieve a pre-defined 
outcome. Whilst costs are relatively easy to identify and measure, what constitutes 
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meaningful patient outcome measures is still debated in the scientific community. 
Survival, also defined as life years gained (LYG), is undoubtedly the primary outcome 
to achieve (or to maximize) in most medical conditions [35]. However, even in a life-
threatening disease such as cancer, survival is not the only measure of effectiveness and 
additional elements should be considered when evaluating a new treatment. In 
oncology, clinicians are particularly required to balance any survival gains with drug-
related toxicities. As a composite measure combining length of life with the quality of 
the life itself, there is consensus that the QALY represents a good “proxy” for value, 
which has been increasingly recognized as a multidimensional concept. The theory 
underlying the QALY and synthetized in the paper by Weinstein et al [36] is that 
individuals move across health states over time and attach a value to them, which is 
defined indeed as HSUV; a health state that is more desirable is also more valuable. 
Thus, value is equated with “preference” or “desirability” or “utility”. HSUVs usually 
range between 0, which is the value attached to the state of death, and 1 corresponding 
to perfect health, although some methods allow for below zero utilities in case of states 
valued as worse than being dead. Accordingly, the per patient outcome to maximize is 
defined as the value-weighted time accumulated over lifetime to yield QALYs. The 
QALY is currently the standard outcome metric used in cost-effectiveness analysis to 
inform reimbursement decisions of cancer treatments in several countries.  
In recent years, a discussion arose in the literature regarding the ability of the QALY to 
summarize appropriately the experience of cancer patients, and the use of alternative 
outcome metrics in the assessment of value in oncology [37]. Indeed, there are a few 
challenges in estimating HSUVs and, consequently, QALYs in cancer patients. The 
article from Devlin and Lorgelly [38] and from Garau et al [39] highlighted most of 
them. First, overall survival is required for the estimation of QALYs, whilst RCTs in 
oncology rarely are long enough to cover the full patient’s life span and tend to focus 
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instead on progression-free survival or other intermediate outcomes, which may not 
capture the whole treatment effect and be a valid surrogate for overall survival [40] [41] 
[42]. Moreover, post-progression therapies, either protocolled or prescribed once the 
patient has left the trial, may affect overall survival estimates [43]. 
Second, the measurement of HSUVs is not straightforward. There are a range of 
methods that can be used to estimate preference weights encompassing direct 
techniques (i.e. visual analogue scale, VAS; standard gamble, SG; time trade-off, TTO) 
and generic HRQoL preference-based tools, among which the most common one is EQ-
5D. The TTO method is mostly used to generate EQ-5D preference weights and is 
accordingly the most preferred by the National Institute for Health and Care Excellence 
(NICE) among the direct techniques. Some argue that the ‘constant proportional trade-
off’ assumption in TTO might be violated in the end-of-life state, since people with a 
short life expectancy are less likely to give up any of the remaining time to improve 
their health status [44] [45]. However, the current evidence is conflicting and not strong 
enough to support the hypothesis that HSUVs are higher for patients closer to death, but 
rather for those with a short time from terminal diagnosis, and any way this effect is 
likely to be small [46]. Additionally, the question of whether patients or the public 
should value health states (through direct methods or generating preference-based 
scoring algorithms for generic HRQoL measures) is debated in the literature, although 
many scholars argue that weights should come from the general population as taxpayers 
and potential patients. Moreover, in advanced stages, cancer patients are too sick to fill 
in questionnaires or take part in interviews, thus limiting the possibility of self-valuing 
their health state. According to others, however, the general population is at risk of 
underestimating the impact of living with cancer. Finally, some generic preference-
based tools used to elicit HSUVs might not be the best way of assessing HRQoL in 
cancer, since they have been shown to not be sensitive enough to changes in patient’s 
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health status and to not cover relevant aspects in cancer, such as vitality, energy, or 
fatigue [47]. For this reason, most RCTs adopt cancer-specific questionnaires such as 
the EORTC QLQ-C30 or the Functional Assessment of Cancer Therapy – General 
(FACT-G), which are not provided with a preference-based algorithm or, if they have 
one (e.g. EORTC 8D), generate HSUVs that are hardly comparable across other disease 
areas.  
Third, there is the question if the cost-effectiveness threshold should be different for 
cancer, especially at advanced and final stages. There is some evidence that individuals 
put a greater value on cancer therapies, and even on the “hope” of new therapies, since 
cancer is a frightening and common disease. In a recent survey [48], more than two 
thirds of cancer patients preferred “hopeful gambles” (i.e. treatments with a variety of 
outcomes but potentially offering a longer survival time) to “safe bets” (i.e. treatments 
providing similar average survival but less chance of large gain). These results suggest 
that current health technology assessment (HTA) techniques, which traditionally focus 
on average survival gains, might omit a relevant value element (i.e. hope) and should 
find a way to incorporate it. In England and Wales, higher cost-effectiveness thresholds 
have been adopted by NICE for end-of-life care since 2009; however, this might cause 
substantial financial pressure on healthcare services and potential QALY losses, unless 
a societal preference for end-of-life gains is clearly shown [49].  
Fourth, the standard definition of ‘value’ only depends on the measures of outcome (i.e. 
QALY) and not on inputs or the process of care used [35]. There is growing interest in 
patient’s preferences regarding the process of care, such as the value attached to a 
home-based palliative care service versus a hospital-based one. These preferences have 
been shown to impact directly on the clinical outcome through psychological factors or 
indirectly via compliance and adherence [50]; however, despite their increasing use in 
treatment decision-making, there is little consensus on how cost-effectiveness analyses 
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should account for individual preferences to inform decisions on allocation of 
healthcare resources.  
1.6 Measuring ‘value’ in oncology: alternative frameworks 
In 2015, five health-related organizations developed frameworks to assess the value of 
oncological drugs. These new tools share with the traditional “cost per QALY” 
approach the overall idea that ‘value’ is determined by the amount of a treatment’s 
clinical benefit balanced against costs. However, they vary considerably in the 
definition of outcome, in the types of costs addressed, and in the purpose of the 
evaluation. A brief description of each tool follows. 
1. The American Society of Clinical Oncology (ASCO) launched in 2015 a first 
version of its frameworks to assess the value of medical cancer therapies; an 
updated version appeared in 2016 in response to comments received via a web-
based survey [51]. One framework deals with advanced, non-curative disease 
(scored out of 130), while the latter with potentially curative disease (i.e. 
adjuvant therapy, scored out of 100). Each incorporates three essential elements 
including clinical benefit, toxicity, and costs. In the advance disease framework, 
the relative weights are modifiable according to patient’s preferences; for 
example, the toxicity score may have a higher weight than survival. The tool 
grants bonus points for some health gains including symptom palliation, HRQoL 
improvement, and survival increase at the end of the curve. The sum of clinical 
benefit, bonus points, and toxicity scores generates a Net Health Benefit (NHB), 
which represents a measure of relative improvement of a new treatment 
compared with the standard of care within a clinical trial. The net health benefit 
is reported with the direct treatment cost including the patient’s co-payment.  
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2. In the same year, ESMO developed the Magnitude of Clinical Benefit Scale 
(MCBS) as a framework to define the value of new anti-cancer drugs approved 
in Europe [52]. Drugs are assigned a clinical benefit grade, ranging from A to C 
in the curative (adjuvant) setting, and 1 to 5 in the non-curative setting. Overall 
survival and disease-free survival are the outcomes considered as primary 
efficacy measures, while lower scores are assigned to progression-free survival, 
response rate, time to response and HRQoL. Scores are awarded based on the 
level of clinical improvements in the relevant variables obtained within an RCT 
or cohort study. Costs are not included in this framework since European 
countries have their own pricing strategies.  
3. The NCCN has incorporated ‘evidence blocks’ into their clinical guidelines [53]. 
Five domains are considered in this value framework including efficacy, 
toxicity, quality/quantity of evidence, consistency of evidence, and affordability; 
each dimension is scored between 1 (least favourable) and 5 (most favourable). 
The affordability domain includes drug costs, supportive care, administration 
costs, and monitoring/management of toxicities. The evidence blocks are 
currently available for ten cancer types within the NCCN guidelines. 
4. The Memorial Sloan Kettering Cancer Centre in New York developed an 
interactive drug tool (Drug Abacus) to inform physician and policy-makers 
about the value of cancer drugs and to establish fair prices [54]. Based on 
clinical data and expert opinion, the tool measures six attributes including 
efficacy, tolerability, novelty, research and development (R&D) costs, rarity, 
and population health burden. Contrary to other value frameworks, the output of 
Drug Abacus is not a “value score” but rather a “price” that should be assigned 
to the drug. 
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5. The Institute for Clinical and Economic Review (ICER), which provides 
independent HTA reports on drugs, devices, and other medical services in the 
United States, introduced an ICER Value Assessment Framework to calculate a 
reasonable price for treatments (not only in oncology). The framework includes 
two broad components: “care value”, considering clinical effectiveness and 
incremental cost per clinical outcome achieved, and “health system value”, 
assessing the short-term budget impact. A cost-effectiveness threshold of 
$100,000-150,000 is used to calculate a reasonable price range. Moreover, the 
drug’s potential budget impact should stay below $904 million per year, above 
which a new treatment is likely to increase healthcare costs excessively [55]. 
All these “new” value frameworks have shown several limitations that make them 
difficult to overcome the QALY approach, at least in their current formulation. First, 
‘value’ is still an indefinable concept and there is no consensus across the frameworks 
on what domains should it comprise. Second, many frameworks rely on evidence from 
RCTs only, disregarding any information coming from observational studies or other 
types of real-world data (e.g. cancer registries) [56]. Third, most of them focus on 
clinical efficacy defined as survival without incorporating HRQoL, which is only 
partially captured by toxicity domains in some frameworks. Fourth, in determining 
“value for money” most tools consider the drug acquisition cost only without assessing 
other relevant medical costs (e.g. cost saving from avoidance of surgical interventions), 
non-medical costs and productivity losses in the societal perspective. Fifth, the new 
frameworks explicitly address drug therapies in cancer, but hardly fit with the value 
assessment of non-drug interventions, such as screening programs or surgical 
procedures; consequently, these value assessment results are not comparable with other 
types of interventions or diseases from a health economics perspective. 
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Therefore, the QALY remains the standard of outcome measurement for economic 
evaluation. The QALY approach is well established internationally and increasingly 
accepted by most HTA agencies worldwide including emerging economies (e.g. China, 
Brazil) and developed ones (e.g. United States, where researcher and policy-makers are 
beginning to use QALYs) [38]. The cost-utility framework using QALYs captures most 
of the assessment elements (i.e. survival, HRQoL, costs) considered by alternative value 
frameworks suggested in the literature; moreover, it covers the full range of 
interventions provided in healthcare (and not drugs only). The ICER Value Assessment 
Framework only explicitly mentions QALYs and cost-effectiveness ratios for the price 
calculation, which is not the original purpose of the cost-utility approach. As a 
multidimensional concept, the QALY already provides a metric to incorporate survival 
and HRQoL within a unique value framework. Moreover, cost-utility analyses can be 
characterized according to the source of the clinical information. Model-based 
economic evaluations, unlike trial-based ones, synthesize all the available clinical 
evidence deriving from various studies and not limited to a single RCT; when adopting 
a lifetime horizon, these studies provide a framework to estimate all medical and non-
medical costs arising from the alternative interventions. Additionally, the use of QALYs 
facilitates comparison of outcomes across different disease areas, which is relevant to 
achieve an efficient allocation of the healthcare budget. Thus, despite the challenges 
posed by its measurement, the QALY remains a powerful conceptual tool that has given 
a relevant contribution to decision-making in healthcare over the last few decades [36]. 
At the same time, the above-mentioned, newly developed approaches have the merit of 
enriching the debate about ways to incorporate patient’s wishes into value definition 
within an emerging vision of personalized medicine. However, the enlargement of the 
definition of ‘value’ to include additional elements, such as patient’s preferences or the 
quality of scientific evidence, still not considered by QALYs, requires a careful 
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consideration of the feasibility of measuring these aspects and systematically 
incorporating them into the HTA decision-making process.  
1.7 ‘Value’ in head and neck cancer follow-up 
The ‘value’ of non-drug interventions is less clearly identifiable compared to 
pharmaceuticals. Most economic evaluations in cancer care have been in the treatment 
phase, such as cost-effectiveness analyses of chemotherapeutics or radiotherapy 
techniques [57]. In 2013, in the United States, only 15% of the research portfolio in 
HNC was devolved to the cancer control, survivorship, and outcomes research area 
(https://www.cancer.gov). This is also due to more difficulties in performing RCTs for 
non-pharmaceutical interventions such as follow-up programs, where blinding is 
difficult to achieve (and to maintain), and its absence can lead to biased outcome 
assessment [58] [59]. Moreover, any survival gains of surveillance programs may only 
become evident after decades and hardly captured by time-limited RCTs. In HNC, this 
is particularly true after the recent epidemiological changes and the rising number of 
HPV-related cases with younger age at diagnosis, better prognosis, and longer life 
expectancy [1]. In the post-treatment-phase, the primary objective of follow-up is not 
the direct achievement of improved health status, but rather the avoidance of a worst 
one through the early identification of cancer relapses. Secondary functions such as 
psychological support, the management of side effects of primary treatment, and 
education for healthy lifestyles impact instead directly on HRQoL. Thus, even a 
program that was not able to show any survival benefits could be “valuable” in 
enhancing HRQoL, speeding-up the process of recovery and return to normal life. An 
increase in overall survival, however, remains the primary goal of follow-up, although 
only achievable through intermediate outcomes, i.e. the early identification of 
potentially curable recurrences and second primaries and timely administration of 
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salvage treatments. The measurement of intermediate endpoints, such as the rate of 
detection of potentially curable recurrences, represents useful clinical information 
routinely reported by studies in the field. However, if not supplemented with an 
extrapolation of final outcomes (i.e. survival) through statistical techniques [60], these 
results pose a problem of comparability with other healthcare interventions and disease 
areas from a health economics perspective. For this reason, model-based economic 
evaluations are particularly useful in assessing the cost-effectiveness of surveillance 
programs by projecting future costs and QALY over longer time horizons.  
As well as cancer treatments, follow-up programs might have also some ‘side effects’. 
In particular, anatomical imaging (i.e. PET-CT) using radioactive substances might 
cause discomfort, fear, and long-term toxicities to patients, besides posing a substantial 
burden to healthcare systems and societies. Accordingly, any survival gains should be 
weighed against potential adverse effects and costs (i.e. medical and non-medical costs, 
productivity losses) arising from an intense use of these diagnostic tools. The long-term 
toxicities arising from prolonged exposure to PET-CT radiations might be important for 
younger, HPV-positive patients with a good prognosis, but be irrelevant for other HNC 
patients with poor life expectancy; thus, sub-groups analyses may be helpful in 
measuring value for this cancer population. Additionally, patients’ preferences 
regarding the healthcare services delivered in the post-treatment phase should be 
considered, although not explicitly addressed within the QALY approach. Lastly, the 
quantity and quality of evidence (pointed out by the NCCN in their Evidence Blocks) is 
another important aspect when evaluating post-treatment programs in oncology since, 
unlike drug interventions, their definition is frequently based on current practice or 
retrospective data analyses in the absence of prospective comparative trials.  
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1.8 Knowledge “gaps” 
‘Value’ in the post-treatment phases of HNC remains largely unmeasured and follow-up 
services are often delivered without a sound scientific base. Within this thesis, a few 
“gaps” in the literature have been identified with respect to four main topics: (1) 
survival, (2) quality-adjusted survival using HSUVs, (3) costs and cost-effectiveness, 
(4) patient’s preferences (Table 1.4). 
1. The first unsolved question is with respect to the primary outcome represented 
by overall survival, which is used in the QALY calculation (Figure 1.1). The 
current available evidence, indeed, is not able to state definitely whether an 
intensive follow-up program with frequent radiological examinations can detect 
recurrences and second primaries at a time when it is more feasible to administer 
potentially salvage treatments compared to a symptom-driven surveillance. 
Additionally, whether an early diagnosis of cancer relapse with subsequent 
administration of salvage treatments (i.e. surgery or re-irradiation) leads to 
significant survival gains remains even more controversial. So far, the available 
re-treatment options have shown a small possibility of long-term survival but a 
very high chance of treatment-related toxicity including death [61]. 
Figure 1.1 The potential ‘value’ of follow-up programs in improving survival.  
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2. As stated above, it is now commonly accepted that ‘value’ is a multi-
dimensional concept implying that quantity of life should be weighed against the 
quality of life to evaluate any treatment’s effects. The QALY meets this 
requirement but its calculation needs utility values for each health state 
experienced by the patient during the process of care. At present, very few 
clinical studies report HSUVs for post-treatment, salvage treatments and 
palliative stages in HNC, thus limiting the possibility to assess properly the 
value of follow-up programs. This is mainly due to the poor health of cancer 
patients with advanced/terminal disease, which makes it difficult to collect 
patient-reported outcomes at these stages. Additionally, as in other disease areas, 
most clinical studies prefer to adopt cancer-specific questionnaires to evaluate 
HRQoL in oncological patients, since they target specific health issues and are 
more sensitive to changes in disease symptoms [62] [63]. In HNC, the most 
common tools are the EORTC QLQ-C30 (supplemented with the H&N35 
module) and the Functional Assessment of Cancer Therapy - Head and Neck 
(FACT-H&N). These questionnaires were not originally provided with a scoring 
system for HSUVs calculation. The EORTC-8D was subsequently developed 
using the 30-item EORTC QLQ-C30 for use as a preference-based measure in 
cancer [64]; however, being a disease-specific tool, utility values from EORTC-
8D cannot be compared with those derived from generic preference-based 
instruments (e.g. EQ-5D) and thus are not transferable to other therapeutic areas. 
In recent years, “mapping” or “cross-walking” has become a common technique 
to transform disease-specific scores onto preference-based utilities, but a 
function relating EORTC QLQ-C30 to EQ-5D has yet to be developed for HNC. 
Moreover, the techniques adopted so far to predict HSUVs from disease-specific 
scores have shown a poor fit with the typical EQ-5D data distribution. 
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3. Third, long-term cancer survivorship, although of unquestionable value for 
patients and societies, imposes a substantial financial burden on healthcare 
systems. The overall prevalence of people living after a diagnosis of HNC is 
increasing in all developed countries, with millions more patients who are going 
to be classified as survivors in the next few years [23]. Follow-up programs can 
consume a large amount of scarce healthcare resources and might cause delays 
in the diagnosis and treatment of new cancer patients. At the same time, the best 
way to save money is often to spend more on some services to reduce the needs 
for others [35], which might be translated, in this case, as investing resources on 
effective follow-up to avoid extra-morbidity in patients, such as metastases, with 
subsequent increase of medical and non-medical costs. Few attempts have been 
made so far to measure the healthcare costs associated with routine surveillance 
and secondary treatments in HNC, and no data are available for Italy. Moreover, 
no studies have tried to combine costs and outcomes (i.e. survival or QALYs) of 
alternative follow-up programs for HNC survivors to inform about an efficient 
allocation of scarce resources in oncology. 
4. Fourth, the strength of preferences for alternative ways of delivering follow-up 
after the end of primary treatments for HNC has never been investigated with 
stated preference methods such as discrete choice experiments (DCEs). Most 
studies investigating patient’s preferences in HNC are priority scales [18] not 
even focussed on follow-up services. Moreover, in tax-based healthcare systems, 
such as Italy, there is limited interest in estimating the willingness-to-pay for 
additional or improved services, thus reducing the amount of research devoted to 
preference elicitation. Although ‘value’ in healthcare is not simply a ‘proxy’ of 
the quality (or quantity) of care delivered [35], the incorporation of individual 
expectations within a value framework beyond the main clinical outcome(s) 
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might improve adherence to care, contain medical and non-medical costs and 
personalize value for each patient [18]. Research on preference elicitation with 
clear trade-offs among surveillance options is thus needed in HNC. 
 
1.9 Thesis overview 
This PhD thesis addresses some of the knowledge “gaps” existing around the ‘value’ 
assessment of follow-up in HNC (Table 1.4). The thesis is closely linked to the ongoing 
HETeCo trial in a bidirectional way; on one side, it relies on the clinical study to 
generate research questions, collect preliminary data, and gain clinical knowledge on 
the topic, whilst on the other it contributes to the trial by synthesizing evidence from the 
literature, testing hypotheses, and providing information on additional aspects not 
considered within the main clinical study. 
In Chapter II, the published economic evaluations of cancer follow-up (in general) are 
reviewed systematically. This work has multiple purposes. First, it aims to identify any 
potential studies relating costs and outcomes in HNC follow-up. Second, it collects and 
synthetize the available economic evaluation studies in the field of cancer surveillance. 
Third, the collection of these studies provided an opportunity to critically evaluate their 
quality and to identify any methodological weaknesses from the perspective of health 
economics research. For example, outcomes reported in the studies are identified as 
either intermediate (e.g. number of recurrences detected) or final (i.e. survival or 
quality-adjusted survival). Overall, the way of assessing the ‘value’ of follow-up 
services within an economic evaluation is investigated and commented, mainly to 
inform the modelling study presented in Chapter V and future data analyses within the 
HETeCo trial.  
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The work presented in Chapter III involves a systematic search of the published 
literature to identify all the available HSUVs in HNC, which can inform future 
economic evaluations in this area. Additionally, a quality evaluation of studies reporting 
original HSUVs is performed by referring to recent recommendations on the topic. This 
review is of interest on its own but also provides some parameter values for the model-
based cost-utility analysis described in Chapter V, where results are expressed as 
incremental costs per QALY gained. Since the EQ-5D-5L is not collected after a 
patient’s relapse in the HETeCo trial, HSUVs for recurrent and palliative states are 
retrieved from the literature to populate the model. Moreover, a broader discussion 
regarding the best techniques to measure HSUVs in HNC is provided within this 
chapter, to contribute to the current debate on QALY measurement in oncology. 
Chapter IV presents a ‘mapping work’ aiming to derive HSUVs from two non-
preference-based instruments frequently adopted to measure HRQoL in HNC patients. 
Using a sample of questionnaires collected from the patients in the HETeCo trial, a set 
of mapping functions is developed to predict EQ-5D-5L utility values from EORTC 
QLQ-C30 and H&N35 responses. A few EQ-5D-5L tariff sets (available at the time of 
the analysis) are used to generate HSUVs. The most recent techniques suggested by 
good practices and previous studies on mapping are adopted to contribute to knowledge 
advancements in the field. The developed functions might be useful for future 
researchers in studies not collecting EQ-5D data but planning to calculate QALYs. 
Chapter V represents the ‘core’ of the research project and reports the first economic 
evaluation comparing follow-up programs of different intensity in HNC. An exploratory 
Markov model is developed to compare the same two surveillance strategies (arm A and 
B) under evaluation in the HETeCo trial and is populated with data from a variety of 
sources, such as the trial protocol, trial preliminary data, published literature, and expert 
opinion. Results are expressed as incremental cost-effectiveness ratios (ICERs) and 
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incremental cost-utility ratios (ICURs) and tested in extended deterministic and 
probabilistic sensitivity analyses. Moreover, because the uncertainties related to the 
efficacy parameters will be reduced only once the trial is completed, value of 
information methods are applied to estimate the ‘value’ of completing the ongoing 
clinical study. 
The work presented in Chapter VI, using a best-worst scaling (BWS) technique, aims to 
elicit patients’ preferences for alternative ways of delivering follow-up in HNC. Since 
the clinical outcomes are still uncertain in the literature and under evaluation in the 
ongoing HETeCo trial, the survey is limited to analyse the preferences for process-
related aspects of follow-up. Four attributes, each with three levels are identified to 
describe hypothetical follow-up programs in HNC; two of each attribute’s levels 
correspond to key features distinguishing the alternative programs (arm A and B) 
compared within the trial to provide the clinicians with additional information about the 
patient’s preferences for the same interventions evaluated in terms of clinical outcomes 
and cost-effectiveness. 
Finally, a conclusion chapter (Chapter VII) summarizes the main thesis’s finding, and 
discusses any limitations, contributions to research, policy implications and future areas 
of study. 
Since the HETeCo trial inspiring this thesis is a multicentre study based in Italy, some 
findings in this thesis are inevitably related to the Italian context; particularly, in the 
model-based economic evaluation (Chapter V), the cost analysis is conducted from the 
perspective of a major Italian region (i.e. Lombardy). In Chapter VI, for feasibility 
reasons, recruitment to the survey was limited to a sample of HNC patients in follow-up 
at the NCI, based in Milan (Lombardy). Conversely, many other results including the 
synthesis of economic evaluation studies in cancer surveillance (Chapter II), the 
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overview of HSUVs in HNC (Chapter III), the mapping functions converting cancer-
specific HRQoL into EQ-5D-5L utilities (Chapter IV), and the survival/QALY 
predictions of patients receiving alternative follow-up programmes (Chapter V) are not 
country-specific and could be generalizable to other contexts. However, even chapters 
presenting more local findings should be easily adapted within research projects 
conducted in other contexts; for example, the questionnaire developed for the BWS 
survey could be modified to reflect the elements characterizing surveillance schemes 
routinely offered by different hospitals, regions, or countries. A synthesis of the 
geographical perspectives and data sources adopted in each chapter are reported in 
Figure 1.2. Overall, the thesis aims to provide an HNC follow-up value framework that 
can be populated and tested with data collected anywhere.  
Figure 1.2 Data sources and study perspectives in thesis’s chapters. 
 
EQ-5D-5L: EuroQol Five-Dimension Five-Level; HETeCo: Health and Economic Outcomes of Two Different 
Follow Up Strategies in Effectively Cured Advanced Head and Neck Cancer; HRQoL: health-related quality of life. 
•Data source(s): published literature 
•Perspective(s): internationalChapter II
•Data source(s): published literature
•Perspective(s): international
Chapter III
•Data source(s): multicentre HETeCo trial, published EQ-5D-5L 
value sets 
•Perspective(s): national (HRQoL data); international (mapping 
algorithms)
Chapter IV
•Data source(s): multicentre HETeCo trial, published and 
unpublished literature, clinical opinion, regional tariffs 
•Perspective(s): international (outcomes); regional (costs), or even 
national, since differences across Regions are minimal
Chapter V
•Data source(s): cross-sectional survey at the NCI (Milan) 
•Perspective(s): local (or even regional/national, depending on 
the type of follow-up administered by other hospitals in Italy)
Chapter VI
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Table 1.4 Knowledge “gaps” and objectives of the thesis. 
 
BWS: best-worst scaling; EORTC: European Organization for Research and Treatment of Cancer; HETeCo: Health and Economic Outcomes of Two Different Follow Up Strategies in Effectively 
Cured Advanced Head and Neck Cancer; HNC: head and neck cancer; HRQoL: health-related quality of life; HSUV: health state utility value; LYG: life year gained; QALY: quality-adjusted life year; 
QLQ-C30: 30-item Core Quality of Life Questionnaire; QLQ-H&N35: 35-item Head and Neck Cancer Quality of Life Questionnaire. 
Clinical outcomes Knowledge "gap": The overall survival gains achievable by an intensive follow-up program of radiological 
investigations compared to a less intensive surveillance based on symptom reporting in HNC. 
Thesis’s aim: To obtain model predictions of LYG and QALYs gained by intensive and non-intensive follow-up using 
preliminary data from the HETeCo trial and published literature (Chapter V).
Health state utility 
values
Knowledge "gap": The measurement of HSUVs in HNC during the post-treatment phase including recurrent and 
palliative states; a mapping algorithm predicting HSUVs from two widely used HRQoL tools (i.e. EORTC QLQ-C30 
and QLQ-H&N35).
Thesis’s aim: To perform a systematic literature review of HSUVs in HNC (Chapter III); to develop a set of mapping 
functions to derive HSUVs from HNC-specific HRQoL questionnaires using preliminary data from the HETeCo trial 
(Chapter IV).
Costs and cost-
effectiveness
Knowledge "gap": The economic burden of follow-up in HNC and the cost-effectiveness of alternative programs 
with different intensity from a healthcare system perspective. 
Thesis’s aim: To perform a systematic literature review of economic evaluations of follow-up in any cancer type 
(Chapter II). To develop an exploratory Markov model comparing the HETeCo trial arms in terms of incremental costs 
per LYG and QALY gained (Chapter V). 
Patient's preferences Knowledge "gap": The strength of preferences for alternative ways of delivering follow-up in HNC and any 
heterogeneity in preferences according to individual characteristics.
Thesis’s aim: To elicit patients' preferences for several features describing follow-up using a stated preference 
approach (i.e. BWS); to calculate the overall utility for a range of hypothetical follow-up programs including the two 
under evaluation in the HETeCo trial (Chapter VI).
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2 ECONOMIC EVALUATIONS OF FOLLOW-UP 
STRATEGIES FOR CANCER SURVIVORS: A 
SYSTEMATIC REVIEW AND QUALITY APPRAISAL OF 
THE LITERATURE 
2.1 Introduction 
In recent years, oncological services worldwide have experienced an increasing number 
of cancer survivors due to advances in diagnostic tools, curative treatments, and 
prevention campaigns. As already described for HNC (Chapter I), after being treated 
with curative intent, all cancer patients usually enter a program of post-treatment 
follow-up which may last for several years [65]. These programs usually involve 
hospital-based consultations with specialist cancer physicians, but the frequency of 
visits and the healthcare settings and professionals involved may vary according to 
geographical contexts and tumour sites [66]. Routine surveillance is primarily aimed at 
detecting loco-regional recurrences of cancer, metastases or second primaries at the 
earliest opportunity in order to administer potentially salvage treatments [67] [68]. 
Secondary aims include addressing treatment-related side effects, managing the 
rehabilitation process, and providing psychological and social support to patients and 
caregivers [66] [69]. 
A variety of recommendations have been provided at national and international level to 
guide clinicians in the follow-up process of cancer care; however, the most efficient 
scheme for monitoring patients after the end of primary treatment is still under debate 
for most malignancies [70]. Firstly, whether repeated investigations can improve long-
term clinical outcomes in cancer survivors remains controversial in oncology [67]. 
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Secondly, the clinical benefit of early detection of a cancer relapse strictly depends on 
the availability of secondary treatments able to extend survival. Thirdly, cancer patients 
who are monitored intensively after the end of primary treatment may experience either 
positive (reassurance, relief) or negative (discomfort, anxiety) feelings [67] [71].  
Cancer surveillance schemes extended in time also raise economic considerations. The 
opportunity cost of delivering post-treatment services is significantly high [67] and the 
long-term sustainability of these programs must be carefully evaluated. The assessment 
of the effectiveness and the cost-effectiveness of follow-up services in oncology may 
not be straightforward; any health benefits may become evident long after the 
interventions, which often involve different medical specialties and consume a variety 
of healthcare resources.  
This chapter presents the results of a systematic literature search undertaken to review 
published economic evaluations of post-treatment interventions in any cancer 
population. Given the focus of the thesis, the first aim of this work is to establish 
whether there are any economic evaluations of follow-up programs in HNC, to identify 
any literature “gap” that the thesis can fill. The second aim is to retrieve and narratively 
describe all the available health economic studies on cancer follow-up in general to 
identify the recent common and conflicting issues around this topic. The third purpose 
is to appraise the quality of the studies to understand the methodological limitations of 
the existing literature and test the suitability of a newly developed checklist. Overall, 
this work informs the development of the cost-effectiveness model presented in Chapter 
V.  
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2.2. Methods 
2.2.1 Study identification and selection 
A systematic literature review was undertaken searching three major electronic 
databases (i.e. PubMed, EMBASE, and the Cochrane Library). The Preferred Reporting 
System for Systematic Review and Meta-Analysis (PRISMA) strategies were used to 
ensure systematic selection of studies and the corresponding checklist completed (Table 
A2.1) [72]. Keywords were defined according to PICOS (population, 
intervention/comparator, outcome, study design) elements (Table 2.1). Economic 
evaluations comparing (two or more) follow-up interventions for adult patients (i.e. ≥ 18 
years) after curative treatment for any cancer were included; both health and economic 
outcomes (i.e. costs) had to be reported. Childhood malignancies were excluded due to 
different outcomes and costs trajectories and longer time horizon. Other reasons for 
exclusion were: follow-up strategies for premalignant lesions not yet treated; screening 
programs for high-risk populations; clinical studies not reporting cost data; cost 
analyses focusing on only one alternative. 
Table 2.1 Search keywords according to PICOS elements. 
PICOS Inclusion Criteria Keywords 
Population Adults patients 
after any cancer 
treatment 
cancer OR carcinoma OR tumor OR neoplasm 
OR neoplasia 
Intervention/Comparator Post-treatment 
follow-up 
strategies 
‘follow up’ OR surveillance 
Outcomes Any health 
outcomes; costs 
Not specified 
Study design Economic 
evaluations 
‘economic evaluation’ OR ‘cost effectiveness’ 
OR ‘cost utility’ OR ‘cost benefit’ OR ‘cost 
minimization’ OR ‘cost consequences’ 
 
An initial search was made for studies published in the period 2000-2014; an updated 
search was performed for studies published between 2015 and June 2017. The reference 
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lists of relevant articles were searched to avoid missing other pertinent studies. Only 
original full-text articles (i.e. not conference abstracts or editorial comments) were 
selected; no language restriction was applied to the search. The candidate reviewed the 
retrieved studies in close consultation with her supervisor and, in case of disagreement, 
issues were resolved by discussion. A data extraction template was designed to include 
all relevant information from the studies identified including country, setting, patient 
population, number of patients, intervention and comparator, type of economic analysis 
(e.g. modelling vs. clinical study-based), health and economic outcomes, time horizon, 
cost perspective, currency, conversion and discounting, uncertainty analysis, data 
sources, study results, and conclusions.  
2.2.2 Study quality assessment 
The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 
Statement was adopted for the critical appraisal of the studies. The CHEERS checklist 
was recently developed by the International Society of Pharmacoeconomics and 
Outcomes Research (ISPOR) and jointly endorsed by the BMJ and nine other journals. 
Previous health economic evaluation guidelines were aggregated into a single standard 
to help authors report studies or reviewers assess them for publications. The CHEERS 
tool consists of a 24-item checklist composed by five broad categories: title and abstract 
(2 items); introduction (1 item); methods (14 items); results (4 items); discussion (3 
items) [73]. The 24-item checklist was completed for each study included in the review, 
indicating “yes” when the criteria were met, “no” when they were unfulfilled and “not 
applicable” when they were not required for that type of study. Although the CHEERS 
checklist is not a scoring instrument, papers were divided into three quality categories 
according to the proportion of items achieved: high (≥75%), average (50%-75%) and 
poor (<50%) based on other review studies adopting the same tool [74] [75] [76] [77].  
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2.3 Results 
Figure 2.1, a PRISMA diagram, displays the data for the number of titles initially 
identified (n=3507), 1224 of them were duplicates. After title and/or abstract screening 
of the remaining 2283 records, 2212 publications were excluded for a variety of criteria 
(mainly studies on cancer treatment and cancer prevention/screening in high-risk 
populations). 71 full-text articles were assessed for eligibility in the study, but only 53 
finally met all inclusion criteria and were included in the review.  
2.3.1 Study characteristics 
Table 2.2. provides a synthesis of the characteristics of the 53 included papers [78] [79] 
[80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] 
[98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] 
[113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] 
[127] [128] [129] [130]. Of these, twelve studies were conducted in the US, ten in the 
Netherlands, seven in the UK, four each in Canada and Sweden, three in Australia, two 
each in Italy, France and Spain; the remaining studies, one per country, were carried out 
in Germany, Finland, Norway, Israel, Iran, Korea, and China.  
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Figure 2.1 Flow diagram. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3507 citations identified by 
searches: 
PubMed: N= 1057 
EMBASE: N= 1709 
The Cochrane Library: N= 741 
 
 
2283 papers screened by 
title/ abstract 
 
 
71 papers retrieved for 
detailed inspection 
 
 
53 papers included in 
the review 
 
 
1224 duplicates 
removed 
 
2212 papers excluded: 
661 drug or surgical treatments, 440 population screening, 
124 diagnosis/disease staging, 132 no cancer, 76 no 
economic data, 53 health promotion, 44 psycho-oncology, 
47 methodological studies, 128 reviews, 287 conference 
abstracts, 23 HPV vaccination, 26 epidemiological 
studies, 24 cost-of-illness studies, 24 clinical guidelines, 
22 genetic counselling, 7 no full-text, 13 quality of 
life/health utility assessment, 8 editorial comments, 8 
paediatric cancer, 44 trial protocols, 3 fertility 
preservation, 10 follow-up of low grade precursor lesions, 
4 not relevant comparator (surgery), 3 physical 
activity/rehabilitation, 1 meta-analysis. 
18 papers excluded: 
6 no well-defined comparator, 4 
no comparator group, 2 follow-
up of low-grade precursor 
lesions, 2 pre-treatment, 1 not 
relevant comparator (surgery), 1 
no economic data, 1 quasi-
duplicate, 1 meta-analysis 
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The range of tumour sites was quite wide. A quarter of the articles (n=13) were related 
to breast cancer, followed by cervical (n=9; 17%), colorectal (n=9; 17%), lung (n=5; 
9%), and bladder (n=4; 7%); finally, two studies each dealt with oesophageal cancer, 
prostate cancer, Hodgkin’s lymphoma, and melanoma, and one each with anal, 
pancreatic, ovarian, head and neck, and thyroid cancer. The age range of patients was 
not systematically recorded, but all were adult subjects according to the review 
inclusion criteria. 
Twenty-one studies explicitly adopted a modelling framework (fourteen Markov 
models; three discrete event simulations (DES); two decision trees; one semi-Markov 
model, one decision tree followed by Markov model) involving data extrapolation 
and/or evidence synthesis. Two papers [79] [113] were based on unspecified modelling. 
Twenty studies (38%) were analyses of empirical data from clinical trials. Among the 
remaining articles, four each were (non-randomized) prospective [78] [97] [104] [122] 
and retrospective studies [83] [98] [101] [117]; one paper [124] was classified as a 
retrospective study plus (unspecified) modelling and another one [86] as retrospective 
study plus DES. The number of participants recruited in non-modelling studies (n=28) 
ranged between 69 [115] [129] and 3223 [127], averaging at 360 patients.  
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Table 2.2 Key features of economic evaluation studies included in the review (n=53). 
First 
author  
(Year) 
Country Intervention  Comparator Study design Cost 
perspective 
Time 
horizon 
Health 
outcomes 
Economic  
Outcomes 
Quality 
score 
Ref. 
Cancer Economic 
evaluation 
Discount 
rate 
Comparisons of follow-up strategies of different intensity  
Auguste 
(2014) 
UK PET-CT imaging 
plus current 
practice 
Current practice 
alone 
Markov 
model 
Healthcare 
system 
5 years QALYs gained: 
4.1096 
∆Cost/∆QALY: £1 
million 
96% [82] 
Cervical CUA Costs: 
3.5% 
Bessen 
(2014) 
Australia (1) Current annual 
mammography 
FUP (2) Mixed 
FUP 
Less intensive 
FUP (2-year 
mammography) 
DES model Healthcare 
system 
10 years QALYs gained: 
0.002-0.006 (50-
69 y old); 0.000-
0.003 (70-79 y 
old) 
∆Cost/∆QALY: 
AU$21,481-AU$133,525 
(50-69 y old); 
AU$40,706-AU$413,230 
(70-79 y old) 
83% [85] 
Breast CUA No 
Bessen 
(2015) 
Australia (1) Current annual 
mammography 
FUP (2) Mixed 
FUP (annual 
mammography 
for 5 years and 2 
yearly thereafter) 
Less intensive 
FUP (2-year 
mammography) 
Retrospective 
cohort + DES 
Healthcare 
system 
Lifetime QALY gained 
(mixed vs. 2 
yearly): 0.000-
0.010; QALY 
gained (annual 
vs. 2 yearly): 
0.000-0.006. 
ICER (mixed vs. 2 
yearly): $14,676-
$327,898; ICER (annual 
vs. 2 yearly): $40,381-
dominated. 
79% [86] 
Breast CUA No 
Borie 
(2004) 
France CEA-based 
standard FUP 
Simplified FUP Markov 
model 
Healthcare 
system 
7 years QALYs gained: 
0.25 
∆Cost/∆QALY: €3,114 58% [87] 
Colorectal CUA No 
Damude 
(2016) 
Netherlands Experimental 
schedule group 
(ESG, 1-3 visits 
first year) 
Conventional 
schedule group 
(CSG, 4 visits 
first year) 
RCT Healthcare 
system 
12 months Recurrence rate: 
8.6% in the CSG 
vs. 8.0% in the 
ESG (p = 0.89). 
Less cancer-
related stress in 
ESG than in 
CSG (p = 0.01). 
Cost/patient: €418 (ESG) 
vs. €762 (CSG) (p=0.01) 
71% [91] 
Melanoma CCA No 
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Table 2.2 (cont.) Key features of economic evaluation studies included in the review (n=53). 
First 
author  
(Year) 
Country Intervention  Comparator Study design Cost 
perspective 
Time 
horizon 
Health outcomes Economic  
Outcomes 
Quality 
score 
Ref. 
Cancer Economic 
evaluation 
Discount 
rate 
Comparisons of follow-up strategies of different intensity (cont.) 
Erenay 
(2016) 
US US guidelines Other less 
intensive 
guidelines and 
hypothetical 
more intensive 
options 
DES Societal 20 years US guidelines: 
MCRC incidence of 
1.7%-12.8%; 7.84-
8.18 discounted LYs 
per patient 
US guidelines: total cost 
of $49,101-$55,162 per 
patient; ICER 
(compared to less 
intensive guidelines): 
$140,000/LYG. 
More intensive options: 
ICER (compared to US 
guidelines): 
≤$63,822/LYG 
91% [96] 
Colorectal CEA 3% 
Forni (2007) Italy Simplified FUP 
(SCC antigen 
plus gynecologic 
examination) 
Complete FUP Prospective 
cohort 
Healthcare 
system 
5 years Rate of missed 
recurrences: 2.2% 
Cost/patient: €298.5 vs. 
€3,653.4 
52% [97] 
Cervical CCA No 
Guadagnolo 
(2006) 
US Annual CT for 5 
or 10 years 
FUP with non-
CT modalities 
only 
Markov 
model 
Societal 
(modified) 
Lifetime QALY gained: 
0.0005 
∆Cost/∆QALY: 
$9,042,300 
87% [99] 
Hodgkin's 
lymphoma 
CEA; CUA 3.0% 
Hatam 
(2016) 
Iran Intensive FUP Standard FUP Retrospective 
cohort  
Health 
insurance (or 
patient) 
6 years Early detection rate 
(before appearance 
of clinical signs): 
0.137 vs. 0.018 
(p<0.001); mortality 
rate: 17% vs. 22% 
(p=NS) 
Cost/patient: $311.5 vs. 
$112.9 (p<0.001). 
ICER (incremental cost 
per early case detected): 
$148,196.2 
95% [101] 
Breast CCA No 
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Table 2.2 (cont.) Key features of economic evaluation studies included in the review (n=53). 
First 
author  
(Year) 
Country Intervention  Comparator Study 
design 
Cost 
perspective 
Time 
horizon 
Health outcomes Economic  
Outcomes 
Quality 
score 
Ref. 
Cancer Economic 
evaluation 
Discount 
rate 
Comparisons of follow-up strategies of different intensity (cont.) 
Hengge 
(2007) 
Germany Established FUP 
practice 
Less intensive 
FUP 
Markov 
model 
Healthcare 
system 
5 years No difference in 
survival 
Cost/QALY: €63,252 vs.  
€42,433  
50% [103] 
Melanoma CEA; CUA No 
Kokko 
(2005) 
Finland Four strategies combining different 
visit timing and diagnostic tools 
RCT Healthcare 
system 
5 years Recurrences 
detected: 28-35 
(range); no difference 
in SDF and OS 
Cost/recurrence detected: 
€4,166 - €9,149 (range) 
57% [108] 
Breast CEA No 
Lu (2012) Netherlands 5-year FUP with 
annual 
mammography  
Three less 
intensive 
strategies 
DES model Healthcare 
system 
5 years No difference in 
recurrences detected 
Cost (x1000)/1% increase 
in recurrences detected: 
range: €62.1 – €83.1 
(current strategy) 
65% [111] 
Breast CEA No 
MacAfee 
(2007) 
UK Intensive FUP Standard FUP Model (NS) Healthcare 
system 
5 years Additional 
recurrences detected: 
853 
∆Cost/∆recurrence 
detected: £18,077 
78% [113] 
Colorectal CEA Costs: 
3.5% 
Oltra 
(2007) 
Spain 
 
FUP with annual 
mammography 
(n=63) 
A more 
intensive FUP 
(n=58) 
RCT Healthcare 
system 
3 years Recurrences 
detected: 11 (17.5%; 
95% CI: 9.6%-
25.3%) vs. 13 
(22.4%; 95% CI: 
13.4%-31.4%) 
Cost/patient: €390 vs. 
€1,278. Total cost: 
€24,567 vs. €74,171 
33% [118] 
Breast CCA No 
Phippen 
(2016) 
US Routine 
surveillance plus 
one PET/CT scan 
Routine 
surveillance 
Decision 
tree 
Medicare 3 years Recurrence rate: 26% 
vs. 32% 
Cost/patient: $16,579 vs. 
$15,450. ICER: $20,761 
per recurrence prevented 
83% [119] 
Cervical CEA No 
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Table 2.2 (cont.) Key features of economic evaluation studies included in the review (n=53). 
First 
author  
(Year) 
Country Intervention  Comparator Study 
design 
Cost 
perspective 
Time 
horizon 
Health outcomes Economic  
Outcomes 
Quality 
score 
Ref. 
Cancer Economic 
evaluation 
Discount 
rate 
Comparisons of follow-up strategies of different intensity (cont.)  
Secco 
(2002) 
Italy Risk-adapted 
FUP (n=192) 
Minimal 
surveillance 
(n=145) 
RCT Healthcare 
system 
5 years Risk of recurrence: 
52.6% vs. 57.2% 
(p<0.05) 
No difference in cost 48% [121] 
Colorectal CCA No 
Tzeng 
(2013) 
US Four strategies of 
increasing 
intensity 
No scheduled 
FUP 
Markov 
model 
Medicare Lifetime OS (months): 24.6 
(no surveillance) 
vs. 32.8 
(surveillance) 
∆Cost/LYG: US$5364 - 
US$294,696 (range) 
96% [125] 
Pancreatic CEA 3.0% 
Verberne 
(2016) 
Netherlands  Intensive FUP 
with more 
frequent CEA 
measurements 
Usual FUP 
(Dutch 
guidelines) 
RCT Societal 2 years The intensive FUP 
was proved to 
detect cancer 
recurrences earlier 
than usual FUP 
Medical cost/patient (yearly): 
€548 vs. €497. Non-medical 
cost/patient (yearly):  €509 vs. 
€488. ICER: €94/additional 
1% of recurrences detected 
and €607/additional 1% of 
curable recurrences detected 
86% [127] 
Colorectal CEA No 
Wu 
(2015) 
US Annual 
surveillance  
(5 years)  
plus 3-year 
surveillance 
(thereafter) 
Perpetual 
annual 
surveillance 
Markov 
model 
Medicare 38 years QALY gained 
(perpetual annual 
surveillance): 0.01 
Cost/patient (yearly): $5,239 
(perpetual annual 
surveillance) vs. $2,638 (3-
year strategy). ICER 
(perpetual annual 
surveillance): $260,100. 
87% [130] 
Thyroid CUA Costs: 3% 
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Table 2.2 (cont.) Key features of economic evaluation studies included in the review (n=53). 
First 
author  
(Year) 
Country Intervention  Comparator Study design Cost 
perspective 
Time 
horizon 
Health outcomes Economic  
outcomes 
Quality 
score 
Ref. 
Cancer Economic 
evaluation 
Discount 
rate 
Comparisons among different diagnostic tools 
Assoumou 
(2013) 
US Five strategies using high resolution 
anoscopy (HRA) and/or cytology 
Markov 
model 
Medicare Lifetime QALYs gained: 0.0723-
0.1061 (range) 
Cost/QALY: 
US$4,446-
US$17,373 (range) 
96% [80] 
Anal CUA 3.0% 
Dansk 
(2016) 
Sweden Hexaminolevulinate 
hydrochloride-
guided blue-light 
flexible cystoscopy 
(HAL BLFC) plus 
white-light flexible 
cystoscopy (WLFC) 
White-light 
flexible 
cystoscopy 
(WLFC) 
alone 
Decision tree 
+ Markov 
model 
Hospital 
(and other 
healthcare 
providers) 
5 years HAL BLFC improved 
recurrence detection and 
reduced transurethral 
resection of the bladder 
tumours, cystectomies, 
bed days and operating 
room time 
HAL BLFC 
resulted in minimal 
budget impact 
(+1.6% total cost/5 
years, or 189 SEK 
per patient/year), 
and translated to 
cost savings from 
year 2 
96% [92] 
Bladder CCA Costs: 3% 
de 
Bekker-
Grob 
(2008) 
Netherlands 
 
Semi-automated 
MA plus 
cystoscopy 
Cystoscopy 
alone 
Semi-Markov 
model 
Societal 2 years Probability (no recurrence 
after 2 years): 86.3% vs. 
86.6% 
Cost/patient: 
€4,104 vs. €3,433 
78% [94] 
Bladder CCA No 
Kamat 
(2011) 
US Five strategies combining 
cystoscopy, cytology, NMP22 and 
FISH 
Prospective 
cohort 
Medicare 4 months Detection rate: 52%-72% 
(range) 
Cost/recurrence 
detected: US$7,692 
- US$26,462 
(range) 
67% [104] 
Bladder CEA No 
Monteil 
(2010) 
France CDET imaging with 
18-FDG (n=36) 
Conventional 
imaging 
(n=33) 
RCT Healthcare/ 
Societal 
2 years Recurrences detected: 16 
(44.4%) vs. 9 (27.3%) 
(p=0.14). Time to 
recurrences detection 
(months): 12±9.9 vs. 
18±11.8 
Cost/patient: 
€1,104.96 vs. 
€755.47 (p<0.001) 
67% [115] 
Lung CCA No 
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Table 2.2 (cont.) Key features of economic evaluation studies included in the review (n=53). 
First 
author  
(Year) 
Country Intervention  Comparator Study design Cost 
perspective 
Time 
horizon 
Health outcomes Economic  
Outcomes 
Quality 
score 
Ref. 
Cancer Economic 
evaluation 
Discount 
rate 
Comparisons among different diagnostic tools (cont.) 
Ok (2014) Korea Seven strategies combining CT, 
cytology, and urinalysis 
Retrospective 
cohort 
Health 
insurance 
6 months Rate of 
recurrences 
detected: 24.5% - 
77.6% (range) 
Cost/recurrence 
detected: range: 
KRW11,049 - 
KRW100,647  
67% [117] 
Bladder CEA No 
Van Loon 
(2010) 
Netherlands (1) PET-CT scan; 
(2) chest-CT scan 
Conventional 
chest X-ray 
scan 
Markov model Healthcare 
system 
5 years QALYs: (1) 1.30 
(2) 1.28; OS 
(months): (1) 25; 
(2) 24 
∆Cost/∆QALY: (1) 
€69.086; (2) €264.033 
92% [126] 
Lung CUA Costs: 
4.0%; 
effects: 
1.5% 
HPV testing versus conventional cytology in cervical cancer follow-up 
Almog 
(2003) 
Israel HPV testing 
(n=67) 
Conventional 
cytology (n=63) 
Prospective 
cohort  
Health 
insurance 
53 
months 
No difference in 
recurrences 
detected 
Cost/recurrence 
detected: US$3,485 vs. 
US$3,573 
57% [78] 
Cervical CEA No 
Coupé 
(2007) 
Netherlands Six strategies with 
adjunct HPV 
testing 
Current 
cytological 
FUP 
Markov model Societal 5 years Reduction in 
missed cases: 
32%-77% (range) 
Cost/patient: €178-
€351 (range) 
70% [88] 
Cervical CCA Costs: 
3.0% 
Legood 
(2012) 
UK (1) Sentinel sites 
HPV test; (2) 
Extended HPV test  
Conventional 
cytology FUP 
Markov model Healthcare 
system 
10 years Case averted: 8 ∆Cost/∆Case  
averted: (1) -£1,120; 
(2) £6,474 
87% [110] 
Cervical CEA Costs: 
3.5% 
Melnikow 
(2010) 
US Twelve strategies combining 
cytology, colposcopy, and HPV 
testing 
Markov model Medicare Lifetime LYG: 0.001 vs. 
0.108; QALY 
gained: 0.153 – 
0.363 (range) 
Cost/LYG: US$4,083 - 
US$1,160,000 
Cost/QALY: US$54 - 
US$5,246 (range) 
100% [114] 
Cervical CEA; CUA 3.0% 
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Table 2.2 (cont.) Key features of economic evaluation studies included in the review (n=53). 
First 
author  
(Year) 
Country Intervention Comparator Study design Cost 
perspective 
Time 
horizon 
Health outcomes Economic  
outcomes 
Quality 
score 
Ref. 
Cancer Economic 
evaluation 
Discount 
rate 
Comparisons between follow-up programs and ‘do nothing’ options 
Cromwell 
(2016) 
Canada Anal cytology No anal screening Markov model Healthcare 
system 
50 years LYG: 0.004;  
QALY gained: 
zero. 
ICER: $20,561/LYG 96% [90] 
Cervical CEA; CUA 5% 
Das (2006) US Annual low-dose 
CT screening 
No screening Markov model Societal 
(modified) 
Lifetime LYG: 0.64 and 
0.16; QALYs 
gained: 0.58 and 
0.14 (smokers and 
non-smokers) 
∆Cost/∆QALY: 
US$34,100 
(smokers); 
US$125,400 (non-
smokers) 
92% [93] 
Hodgkin's 
lymphoma 
CEA; CUA 3.0% 
Hassan 
(2009) 
US 1-year endoscopy 
surveillance 
No early 
endoscopy 
Decision tree Societal Lifetime LYG: 2,653 ∆Cost/∆LYG: 
US$40,313 
87% [100] 
Colorectal CEA No 
Kent 
(2005) 
US Annual CT-based 
FUP 
No annual CT-
based FUP 
Markov model Medicare 5 years QALYs gained: 
0.16 
∆Cost/∆QALY: 
US$47,676 
75% [105] 
Lung CUA 3.0% 
Tergas 
(2013) 
US Colposcopy 
(n=27 low-grade 
Pap; n=60 high-
grade Pap) 
No colposcopy 
(n=23 low-grade 
Pap; n=18 high-
grade Pap) 
Retrospective 
cohort and 
model (NS) 
Medicare 34 
months 
Rate of 
recurrences 
detected: 8.3% vs. 
0.0% 
Cost/recurrence 
detected: US$7481 
71% [124] 
Cervical CEA No 
Comparisons among different organizational aspects of post-treatment follow-up 
Armstrong 
(2014) 
Canada Mobile-app FUP 
care  
Conventional, in-
person FUP care 
Model (NS)  Societal 30 days None Cost/patient: C$136 
vs. C$381  
61% [79] 
Breast CMA No 
Augestad 
(2013) 
Norway GP-organized 
FUP (n=55) 
Hospital surgeon-
based FUP (n=55) 
RCT Societal 2 years No difference in 
QoL and time to 
recurrences 
detection 
Cost/patient:  £8,233 
vs. £9,889 (p<0.001) 
95% [81] 
Colorectal CMA 3.0% 
Baena-
Canada 
(2013) 
Spain Primary care 
FUP (n=60) 
Hospital specialist 
care FUP (n=38) 
Retrospective 
cohort 
Healthcare 
system 
5 years No difference in 
recurrences 
detected or QoL 
Cost/patient: 
€112.86 vs. €184.61 
(p=0.0001) 
62% [83] 
Breast CCA No 
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Table 2.2 (cont.) Key features of economic evaluation studies included in the review (n=53). 
First 
author  
(Year) 
Country Intervention Comparator Study design Cost 
perspective 
Time 
horizon 
Health outcomes Economic  
Outcomes 
Quality 
score 
Ref. 
Cancer Economic 
evaluation 
Discount 
rate 
Comparisons among different organizational aspects of post-treatment follow-up (cont.) 
Beaver 
(2009) 
UK Hospital-based 
FUP (n=183) 
Nurse-led 
telephone FUP 
(n=186) 
RCT Healthcare/ 
Societal 
2 years No difference in 
psychological 
morbidity (STAI), 
recurrence rate or 
time to recurrence 
NHS FUP cost/patient: 
£124 vs. £179. 
Recurrences treatment 
cost/patient: £143 vs. 
£182. Transport and 
productivity cost/patient: 
£67 vs. £19 
95% [84] 
Breast CMA Costs: 
3.5% 
Emery 
(2017) 
Australia Shared care 
(mixed 
hospital/GP-
based) 
Usual care 
(hospital-
based) 
RCT Healthcare 
system 
12 
months 
No differences in 
psychological 
distress, unmet needs, 
HRQoL, patient’s 
satisfaction, and 
patient’s preferences 
Cost savings: $323 (range: 
$91-$554) 
76% [95] 
Prostate CMA No 
Gilbert 
(2000) 
Canada FP-led FUP Surgeon-led 
FUP 
Retrospective 
cohort 
Healthcare 
system 
5 years Recurrences detected: 
78 (70.3%) vs. 26 
(23.4%) 
Cost/recurrence detected: 
C$1,105 vs. C$4,387 
48% [98] 
Lung CEA No 
Helgesen 
(2000) 
Sweden On-demand 
nurse-led FUP 
(n=200) 
Urologist-led 
FUP (n=200) 
RCT Healthcare 
system 
3 years No differences in 
medical safety and 
HAD scale 
Cost/patient: SEK17,033 
vs. SEK19,454  
71% [102] 
Prostate CCA No 
Kimman 
(2011) 
Netherlands Four strategies combining 
hospital-based or telephone nurse-
led FUP with or without EGP 
RCT Societal 12 
months 
QALYs: 0.776 vs. 
0.772  
∆Cost/∆QALY: €235.750 
(hospital + EGP vs. 
telephone + EGP) 
91% [106] 
Breast CUA No 
Koinberg 
(2009) 
Sweden Physician-led 
FUP (n=131) 
On-demand 
nurse-led FUP 
(n=133) 
RCT Healthcare 
system 
5 years No difference in 
HADS, patient 
satisfaction, 
recurrences, and 
mortality 
Cost/patient/year: €630 
(95% CI: €557-€1,055) vs. 
€495(95% CI: €410-€797) 
81% [107] 
Breast CMA 3.0% 
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Table 2.2 (cont.) Key features of economic evaluation studies included in the review (n=53).  
First 
author  
(Year) 
Country Intervention Comparator Study 
design 
Cost 
perspective 
Time 
horizon 
Health outcomes Economic  
Outcomes 
Quality 
score 
Ref. 
Cancer Economic 
evaluation 
Discount 
rate 
Comparisons among different organizational aspects of post-treatment follow-up (cont.) 
Lanceley 
(2017) 
UK Individualized 
nurse-led FUP 
Conventional 
FUP 
RCT Healthcare 
system 
2 years Improved QoL (QLQ-C30, 
p=0.013 and QLQ-OV28, 
p=0.14) and patient’s 
satisfaction (PSQ III, 
p=0.002). No difference in 
HADS (p=0.42). 
Cost savings: £700 
(p=0.07) 
81% [109] 
Ovarian CCA No 
Lyu 
(2017) 
China FUP on 
WeChat (WFU) 
FUP on 
telephone 
(TFU) 
RCT Healthcare 
system 
6 months Lost to FUP rate: 7.0% vs. 
9.8% (p=0.732); patient’s 
satisfaction: 94.3% vs. 
80.4% (p=0.034) 
Time consumption (per 
patient): 23.4±6.2 min 
vs. 42.9±7.1 min 
(p<0.001). 
Cost/patient: 90 Yuan 
vs. 196 Yuan (p=NS).  
76% [112] 
Head and 
neck 
CCA No 
Moore 
(2002) 
UK 
 
Nurse-led FUP 
(n=100) 
Conventional 
medical FUP 
(n=103) 
RCT Health and 
social care 
system 
12 
months 
No difference in survival or 
disease progression 
Cost/patient: £696.50 
vs. £744.50 (p=0.66) 
71% [116] 
Lung CCA No 
Polinder 
(2009) 
Netherlands Surgeon-led 
FUP (n=55) 
Home-based 
nurse-led FUP 
(n=54) 
RCT Societal 12 
months 
No difference in 
recurrences detected, 
patient satisfaction and QoL 
Cost/patient: €3,798 
vs. €2,592 (p=0.11) 
86% [120] 
Esophageal CMA No 
Siddika 
(2015) 
UK Remote 
surveillance 
(Hypothetical) 
hospital-based 
surveillance 
Prospective 
cohort 
Healthcare 
system 
5 years Local recurrence/distant 
metastasis rate (remote 
surveillance): 4%/10.3%. 
Survival rate: 88.8% 
(comparable with national 
statistics). Patient’s 
satisfaction: 97% (overall). 
Cost savings: £52,593. 43% [122] 
Colorectal CMA No 
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Table 2.2 (cont.) Key features of economic evaluation studies included in the review (n=53).  
First 
author  
(Year) 
Country Intervention Comparator Study 
design 
Cost 
perspective 
Time 
horizon 
Health outcomes Economic  
outcomes 
Quality 
score 
Ref. 
Cancer Economic 
evaluation 
Discount 
rate 
Comparisons among different organizational aspects of post-treatment follow-up (cont.) 
Strand 
(2011) 
Sweden Nurse-led FUP 
(n=54) 
Surgeon-led FUP 
(n=56) 
RCT Healthcare 
system 
NS Metastases detected: 8 
vs. 7 (p=0.953) 
Cost/patient: €51 
vs. €55 (p=0.779) 
57% [123] 
Colorectal CCA No 
Verschuur 
(2009) 
Netherlands Home-based, 
nurse-led FUP 
(n=54) 
Standard 
outpatient clinic-
based FUP (n=55) 
RCT Healthcare 
system 
13 months No difference in QoL 
and patient 
satisfaction 
Cost/patient: 
€2600 vs. €3800 
(p=0.11) 
71% [128] 
Esophageal CCA No 
Visser 
(2015) 
Netherlands Group medical 
consultations 
Individual 
outpatient visits 
RCT Societal 3 months No difference in 
patient’s satisfaction, 
efficacy outcomes 
(i.e. psychological 
distress and 
empowerment). 
Cost/patient: €53 
vs. €35; p<0.001. 
81% [129] 
Breast CMA No 
Follow-up with education program versus follow-up without educational program  
Coyle 
(2013) 
Canada Survivorship 
care plane 
(SCP) 
Current practice 
(no SCP) 
RCT Healthcare/ 
Societal 
2 years No difference in 
QALYs 
Cost/QALY: SCP 
is dominated 
86% [89] 
Breast CUA 5.0% 
CCA: cost-consequences analysis; CDET: Coincidence detection system; CEA: carcinoembryonic antigen; CEA: cost-effectiveness analysis; CMA: cost-minimization analysis; CSG: conventional 
schedule group; CT: computed tomography; CUA: cost-utility analysis; DES: discrete event simulation; DFS: disease-free survival; EGP: educational group program; ESG: experimental schedule 
group; FDG: fluorodeoxyglucose; FISH: fluorescence in situ hybridization; FP: family physician; FUP: follow-up; GP: general practitioner; HADS: hospital anxiety and depression scale;  HPV: human 
papilloma virus; ICER: incremental cost-effectiveness ratio; KRW: Korean Won; LYG: life year gained; MA: microsatellite-analysis; MCRC: metachronous colorectal cancer; NMP22: BladderCheck®; 
NS: not specified; NS: not significant; OS: overall survival; PET: positron emission tomography; PSQ: patient satisfaction questionnaire; QALY: quality-adjusted life year; QLQ-C30: 30-item Core 
Quality of Life Questionnaire; QLQ-OV28: 28-item Ovarian Cancer Quality of Life Questionnaire; QoL: quality of life; RCT: randomized controlled trial; SCC: squamous cell carcinoma; SCP: 
survivorship care plane; SEK: Swedish crowns; STAI: State-Trait Anxiety Inventory; TFU: telephone follow-up; WFU: web-follow-up.  
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In Table 2.2, studies were clustered according to different types of follow-up programs 
compared. More than one third of the studies (19 out of 53) were classified as 
comparisons of follow-up strategies of different ‘intensity’; among them were included 
studies addressing follow-up schemes with different timing of controls (e.g. annual or 2-
year mammography) or with novel diagnostic tests (e.g. PET-CT imaging) added to 
routine investigations. Seven studies [80] [92] [94] [104] [115] [117] [126] examined 
outcomes and costs of a variety of diagnostic tools (e.g. PET vs. CT), while four studies 
[78] [88] [110] [114] related to cervical cancer compared HPV test versus cytology as 
potential instruments to detect new lesions. Five studies [90] [93] [100] [105] [124] 
compared costs and health gains arising from a surveillance program versus a ‘do 
nothing’ strategy; thirteen studies examined traditional hospital-based follow-up 
programs in comparison with programs led by other healthcare professionals (i.e. in 
nine cases [84] [102] [106] [107] [109] [116] [120] [123] [128] the nurse and in four 
[81] [83] [95] [98] the family physician). Three studies compared a mobile-app follow-
up versus traditional in-person consultations [79] [122] or versus a follow-up using 
telephone [112]; lastly, one study [89] described two programs with (and without) an 
educational session and another one [129] group medical consultations with individual 
outpatient visits. 
Almost half of the papers (26 out of 53) adopted a limited healthcare perspective where 
only direct medical costs were considered; one study [116] from UK included the costs 
borne by social services as well. Nine US-based studies [80] [99] [104] [105] [114] 
[119] [124] [125] [130] carried out the analysis from the national social insurance 
program (i.e. Medicare) perspective. Three authors [78] [101] [117] calculated the costs 
borne by the health insurance companies in their countries (i.e. Israel, Iran, and Korea), 
while a Swedish study [92] adopted the hospital’s (or other healthcare providers’) 
perspective. Ten studies embraced a societal perspective estimating broader costs to 
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society irrespective of the payer and, thus, including also out-of-pocket costs, informal 
care, and productivity losses. The remaining three articles [84] [89] [115] presented 
study results according to both healthcare and societal perspectives. 
More than half of the included papers (30/53) compared post-treatment surveillance 
outcomes and costs over a period between 1 and 5 years. Eight studies [79] [104] [106] 
[112] [116] [117] [120] [129] adopted a shorter timeframe (≤ 1 year), and five studies 
[85] [87] [96] [101] [110] a longer one (6-20 years). For nine studies [80] [86] [90] [93] 
[99] [100] [114] [125] [130] the model was run over a lifetime horizon. In one case 
[123] the time horizon was not specified. The fourteen studies adopting a longer 
timeframe (i.e. >5 years) were all modelling studies but one that was retrospective 
[101]; conversely, when primary data collection was performed (i.e. RCTs and cohort 
studies) the time horizon did not exceed 5 years.  
Thirty-four articles did not report any discount rate for future costs and health 
outcomes. Seven papers [82] [84] [88] [92] [110] [113] [130] applied a discount rate to 
costs only (i.e. either 3.0% or 3.5%). In eleven articles costs and effects were discounted 
at the same rate (i.e. 3.0% in nine cases, 5.0% in two). The last paper [126] adopted a 
1.5% discount rate for outcomes and 4.0% for costs. Among the studies (44 out of 53) 
adopting a time horizon ≥ 1 year, discounting was not applied in more than half of the 
cases (25/44), while seven studies applied a discount factor to costs only; the remaining 
twelve articles discounted both costs and health outcomes at rates ranging between 3% 
and 5%. 
All types of economic evaluations were represented other than cost-benefit analysis. 
Fourteen studies were cost-effectiveness analyses where outcomes were expressed in 
natural units, either intermediate (e.g. number of recurrences detected) or final ones 
(e.g. survival). Fifteen articles assessed the effects of an intervention in terms of 
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QALYs, either alone or in combination with physical outcomes (e.g. survival) and were 
classified as cost-utility analyses. Eight studies were cost-minimization analyses 
assuming the equivalence of outcomes between interventions and comparators; sixteen 
were cost-consequences analyses where costs and effects were not combined in a single 
metric and economic results were usually expressed in terms of cost per patient or total 
costs.  
2.3.2 Study findings 
Among the five studies [90] [93] [100] [105] [124] comparing a follow-up program for 
cancer survivors versus not performing one (i.e. ‘do nothing’ option), all showed the 
intervention strategy was a cost-effective option through the calculation of incremental 
cost per QALY (or life year) gained or recurrence detected. 
Some studies (n=7) compared several diagnostic tools to be adopted in post-treatment 
setting and the results in terms of costs and health outcomes varied considerably. One 
study [126] evaluating PET combined with CT (PET-CT) showed that it was a cost-
effective diagnostic instrument compared to CT alone or X-ray in lung cancer patients. 
Another study dealing with lung cancer [115] and comparing coincidence detection 
system imaging (CDET) with 18-fluorodeoxyglucose (FDG) with conventional 
technique imaging concluded that the two groups were similar in term of recurrences 
detected and survival, and FDG-18 was costlier. Three authors [94] [104] [117] reported 
that selected innovative tools (i.e. semi-automated microsatellite-analysis and NMP22 
bladder check) were not cost-effective in detecting bladder cancer recurrences. One 
paper [80] comparing several diagnostic strategies for HIV-infected men with anal 
cancer found that a combination of high-resolution anoscopy (HRA) and cytology 
provided the greater benefit at an acceptable cost/QALY gained. Lastly, a modelling 
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study [92] revealed that the addition of an innovative diagnostic tool to the traditional 
cystoscopy improves detection rates with a minimal cost increase in bladder cancer. 
Four papers aimed at women with cervical intraepithelial neoplasia (NIP) compared 
follow-up strategies involving diagnostic tools such as HPV testing, cytology, and 
colposcopy. Three of these studies [78] [88] [110] concluded that HPV testing was cost-
effective compared to a conventional cytological approach; on the contrary, one study 
[114] concluded that HPV testing added limited improvement to survival at higher costs 
than cytology. 
A broad group of papers (n=19) were categorized as economic evaluations of follow-up 
programs of different ‘intensity’. In seven cases [82] [87] [97] [101] [103] [118] [119], 
one or more diagnostic tests were added to routine surveillance (e.g. PET-CT imaging 
plus standard practice); of these, five [82] [87] [97] [103] [118] concluded that a less 
intensive follow-up program was clinically and economically justified for a variety of 
malignancies (i.e. breast, cervical and colorectal cancer, and melanoma). One study 
[101] showed that an intensive follow-up could yield a higher detection of recurrences 
before the appearance of clinical signs and a lower mortality rate; however, the ICER 
calculated as incremental cost per case detected was considered too high compared to 
the threshold recommended by the World Health Organization (i.e. three times Gross 
Domestic Product per capita). On the contrary, another study [119] stated that the 
addition of PET-CT scan in cervical cancer follow-up was cost-effective in terms of 
cost per recurrence prevented. A further group of seven studies [85] [86] [91] [96] [108] 
[113] [130] compared the same types of diagnostic exams but administered with 
different timing, either in terms of number of tests per year or of follow-up length (or 
both); among them, five studies stated that less frequent options were cost-effective [85] 
[86] [130] or even cost saving [91] [108] compared to a more intensive program. On the 
contrary, the studies by Macafee [113] and Erenay [96] showed that more intensive 
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strategies could be cost-effective compared to standard guidelines in colorectal cancer 
follow-up. In three articles [99] [125] [127] the definition of ‘intensity’ combined both 
concepts (i.e. increased frequency and additional tests); in two cases [99] [125], less 
intensive options were preferred since they provided comparable clinical outcomes (i.e. 
overall survival, number of recurrences detected) at significantly lower costs, whilst one 
study [127] showed that the incremental cost per curable recurrence detected by more 
frequent carcinoembryonic antigen (CEA) measurements was reasonably low. One 
study [121] showed that a risk-adapted follow-up, with the timing of clinical controls 
and radiological investigations modulated according to the risk of recurrence, was cost 
saving compared with a common strategy for all. Lastly, the study by Lu [111] 
performed a comparison of three follow-up strategies where the time in hospital was 
progressively shortened by a shift of care to the GP; once again, the simplified follow-
up showed an acceptable cost-effectiveness profile. 
The results from 17 studies dealing with different organizational aspects of post-
treatment surveillance supported the current trend of moving towards less structured 
healthcare programs. However, clinical results were seldom expressed as relevant final 
outcomes (i.e. LYG or QALYs). Eight [102] [106] [107] [109] [116] [120] [123] [128] 
out of nine papers comparing hospital-based versus nurse-led follow-up revealed the 
latter option was less costly without compromising patients’ health or acceptability. A 
UK-based cost-minimization analysis [84] concluded that, given the equivalence of 
health outcomes, a nurse-led telephone follow-up compared to a traditional hospital-
based one might reduce patient’s travel and productivity costs but did not lead to cost or 
salary savings in the National Health Service perspective. In a similar way, four studies 
[81] [83] [95] [98] showed that a general practitioner-led follow-up did not affect 
survival, quality of life, time to detection of recurrence, or patient’s satisfaction. Three 
studies [79] [112] [122] concluded that a mobile-app-based follow-up was cost-saving 
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compared to traditional in-person or telephone-based approaches. The study by Visser 
[129] showed no differences in efficacy outcomes and limited cost increase for group 
medical consultations compared to traditional individual visits in breast cancer follow-
up. 
Finally, the study by Coyle [89] assessed a survivorship care plan (SCP) for women 
after breast cancer treatment, including an educational session for patients and full 
follow-up guidelines for general practitioners. SCP was not cost-effective since the 
control group had better outcomes and lower costs than the SCP group. 
2.3.3 Study quality assessment 
The quality evaluation of the included studies based on the CHEERS checklist is 
summarized in Tables 2.3-2.4. Three items (i.e. preference measurement, model choice 
and model assumption) were applicable only to a limited number of studies; in detail, 
item 12 was related to cost-utility analyses using QALYs, while items 15-16 concerned 
modelling studies only. For this reason, the quality judgment was expressed in terms of 
percentage (instead of absolute number) of checklist criteria met. 
Thirty-one papers were categorized as high-quality studies as more than 75% of criteria 
were fulfilled. For eighteen studies, the quality estimated was of average level (between 
50% and 75% of items met), while the remaining four studies met less than 50% of the 
checklist criteria and were categorized as poor. The average proportion of items 
achieved was 76% (range: 33% - 100%).  
The most commonly missing quality criteria (i.e. in more than half of the studies) were: 
not accounting for patients’ heterogeneity in reporting results (Item 21; missing: 74%); 
outcomes and costs not discounted and/or justification not given for the adopted (or not 
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adopted) discount rate (Item 9; missing: 60%); a non-explicative title of the 
interventions compared and the economic evaluation performed (Item 1; missing: 57%).   
On the other hand, the CHEERS items most often reported in the studies were the 
specification of the target population (Item 4; fulfilled: 98%) and the time horizon of the 
study (Item 8; fulfilled: 96%), followed by description of health outcomes and the 
methods and/or sources adopted to measure them (Items 10-11; fulfilled: 94-96%). 
Despite the estimated quality being rather high (76%) across studies, several CHEERS 
points have been weakly considered by selected authors and need further discussion. 
First, discounting (Item 9) was disregarded by 32 studies (since two studies [101] [120] 
provided justification for not discounting, thus they were considered to fulfil the 
criterion); of these, twenty-one used a time horizon longer than 2 years, thus a discount 
factor was required. Moreover, even in studies adopting a short timeframe (i.e. ≤1 year) 
CHEERS recommends reporting a 0% rate for clarity. Among the few studies (n=21) 
which carried out some discount technique, most explicitly referred to published 
guidelines or health jurisdictions; all UK papers in this group [82] [84] [110] [113] 
adopted the most recent recommendations from NICE for discounting (i.e. 3.5%) but 
applied the rate to costs only. 
A second issue is the specification of model choice and assumptions (Items 15-16). In 
fact, only four studies [82] [85] [87] [92] gave reasons for the specific type of model 
used and six modelling studies [79] [93] [99] [110] [113] [130] did not provide a 
graphical representation of the model structure; moreover, five articles [87] [103] [111] 
[113] [130] did not properly describe the assumptions underlying the decision-analytic 
model. Moreover, a table reporting cost (and utility, if required) parameters with 
probability distributions (Item 18) was not provided by twenty-two studies. 
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Thirdly, with reference to analytic methods (Item 17) a positive judgment (‘yes’) has 
been given if at least one of the following was reported in the article: methods for 
dealing with skewed, missing, or censored data; approaches to validate or adjust a 
model (e.g. half-cycle correction); methods for handling heterogeneity or uncertainty. 
Uncertainty was considered by the great majority (87%) of the studies, either through 
sensitivity analyses in modelling studies and statistical tests (e.g. t-test, chi-square) or 
95% confidence intervals in RCTs; conversely, a limited number of papers fulfilled the 
other two methodological requirements. Data skewness was taken into account by seven 
studies [81] [84] [106] [109] [116] [120] [128] which adopted non-parametric 
bootstrapping techniques (e.g. Mann-Whitney test) for skewed cost data. One study [89] 
used standard methods for handling censored data; two recent studies [109] [129] 
specified how to deal with missing data (e.g. using multiple imputation). Among the 
modelling studies, only one [93] reported adjustments for lead-time bias. 
Fourthly, the checklist section about costs (Items 13-14) was only partially fulfilled. In 
two papers adopting a societal perspective [88] [94] the source of travel, production and 
other patient costs was not reported. Among the papers which met this requirement, six 
studies [81] [84] [89] [106] [127] [129] empirically collected non-medical direct costs 
(i.e. transportation, co-payments, other patient/family expenses) through ad hoc surveys, 
cost diaries and local sources; in two studies [79] [115] transportation costs were 
calculated as a function of the distance between home and hospital. Productivity losses 
were estimated based on average national wages [79] [84] [100] [127] or using the 
friction cost method  [129]. In one study [96], patient’s costs were estimated from the 
literature. 
Fifthly, with reference to Item 14 (currency, price date and conversion), twelve studies 
[83] [91] [94] [95] [97] [111] [112] [117] [118] [121] [122] [123] did not specify the 
year of reported costs, while three authors [97] [101] [103] failed to report the exchange 
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rate between currencies. The remaining 38 studies satisfied the criterion. In US-based 
studies, medical costs (in US dollars) were always adjusted using the medical 
component of the consumer price index (PCI) for the study year and mainly derived 
from Medicare reimbursement data; the only exception was a study [96] that estimated 
costs fully from the literature and updated them using the PCI. In the study from 
Norway [81] cost elements were converted from Norwegian kroner (NOK) into British 
pounds at the study year exchange rate. One study from Israel [78] reported healthcare 
costs in US dollars. Three studies [79] [97] [103] reported results both in local 
currencies (i.e. Canadian dollars and euros) and US dollars; all the other studies 
estimated costs in the same currency of the country where the analysis was performed.  
Sixthly, twenty studies only reported results as ICERs, either as cost/QALY, cost/LYG 
or cost/additional treatable recurrence. Fifteen studies reported mean differences in 
effects and costs between (or among) the alternative interventions, without combining 
them in an ICER. These two groups of studies combined (n=35) were considered to 
fulfil the Item 19 criterion. Conversely, the remaining eighteen studies simply indicated 
mean values for the main categories of estimated costs and health outcomes for each 
follow-up strategy analysed; this approach is typical of cost-consequences analyses, 
where costs and consequences are not aggregated into a single measure. 
Finally, intervention results in cancer care may vary according to patients’ 
characteristics and disease severity; however, a limited group of papers (14 out of 53) 
handled population heterogeneity (Item 21) in the decision model. In these studies, 
results were stratified according to several factors, such as age, treatment, cancer stage, 
smoking status, presence/absence of metastasis, high/low recurrences risk, and 
symptomatic/asymptomatic disease.  
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Table 2.3 Quality assessment of the included studies (n=53) based on the CHEERS checklist (Items:1-12). 
Ref. Title 
Structured 
abstract 
Rationale/ 
objectives 
Target 
population 
Setting 
Study 
Perspective 
Comparators 
Time 
horizon 
Discount 
rate 
Health 
outcomes 
Effectiveness 
measurement 
Preferences 
measurement 
Items 
sum 
Quality 
[78] N N Y Y Y Y Y Y N Y Y NA 12/21 Average 
[79] Y Y Y N N Y N Y N Y N NA 15/23 Average 
[80] Y Y Y Y Y Y Y Y Y Y Y Y 23/24 High 
[81] Y Y Y Y Y Y Y Y Y Y Y NA 20/21 High 
[82] N Y Y Y Y Y Y Y Y Y Y Y 23/24 High 
[83] N Y Y Y N N Y Y N Y Y NA 13/21 Average 
[84] Y Y Y Y Y Y Y Y Y Y Y NA 20/21 High 
[85] N Y Y Y Y N Y Y N Y Y Y 20/24 High 
[86] Y Y Y Y Y Y Y N N Y Y Y 20/24 High 
[87] Y N N Y Y Y N Y N Y Y Y 14/24 Average 
[88] N Y Y Y Y Y Y Y Y Y Y NA 16/23 Average 
[89] N Y Y Y Y Y Y Y Y Y Y Y 19/22 High 
[90] Y Y Y Y Y Y Y Y Y Y Y Y 23/24 High 
[91] N Y Y Y Y Y Y Y N Y Y NA 14/21 Average 
[92] Y Y Y Y Y Y Y Y Y N Y NA 22/23 High 
[93] Y Y Y Y Y Y Y Y Y Y Y Y 22/24 High 
[94] Y Y Y Y Y Y Y Y N N Y NA 18/23 High 
[95] N Y Y Y Y Y Y Y N Y Y NA 16/21 High 
[96] Y Y Y Y Y Y Y Y Y Y Y NA 21/23 High 
[97] N Y Y Y N N N Y N Y Y NA 11/21 Average 
[98] N Y N Y Y N Y Y N Y Y NA 10/21 Poor 
[99] N Y Y Y Y Y Y Y Y Y Y Y 21/24 High 
[100] Y Y Y Y Y Y Y Y N Y Y NA 20/23 High 
[101] Y Y Y Y Y Y Y Y Y Y Y NA 19/21 High 
[102] N Y Y Y Y Y Y Y N N Y NA 15/21 Average 
[103] N Y Y Y Y Y N Y N Y Y N 13/24 Average 
[104] N Y Y Y Y Y Y Y N Y Y NA 14/21 Average 
[105] Y Y N Y Y Y Y Y Y Y Y N 18/24 High 
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Table 2.3 (cont.) Quality assessment of the included studies (n=53) based on the CHEERS checklist (Items:1-12). 
Ref. Title 
Structured 
abstract 
Rationale/ 
objectives 
Target 
population 
Setting 
Study 
perspective 
Comparators 
Time 
horizon 
Discount 
rate 
Health 
outcomes 
Effectiveness 
measurement 
Preferences 
measurement 
Items 
sum 
Quality 
[106] Y Y Y Y Y Y Y Y N Y Y Y 20/22 High 
[107] N Y Y Y Y Y Y Y Y Y Y NA 17/21 High 
[108] N N Y Y Y Y Y Y N Y Y NA 12/21 Average 
[109] N Y Y Y Y Y Y Y N Y Y NA 17/21 High 
[110] Y Y Y Y Y Y Y Y Y Y N NA 20/23 High 
[111] Y Y Y Y Y N Y Y N Y Y NA 15/23 Average 
[112] N Y Y Y Y Y Y Y N Y Y NA 16/21 High 
[113] N Y Y Y Y Y Y Y Y Y Y NA 18/23 High 
[114] Y Y Y Y Y Y Y Y Y Y Y Y 24/24 High 
[115] N N N Y N Y Y Y N Y Y NA 13/21 Average 
[116] N Y N Y Y Y Y Y N Y Y NA 15/21 Average 
[117] Y Y Y Y Y Y Y Y N Y Y NA 14/21 Average 
[118] N N Y Y Y N Y Y N Y Y NA 7/21 Poor 
[119] N Y Y Y Y Y Y Y N Y Y NA 19/23 High 
[120] Y Y Y Y Y Y Y Y Y Y Y NA 18/21 High 
[121] N Y Y Y N N N Y N Y Y NA 10/21 Poor 
[122] N Y Y Y Y Y Y Y N Y Y NA 9/21 Poor 
[123] N Y Y Y Y Y Y N N Y Y NA 12/21 Average 
[124] N Y Y Y Y Y Y Y N Y Y NA 15/21 Average 
[125] Y Y Y Y Y Y Y Y Y Y Y NA 22/23 High 
[126] N Y Y Y Y Y Y Y Y Y Y Y 22/24 High 
[127] Y Y Y Y Y Y Y Y N Y Y NA 18/21 High 
[128] N N Y Y Y Y Y Y N Y Y NA 15/21 Average 
[129] N Y Y Y Y Y Y Y N Y Y NA 17/21 High 
[130] Y Y Y Y Y Y Y Y Y Y Y Y 21/24 High 
Y 23 43% 47 89% 48 90% 52 98% 48 90% 46 87% 48 90% 51 96% 21 40% 50 94% 51 96% 13 24%   
N 30 57% 6 11% 5 10% 1 2% 5 10% 7 13% 5 10% 2 4% 32 60% 3 6% 2 4% 2 4%   
NA 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 38 72%   
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Table 2.4 Quality assessment of the included studies (n=53) based on the CHEERS checklist (Items:13-24). 
Ref. 
Resources/ 
costs 
Currency/ 
price date 
Model 
choice 
Model 
Assumptions 
Analytic 
methods 
Study 
parameters 
∆costs/ 
∆outcomes 
Uncertainty 
Heterogeneity 
(subgroups) 
Discussion 
Funding 
Source 
Conflict 
interest 
Items 
sum 
Quality 
[78] Y Y NA NA Y N N Y N N N N 12/21 Average 
[79] Y Y N N Y Y Y Y N Y Y Y 15/23 Average 
[80] Y Y Y Y Y Y Y Y N Y Y Y 23/24 High 
[81] Y Y NA NA Y Y Y Y N Y Y Y 20/21 High 
[82] Y Y Y Y Y Y Y Y Y Y Y Y 23/24 High 
[83] Y N NA NA Y Y N Y N N Y Y 13/21 Average 
[84] Y Y NA NA Y Y Y Y N Y Y Y 20/21 High 
[85] Y Y Y Y Y Y Y Y Y Y Y N 20/24 High 
[86] N Y Y Y Y N Y Y Y Y Y Y 20/24 High 
[87] N Y Y N Y N Y Y Y N N N 14/24 Average 
[88] N Y Y Y Y Y N Y N N N N 16/23 Average 
[89] Y Y NA NA Y Y Y Y N N Y Y 19/22 High 
[90] Y Y Y Y Y Y Y Y N Y Y Y 23/24 High 
[91] N N NA NA Y N N Y N Y Y Y 14/21 Average 
[92] Y Y Y Y Y Y Y Y Y Y Y Y 22/23 High 
[93] Y Y N Y Y Y Y Y Y Y Y N 22/24 High 
[94] N N Y Y Y Y Y Y N Y Y Y 18/23 High 
[95] Y N NA NA Y N Y Y N Y Y Y 16/21 High 
[96] N Y Y Y Y Y Y Y N Y Y Y 21/23 High 
[97] Y N NA NA Y Y N Y N N N Y 11/21 Average 
[98] N N NA NA Y N N Y N N Y N 10/21 Poor 
[99] Y Y N Y Y Y Y Y Y Y N Y 21/24 High 
[100] Y Y Y Y Y Y Y Y N Y N Y 20/23 High 
[101] Y N NA NA Y N Y Y Y Y Y Y 19/21 High 
[102] Y Y NA NA Y N Y Y Y N Y N 15/21 Average 
[103] Y N Y N N N Y N N N Y Y 13/24 Average 
[104] Y Y NA NA N N N N N Y Y Y 14/21 Average 
[105] Y Y Y Y Y N Y Y N Y N N 18/24 High 
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Table 2.4 (cont.) Quality assessment of the included studies (n=53) based on the CHEERS checklist (Items:13-24). 
Ref. 
Resources/ 
costs 
Currency/ 
price date 
Model 
choice 
Model 
Assumptions 
Analytic 
methods 
Study 
Parameters 
∆costs/ 
∆outcomes 
Uncertainty 
Heterogeneity 
(subgroups) 
Discussion 
Funding 
Source 
Conflict 
interest 
Items 
sum 
Quality 
[106] Y Y NA NA Y Y Y Y N Y Y Y 20/22 High 
[107] Y Y NA NA Y Y Y Y N Y N N 17/21 High 
[108] Y Y NA NA N Y N N N N Y N 12/21 Average 
[109] Y Y NA NA Y N Y Y N Y Y Y 17/21 High 
[110] Y Y N Y Y Y Y Y N Y Y Y 20/23 High 
[111] Y N Y Y Y N N Y N N N Y 15/23 Average 
[112] Y N NA NA Y N Y Y N Y Y Y 16/21 High 
[113] Y Y N N Y Y Y Y Y N N Y 18/23 High 
[114] Y Y Y Y Y Y Y Y Y Y Y Y 24/24 High 
[115] Y Y NA NA Y Y N Y N Y N Y 13/21 Average 
[116] Y Y NA NA Y N N Y N Y Y Y 15/21 Average 
[117] Y N NA NA N N N Y N Y N Y 14/21 Average 
[118] N N NA NA N N N N N N N N 7/21 Poor 
[119] Y Y Y Y Y Y Y Y N Y N Y 19/23 High 
[120] Y Y NA NA Y Y N Y N Y N Y 18/21 High 
[121] N N NA NA Y N N Y Y Y N N 10/21 Poor 
[122] N N NA NA N N N N N N N N 9/21 Poor 
[123] Y N NA NA Y N N Y N Y N N 12/21 Average 
[124] Y Y NA NA N N Y N Y Y N Y 15/21 Average 
[125] Y Y Y Y Y Y Y Y N Y Y Y 22/23 High 
[126] Y Y Y Y Y Y Y Y Y Y N Y 22/24 High 
[127] Y Y NA NA Y Y Y Y N N Y Y 18/21 High 
[128] Y Y NA NA Y N N Y N Y Y Y 15/21 Average 
[129] Y Y NA NA Y Y Y Y N N Y Y 17/21 High 
[130] Y Y N N Y Y Y Y N Y Y Y 21/24 High 
Y 43 81% 38 72% 18 34% 19 36% 46 87% 31 58% 35 66% 47 89% 14 26% 37 70% 33 62% 39 74%   
N 10 19% 15 28% 6 11% 5 9% 7 13% 22 42% 18 34% 6 11% 39 74% 16 30% 20 38% 14 26%   
NA 0 0% 0 0% 29 55% 29 55% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%   
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2.4 Discussion 
2.4.1 Summary of evidence 
This is the first-time health and economic outcomes from post-treatment follow-up 
interventions have been compared across countries and for all types of cancer. There 
exist around twenty-five reviews published in the last few years dealing with cancer 
follow-up care, but they are all limited to clinical studies only, specific cancer 
populations or types of interventions (e.g. primary versus secondary care). A dated 
paper by Edelman [131] reviewed surveillance strategies and assessed follow-up costs 
for the most common malignancies based on the studies retrieved. A study by Hex [132] 
aimed at reviewing the cost-effectiveness of follow-up care in paediatric tumours and 
highlighted a trend towards risk-based personalized approaches for long-term childhood 
cancer survivors. The target population addressed by Hex was exactly complementary 
to that of the current study, as this search was focused on adult cancer patients only. 
Moreover, none of these reviews addressed the quality of the included studies. 
This review provides insights into the clinical and economic value of a variety of post-
treatment follow-up programs across many types of malignancies. Due to recent 
improvements in cancer therapies and survival rates, the number of patients requiring 
post-treatment services is rapidly increasing and posing a substantial burden on 
healthcare systems. The fifty-three studies included in the review represent the best 
economic evidence available around cancer follow-up. From study findings, a general 
tendency emerged towards less intensive options in terms of frequency of visits and/or 
length of program, risk-adapted follow-up according to age or tumour stage, and service 
delivery in primary care or through mobile-app technologies replacing traditional 
hospital-based investigations. In most studies, these simplified follow-up schemes were 
to be preferred to the more intensive ones according to their favourable cost-
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effectiveness profile. However, study results, even for the same type of follow-up, were 
contradictory and estimates varied considerably by study setting and cancer type. In 
some cases, indeed, the addition of sophisticated diagnostic techniques, such as PET-CT 
and hexaminolevulinate hydrochloride-guided blue-light flexible cystoscopy (HAL 
BLFC) were recommended as cost-effective options. Moreover, most studies reported 
the equivalence (or a non-significant difference) of health outcomes between traditional 
and novel options for post-treatment surveillance, with a cost saving when less intensive 
or non-hospital-based programs were implemented; indeed, none of them led to 
significant improvements in health outcomes such as the number of recurrences 
detected or overall patient’s survival.  
The average quality score (76%) of the studies retrieved was good, with most of them 
(n=31; 58%) performing very well in reporting economic evaluations. Among high-
quality studies, cost-utility analyses, Markov model- and UK/US-based studies were 
mainly identified; these studies, indeed, generally measure outcomes in terms of 
QALYs and cost/QALY is the ratio adopted by more recent studies to determine the 
cost-effectiveness of healthcare programs. Markov model is an appropriate instrument 
to conduct economic evaluations in chronic diseases where the occurrence of the events 
(e.g. cancer recurrence) is uncertain and these may happen more than once [133]. 
Compared to other types of modelling (e.g. discrete event simulation) equally valid for 
the purpose, the Markov model requires less clinical information but a validation of the 
underlying assumptions. Moreover, studies conducted in UK and US are more likely to 
adhere to recommendations from NICE or other HTA agencies. Finally, the average 
quality score (i.e. 81%) of the studies published since 2015 (n=14) is considerably 
higher than the mean score (i.e. 61%) across the articles dated between 2000 and 2005. 
Thus, it is reasonable to assume that more recent economic evaluations tend to better 
adhere to published recommendations in this field. 
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2.4.2 Critical issues 
A number of issues characterizing long-term cancer survivorship should be carefully 
evaluated by the health economics literature in this field. First, the setting (e.g. GP- 
versus hospital-based) where follow-up care is conducted can greatly affect patient’s 
quality of life and private costs (i.e. travel expenses and productivity losses), especially 
in peripheral areas with long distances to travel to hospitals. Secondly, little is known 
about potential damages (and related costs) of follow-up, in terms of patient’s 
dissatisfaction, long-term toxicity, and false positive results; thus, economic evaluations 
including also these cost categories are encouraged. Thirdly, the topic of heterogeneity 
in cancer patients affected by the same malignancy is still unexplored in the literature. 
Post-treatment surveillance programs, indeed, may yield different survival gains 
according to age, cancer stage and comorbidities; thus, economic evaluations should 
routinely report differences in cost-effectiveness results for relevant subgroups of 
patients. A further weakness observed in the reviewed articles is related to the choice of 
health outcomes; most studies, indeed, evaluate follow-up interventions in terms of 
intermediate outcomes (e.g. number of recurrences detected). However, the ‘value’ of 
an early diagnosis of cancer relapse is closely linked to the availability and effectiveness 
of secondary treatments able to extend survival. Future economic studies are 
encouraged to adopt longer timeframes in order to catch the full health effects and cost 
paths arising from different surveillance options and potential curative treatments 
administered in case of recurrence. A longer time horizon is also necessary to capture 
long-term side effects related to intensive radiological examinations. As medical 
advances have improved post-treatment prognosis, the health issues experienced by 
cancer survivors tend to be more episodic and to occur over a longer timeframe. Thus, 
model-based economic evaluations are increasingly required to extend clinical trial 
results over patient’s lifetime. 
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2.4.3 Strengths and limitations  
This systematic review presents a number of limitations. First, the databases searched 
were limited to the most common ones (i.e. PubMed, Medline, and EMBASE). This 
may result in selection bias that was reduced by searching the references of each 
selected article manually. Secondly, as in all searches of the published literature, there 
may be publication bias and unpublished studies could affect the review findings; 
however, this is particularly common in studies funded by private companies of which 
there are few in this review as it deals with non-pharmaceutical interventions. Thirdly, 
most of the included studies were conducted in the developed world, thus likely 
representing the most healthy and affluent group of cancer survivors [66]. For these 
reasons, the extension of these results to other settings needs to be done cautiously.  
Moreover, comparison of economic outcomes is complicated due to the high variability 
in time periods, currencies, and health systems involved. Although it is reasonable to 
assume that the relative price of some common diagnostic technologies (e.g. PET-CT 
scan) might be similar across many developed countries [74], other cost categories (e.g. 
nurse salaries, consultation fees) or reimbursement policies may differ a lot. Even in 
studies assessing standard health outcomes such as survival or QALYs, comparison is 
hard to perform due to a wide range of cancers addressed in the review and, even across 
studies related to the same malignancy, heterogeneous follow-up interventions and 
patient populations by age or cancer stage. Moreover, the concentration on economic 
evaluations as inclusion criterion may have excluded other important clinical studies in 
cancer follow-up research. 
A further limitation is the use of the CHEERS checklist as a measure of quality in 
economic evaluations. This checklist gives an indication of how much the published 
studies adhere to reporting criteria but does not state their relative importance. For 
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example, reporting discounting may be more relevant than funding source and a simple 
addition of the criteria met may result in a misleading assessment of quality. However, 
as the CHEERS checklist does not provide any weights to be applied to quality criteria, 
summing the number of items achieved with a qualitative discussion in text was 
assumed an appropriate methodology to differentiate the quality of studies.  
In general, the use of checklists to evaluate the quality of economic evaluation studies 
can be viewed as overly simplistic. For example, the standard checklists emphasize how 
well the study is reported rather than whether it can inform good policy decisions, since 
they evaluate the publication itself and not its implications for clinical practice. 
Moreover, not reporting an element in the article does not necessarily mean that the 
authors in the analysis have not addressed that aspect. In addition, most checklist 
criteria require that the reasons behind the choice of a given item (e.g. time horizon) are 
specified, but the authors often disregard this aspect and just indicate the parameter 
value; thus, the simple addition of the items reported by each study does not inform 
about the appropriateness of a method. Especially in model-based economic 
evaluations, different assumptions around the study parameters may significantly alter 
the cost-effectiveness results with important consequences for evidence-based medical 
and policy decisions. A well-reported study will not necessarily be fit for purpose but at 
least it may be easier to determine whether it is fit for purpose compared with a less 
well-reported study. 
In spite of these limitations and compared to previous guidelines (e.g. Drummond 
[134]), the CHEERS checklist appears more comprehensive and suitable for model-
based studies which are becoming increasingly important, partly due to the financial and 
logistic constraints on performing primary data collections (e.g. RCTs) but also because 
of the well-known limitations of trial-based evaluations for informing decision-making. 
The checklist, indeed, asks authors to specify more details about model assumptions and 
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analytic methods (i.e. skewed, missing, censored, and pooled data) that were not 
provided in older guidelines. Moreover, a greater emphasis is given to the need of 
characterizing heterogeneity in reporting study results, in line with the recent trend 
towards a more personalized medicine according to patient’s characteristics.  
2.5 Conclusions 
Health economic analyses are increasingly used to inform policy-makers about the 
efficient allocation of limited healthcare resources. Economic evaluations in cancer care 
have been mainly applied to drug therapies, while less evidence is available for other 
types of interventions. In recent years, a debate arose among oncologists around how to 
design post-treatment programs for cancer survivors. This chapter summarizes the 
current body of knowledge regarding economic evaluations in cancer follow-up and 
may help clinicians and policy-makers interpret health economic results according to 
study quality and update post-treatment surveillance schemes based on a sound 
scientific evidence.  
The quality of the studies retrieved from the literature is generally high. However, many 
of them report cost-effectiveness results as intermediate outcomes (e.g. cost per 
recurrences detected), or without combining costs and outcomes in a single measure 
(i.e. as cost-consequence analyses); these study characteristics pose an issue of 
comparability with economic evaluations in other disease areas and with commonly 
accepted thresholds, which are expressed as incremental cost per QALY gained. High-
quality studies in the review often use a modelling approach, confirming that model is 
increasingly an unavoidable instrument in health economic analyses to project the costs 
and the effects of a healthcare intervention beyond the usual limited length of clinical 
trial. Although judging the quality of scientific work is inevitably controversial, the 
CHEERS checklist appears suitably up-to-date and comprehensive to facilitate this task.  
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This review indicates that less intensive, nurse-led and primary-care based follow-up 
schemes are frequently clinically equivalent and economically justified in oncology. 
However, no studies reported any efficacy gains in favour of these simplified programs 
and results vary considerably across studies. HPV testing appears a cost-effective 
alternative to traditional cytological approach for cervical cancer patients. There is also 
evidence of increasing interest in delivering post-treatment services using technology 
(e.g. mobile apps), although not yet sufficient to state whether remote cancer follow-up 
may replace traditional face-to-face surveillance.  
Most of the reviewed literature focused on widely spread neoplasms such as breast, 
colorectal and cervical cancer. In the context of this thesis, the search identified the first 
economic evaluation study [112] comparing two follow-up programs in HNC. 
However, the study presents several weaknesses, including the use of patient-reported 
outcomes of limited clinical significance (e.g. patient’s satisfaction and loss to follow-
up), and a short time horizon (i.e. 6 months); thus, a model-based economic evaluation 
comparing follow-up strategies of different intensity over the patient’s lifetime is still 
lacking in HNC, and the rationale for a valuable contribution from this thesis is made 
evident. Overall, high-quality scientific evidence on the cost-effectiveness of 
surveillance, and especially for less common malignancies, continues to be urgently 
required. 
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3 A SYSTEMATIC LITERATURE REVIEW OF HEALTH 
STATE UTILITY VALUES IN HEAD AND NECK 
CANCER 
3.1 Introduction 
Cost-utility models are increasingly used to establish whether the cost of a new 
treatment is justified in terms of health gains. This approach usually adopts the QALY 
as a measure of health effectiveness. As already described in Chapter I, the QALY 
corresponds to the time spent in a series of quality-weighted health states, where the 
weights represent the desirability of living in that state [36] [135]. The basic idea is that 
individuals move through health states over time and that each health state has a 
preference weight attached to it [36], also known as a HSUV. Thus, the HSUV can be 
interpreted as the strength of preference for a given health state on a cardinal scale 
anchored at 0 (‘death’) and 1 (‘full health’), with some instruments also allowing for 
negative values representing states worse than death [136]. Therefore, QALYs are 
obtained by summing-up the products of the time spent in each health state and its 
corresponding preference-based value [137].  
HSUVs can be estimated in a variety of ways including direct methods, multi-attribute 
utility instruments (MAUIs), mapping functions and expert opinion. The most common 
ways of eliciting HSUVs directly are gambling with respect to a hypothetical treatment 
that may result in perfect health or death (standard gamble, SG) or trading-off part of 
future life for a shorter time in perfect health (time trade-off, TTO) [138]. A further, 
simpler option is to use a VAS, also known as rating scale, which provides an 
immediate valuation of the current (or a hypothetical) health state on a graduated scale, 
usually ranging between 0 and 100. This technique is generally considered to be 
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methodologically inferior to choice-tasks such as SG and TTO, which incorporate some 
extra information about the individual risk attitude [137]; VAS scores, indeed, are 
elicited in a choice-less context, and thus do not require respondents to make trade-offs 
within their utility function [139]. Moreover, rating scales are well-known to present 
measurement biases such as context bias, spacing-out bias, and end-aversion bias [137] 
[140]. Context bias occurs when several VAS questions are presented at the same time 
and the ratings for some tasks are affected by the context of the questionnaire, while 
spacing-out bias refers to respondents spacing out their scores to fill the entire range 
presented. The end-aversion bias occurs instead when respondents avoid using the 
extreme ends of the scale, thus compromising the integrity of the measurement [141]. 
Additionally, there is now consensus that HRQoL is a multi-dimensional concept, 
which includes domains related to physical, mental, emotional, and social functioning 
that are difficult to measure on a single scale [142]. 
Direct measurement of health utility through SG or TTO can be complicated and time-
consuming and lead to incomparable results across the studies due to arbitrary health 
state descriptions (also called ‘vignettes’) [143] [144]. Consequently, in recent years, 
HSUVs have been increasingly estimated indirectly using MAUIs. These tools are 
formed of a generic HRQoL questionnaire and an accompanying formula or set of 
weights (or “tariffs”) elicited from a sample of the general population for converting 
responses into HSUVs; thus, the utility measure can be considered as a preference-
based evaluation of a given health state described by the dimensions of the tool [145] 
[146]. NICE and the European Network for HTA (EUnetHTA) recommend the EQ-5D 
(https://euroqol.org) [147] [148]. Accordingly, the TTO with a 10-year time horizon is 
the most frequently used approach among the direct techniques, because of greater 
comparability with the method used to develop the EQ-5D scoring algorithm [149]. The 
other generic MAUIs mostly adopted in the literature [145] are the Health Utility Index 
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(HUI mark 2, HUI2 or mark 3, HUI3) [150], the Short Form-6-dimension (SF-6D) 
questionnaire derived from the 36-item Short Form Survey (SF-36) 
(www.sheffield.ac.uk), the 15D (www.15d-instrument.net), the Quality of Wellbeing 
(QWB) index [151] and the Assessment of Quality of Life (AQoL) instruments [152].  
In many situations, clinical studies neither administer preference-based MAUIs nor 
elicit HSUVs directly but collect instead disease-specific HRQoL data or other clinical 
measures that are not associated with a preference-based scoring system; thus, QALY 
calculation from these studies is not possible. Therefore, “mapping” or “cross-walking” 
has been developed to predict HSUVs from non-preference-based scores, provided that 
a statistical relationship can be established between the two instruments and, sometimes, 
allowing for the mediating effect of demographic and clinical characteristics [153]. In 
most cases, however, it is still preferable to collect HSUVs directly or use MAUIs, and 
mapping should be viewed as a “second-best” solution [154].  
This chapter focuses on HSUVs in HNC. Patients with HNC often undergo several 
rounds of treatment during which they experience acute toxicity and other side effects, 
such as loss of verbal abilities, difficulties in swallowing, and considerable pain [155]. 
This HRQoL impairment may continue long after treatment through persistent 
functional deficits, physical disfigurement, psychological distress, and recurrent disease. 
There is an extensive HRQoL literature in HNC, although mainly comprised of disease-
specific, non-preference-based data unsuitable for cost-utility comparisons. Due to the 
paucity of HSUVs for some health states in HNC, some previous cost-effectiveness 
analyses [156] [157] relied on values calculated for other cancers (such as breast or 
lung) to populate their models with utility parameters. A systematic review published in 
2006 [158] identified eight studies providing utility values in HNC elicited through 
VAS, TTO or SG. The current work extends the collection of utility values related to 
this medical condition by systematically reviewing the studies published to date. This 
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review considers for inclusion studies of any design in which utility values in HNC 
were: 
• directly elicited using standard techniques such as TTO or SG either in patient-
based studies or in the general population; 
• calculated indirectly from patient’s responses to generic MAUIs (e.g. EQ-5D) 
through a set of tool- and country-specific preference weights; 
• predicted from non-preference based HRQoL instruments using mapping 
algorithms. 
The PRISMA statement [72] is not entirely applicable to systematic reviews of HSUVs 
[159], since the standard Population, Intervention, Comparator, and Outcome (PICO) 
elements do not provide a useful framework for identifying utility values for health 
states that are not necessarily attached to a given intervention [160]. Thus, this study 
followed the recommendations provided by Papaioannou et al. [160]. The ultimate 
objective is to generate a database of HSUVs that might be useful to populate future 
cost-utility models of interventions in HNC, including the one comparing alternative 
follow-up programs based on the HETeCo trial, which, indeed, stops collecting EQ-5D 
after any patient’s relapse (Chapter V). In addition, the included studies were critically 
appraised by highlighting a few elements that should be considered when selecting 
utility parameters for modelling. 
3.2 Methods 
A systematic literature search was carried out of the PubMed, EMBASE and Cochrane 
Library databases for studies published from 2000 until the end of 2016 using a range of 
free-text terms in title/abstract (Figure 3.1). Since Medical Subject Headings (MeSH) 
terms provide little coverage of HSUVs [159] [160], a few relevant free-text terms were 
identified by referring to the published recommendations [160] and recent analogous 
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systematic reviews [159] [161] [162]. Tool- (e.g. EQ-5D) and method-specific (e.g. SG) 
terms were combined with vocabulary related to HNC including the most frequent 
cancer sites; in using free-text terms, it was considered that some instruments may be 
referred to or spelled in different ways. The VAS term was not explicitly included 
among the keywords, due to the above-mentioned limitations in using this tool for 
measuring utility. Other search strings were used to identify cost-effectiveness and cost-
utility studies using HSUVs to calculate QALYs. A direct search of utility weights in 
the Tufts Cost-Effectiveness Analysis (CEA) Registry [163] and the University 
Sheffield School of Health and Related Research Health Utilities Database was done 
(ScHARRHUD) [164]. An additional search was carried out of the Health Economics 
Research Centre (HERC) database [165] [166] to retrieve mapping studies deriving 
utility values from non-preference-based instruments in HNC. The relevant databases 
were selected based on previous recommendations [160] and systematic reviews on the 
topic [167]. Web searches of grey literature were not performed to avoid obtaining 
contents which are frequently subject to changes and cannot be identified in a 
systematic manner. 
All search results were extracted in an Excel spreadsheet and duplicates removed. Titles 
and abstracts were screened by two independent reviewers (i.e. the candidate and the 
supervisor) and records excluded if not meeting the inclusion criteria; full-text papers 
were retrieved in case of doubtful results. Articles estimating HNC utility values using 
established methods were included; studies using the VAS instrument were not 
considered for inclusion, unless alongside other valuation techniques. This choice is 
consistent with the suggestion that VAS should be used as an introductory task but not 
as a definitive method to elicit utility values alone [168]. The included studies had to be 
published as full-text with no time or language restrictions; conference abstracts, 
editorials, and reviews were not suitable for inclusion. Studies were excluded if they did 
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not report original utility values in HNC; however, the bibliography of studies referring 
to secondary sources for HSUVs was checked to avoid missing any relevant 
publications. The reviewers resolved any disagreements by discussion until consensus 
was reached.  
Figure 3.1 Free-text terms for electronic database searching. 
 
 
 
 
 
 
 
 
 
The characteristics of the included studies were extracted by the candidate using a form 
developed following previous studies [159] [160] [161], and subsequently crosschecked 
by the supervisor. Information collected included: study country, study design, sample 
size, valuation technique, administration method, cancer subsite addressed, and clinical 
and demographic characteristics of respondents. For each HSUV, the number of 
respondents, the point estimate (i.e. mean or median) and its measure of variance (e.g. 
standard deviation) were recorded; the same information was collected for each study 
subgroup (or time point) whenever applicable.  
1. head neck 
2. oropharyn* 
3. hypopharyn* 
4. laryn* 
5. oral cavity 
6. cancer or carcinoma  
7. (1 or 2 or 3 or 4 or 5) and 6 
8. health utilit* 
9. EQ 5D or EQ5D or EuroQol or Euro Qol 
10. SF 6D or SF6D or short form 6D 
11. 15D  
12. QWB  
13. AQoL or assessment quality life 
14. HUI or health utility index 
15. standard gamble 
16. time trade off or time tradeoff   
17. cost utility 
18. cost effectiveness 
19. economic evaluation 
20. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 
21. 7 and 20 
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Although there are no agreed reporting standards for HSUVs studies, the 
methodological quality of each included study was evaluated through a set of generic 
criteria as reported by the guidelines from Papaioannou et al [160]. Thereafter, one 
point was awarded to each of the following criteria: (1) sample size ≥100; (2) 
description of respondent selection and recruitment; (3) description of 
inclusion/exclusion criteria; (4) response rate ≥60% [169]; (5) reporting of the amount 
and reasons of loss to follow-up (only for longitudinal studies); (6) reporting of missing 
data pattern and methods to deal with it; (7) appropriateness of measure (based on the 
authors’ judgment). Lastly, the scores were summed for each article to yield an overall 
quality score, ranging from 0 to 7 where higher scores indicated higher quality [170]. 
Any other problems arising from the studies (criterion 8) were narratively discussed. 
Additionally, ISPOR recently published a set of recommendations for mapping studies 
[153] that were used to evaluate the quality of mapping studies retrieved by the 
systematic search. 
3.3 Results 
3.3.1 Study selection 
The PRISMA diagram [72] for this literature search is presented in Figure 3.2. In total, 
the search strategy identified 1048 articles: 1046 were retrieved by searching the online 
databases (PubMed; EMBASE; The Cochrane Library; CEA Registry; HERC 
database), and two by manually searching the bibliography of model-based economic 
evaluations retrieved from the online search. No articles were obtained from the 
ScHARRHUD database. After removing 743 duplicates, 305 records were scanned for 
title/abstract and 221 were excluded in this first phase for a variety of reasons reported 
in the chart. Subsequently, 84 full-text articles were retrieved and a further 56 records 
87 
 
were excluded for not complying with the inclusion/exclusion criteria. Accordingly, 28 
studies were definitively included in the review. 
 
Figure 3.2 PRISMA flow chart. 
 
 
Figure 3.2 PRISMA flow chart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database 
searching (n = 1046) 
PubMed (n=454); EMBASE (n=432); 
The Cochrane Library (n=121); CEA 
Registry (n=38); HERC database (n=1) 
 
S
c
r
e
e
n
in
g
 
In
c
lu
d
e
d
 
E
li
g
ib
il
it
y
 
Id
e
n
ti
fi
c
a
ti
o
n
 Additional records identified 
through additional sources (n = 2) 
 
reference lists of economic evaluation 
studies (n=2) 
 
Records after duplicates removed 
(n = 305) 
Records screened by 
title/abstract 
(n = 305) 
Records excluded, with 
reasons (n = 221) 
clinical studies (n=68); 
HRQoL studies not 
eliciting utility values 
(n=19); economic 
evaluation not reporting 
QALYs (n=29); cost 
analyses (n=11); study 
protocols (n=3); other 
reasons (n=91)  
Full-text articles assessed 
for eligibility 
(n = 84) 
Full-text articles 
excluded, with reasons 
(n = 56) 
HRQoL studies not 
eliciting HSUVs (n=11); 
economic evaluation not 
reporting QALYs or 
original HSUVs (n=36); 
studies reporting 
aggregate HSUVs for 
head and neck and other 
cancers (n=2); study 
protocols (n=2); 
conference abstracts 
(n=3); duplicate data 
(n=2) 
Studies included in 
qualitative synthesis 
(n = 28) 
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3.3.2 Study characteristics 
The 28 journal articles included in the review are categorized into three groups: studies 
using direct elicitation methods (n=10), studies administering MAUIs (n=13) and 
studies deriving HSUVs using mapping (n=3); two studies [171] [172] adopted both 
direct methods and MAUIs. The characteristics of the 25 studies using direct and 
indirect techniques (i.e. MAUIs) are listed in Table 3.1, while the three mapping studies 
are separately described in Table 3.2.  
Studies using direct or indirect methods 
Among the studies using direct elicitation techniques, SG alone was adopted in two 
cases [155] [173] and TTO alone in five [174] [175] [176] [177] [178]. In four studies 
[172] [179] [180] [181], more than one direct methodology (i.e. SG, TTO, VAS) was 
adopted to derive utility values. The study by Noel et al. [172] compared these direct 
techniques with MAUIs (i.e. EQ-5D, HUI3), while a further study [171] used both TTO 
and EQ-5D instruments.  
In studies administering MAUIs, EQ-5D was the most common (n=11); five of these 
studies [171] [172] [182] [183] [184] did not report which scoring algorithm was used, 
two studies [185] [186] explicitly adopted the UK algorithm, another two [187] [188] 
adopted the US one, one study [189] used the Dutch tariff and another one [190] the 
Belgian one. Moreover, nine of the studies using EQ-5D [171] [182] [183] [185] [186] 
[187] [188] [189] [190] explicitly referred to the 3-level version (EQ-5D-3L) and one 
[172] to the newer 5-level one (EQ-5D-5L); one study [184] did not specify the 
instrument’s version adopted. Additional generic, preference-based HRQoL tools 
retrieved by this search were 15D (n=2), HUI3 (n=2) and SF-6D (n=1); no studies used 
the QWB scale or the AQoL-8D utility instrument.  
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Table 3.1 Studies estimating HSUVs in HNC using direct or indirect methods (n=25). 
Author 
(year) 
Country Study design Cancer 
subsite(s) 
Valuation 
method  
Mode of 
administration 
Sample 
size 
Response rate Participants (Mean) age; % 
male 
Aro (2016) 
[191] 
Finland Longitudinal All 15D Self-completion (by 
post) 
214 72% Patients 63.0; 66% 
Conway 
(2012) [173] 
Australia Cross-
sectional 
Oropharynx SG 1-hour group 
session 
99 84% Healthy subjects 43.0; 54% 
de Almeida 
(2014) [179] 
US Cross-
sectional 
Oropharynx SG; VAS Face-to-face 
interview 
59  NA Healthy subjects 
(n=50) and 
experts (n=9) 
Healthy subjects: 
34.8; 42%. 
Experts: 45.3; 
89%  
del Barco 
Morillo 
(2016) [182] 
Spain Longitudinal All EQ-5D-3L  NA 40 NA Patients 61 (Median); 
87% 
Govers 
(2016) [189] 
Netherlands Cross-
sectional 
Oral cavity EQ-5D-3L  Self-completion (by 
post) 
181 62% Patients 64.4; ≥50% 
Hamilton 
(2016) [174] 
UK Cross-
sectional 
Larynx TTO Face-to-face 
interview 
114 NA Healthy subjects 
(n=51) and 
COPD patients 
(n=63) 
67.3; 49% 
Higgins 
(2011) [192] 
Canada Cross-
sectional 
Larynx HUI3 Self-completion 30 NA Patients NA 
Hollenbeak 
(2001) [175] 
US Cross-
sectional 
All TTO NA 8 80% Patients NA 
Jalukar 
(1998) [176] 
US Cross-
sectional 
All TTO Self-completion (on 
site for patients; by 
email for healthcare 
professionals) 
185 Patients: 78%; 
healthcare 
professionals: 
42%; students: 
NA  
Patients (n=49); 
healthcare 
professionals 
(n=50); students 
(n=86) 
Patients: 57.2; 
71%.  
Healthcare 
professionals: 
40.1; 40%. 
Students: NA  
Kent (2015) 
[193] 
US Cross-
sectional 
Oral cavity and 
pharynx 
SF-6D/VR-6D Mail or telephone 580 62% Patients 67.7; 60% 
Llewellyn-
Thomas 
(1993) [180] 
Canada Longitudinal Larynx TTO/VAS Interview 66 NA Patients NA; 86% 
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Table 3.1 (cont.) Studies estimating HSUVs in HNC using direct or indirect methods (n=25). 
Author 
(year) 
Country Study design Cancer 
subsite(s) 
Valuation 
method  
Mode of 
administration 
Sample 
size 
Response rate Participants (Mean) age; % 
male 
Loimu 
(2015) [194] 
Finland Longitudinal Pharynx, 
larynx, nasal 
cavity 
15D Self-completion: on 
site (first 
assessment); by 
post (afterwards) 
64 76% Patients 61.6; 75% 
Marcellusi 
(2015) [171] 
Italy Cross-
sectional 
All TTO; EQ-5D-3L  Computer-guided 79 NA Patients 65.0; 78.5% 
Noel (2015) 
[172] 
Canada Cross-
sectional 
All SG; TTO; VAS; 
EQ-5D-5L; 
HUI3 
Face-to-face 
interview 
100 79% Patients 61.0; 75% 
Ouattassi 
(2016) [183] 
Morocco Cross-
sectional 
All EQ-5D-3L Self-completion 120 NA Patients 57.0; 60% 
Parrilla 
(2015) [184] 
Italy Longitudinal Larynx EQ-5D  Self-completion 30 NA Patients 68.7; 93% 
Pickard 
(2016) [187] 
US Cross-
sectional 
All EQ-5D-3L Self-completion 50 NA Patients 56.0; NA 
Pottel (2015) 
[190] 
Belgium Longitudinal All EQ-5D-3L  Self-completion or 
interview on site 
(first assessment); 
by post (afterwards) 
81 81% Patients 72.0; 86% 
Ramaekers 
(2011) [186] 
Netherlands Cross-
sectional 
All EQ-5D-3L  Self-completion 396 93% Patients 63.2; 70% 
Ringash 
(2000) [177] 
Canada Cross-
sectional 
Larynx TTO Face-to-face 
interview 
120 49% Patients 65; 83% 
Rogers 
(2006) [185] 
UK Cross-
sectional 
Oral cavity and 
oropharynx 
EQ-5D-3L Self-completion (by 
post) 
224 64% Patients 65; 58% 
Szabo (2012) 
[155] 
Canada Cross-
sectional 
Larynx, lip, oral 
cavity, 
oropharynx 
SG Interview using 
script and prop 
101 95% Healthy subjects 47; 48% 
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Table 3.1 (cont.) Studies estimating HSUVs in HNC using direct or indirect methods (n=25). 
Author 
(year) 
Country Study design Cancer 
subsite(s) 
Valuation 
method  
Mode of 
administration 
Sample 
size 
Response rate Participants (Mean) age; % 
male 
Truong 
(2016) [188] 
US RCT Oropharynx, 
hypopharynx, 
larynx 
EQ-5D-3L Self-completion 818 87% Patients Arm CIS: 56.1; 
86%. Arm 
CET/CIS: 57.3; 
89% 
van der Donk 
(1995) [181] 
Netherlands Cross-
sectional 
Larynx TTO/SG/VAS Face-to-face 
interview 
39 NA Laryngeal cancer 
patients (n=10), 
FOM cancer 
patients (n=10), 
experts (n=9), 
healthy subjects 
(n=10) 
Laryngeal cancer 
patients: 62; NA. 
FOM cancer 
patients: 56; NA. 
Experts: 43; NA. 
Healthy subjects: 
36; NA. 
Weiss (1994) 
[178] 
US Cross-
sectional 
Pharynx, larynx TTO NA 3 NA Clinical experts NA 
CIS: radiation-cisplatin without cetuximab; CET/CIS: radiation-cisplatin with cetuximab; COPD: chronic obstructive pulmonary disease; EQ-5D-3L: EuroQol 5-dimension 3-Level; EQ-5D-5L: 
EuroQol 5-dimension 5-Level; FOM: floor-of-the-mouth; HNC: head and neck cancer; HSUV: health state utility value; HUI3: Health Utility Index Mark 3; NA: not available; SF-6D: Short Form-6-
dimension; SG: standard gamble; TTO: time trade off; VAS: visual analogue scale; VR-6D: Veterans RAND-6-dimension. 
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The 25 articles reported on HNC utility-related studies conducted in several European 
(Belgium, n=1; Finland, n=2; Italy, n=2; Netherlands, n=3 Spain; n=1 United Kingdom, 
n=2) and non-European countries (Australia, n=1; Canada, n=5 Morocco, n=1; United 
States, n=7). The great majority of the HSUVs came from cross-sectional surveys 
(n=18); the remaining articles (n=7) adopted a longitudinal design, including five 
prospective cohort studies [180] [184] [190] [191] [194] and two clinical trials [182] 
[188].  
Sample sizes varied widely from 3 [178] to 818 [188], with a mean of 152 respondents 
per study. The response rate was between 49% [177] and 95% [155]. In most of the 
studies (n=18), the participants were HNC patients at various stages of disease and 
treatment pathway; in two studies [155] [173] healthy individuals from the general 
population were surveyed through the SG techniques, while in one case [178] the utility 
assessment was based on a consultation with a panel of experienced physicians. The 
remaining four studies [174] [176] [179] [181] retrieved utility measures from multiple 
subjects (i.e. healthy people, clinical experts, HNC patients and patients with other 
medical conditions) and reported HSUVs from each group separately.  
In studies recruiting HNC patients, most were male, and the mean age was always 
above 55. Conversely, responders were generally younger and with a higher proportion 
of females in studies surveying individuals from the general population or clinical 
experts. The range of cancer subsites addressed by each study was quite broad: ten 
studies [171] [172] [175] [176] [182] [183] [186] [187] [190] [191] generally 
investigated utility in HNC without specifying any cancer site, six [174] [177] [180] 
[181] [184] [192] were related to laryngeal cancer, two [173] [179] addressed cancer in 
the oropharynx, one [189] recruited patients affected by cancer in the oral cavity and the 
remaining six [155] [178] [185] [188] [194] [193] focused on selected multiple sites 
(e.g. oropharynx, hypopharynx, and larynx). 
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The most common way (n=12 [176] [183] [184] [185] [186] [187] [188] [189] [190] 
[191] [192] [194]) of collecting utility data was by self-completion of a written survey 
(administered on site or by post/e-mail), followed by face-to-face interviews (n=6 [172] 
[174] [177] [179] [180] [181]); four studies adopted different administration options 
including group session (n=1 [173], telephone or mail interview (n=1 [193]), interview 
using a script/prop (n=1 [155]), and computer-guided data collection (n=1 [171]). The 
administration method was not specified in three cases [175] [178] [182]. When HSUVs 
were obtained from the patients, the survey (or the interview) was usually scheduled 
during a clinical appointment or a hospital admission; in longitudinal studies [190] 
[194], surveys after the first were frequently delivered by post to the patient’s address.  
Mapping studies 
The three studies deriving HSUVs in HNC using a mapping technique are described in 
Table 3.2. Among them, the first one [195] developed an original mapping algorithm 
using responses from HNC patients and was retrieved from the HERC database. 
Ordinary Least Square (OLS) regression was applied to establish a statistical 
relationship between the University of Washington Quality of Life questionnaire 
version 4 (UW QOL v4) and the EQ-5D-3L using a dataset of 89 patients treated for 
HNC. Thereafter, the responses of an additional 48 patients enrolled in the study were 
used as a validation database. The second study [196] was a cost-utility analysis 
reporting a mapping formula without any details on the technique adopted; the rationale 
for this mapping was based on a previous article showing a comparable responsiveness 
of EQ-5D and EORTC QLQ-C30 in patients with liver metastases [197]; QLQ-C30 
data were retrieved from a randomized trial in HNC [198]. The third study [199] was a 
model-based economic evaluation reporting HSUVs for several HNC-related health 
states by applying an existing OLS model developed from data collected on various 
patients [200] to HRQoL data retrieved from a study in nasopharyngeal cancer [201].
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Table 3.2 Mapping studies predicting HSUVs in HNC (n=3). 
Author 
(year) 
Country Mapping 
technique 
From 
(tool 1) 
To  
(tool 2) 
Sample’s 
description 
(algorithm) 
Sample size 
(algorithm) 
Study ref. 
(algorithm) 
Sample’s 
description  
(tool 1) 
Sample 
size  
(tool 1) 
Study ref. 
(tool 1) 
Chan 
(2014) 
[195] 
Canada OLS UW QOL 
v4 
EQ-5D-
3L 
Patients 
treated for 
HNC 
89 (estimation); 
48 (validation) 
    
Parthan 
(2009) 
[196] 
UK NS EORTC 
QLQ-C30 
EQ-5D-
3L 
NS NS  Patients with locally 
advanced inoperable 
HNC 
358 Vermorken 
(2007) [198] 
Yong 
(2012) 
[199] 
Canada Application 
of a 
published 
algorithm 
using OLS 
SF-36 HUI2 Various 
patients 
6921 Nichol 
(2001) [200] 
Patients with early 
stage nasopharyngeal 
cancer 
51 Pow (2006) 
[201] 
EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; EQ-5D-3L: EuroQol 5-dimension 3-Level; HNC: head and neck cancer; HSUV: 
health state utility value; HUI3: Health Utility Index Mark 3; NS: not specified; OLS: ordinary least square regression; SF-36: 36-Item Short Form Health Survey; UW QOL v4: University of 
Washington Quality of Life questionnaire, version 4. 
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3.3.3 Study quality assessment 
The quality assessment of the 25 studies using direct or indirect methods was based 
upon eight criteria, of which seven were given a score (Table 3.3). In all studies, the 
instrument adopted to estimate HSUVs was considered appropriate in relation with the 
participants enrolled. Additionally, most studies (84%) reported a description of the 
participants recruitment process, whilst only 56% of them clearly stated the 
inclusion/exclusion criteria. Information on missing data and techniques to deal with 
them were reported by a limited number of studies (24%). In half of the studies, the 
sample size was rather small (<100) and response rate was either low (<60%) or not 
reported. In reviewing these studies, it was evident that a few additional issues (criterion 
8 [160]) should be considered when selecting sources to populate health economic 
models with utility parameters. First, some of the included studies are quite dated 
(published before 2000), thus describing health states that might not be realistic 
nowadays because of emerging treatment modalities, improvements in treatment-related 
morbidity and organ preservation techniques. Second, there might be potential sources 
of bias in reporting HRQoL results in clinical studies investigating one or more 
interventions, although the number of comparative trials retrieved by this search was 
very limited. Third, in some studies [171] [183] [193] [195], and especially those 
analysing HRQoL in multiple cancers including head and neck [171] [193], patient’s 
characteristics (e.g. cancer stage/site, treatment phase) are poorly reported, thus making 
it difficult to match the study’s HSUVs with the health states described in a cost-
effectiveness model. Lastly, the great majority of studies are cross-sectional surveys, 
representing the quickest and cheapest method for gathering HRQoL data; however, 
longitudinal data collections are often more valuable since they facilitate capture of 
changes in utility values as cancer progresses through different phases. 
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With reference to mapping studies, only one [195] reported details on the developed 
algorithm, thus preventing a comparative evaluation of studies. This study presented a 
four-variable model to predict EQ-5D-3L utilities using OLS regression; coefficient 
values and error terms were clearly reported, and box-plot distributions of actual and 
predicted utilities provided. However, the authors did not justify the model choice in 
relation to the observed EQ-5D distribution, nor any additional tests or judgments made. 
The goodness-of-fit was presented as R2, mean absolute error (MAE) and root mean 
squared error (RMSE), which are considered of limited value in the mapping field. No 
demographic or clinical variables were included as covariates, which was recognized as 
a study limitation by the same authors. Moreover, when the sample size is small (as it 
was in this study), the most recent guidelines do not recommend splitting it for 
empirical validation [153]. 
3.3.4 Overview of HSUVs 
A total of 346 original HSUVs were retrieved from 27 studies included in the review 
(Table A3.1), since one study [176] reported results only graphically in the article. The 
studies [172] [179] [181] providing the highest number of HSUVs (i.e. over 40) either 
adopted multiple techniques or interviewed several groups of respondents that yielded 
different values for each health state. In other cases [180] [184] [188] [190] [191] [194] 
[199], different HSUVs have been collected by the same participants over the study 
time points. HSUVs were reported as means in the great majority of studies (n=25), of 
which four [155] [173] [186] [188] also reported the median; the remaining two studies 
[182] [190] calculated a median value only. Among the measures of variance, standard 
deviation was the most frequently adopted (n=12), followed by the min-max range 
(n=7), and the interquartile range (n=5); several studies reported more than one measure 
type. In some cases [174] [178] [181] [192] [199], no measures of variability were 
reported, thus limiting the usefulness of the health state utility data.                                  
97 
 
Table 3.3 Quality assessment criteria in studies using direct or indirect methods (n=25). 
Criteria* [191] [173] [179] [182] [189] [174] [192] [175] [176] [193] [180] [194] [171] [172] [183] [184] [187] [190] [186] [177] [185] [155] [188] [181] [178] Tot 
Sample size 1 0 0 0 1 1 0 0 1 1 0 0 0 1 1 0 0 0 1 1 1 1 1 0 0 12 
Selection and 
recruitment 
1 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 0 21 
Inclusion/ 
exclusion 
criteria 
0 1 1 1 0 1 0 0 1 0 1 0 1 1 0 1 0 1 1 1 0 1 0 1 0 14 
Response  
rate** 
1 1 0 0 1 0 0 1 0 1 0 1 0 1 0 0 0 1 1 0 1 1 1 0 0 12 
Loss to  
follow-up*** 
1 C C 0 C C C C C C 0 1 C C C 1 C 1 C C C C 1 C C 5 
Missing data 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 1 1 0 0 0 1 1 0 6 
Appropriateness 
of measure 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 25 
Total score 5/7 4/6 3/6 3/7 4/6 4/6 1/6 2/6 4/6 5/6 3/7 5/7 3/6 5/6 3/6 4/7 2/6 6/7 6/6 4/6 4/6 5/6 5/7 4/6 1/6  
*The criteria come from Papaioannou et al. 2013 [160] ** Response rate is set equal to 0 if <60% or not reported in the study; ***C: cross-sectional study (not applicable criterion). 
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3.4 Discussion 
This study reviews systematically published studies reporting HSUVs in HNC. 
Compared to a previous review [158], many more studies have been identified, most of 
which use the EQ-5D and were published from 2011 onwards. Overall, this review 
shows that HNC patients suffer from substantial HRQoL impairment over the different 
disease phases. However, there is a lack of research into the HRQoL in the recurrent 
and/or metastatic health states, with only one study [182] reporting a median EQ-5D 
utility value (i.e. 0.7) from the patients, which is less useful for the purposes of 
economic evaluation that focuses on mean costs and effects. Another study [179] elicits 
values for a range of recurrent disease states from healthy subjects and clinical experts 
using SG and VAS and obtains extremely heterogeneous results across the types of 
participants and methods. The same paucity of HSUVs was observed for treatment-
related complications, which are addressed by three studies [155] [179] [180] only, 
possibly because of the infrequency of some of these events that restricts the data from 
patients in that health state. 
Differences in utilities were found across studies even in the pre-treatment state. The 
choice of baseline utility is particularly relevant because it affects the incremental gain 
achievable by different therapeutic options [147], thus potentially biasing the estimated 
cost-effectiveness. The two Finnish studies [191] [194] using the 15D yielded higher 
utility values in patients shortly after diagnosis than those using the EQ-5D [188] [189]. 
This phenomenon has previously been observed in studies addressing other medical 
conditions [167] [202] [203]. There are many possible explanations for these 
discrepancies: different number of dimensions; the EQ-5D has generally been valued 
using TTO rather than VAS [204]; the preference weights have come from different 
populations (a Finnish value set is usually adopted for 15D) [202]; the EQ-5D, unlike 
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the 15D, can take negative values [204] [205]. The participants’ characteristics might 
have also affected study results. For example, a study [190] addressing HRQoL in 
patients aged ≥65 years with HNC consistently provided lower HSUVs than other 
studies in either the pre-treatment, treatment, and follow-up phases, probably because of 
comorbidities and functional impairments usually affecting elderly people 
independently from cancer. Moreover, the use of different scoring algorithms may have 
contributed to variation in HSUVs in studies administering the EQ-5D. 
Heterogeneity in utility values was particularly evident in the studies applying more 
than one technique to evaluate the same health state. Among them, in a study reporting 
HSUVs for different treatments, treatment-related complications, and 
remission/recurrence states in oropharyngeal cancer [179], the values obtained using a 
VAS scale were consistently lower that for the SG. In the study by Marcellusi et al. 
[171], patients in follow-up after treatment for HNC reported lower utility values when 
performing the TTO task than when responding to the EQ-5D questionnaire. Another 
study [172] compared five different (direct and indirect) methods to retrieve HSUVs 
from patients experiencing a similar health state (i.e. three months after completion of 
treatments and no evidence of recurrent disease). Unlike Marcellusi et al. [171], the 
method yielding the highest utility value in the overall sample (n=100) was TTO (0.94), 
followed by SG (0.91), EQ-5D (0.82), VAS (0.76) and HUI3 (0.75). That VAS scores 
are consistently lower than SG scores is well-known in the literature; in 2001, Torrance 
et al [168], after reviewing several studies, concluded that the relationship between the 
two instruments can be represented by a concave curve passing through 0 and 1. 
Moreover, the indirect methods involving MAUIs have been shown to yield 
systematically lower utility values than the direct ones in a wide range of diseases [206] 
for a variety of reasons. First, in MAUIs participants are not asked to consider their 
health status relative to death and thus, there is no disincentive in reporting more severe 
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health problems [207]. Second, respondents are forced to describe their complex 
medical conditions through a limited number of attributes, thus ignoring any positive 
feelings that would boost utility values. Third, it is likely that the general population 
used to obtain tariffs for MAUIs make a different trade-off between a given health state 
and death because they tend to be younger and healthier. Finally, the vignettes described 
in direct valuation tasks are usually more detailed than the MAUI health states [206]. In 
studies comparing alternative MAUIs, EQ-5D has been shown to provide higher 
utilities values compared to HUI2 and HUI3, which in turn yield higher values than SF-
6D. As for the differences between EQ-5D and 15D, potential explanations are likely to 
be found in descriptive systems, preference measurement, source of community 
preferences, and scoring methods [208]. 
In addition, studies can be classified by the type of responders who valued the health 
states, either patients or healthy subjects. In the literature, some argue that patients are 
best placed to value the relevant health states, while others advocate valuation by 
healthy people who will not directly benefit from a new treatment but, in tax-based 
systems, will bear its cost. The latter claim that this will provide an unbiased estimate of 
the hypothetical health states [140] [209] and more consistency across appraisal of very 
different interventions. The review by Komatsuzaki et al. [158] showed that patients 
usually reported lower utilities than physicians and healthy people for health states 
associated to HNC. In the current review, only a few studies recruited participants from 
the general population, thus limiting the number of utilities comparisons across different 
types of responders. One study [181] confirms the conclusions reached by the previous 
review [158], whilst others [176] [179] found healthy subjects consistently providing 
lower utility estimates compared to patients and healthcare professionals.  
This study facilitates the identification of HSUVs for use in future HNC economic 
evaluations, including the one presented in this thesis (Chapter V). The number of 
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retrieved studies was quite large, with almost 350 distinct HSUVs collected from them. 
Most of the utility values were collected during the treatment phase or shortly after the 
completion of treatment, whilst limited evidence is available for the health-related 
utility assessment in HNC recurrent and end-of-life states. Due to the variety of health 
state definitions and valuation techniques across the studies, it was not possible to 
perform a quantitative synthesis of the results [136]. Moreover, unlike cost-
effectiveness studies where structured guidelines exist to support authors and reviewers 
in assessing their quality [73], recommendations for valuation studies specifically aimed 
at measuring HSUVs are more fragmented or method-specific [144]. In this review, the 
assessment of study quality was based on a set of generic recommendations elaborated 
by a previous study [160] and arbitrarily modified to allow a quantitative scoring of the 
studies adopting direct and indirect techniques to estimate HSUVs; for mapping studies, 
the analysis relied instead on recent ISPOR guidelines [153]. 
Although there is no universally accepted theoretical basis for choosing direct or 
indirect methods [206], the use of the EQ-5D is favoured by several agencies including 
NICE, the Canadian Agency for Drugs and Technologies in Health and the French 
National Authority for Health [136]. In a recent position statement [210], NICE 
recommends the use of EQ-5D-3L for base-case analyses, or mapping EQ-5D-5L 
responses onto the 3L valuation set, to derive HSUVs, since further research is needed 
to explore the impact of adopting the 5L valuation set on technology appraisal. In 
model-based cost-effectiveness studies, where there is a choice of HSUVs, those using 
the value set of the jurisdiction for which a decision is being made are usually preferred. 
Moreover, HSUVs should be collected from studies enrolling patients with 
demographic and clinical characteristics that mostly resemble those of potential 
recipients of the intervention under investigation in the model. Until now, studies 
relying on direct techniques represent the only available source to retrieve HSUVs for 
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recurrent disease, palliative states, or treatment-related complications in HNC. Although 
considered as qualitatively inferior to MAUIs [136], these methods can provide values 
for cost-effectiveness analyses where the ‘vignettes’ presented in the choice task fit with 
the health states addressed in the model. Finally, in the absence of preference-based 
data, mapping from disease-specific instruments to generic MAUIs may represent a 
valuable alternative [209]; however, the only algorithm published to date in HNC [195] 
does not map from one of the HRQoL tools most frequently adopted in cancer studies, 
such as the EORTC QLQ-C30 [211] and the FACT-G [212]. Greater availability of 
mapping functions would facilitate the comparison of treatments using HRQoL data 
from many randomized controlled trials that only collected disease-specific health status 
information. Overall, the use of different techniques for utility elicitation might have 
substantial implications in cost-utility analyses; for example, it has been shown [206] 
that MAUIs, compared to direct valuation, tend to favour non-lifesaving treatments over 
interventions preventing or delaying death. Thus, regulatory bodies should avoid a 
mixture of methods in their decision processes to avoid a biased allocation of healthcare 
resources. Moreover, health economic modelers are always recommended to 
extensively test the uncertainty around the utility parameters in sensitivity analyses 
[206]. 
3.5 Conclusions 
This study improves understanding of preference-based HRQoL measurement in HNC 
by systematically reviewing and critically evaluating studies that estimated HSUVs in 
this cancer setting. Utility values are an essential parameter but also a major source of 
uncertainty in model-based economic evaluations, where it is common to select them 
from a single study based on clinical considerations [136] [162]. Further studies on the 
health-related utility assessment from HNC patients using MAUIs in recurrent and 
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terminal states are encouraged; this is a major issue in models evaluating follow-up 
programs, which inevitably includes such severe health states. Additional research on 
mapping algorithms to convert disease-specific HRQoL results onto preference-based 
HSUVs would be of value in this cancer population; this thesis, indeed, provides the 
first set of algorithms converting EORTC QLQ-C30/-H&N35 scores into EQ-5D utility 
values using HNC data (Chapter IV). Overall, the methods used to identify utility values 
within a growing body of HRQoL literature should be increasingly systematic and 
justified in future studies. 
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4 MAPPING THE CANCER-SPECIFIC EORTC QLQ-C30 
AND QLQ-H&N35 TO THE GENERIC EQ-5D-5L IN HEAD 
AND NECK CANCER 
4.1 Introduction 
Overall survival and progression free-survival are commonly accepted primary 
endpoints in cancer studies; however, due to the aggressiveness of treatments, HRQoL 
is often measured as well through a variety of tools [213]. As extensively discussed in 
Chapter III, cost-utility analyses are increasingly required to demonstrate the clinical 
and economic value of expensive cancer therapies. The primary outcome of these 
analyses is the QALY that, for its calculation, requires the assessment of HSUVs, 
defined as the preference weights associated to each health state experienced by the 
patient over time. Some generic HRQoL instruments, also known as MAUIs, such as 
the EQ-5D questionnaire, provide utility values for the health states described by the 
tool’s dimensions and levels based on the preferences elicited from the general 
population. However, these tools are not routinely included in clinical studies, because 
clinicians tend to prefer disease-specific questionnaires, which are more sensitive to 
changes in symptomatology and cover a wider range of health issues related to a 
condition [62] [214]. Among them, the EORTC QLQ-C30 (QLQ-C30 thereafter) is the 
most commonly used HRQoL tool in cancer [214] and has been widely applied in 
several oncological studies across Europe [215]. In their original form, QLQ-C30 scores 
cannot be used directly in economic evaluation studies, as they are not measures of 
utility elicited from the general population [216]. EORTC-8D was recently developed 
using the QLQ-C30 for use as a cancer-specific preference-based measure [64]. 
However, HSUVs generated from generic MAUIs (and, among them, preferably the 
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EQ-5D) are usually recommended for comparability across different therapeutic areas 
[217].  
Mapping (or cross walking) is a useful tool to calculate patient-level HSUVs in studies 
that do not adopt any generic preference-based MAUIs [218]. The mapping’s task is to 
establish a statistical relationship between a ‘source’ measure and, usually, a generic 
‘target’ one. In the absence of generic preference-based data, NICE endorses mapping 
from other HRQoL measures collected in the relevant trials to the EQ-5D. Over the last 
few years, several mapping functions for deriving EQ-5D utilities from QLQ-C30 
scores have been published for a variety of cancers. However, the existing studies do 
not cover the full spectrum of malignancies and it is not clear whether any function 
might reasonably be extended to other types of cancers [219]. Moreover, most 
algorithms mapped to the 3-level version of EQ-5D (EQ-5D-3L) [165], which is 
beginning to be replaced by the 5-level one (EQ-5D-5L). Finally, linear regression is the 
most widely applied technique for mapping, although it has been shown to be 
systematically biased in modelling EQ-5D data since it poorly fits with their typical 
distribution characteristics (i.e. boundedness, skewness, multimodality) [216] [220]. 
This thesis is focussed on HNC, which is a major public health concern in the 
developed world. As reported in Chapter III, treatments for HNC are usually aggressive 
and significantly affect patient’s HRQoL through functional impairments, physical 
disfigurement, and psychological distress. Surgical procedures often cause facial 
alterations or change an individual’s appearance, with subsequent worsening in social 
interaction and eating. Some of these consequences (such as pain) may improve over 
time, whilst others (e.g. dysphagia, speaking/chewing difficulties, and dryness of 
mouth) may last for several months after treatment ends [221]. Thus, HRQoL is 
increasingly viewed as an important outcome in clinical studies of HNC, alongside 
other traditional parameters such as survival, recurrence, and drug toxicity [222] [223]. 
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A variety of validated instruments are available to measure HRQoL in HNC; among 
them, the most popular are the QLQ-C30 supplemented with a 35-item HNC cancer 
module (QLQ-H&N35; H&N35 thereafter), the University of Washington Quality of 
Life (UWQOL) questionnaire and the FACT-G/FACT-H&N questionnaire [221]. 
However, as shown in Chapter III, the literature on HSUVs and, particularly, their 
measurement using EQ-5D are still limited in HNC, especially for advanced cancer 
stages. Moreover, until now, there are no published original algorithms to map EQ-5D 
utility values from QLQ-C30 and H&N35.  
This chapter contributes to filling knowledge “gaps” in mapping in three different ways. 
First, using data from the ongoing HETeCo trial, it maps from the QLQ-C30 and 
H&N35 scales/items to EQ-5D-5L in HNC, thus extending the mapping literature in 
cancer in general and providing the first mapping in HNC using the EORTC 
questionnaires. Second, it provides a set of mapping functions for the available EQ-5D-
5L tariffs, which correspond to the preference weights elicited from the general 
population in different countries, so that future users can select the most appropriate 
model for their data. Third, it tests (and compares) alternative mapping techniques as 
suggested by the most recent literature on the topic. Overall, this work aims at 
facilitating the assessment of HSUVs in HNC in the absence of original EQ-5D data, 
and, consequently, the performance of cost-utility comparisons of novel treatments in 
this cancer population.  
4.2 Methods 
In carrying out the analyses, the recently published guide to good practices from ISPOR 
[153] is mainly followed. The MAPS statement [224] [225], a 23-item checklist of 
recommendations that authors should consider when reporting mapping studies, is also 
completed, and attached to the appendix (Table A4.1). Furthermore, the analyses refer 
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to the recommendations from Longworth et al. [215] and other recent studies obtaining 
EQ-5D utilities from QLQ-C30 [63] [226]. 
4.2.1 Instruments 
The EQ-5D is a commonly used generic instrument for measuring HRQoL in a variety 
of medical conditions. The instrument consists of five dimensions (i.e. mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression) plus a 100-point visual 
analogue scale (EQ-VAS) for rating overall health status. In its original version (EQ-
5D-3L), each dimension has three levels: no problems, moderate problems, and extreme 
problems; two intermediate levels (i.e. slight problems and severe problems) have been 
added between levels 1 and 2 and levels 2 and 3, respectively (http://www.euroqol.org) 
in the EQ-5D-5L, which is adopted in the HETeCo trial. EQ-5D responses can be 
converted into a summary utility score using one of the existing sets of country 
preference weights (or “tariffs”). A number of tariff sets (i.e. England [227], 
Netherlands [228], Canada [229], Uruguay [230], Japan [231], South Korea [232], and 
China [233]), as reported on the EuroQol website (last updated: 18th April 2017) are 
used to calculate the EQ-5D-5L overall utility in this chapter. Where a full dataset of 
HSUVs is not provided, the preferred model as specified by the authors is used to 
calculate EQ-5D-5L values. 
The QLQ-C30 is a cross-culturally validated 30-item questionnaire to assess HRQoL in 
cancer patients. Version 3.0 is currently the standard recommended for use in clinical 
studies. A scoring system transforms raw responses into 15 overall indexes including 
five functional scales (physical, role, emotional, cognitive, and social), three symptoms 
scales (fatigue, nausea or vomiting, and pain), a global health status, and six single 
items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial 
difficulties). Possible scores range from 0 to 100, with higher mean scores on the 
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functional scales and global status representing better health whilst higher mean scores 
on the symptom scales/items indicate worse symptomatology [211].  
The H&N35 is a supplement of the QLQ-C30 instrument that is recommended for use 
in HNC patients. The module comprises 35 questions that can be combined into 18 
summary scores including seven multi-scale items (i.e. pain, swallowing, senses, 
speech, social eating, social contact, and sexuality) and eleven single items. For all 
scores (0-100), higher numbers indicate more health problems [211]. 
4.2.2 Sample and data collection 
Data for this study are obtained from the ongoing multicentre HETeCo trial [33], 
already described in Chapter I. Patients’ demographics and clinical information, 
together with informed consent, are collected at enrolment. HRQoL tools (i.e. EQ-5D-
5L, QLQ-C30 and H&N35) are administered at the enrolment and at every other visit in 
the first two years and then at each visit; follow-up visits occur every 2-6 months 
according to cancer site and study time. This chapter uses HRQoL data from a sample 
of patients enrolled in the trial until March 2018; data from all time points are pooled to 
increase the sample size and therefore the statistical precision of the estimates. Missing 
values are assumed to occur completely at random; for QLQ-C30 and H&N35 
functional/symptom scales, the approach reported in the scoring manual is followed to 
calculate the missing scores, whenever at least half the items are completed [211]. 
Single QLQ-C30 and H&N35 items and EQ-5D-5L responses are imputed instead 
through the Last Observation Carried Forward (LOCF) method given the longitudinal 
nature of the data; according to this rule, the missing item is not imputed when 
occurring at the first visit. Questionnaires without a corresponding observation in the 
alternative instrument are dropped from the analysis [63].  
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4.2.3 Data analysis 
As preliminary analyses, the degree of overlap between the source measures (QLQ-C30 
and H&N35) and the target one (EQ-5D-5L) is assessed using Spearman’s rank 
correlations to justify a mapping exercise [224]. The same technique is applied to QLQ-
C30 and H&N35 summary scores separately to state whether any independent variables 
are highly correlated (i.e. correlation coefficient > |0.7|) and thus not recommended for 
inclusion within the same regression model [215]. Moreover, a plot of EQ-5D-5L value 
distributions is provided according to different country value sets to help inform the 
identification of appropriate regression techniques for mapping; models’ choice also 
follows the existing literature [153] [215]. 
Three mapping techniques are applied to model the EQ-5D-5L utility values: (1) linear 
mixed-effects regression (mixed command in STATA); (2) random-effects Tobit model 
(xttobit command in STATA) (3) adjusted limited dependent variable mixture model 
(ALDVMM, aldvmm command in STATA).  
(1) The linear model with a random effect is an extension of the OLS model that 
allows for multiple observations per patient (i.e. the ‘cluster’); patient’s 
responses at different time points, indeed, are likely to be correlated. This model 
is also termed a mixed-effects model because the parameters are a mix of fixed 
and random variables; the between-cluster variability is modelled with a random 
effect, i.e. as a random intercept term at the patient level [226]. The model is 
estimated through maximum likelihood (ML) estimator; robust standard errors 
are used to protect against non-normality [234].  
(2) In linear models, predictions are free to range from negative to positive infinity 
and therefore may assume values outside the existing range of the EQ-5D-5L 
utilities (e.g. -0.281 and 1 for the English tariff). Moreover, they tend to 
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overpredict utilities in poor health states and, conversely, under-predict utilities 
in patients in relatively good health [220]. The Tobit model, also known as a 
censored regression model, estimates linear relationships among variables by 
accounting for the bounded nature of EQ-5D. In this study, the lower limit 
(health state 55555) for the dependent variable (EQ-5D-5L utility) varies 
according to the country set adopted, while the upper limit (health state 11111) 
is the same except for the Canadian value set [229], where the maximum value 
is fixed at 0.95 (instead of 1). The predicted values above or below the limits 
take the value of the thresholds themselves, so that they remain in the existing 
instrument range [63] [215] [218]. Again, a random-effects model (xttobit) is 
adopted to account for non-independent observations, using patient id as the 
panel variable.  
(3) The EQ-5D data typically show a few additional characteristics beyond the left 
and right boundedness. There is generally a “mass” of observations at the 
maximum value of 1 corresponding to perfect health, and a “gap” between this 
bulk of observations at 1 and the next feasible value (e.g. 0.951 for health state 
11211 using English tariffs). However, due to the increased number of levels in 
the new version, this decrement is smaller for EQ-5D-5L compared to EQ-5D-
3L, where the next value after 1 is 0.883 [227]. Moreover, the EQ-5D data tend 
to present negative skewness and multimodal distribution, which may invalidate 
the normality assumption of linear models. The Tobit model, which has been 
developed as an alternative to the linear model for dealing with bounding only, 
may not adequately address all these features. The ALDVM model was recently 
developed as a flexible alternative, and with better performance compared to 
traditional regression techniques in modelling EQ-5D data with non-linear or 
unknown distributions. Further details about the model can be found elsewhere 
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[220] [234] [235] [236]. In brief, ALDVMM is an adjusted Tobit model that 
allows several latent classes to be considered simultaneously within a data 
distribution, each expressing a different relationship between the EQ-5D 
dependent variable and the set of independent variables; thus, the same variable 
can be highly significant in certain components and not in others, so that it may 
be erroneously excluded in standard models [215]. ALDVMM is considered 
semiparametric, in the middle between a fully parametric model with one 
component only and a non-parametric one where the number of classes 
coincides with the sample size [234]. In this study, robust standard errors with 
patient id as a cluster variable are used to reflect the correlations between per 
patient observations [220].  
In all developed models, the EQ-5D-5L summary score is the dependent variable, while 
the explanatory variables are the QLQ-C30 and H&N35 scale/item results. Modelling 
from QLQ-C30 increases the usability of the algorithms in cancers other than HNC, 
while functions with H&N35 variables are likely to be more sensitive and responsive to 
the symptoms associated with HNC [237]. Because of the small sample size, models 
including both QLQ-C30 and H&N35 scores are not estimated, according to the rule of 
10 observations per variable [215]. The signs of the QLQ-C30 functional scales and 
global health status are expected to be positive, while those of the QLQ-C30 and 
H&N35 symptom scales/items are expected to be negative. Age and gender (female=1; 
male=0) are included as covariates in all models. In the interest of developing a 
parsimonious mapping, backward elimination with a significance level of 0.05 is used 
to select variables entering the final models, except for ALDVMM where some 
variables may be significant in one component and not in the other(s) [215] [236]; in 
one-component ALDVM models (that are like Tobit but accounting for “gaps” in EQ-
5D distributions [235]), backward selection is applied as usual. However, since this 
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selection process increases the model’s internal validity at the expenses of 
generalizability [215], both full and reduced models are reported. All the developed 
models are additive, thus implying linear independence between explanatory variables 
[226] [237]. Linear model coefficients can be easily applied to external datasets to 
generate EQ-5D utilities [63] [226], although predicting from ALDVMM is more 
complex since the calculation involves the probability each value falls within one of the 
different model components [226]. 
Model goodness-of-fit is measured using penalized likelihood criteria including Akaike 
Information Criterion (AIC) and Bayesian Information Criterion (BIC), where the 
smaller the value, the better the model fit; the BIC is also used as indicator to select the 
best number of components within each ALVDMM [235]. For each model, the Mean 
Absolute Error (MAE) and the Root Mean Square Error (RMSE) are calculated to 
estimate the magnitude of difference between the observed and predicted values [234]. 
In details, the MAE is the average of the absolute differences, while the RMSE is the 
root of the average of the squared differences [62]. Moreover, summary statistics of 
predictions are reported for each model [236]. Scatterplots of observed versus predicted 
EQ-5D-5L are also displayed to investigate how goodness-of-fit varies across the data 
distribution [62] [63]. Predicted EQ-5D-5L utilities are obtained using the command 
predict. All statistical analyses are performed using STATA version 14.0 (StataCorp 
LP, College Station, TX).  
4.3 Results 
4.3.1 Descriptive statistics 
Baseline demographic and clinical variables of the patients (n=97) enrolled in the study 
after being treated for their primary HNC are presented in Table 4.1. Mean age is 
around 63 and most patients (80.4%) are men. HNC is mostly localized in the oral 
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cavity (45.4%), followed by the oropharynx (27.8%), larynx (21.6%) and hypopharynx 
(5.2%). The great majority of the patients (61.9%) are ex-smokers, while 18.5% are still 
smoking at the enrolment time and 19.6% never smoked.  
Table 4.1 Sample’s characteristics. 
 N (%) 
No. of patients 97 (100.00) 
Demographics  
Male  78 (80.41) 
Age (mean ± SD; range) 63.07 ± 10.58; 33-90 
Cancer site  
Oral cavity  44 (45.36) 
Oropharynx 27 (27.84) 
Larynx 21 (21.65) 
Hypopharynx 5 (5.15) 
Smoking status  
Ex-smoker  60 (61.86) 
Never smoked 19 (19.59) 
Current smoker  18 (18.56) 
SD: standard deviation. 
Descriptive statistics of EQ-5D-5L and QLQ-C30 and H&N35 scores, pooling all 
available information across study visits, are summarized in Table 4.2. The number of 
observations per patient range between 1 and 7. A total of 84 unique EQ-5D-5L profiles 
are reported in the database, the most frequent one being 11111 (17.5%) followed by 
11121 (13.5%), and 11122 (5.2%). Level 1 (no problems) is reported most frequently in 
all dimensions except for pain/discomfort, where the modal response is level 2 (slight 
problems). The dimension reporting the highest number of responses at level 1 is self-
care (84.3%), while level 5 (extreme problems) responses are 1.3% in usual activity, 
pain/discomfort, and anxiety/depression, and 0% in mobility and self-care. The 
Uruguayan preference weights yield the highest average utility (0.905±0.11), followed 
by the English (0.839±0.16), Canadian (0.817±0.15), Korean (0.812±0.13), Chinese 
(0.803±0.21), Japanese (0.789±0.16), and Dutch (0.786±0.19).  
The mean QLQ-C30 global health score is equal to 66.73 (±18.60) and varies across the 
entire interval from 0 to 100. Among functional scales, cognitive functioning is the one 
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presenting the highest score (87.36 ±18.10), while emotional is the scale yielding the 
lowest value (78.54 ±21.33). The worst problem experienced by patients is fatigue 
(24.08 ±21.62) followed by insomnia (23.63 ±27.58), financial problems (18.99 ±30.07) 
and constipation (18.44 ±26.73). Among H&N35 scores, the three symptoms reporting 
higher scores (that indicate more problems) are dry mouth (42.14 ±31.43), sticky saliva 
(39.02 ±31.79), and senses problems (26.29 ±24.23).  
Table 4.2 Summary statistics of EQ-5D-5L and QLQ-C30/-H&N35 scores. 
EQ-5D-5L 
(responses) 
N %    
  
Mobility         
  Level 1 146 63.8      
  Level 2 49 21.4      
  Level 3 30 13.1      
  Level 4 4 1.7      
  Level 5 0 0.0      
Self-care         
  Level 1 193 84.3      
  Level 2 19 8.3      
  Level 3 13 5.7      
  Level 4 4 1.7      
  Level 5 0 0.0      
Usual activities         
  Level 1 129 56.3      
  Level 2 58 25.4      
  Level 3 27 11.8      
  Level 4 12 5.2      
  Level 5 3 1.3      
Pain         
  Level 1 69 30.1      
  Level 2 100 43.7      
  Level 3 53 23.1      
  Level 4 4 1.8      
  Level 5 3 1.3      
Anxiety/depression         
  Level 1 120 52.4      
  Level 2 61 26.7      
  Level 3 44 19.2      
  Level 4 1 0.4      
  Level 5 3 1.3      
EQ-5D-5L (utility) N Mean SD Min  Max  Below 0  Ceiling at 1 
England 229 0.839 0.16 0.042 1.000 0 (0%) 40 (17.5%) 
Netherlands 229 0.786 0.19 -0.180 1.000 2 (0.9%) 40 (17.5%) 
Canada 229 0.817 0.15 0.068 0.949 0 (0%) 0 (0%) 
Uruguay 229 0.905 0.11 0.414 1.000 0 (0%) 40 (17.5%) 
Korea 229 0.812 0.13 0.303 1.000 0 (0%) 40 (17.5%) 
Japan 229 0.789 0.16 0.251 1.000 0 (0%) 40 (17.5%) 
China 229 0.803 0.21 -0.061 1.000 2 (0.9%) 40 (17.5%) 
EQ-5D-5L (VAS) 232 70.00 18.05 0 100   
EQ-5D-5L: EuroQol Five-Dimension Five-Level; SD: standard deviation; VAS: visual analogue scale. 
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Table 4.2 (cont.) Summary statistics of EQ-5D-5L and QLQ-C30/-H&N35 scores. 
QLQ-C30 N Mean SD Min Max 
Global health status (GH) 243 66.73 18.60 0 100 
Physical functioning (PF) 245 82.51 17.60 13.33 100 
Role functioning (RF) 245 83.06 22.43 0 100 
Emotional functioning (EF) 244 78.54 21.33 0 100 
Cognitive functioning (CF) 244 87.36 18.10 16.67 100 
Social functioning (SF) 244 82.79 22.92 0 100 
Fatigue (FA) 245 24.08 21.62 0 100 
Nausea and vomiting (NV) 245 3.67 8.93 0 66.67 
Pain (PA) 245 15.78 19.80 0 100 
Dyspnoea (DY) 245 15.78 22.49 0 100 
Insomnia (SL) 244 23.63 27.58 0 100 
Appetite loss (AP) 245 14.69 24.92 0 100 
Constipation (CO) 244 18.44 26.73 0 100 
Diarrhoea (DI) 244 3.82 11.47 0 66.67 
Financial problems (FI) 244 18.99 30.07 0 100 
QLQ-H&N35      
Pain (HNPA) 246 17.89 19.12 0 100 
Swallowing (HNSW) 246 18.49 19.76 0 91.67 
Senses problems (HNSE) 246 26.29 24.23 0 100 
Speech problems (HNSP) 246 23.01 22.41 0 100 
Trouble with social eating (HNSO) 246 21.78 21.58 0 100 
Trouble with social contact (HNSC) 246 13.03 17.80 0 93.33 
Less sexuality (HNSX) 243 23.11 29.72 0 100 
Teeth (HNTE) 245 22.45 33.46 0 100 
Opening mouth (HNOM) 246 25.34 30.18 0 100 
Dry mouth (HNDR) 246 42.14 31.43 0 100 
Sticky saliva (HNSS) 246 39.02 31.79 0 100 
Coughing (HNCO) 246 13.55 20.13 0 100 
Felt ill (HNFI) 246 4.20 12.61 0 100 
Pain killers (HNPK) 246 24.80 43.27 0 100 
Nutritional supplements (HNNU) 246 23.58 42.53 0 100 
Feeding tube (HNFE) 246 4.47 20.71 0 100 
Weight loss (HNWL) 246 15.45 36.21 0 100 
Weight gain (HNWG) 246 23.58 42.53 0 100 
QLQ-C30: 30-item Core Quality of Life Questionnaire; QLQ-H&N35: 35-item Head and Neck Cancer Quality of 
Life Questionnaire. 
 
After removing 20 QLQ-C30 questionnaires and another 20 H&N35 without a 
correspondence in the EQ-5D-5L measure, 225 EQ-5D-5L/QLQ-C30 and 226 EQ-5D-
5L/QLQ-H&N35 questionnaire pairs are finally available for the mapping exercise. 
Moreover, 11 missing EQ-5D-5L responses are imputed based on LOCF; in QLQ-C30 
questionnaires, 13 functional/symptom scales are imputed based on EORTC manual 
instructions and other 22 scores using LOCF; in H&N35, 11 symptom scales are 
imputed using the manual, while 40 scales/items are imputed based on LOCF.  
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A plot of the EQ-5D-5L utility distribution for each value set is reported in Figure 4.1. 
Some common features can be observed, such as the presence of large spikes (especially 
at the health states closest to the perfect health), negative skewness, and multimodality; 
in Korean and Japanese values, a clear “gap” is evident between the mass of 
observations at 1 and the next feasible values.  
Figure 4.1 Observed EQ-5D-5L utility values. 
 
 
4.3.2 Mapping functions 
Table 4.3 reports Spearman’s rank-order correlation coefficients among EQ-5D-5L 
utilities and QLQ-C30/–H&N35 scores. As expected, a positive correlation is found 
between EQ-5D-5L and QLQ-C30 global health status/functional scores, whilst a 
negative correlation exists with QLQ-C30 and H&N35 symptom scales and single items 
(except for weight gain that can be interpreted, indeed, as a healthy effect in cancer 
patients and is not statistically significant). All correlation coefficients (apart from 
weight gain) show a statistically significant value (p<0.05); thus, the amount of overlap 
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between the sources (QLQ-C30 and H&N35) and the target measure (EQ-5D-5L) is 
considered high enough to perform the mapping. Tables 4.4 display instead Spearman 
correlation coefficients for the models’ explanatory variables only (QLQ-C30 and 
H&N35 scores); none of coefficients is above |0.7| and, consequently, no variables are 
excluded from the model at this stage. 
Table 4.3 Spearman’s rank correlation coefficients between EQ-5D-5L utilities and 
QLQ-C30/-H&N35 summary scores. 
 EQ-5D-5L 
 England Netherlands Canada Uruguay Korea Japan China 
GH 0.5557* 0.5497* 0.5591* 0.5713* 0.5623* 0.5787* 0.5844* 
PF 0.6511* 0.6344* 0.6530* 0.6305* 0.6769* 0.6760* 0.6737* 
RF 0.6126* 0.6158* 0.6321* 0.6373* 0.6336* 0.6319* 0.6421* 
EF 0.6503* 0.6585* 0.6192* 0.5719* 0.5922* 0.6444* 0.6090* 
CF 0.4322* 0.4320* 0.4126* 0.4314* 0.4127* 0.4380* 0.4160* 
SF 0.5663* 0.5662* 0.5524* 0.5771* 0.5484* 0.5748* 0.5617* 
FA -0.5538* -0.5534* -0.5433* -0.5436* -0.5353* -0.5506* -0.5346* 
NV -0.3081* -0.3003* -0.2822* -0.2864* -0.2855* -0.3078* -0.2844* 
PA -0.5804* -0.5766* -0.6102* -0.5784* -0.5698* -0.5860* -0.5994* 
DY -0.4445* -0.4267* -0.4296* -0.3966* -0.4493* -0.4396* -0.4189* 
SL -0.5256* -0.5282* -0.5078* -0.4895* -0.4805* -0.5185* -0.5054* 
AP -0.3934* -0.3953* -0.3489* -0.3347* -0.3422* -0.3910* -0.3491* 
CO -0.1970* -0.2038* -0.1819* -0.2233* -0.1854* -0.2151* -0.1966* 
DI -0.2173* -0.2195* -0.2099* -0.1842* -0.2101* -0.2096* -0.2055* 
FI -0.4449* -0.4447* -0.4530* -0.4627* -0.4370* -0.4396* -0.4485* 
HNPA -0.4790* -0.4714* -0.4884* -0.4579* -0.4590* -0.4640* -0.4720* 
HNSW -0.3720* -0.3883* -0.3861* -0.3782* -0.3546* -0.3702* -0.3917* 
HNSE -0.1942* -0.1988* -0.1736* -0.2020* -0.1683* -0.2005* -0.1812* 
HNSP -0.4502* -0.4661* -0.4351* -0.4375* -0.4161* -0.4469* -0.4289* 
HNSO -0.3176* -0.3251* -0.3265* -0.3638* -0.3154* -0.3253* -0.3322* 
HNSC -0.5166* -0.5328* -0.4969* -0.5246* -0.4893* -0.5136* -0.4958* 
HNSX -0.1665* -0.1743* -0.1626* -0.1739* -0.1716* -0.1781* -0.1723* 
HNTE -0.2680* -0.2605* -0.2622* -0.2577* -0.2421* -0.2570* -0.2608* 
HNOM -0.2703* -0.2639* -0.2703* -0.3052* -0.2760* -0.2855* -0.2816* 
HNDR -0.2051* -0.1987* -0.2107* -0.1744* -0.2082* -0.2069* -0.2106* 
HNSS -0.2658* -0.2732* -0.2646* -0.2350* -0.2387* -0.2564* -0.2544* 
HNCO -0.2281* -0.2225* -0.2252* -0.2179* -0.2254* -0.2215* -0.2226* 
HNFI -0.3579* -0.3543* -0.3641* -0.3675* -0.3512* -0.3645* -0.3644* 
HNPK -0.3146* -0.3277* -0.3449* -0.3220* -0.3287* -0.3303* -0.3575* 
HNNU -0.1948* -0.1982* -0.1621* -0.1917* -0.1725* -0.1934* -0.1740* 
HNFE -0.1545* -0.1630* -0.1506* -0.1588* -0.1486* -0.1446* -0.1423* 
HNWL -0.1475* -0.1538* -0.1501* -0.1414* -0.1375* -0.1547* -0.1491* 
HNWG 0.0727 0.0702 0.0817 0.1031 0.0860 0.1054 0.1029 
* p<0.05. GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive 
functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; DY: dyspnoea; SL: insomnia; AP: appetite 
loss; CO: constipation; DI: diarrhoea; FI: financial problems; HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: 
speech problems; HNSO: trouble with social eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; 
HNOM: opening mouth; HNSS: sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional 
supplements; HNFE: feeding tube; HNWL: weight loss; HNWG: weight gain.  
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Tables 4.4 Spearman’s rank correlation coefficients between QLQ-C30/-H&N35 summary scores. 
Table 4.4 (A) Spearman’s rank correlation coefficients between QLQ-C30 summary scores. 
 GH PF RF EF CF SF FA NV PA DY SL AP CO DI FI 
GH 1               
PF 0.5615 1              
RF 0.5651 0.6070 1             
EF 0.4133 0.4671 0.5494 1            
CF 0.4214 0.4770 0.4281 0.4891 1           
SF 0.4280 0.5065 0.5881 0.5324 0.3832 1          
FA -0.5079 -0.6637 -0.6251 -0.5981 -0.5771 -0.4792 1         
NV -0.1399 -0.2429 -0.2986 -0.3055 -0.2576 -0.2645 0.3739 1        
PA -0.4325 -0.5234 -0.5306 -0.5432 -0.3496 -0.4703 0.5290 0.2297 1       
DY -0.3715 -0.5424 -0.5233 -0.4558 -0.3944 -0.3167 0.5071 0.1999 0.3490 1      
SL -0.3287 -0.4762 -0.4598 -0.5790 -0.3033 -0.5006 0.4927 0.2392 0.4518 0.3917 1     
AP -0.3394 -0.4324 -0.3378 -0.4500 -0.3260 -0.3706 0.4742 0.3359 0.3560 0.3086 0.4002 1    
CO -0.2094 -0.2324 -0.2363 -0.2651 -0.3948 -0.1082 0.2734 0.2530 0.1425 0.1387 0.1708 0.1743 1   
DI -0.1587 -0.1681 -0.1635 -0.2276 -0.1420 -0.1140 0.1745 0.0990 0.1068 0.1627 0.2145 0.0883 0.0086 1  
FI -0.3159 -0.3065 -0.4560 -0.4074 -0.2367 -0.5172 0.3614 0.1285 0.4080 0.2642 0.4767 0.2175 -0.0431 -0.0415 1 
Table 4.4 (B) Spearman’s rank correlation coefficients between QLQ-H&N35 summary scores. 
 HNPA HNSW HNSE HNSP HNSO HNSC HNSX HNTE HNOM HNDR HNSS HNCO HNFI HNPK HNNU HNFE HNWL HNWG 
HNPA 1                  
HNSW 0.4634 1                 
HNSE 0.2276 0.2416 1                
HNSP 0.3165 0.4112 0.2835 1               
HNSO 0.4241 0.5768 0.3816 0.3616 1              
HNSC 0.2898 0.3157 0.2644 0.5838 0.5539 1             
HNSX 0.2152 0.3040 0.2718 0.3102 0.4032 0.3614 1            
HNTE 0.4340 0.1634 0.1272 0.2469 0.2159 0.2537 0.1677 1           
HNOM 0.3204 0.4025 0.1647 0.1561 0.4544 0.2745 0.2818 0.1802 1          
HNDR 0.4496 0.3808 0.3049 0.1528 0.2677 0.0977 0.2785 0.1539 0.3323 1         
HNSS 0.4175 0.3895 0.2444 0.3154 0.3367 0.2462 0.2055 0.2273 0.2662 0.5157 1        
HNCO 0.1215 0.1974 0.0411 0.2997 0.1543 0.2453 0.0769 0.1435 -0.0207 0.0312 0.1142 1       
HNFI 0.2915 0.3209 0.0707 0.2130 0.1889 0.1847 0.0356 0.0969 0.0595 0.1443 0.0899 0.1771 1      
HNPK 0.3300 0.2833 0.0138 0.1411 0.1897 0.1766 0.0486 0.1463 0.0424 0.1472 0.1712 0.1142 0.3499 1     
HNNU 0.1663 0.2119 0.0397 0.0408 0.1871 0.1910 -0.0449 -0.0090 0.2208 0.2192 0.2013 0.0893 0.2097 0.1553 1    
HNFE 0.1396 0.2028 0.0321 0.2141 0.2217 0.2050 0.2831 0.2235 0.1254 0.0830 0.1358 0.0752 -0.0016 0.1477 0.0698 1   
HNWL 0.2649 0.2804 0.1005 0.2670 0.2502 0.2000 0.1351 0.1036 0.1670 0.1787 0.2295 0.1590 0.0709 0.0522 0.0234 0.2430 1  
HNWG -0.0873 -0.0376 -0.1515 -0.0142 -0.1032 0.0194 0.0616 -0.0413 -0.0439 -0.0123 -0.0131 0.0627 -0.0751 0.0342 0.0206 0.0208 -0.1809 1 
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; DY: dyspnoea; SL: insomnia; AP: appetite loss; CO: 
constipation; DI: diarrhoea; FI: financial problems; HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; HNOM: 
opening mouth; HNSS: sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding tube; HNWL: weight loss; HNWG: weight gain.  
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Tables A4.2-A4.3 in the appendix show the full regression results for EQ-5D-5L 
utilities predicted through QLQ-C30 and H&N35 scores using linear mixed-effects and 
random-effects Tobit models. The two regression techniques are broadly similar in 
terms of significant variables, although Tobit has a much poorer goodness-of-fit in 
terms of AIC/BIC. Their accuracy prediction in terms of MAE/RMSE is instead almost 
the same. Therefore, in tables 4.5-4.6, only results from the best performing linear-
mixed models are reported; with all tariff sets, reduced models perform better than full 
models. In models using QLQ-C30 scores (Table 4.5), physical functioning is always 
positive and highly statistically significant (p<0.001), and emotional functioning is 
significant in some models only. Among the symptoms scales, the financial difficulties 
score has a significant negative impact on EQ-5D-5L utility, as do nausea and vomiting, 
pain, and diahrroea, although with slight differences across the value sets adopted; 
constipation shows a counterintuitive positive coefficient. The global health score is 
positive and statistically significant in all models. In models using H&N35 scores 
(Table 4.6), pain, trouble with social contact, felt ill and, occasionally, opening mouth, 
weight loss, weight gain and female gender have a significant impact on EQ-5D-5L 
utility. Age does not show any significant association and is thus removed from all 
models. Figures 4.2-4.3 show the plots of predicted versus observed values for all 
country tariff sets and QLQ-C30/-H&N35 models, respectively. The diagonal line 
shows the line of perfect correlation; the vertical distance between the points and the 
line represents the error between observed and predicted utility values. In both scatter 
plot sets, low EQ-5D-5L values tend to be overestimated, while models underestimate 
utility in healthier states, and consistently fail to predict the maximum value of 1 (three 
predictions only are equal to 1, compared to 40 observed values); thus, the min-max 
range of predicted values is smaller compared to the observed ones. No predicted values 
fall outside the theoretical EQ-5D-5L range. For all the tariff sets adopted, the 
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algorithms using QLQ-C30 scales/items fit better than those regressing H&N35. 
Moreover, in both QLQ-C30 and H&N35 models, a better goodness-of-fit is observed 
for the Canadian, Uruguayan, and Korean value sets. 
Additionally, ALDVM models (Tables A4.4-A4.5) are separately run for QLQ-C30 and 
H&N35 scores, by referring to the characteristics of each EQ-5D-5L value set 
distribution and using the BIC as a criterion for identifying the best number of 
components [235]; due to the small sample, models with more than three components 
are not tested [234]. A synthesis of the best performing models is reported in tables 4.7-
4.8. In terms of goodness-of-fit, ALDVM models with one component only perform 
worse than Tobit models and, accordingly, are not considered for model comparison. 
Conversely, the 2- and 3- component models are those generally presenting the lowest 
AIC/BIC across all model types, although BIC reflects a penalty for model complexity 
given the small size of the database [215]. Predictive errors (MAE/RMSE) resulting 
from ALDVMM are comparable with those obtained from the other two regression 
techniques. The number and type of significant covariates vary considerably in these 
models, which yield a complex pattern of relationships between the EQ-5D-5L utility 
and QLQ-C30/-H&N35 scales/items. A better goodness-of-fit is obtained by using 
Canadian and Dutch value sets in QLQ-C30 models, and English, Canadian, and 
Uruguayan ones in H&N35 models, for which data allow the application of multi- 
component models. As observed for linear-mixed models, also the ALDVMM tends to 
overpredict EQ-5D-5L for the poorest states and underpredict the highest values; 
however, the dots appear closer to the diagonal line, especially on the left side of the 
utility scale. As above, models using QLQ-C30 fit better than H&N35 ones (Figures 
4.4-4.5).
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Table 4.5 Synthesis of best performing linear mixed-effects models using QLQ-C30. 
 England Netherlands Canada Uruguay South Korea Japan China 
 Coef. SE P Coef. SE P Coef. SE P Coef. SE P Coef. SE P Coef. SE p Coef. SE p 
Intercept 0.4050 0.0751 0.000 0.2859 0.0929 0.002 0.5628 0.0555 0.000 0.7288 0.0399 0.000 0.5110 0.0466 0.000 0.3203 0.0538 0.000 0.3730 0.0753 0.000 
GH 0.0011 0.0004 0.012 0.0014 0.0005 0.005 0.0009 0.0003 0.002 0.0007 0.0002 0.003 0.0012 0.0004 0.001 0.0014 0.0004 0.000 0.0016 0.0004 0.000 
PF 0.0034 0.0008 0.000 0.0037 0.0009 0.000 0.0028 0.0007 0.000 0.0018 0.0005 0.000 0.0030 0.0006 0.000 0.0035 0.0006 0.000 0.0045 0.0009 0.000 
RF                      
EF 0.0012 0.0005 0.022 0.0016 0.0007 0.022          0.0013 0.0004 0.002    
CF                      
SF                      
FA                      
NV -0.0027 0.0012 0.022 -0.0030 0.0013 0.028       -0.0018 0.0009 0.041 -0.0021 0.0010 0.038    
PA       -0.0011 0.0004 0.003 -0.0008 0.0003 0.013       -0.0016 0.0005 0.004 
DY                      
SL                      
AP                      
CO 0.0007 0.0002 0.006 0.0008 0.0003 0.010 0.0006 0.0002 0.005 0.0005 0.0002 0.005       0.0007 0.0003 0.012 
DI       -0.0020 0.0009 0.026 -0.0013 0.0006 0.030       -0.0019 0.0008 0.012 
FI -0.0008 0.0003 0.002 -0.0011 0.0003 0.001 -0.0009 0.0002 0.000 -0.0007 0.0002 0.000 -0.0009 0.0002 0.000 -0.0008 0.0002 0.001 -0.0012 0.0003 0.000 
Female                      
Age                      
Goodness-of-fit statistics 
AIC -413.60   -323.78   -473.48   -590.39   -459.93   -431.40   -336.13   
BIC -382.90   -293.07   -442.77   -559.69   -436.05   -404.11   -305.43   
MAE 0.0698   0.0883   0.0653   0.0498   0.0671   0.0745   0.0923   
RMSE 0.1012   0.1256   0.0997   0.0738   0.0895   0.0949   0.1296   
Mean 0.843   0.790   0.824   0.910   0.813   0.792   0.813   
SD 0.104   0.123   0.093   0.065   0.083   0.113   0.137   
Min 0.401   0.287   0.447   0.654   0.480   0.350   0.279   
Max 1.000   0.970   0.955   1.006   0.928   0.951   0.994   
Below 0 0; 0%   0; 0%   0; 0%   0; 0%   0; 0%   0; 0%   0; 0%   
Ceiling 1 1; 0.4%   0; 0%   0; 0%   2; 0.9%   0; 0%   0; 0%   0; 0%   
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; DY: dyspnoea; SL: 
insomnia; AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC:  Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; 
SD: standard deviation; SE: standard error. 
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Table 4.6 Synthesis of best performing linear mixed-effects models using QLQ-H&N35. 
 England Netherlands Canada Uruguay South Korea Japan China 
 Coef. SE P Coef. SE P Coef. SE p Coef. SE P Coef. SE P Coef. SE p Coef. SE p 
Intercept 0.9200 0.0118 0.000 0.8818 0.0141 0.000 0.8908 0.0097 0.000 0.9575 0.0081 0.000 0.8721 0.0118 0.000 0.8735 0.0160 0.000 0.9106 0.0182 0.000 
HNPA -0.0020 0.0005 0.000 -0.0024 0.0006 0.000 -0.0017 0.0004 0.000 -0.0011 0.0003 0.001 -0.0017 0.0004 0.000 -0.0018 0.0005 0.000 -0.0023 0.0007 0.000 
HNSW                      
HNSE                      
HNSP                      
HNSO                      
HNSC -0.0026 0.0006 0.000 -0.0031 0.0007 0.000 -0.0023 0.0006 0.000 -0.0018 0.0004 0.000 -0.0022 0.0005 0.000 -0.0025 0.0005 0.000 -0.0034 0.0008 0.000 
HNSX                      
HNTE                      
HNOM                -0.0009 0.0003 0.001 -0.0009 0.0004 0.018 
HNDR                      
HNSS                      
HNCO                      
HNFI -0.0014 0.0005 0.004 -0.0018 0.0006 0.003 -0.0013 0.0004 0.002 -0.0010 0.0003 0.003 -0.0013 0.0004 0.002 -0.0012 0.0005 0.007 -0.0016 0.0006 0.006 
HNPK                      
HNNU                      
HNFE                      
HNWL                0.0004 0.0002 0.026 0.0005 0.0002 0.026 
HNWG                0.0003 0.0001 0.023 0.0004 0.0002 0.028 
Female             0.0437 0.0209 0.036       
Age                      
Goodness-of-fit statistics 
AIC -377.11   -292.37   -435.47   -565.08   -431.10   -377.78   -294.74   
BIC -356.59   -271.85   -414.95   -544.55   -407.16   -346.99   -263.96   
MAE 0.0847   0.1031   0.0776   0.0560   0.0754   0.0973   0.1150   
RMSE 0.1252   0.1520   0.1201   0.0848   0.1048   0.1253   0.1611   
Mean 0.845   0.792   0.825   0.910   0.817   0.795   0.814   
SD 0.074   0.089   0.066   0.048   0.063   0.079   0.100   
Min 0.578   0.463   0.580   0.732   0.572   0.537   0.486   
Max 0.920   0.882   0.891   0.957   0.916   0.909   0.960   
Below 0 0; 0%   0; 0%   0; 0%   0; 0%   0; 0%   0; 0%   0; 0%   
Ceiling 1 0; 0%   0; 0%   0; 0%   0; 0%   0; 0%   0; 0%   0; 0%   
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; HNOM: opening mouth; HNSS: 
sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding tube; HNWL: weight loss; HNWG: weight gain. AIC: Akaike Information Criterion; BIC:  Bayesian 
Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SD: standard deviation; SE: standard error. 
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Figure 4.2 Scatterplots of observed versus predicted EQ-5D-5L for linear-mixed 
models using QLQ-C30. 
 
Figure 4.3 Scatterplots of observed versus predicted EQ-5D-5L for linear-mixed 
models using QLQ-H&N35. 
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Table 4.7 Synthesis of best performing ALDVM models using QLQ-C30. 
 England Netherlands 
 Component 1 Component 2 Component 1 Component 2 Component 3 
 Coef. SE P Coef. SE P Coef. SE P Coef. SE p Coef. SE P 
Intercept 0.8685 0.0039 0.000 0.3562 0.1514 0.019 0.9311 0.0023 0.000 0.8319 0.0553 0.000 -0.5478 0.3278 0.095 
GH 0.0010 <0.0001 0.000 0.0010 0.0007 0.144 0.0003 <0.0001 0.000 0.0009 0.0007 0.168 0.0034 0.0015 0.019 
PF -0.0001 <0.0001 0.000 0.0042 0.0009 0.000 0.0025 <0.0001 0.000 -0.0008 0.0007 0.238 0.0087 0.0014 0.000 
RF -0.0005 <0.0001 0.000 0.0012 0.0007 0.082 0.0002 <0.0001 0.000 -0.0002 0.0001 0.244 0.0022 0.0010 0.029 
EF 0.0007 <0.0001 0.000 0.0016 0.0005 0.003 -0.0011 <0.0001 0.000 0.0013 0.0003 0.000 0.0054 0.0016 0.001 
CF 0.0006 <0.0001 0.000 -0.0007 0.0007 0.290 -0.0008 <0.0001 0.000 0.0005 0.0004 0.148 -0.0010 0.0015 0.514 
SF -0.0003 <0.0001 0.000 0.0003 0.0005 0.551 0.0008 <0.0001 0.000 -0.0008 0.0002 0.000 -0.0014 0.0013 0.279 
FA -0.0013 <0.0001 0.000 0.0005 0.0007 0.541 -0.0049 <0.0001 0.000 0.0002 0.0004 0.594 0.0036 0.0015 0.018 
NV 0.0005 <0.0001 0.000 -0.0037 0.0018 0.034 0.0017 <0.0001 0.000 -0.0009 0.0003 0.001 -0.0117 0.0022 0.000 
PA -0.0008 <0.0001 0.000 -0.0013 0.0006 0.044 -0.0017 <0.0001 0.000 -0.0003 0.0003 0.219 -0.0012 0.0009 0.200 
DY -0.0011 <0.0001 0.000 0.0003 0.0005 0.552 -0.0034 <0.0001 0.000 -0.0007 0.0003 0.011 0.0034 0.0013 0.009 
SL 0.0004 <0.0001 0.000 0.0003 0.0004 0.487 0.0006 <0.0001 0.000 -0.0013 0.0003 0.000 0.0016 0.0010 0.104 
AP -0.0002 <0.0001 0.000 0.0002 0.0005 0.701 -0.0004 <0.0001 0.000 0.0006 0.0002 0.015 0.0008 0.0011 0.469 
CO 0.0013 <0.0001 0.000 -0.0004 0.0003 0.271 0.0001 <0.0001 0.000 0.0002 0.0002 0.325 -0.0003 0.0008 0.669 
DI 0.0012 <0.0001 0.000 -0.0022 0.0009 0.018 -0.0040 <0.0001 0.000 -0.0002 0.0004 0.553 -0.0026 0.0018 0.158 
FI -0.0011 <0.0001 0.000 -0.0009 0.0004 0.017 0.0005 <0.0001 0.000 -0.0003 0.0003 0.363 -0.0028 0.0009 0.003 
Female 0.0398 0.0007 0.000 0.0477 0.0217 0.028 0.0313 0.0004 0.000 -0.0090 0.0166 0.585 0.0634 0.0501 0.205 
Age -0.0012 <0.0001 0.000 -0.0013 0.0010 0.211 -0.0013 <0.0001 0.000 -0.0005 0.0008 0.563 -0.0014 0.0021 0.504 
Probability (constant) -1.6222 0.2222 0.000    -1.4306 0.3064 0.000 -0.2280 0.3213 0.478    
/lns -7.0701 0.1472 0.000 -2.2525 0.0872 0.000 -9.9034 0.4471 0.000 -3.7173 0.2172 0.000 -2.0715 0.1109 0.000 
Sigma 0.0008 0.0001  0.1051 0.0092  <0.0001 <0.0001  0.0243 0.0053  0.1260 0.0140  
Probability 0.1649 0.0306  0.8351 0.0306  0.1175 0.0256  0.3911 0.0689  0.4913 0.0738  
Goodness-of-fit statistics 
AIC -341.64      -383.64         
BIC -208.59      -192.59         
MAE 0.0666      0.0872         
RMSE 0.0943      0.1196         
Mean 0.837      0.794         
SD 0.128      0.143         
Min 0.260      0.161         
Max 0.995      0.963         
Below 0 0; 0%      0; 0%         
Ceiling 1 0; 0%      0; 0%         
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; DY: dyspnoea; SL: 
insomnia; AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC:  Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; 
SD: standard deviation; SE: standard error. 
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Table 4.7 (cont.) Synthesis of best performing ALDVM models using QLQ-C30. 
 Canada China 
 Component 1 Component 2 Component 1 Component 2 Component 3 
 Coef. SE P Coef. SE P Coef. SE P Coef. SE p Coef. SE P 
Intercept 0.7767 0.0412 0.000 0.3011 0.1806 0.095 0.7636 0.0480 0.000 -0.2102 0.4200 0.617 1.0463 0.0032 0.000 
GH 0.0007 0.0003 0.043 0.0001 0.0005 0.789 0.0018 0.0004 0.000 0.0013 0.0010 0.201 <0.0001 <0.0001 0.037 
PF 0.0010 0.0002 0.000 0.0035 0.0011 0.001 0.0014 0.0005 0.008 0.0079 0.0021 0.000 <0.0001 <0.0001 0.657 
RF -0.0001 0.0001 0.252 0.0029 0.0008 0.000 0.0000 0.0001 0.517 0.0018 0.0009 0.039 0.0001 <0.0001 0.000 
EF 0.0014 0.0002 0.000 0.0005 0.0006 0.422 0.0009 0.0004 0.026 0.0022 0.0009 0.018 0.0001 <0.0001 0.000 
CF -0.0003 0.0001 0.018 0.0006 0.0006 0.355 <0.0001 0.0001 0.939 0.0009 0.0010 0.396 -0.0002 <0.0001 0.000 
SF -0.0005 0.0002 0.024 -0.0006 0.0005 0.200 -0.0009 0.0001 0.000 -0.0007 0.0006 0.219 0.0003 <0.0001 0.000 
FA 0.0013 0.0002 0.000 0.0001 0.0008 0.926 0.0010 0.0002 0.000 <0.0001 0.0014 0.977 -0.0005 <0.0001 0.000 
NV -0.0012 0.0002 0.000 -0.0041 0.0014 0.003 -0.0030 0.0003 0.000 -0.0069 0.0027 0.010 -0.0052 <0.0001 0.000 
PA -0.0012 0.0001 0.000 -0.0017 0.0008 0.028 -0.0015 0.0004 0.000 -0.0011 0.0014 0.401 -0.0060 <0.0001 0.000 
DY 0.0007 0.0002 0.000 0.0004 0.0006 0.478 0.0019 0.0003 0.000 0.0011 0.0012 0.358 -0.0026 <0.0001 0.000 
SL -0.0008 0.0002 0.000 0.0002 0.0003 0.507 -0.0021 0.0003 0.000 0.0008 0.0006 0.213 -0.0001 <0.0001 0.000 
AP 0.0005 0.0001 0.000 0.0009 0.0005 0.071 0.0011 0.0001 0.000 0.0017 0.0008 0.035 -0.0008 <0.0001 0.000 
CO -0.0004 0.0001 0.000 0.0005 0.0003 0.115 -0.0008 0.0001 0.000 0.0005 0.0005 0.360 -0.0007 <0.0001 0.000 
DI -0.0012 0.0002 0.000 -0.0016 0.0010 0.099 -0.0017 0.0002 0.000 -0.0004 0.0011 0.732 -0.0043 <0.0001 0.000 
FI -0.0003 0.0002 0.212 -0.0006 0.0004 0.174 -0.0001 0.0001 0.642 -0.0015 0.0005 0.001 -0.0002 <0.0001 0.000 
Female -0.0188 0.0054 0.001 0.0453 0.0210 0.031 0.0086 0.0213 0.687 0.0369 0.0301 0.220 -0.1055 0.0005 0.000 
Age -0.0006 0.0005 0.215 -0.0010 0.0010 0.330 -0.0010 0.0006 0.120 -0.0014 0.0017 0.435 -0.0002 <0.0001 0.000 
Probability (constant) -0.4538 0.3152 0.150    0.4192 0.3344 0.210 1.4316 0.2279 0.000    
/lns -4.3653 0.4044 0.000 -2.5282 0.1004 0.000 -4.4991 0.4309 0.000 -2.2115 0.0974 0.000 -7.5695 0.1339 0.000 
Sigma 0.0127 0.0051  0.0798 0.0080  0.0111 0.0048  0.1095 0.0107  0.0005 0.0001  
Probability 0.3884 0.0749  0.6115 0.0749  0.2268 0.0561  0.6241 0.0575  0.1491 0.0273  
Goodness-of-fit statistics 
AIC -547.84      -313.69         
BIC -414.78      -112.40         
MAE 0.0624      0.0856         
RMSE 0.0921      0.1187         
Mean 0.827      0.800         
SD 0.107      0.169         
Min 0.380      0.094         
Max 0.973      0.989         
Below 0 0; 0%      0; 0%         
Ceiling 1 0; 0%      0; 0%         
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; DY: dyspnoea; SL: 
insomnia; AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC:  Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; 
SD: standard deviation; SE: standard error. 
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Table 4.8 Synthesis of best performing ALDVM models using QLQ-H&N35. 
 England Canada 
 Component 1 Component 2 Component 3 Component 1 Component 2 Component 3 
 Coef. SE P Coef. SE P Coef. SE P Coef. SE P Coef. SE p Coef. SE P 
Intercept 1.0587 0.0548 0.000 0.5542 0.0013 0.000 0.9462 0.0019 0.000 0.8644 0.0200 0.000 0.9904 0.0171 0.000 0.5233 0.0915 0.000 
HNPA -0.0038 0.0007 0.000 -0.0009 <0.0001 0.000 -0.0001 <0.0001 0.000 -0.0003 0.0003 0.282 -0.0024 0.0003 0.000 -0.0065 0.0009 0.000 
HNSW -0.0004 0.0006 0.488 -0.0038 <0.0001 0.000 0.0001 <0.0001 0.000 -0.0006 0.0006 0.352 <0.0001 0.0002 0.797 0.0006 0.0005 0.205 
HNSE 0.0002 0.0004 0.570 0.0024 <0.0001 0.000 -0.0001 <0.0001 0.000 -0.0009 0.0002 0.000 <0.0001 0.0001 0.783 0.0029 0.0004 0.000 
HNSP -0.0002 0.0005 0.667 0.0017 <0.0001 0.000 0.0006 <0.0001 0.000 0.0018 0.0003 0.000 -0.0005 0.0002 0.023 0.0009 0.0010 0.359 
HNSO 0.0003 0.0006 0.616 0.0072 <0.0001 0.000 0.0010 <0.0001 0.000 0.0012 0.0002 0.000 -0.0003 0.0003 0.291 0.0046 0.0011 0.000 
HNSC -0.0035 0.0009 0.000 -0.0024 <0.0001 0.000 -0.0023 <0.0001 0.000 -0.0064 0.0004 0.000 0.0009 0.0003 0.007 -0.0028 0.0003 0.000 
HNSX 0.0009 0.0003 0.002 -0.0017 <0.0001 0.000 -0.0003 <0.0001 0.000 0.0003 0.0001 0.021 0.0004 0.0001 0.002 -0.0013 0.0005 0.013 
HNTE <0.0001 0.0003 0.986 -0.0018 <0.0001 0.000 0.0007 <0.0001 0.000 -0.0005 0.0002 0.003 <0.0001 0.0001 0.861 0.0009 0.0004 0.021 
HNOM -0.0005 0.0003 0.121 0.0010 <0.0001 0.000 -0.0008 <0.0001 0.000 -0.0004 0.0002 0.047 -0.0003 0.0001 0.018 0.0010 0.0005 0.040 
HNDR -0.0002 0.0003 0.564 0.0033 <0.0001 0.000 -0.0003 <0.0001 0.000 -0.0001 0.0003 0.844 -0.0001 0.0001 0.386 0.0017 0.0009 0.067 
HNSS <0.0001 0.0003 0.902 -0.0016 <0.0001 0.000 -0.0006 <0.0001 0.000 0.0003 0.0002 0.106 -0.0005 0.0002 0.004 0.0005 0.0003 0.089 
HNCO -0.0008 0.0004 0.079 -0.0068 <0.0001 0.000 -0.0010 <0.0001 0.000 0.0002 0.0002 0.321 -0.0009 0.0002 0.000 -0.0039 0.0005 0.000 
HNFI -0.0012 0.0007 0.083 -0.0049 <0.0001 0.000 -0.0020 <0.0001 0.000 -0.0119 0.0006 0.000 0.0006 0.0004 0.124 -0.0002 0.0003 0.579 
HNPK -0.0005 0.0002 0.019 -0.0011 <0.0001 0.000 0.0005 <0.0001 0.000 -0.0005 0.0001 0.001 -0.0002 0.0001 0.003 -0.0006 0.0002 0.004 
HNNU -0.0002 0.0002 0.242 -0.0037 <0.0001 0.000 0.0003 <0.0001 0.000 <0.0001 0.0001 0.828 <0.0001 0.0001 0.592 -0.0008 0.0002 0.000 
HNFE -0.0003 0.0003 0.449 -0.0019 <0.0001 0.000 -0.0002 <0.0001 0.000 0.0009 0.0003 0.000 -0.0012 0.0001 0.000 0.0026 0.0003 0.000 
HNWL 0.0005 0.0003 0.054 0.0027 <0.0001 0.000 <0.0001 <0.0001 0.000 -0.0004 0.0001 0.000 0.0004 0.0001 0.000 0.0007 0.0005 0.159 
HNWG 0.0004 0.0001 0.006 0.0001 <0.0001 0.000 -0.0006 <0.0001 0.000 -0.0002 0.0001 0.083 0.0001 0.0001 0.050 0.0013 0.0003 0.000 
Female 0.0407 0.0228 0.075 0.2872 0.0004 0.000 -0.0394 0.0002 0.000 0.0489 0.0113 0.000 -0.0060 0.0074 0.413 0.1885 0.0374 0.000 
Age -0.0012 0.0008 0.142 0.0020 <0.0001 0.000 -0.0005 <0.0001 0.000 0.0008 0.0003 0.010 -0.0008 0.0003 0.007 0.0002 0.0007 0.727 
Probability (constant) 1.8421 0.2146 0.000 -0.0618 0.3030 0.838    0.7863 0.2810 0.005 0.9643 0.2808 0.001    
/lns -2.4564 0.0695 0.000 -8.2578 0.1251 0.000 -10.0190 0.3320 0.000 -3.5098 0.1262 0.000 -3.8609 0.0964 0.000 -3.5452 0.1148 0.000 
Sigma 0.0857 0.0060  0.0003 <0.0001  <0.0001 <0.0001  0.0299 0.0038  0.0210 0.0020  0.0289 0.0033  
Probability 0.7648 0.0295  0.1139 0.0233  0.1212 0.0228  0.3773 0.0515  0.4508 0.0540  0.1719 0.0361  
Goodness-of-fit statistics 
AIC -566.40         -535.52         
BIC -365.64         -304.14         
MAE 0.0834         0.0758         
RMSE 0.1133         0.1097         
Mean 0.831         0.814         
SD 0.109         0.095         
Min 0.368         0.389         
Max 0.977         0.959         
Below 0 0; 0%         0; 0%         
Ceiling 1 0; 0%         0; 0%         
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; HNOM: opening mouth; HNSS: sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: 
nutritional supplements; HNFE: feeding tube; HNWL: weight loss; HNWG: weight gain. AIC: Akaike Information Criterion; BIC:  Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SD: standard deviation; SE: standard error. 
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Table 4.8 (cont.) Synthesis of best performing ALDVM models using QLQ-H&N35. 
 Uruguay China 
 Component 1 Component 2 Component 3 Component 1 Component 2 
 Coef. SE P Coef. SE P Coef. SE P Coef. SE p Coef. SE P 
Intercept 1.0471 0.0282 0.000 0.8676 0.1005 0.000 0.9980 <0.0001 0.000 0.9966 0.0024 0.000 1.0846 0.1082 0.000 
HNPA -0.0010 0.0003 0.000 -0.0031 0.0012 0.010 -0.0012 <0.0001 0.000 -0.0021 <0.0001 0.000 -0.0035 0.0011 0.002 
HNSW 0.0001 0.0002 0.718 0.0036 0.0008 0.000 0.0005 <0.0001 0.000 0.0019 <0.0001 0.000 0.0003 0.0012 0.778 
HNSE -0.0003 0.0002 0.095 0.0053 0.0006 0.000 -0.0004 <0.0001 0.000 -0.0003 <0.0001 0.000 0.0010 0.0006 0.128 
HNSP 0.0002 0.0002 0.390 -0.0067 0.0012 0.000 -0.0005 <0.0001 0.000 0.0013 <0.0001 0.000 -0.0009 0.0009 0.320 
HNSO 0.0005 0.0003 0.067 0.0014 0.0006 0.018 -0.0002 <0.0001 0.000 <0.0001 <0.0001 0.925 0.0025 0.0011 0.023 
HNSC -0.0008 0.0005 0.102 0.0015 0.0008 0.069 -0.0012 <0.0001 0.000 -0.0012 <0.0001 0.000 -0.0075 0.0016 0.000 
HNSX <0.0001 0.0001 0.898 -0.0015 0.0004 0.000 -0.0001 <0.0001 0.000 -0.0008 <0.0001 0.000 -0.0003 0.0007 0.610 
HNTE 0.0001 0.0001 0.142 -0.0019 0.0006 0.002 -0.0001 <0.0001 0.000 0.0001 <0.0001 0.000 -0.0001 0.0004 0.798 
HNOM -0.0008 0.0001 0.000 0.0007 0.0006 0.207 0.0001 <0.0001 0.000 -0.0020 <0.0001 0.000 -0.0010 0.0005 0.040 
HNDR 0.0001 0.0001 0.668 0.0028 0.0008 0.000 -0.0001 <0.0001 0.000 0.0003 <0.0001 0.000 -0.0007 0.0004 0.085 
HNSS -0.0002 0.0002 0.200 -0.0036 0.0009 0.000 -0.0002 <0.0001 0.000 -0.0020 <0.0001 0.000 0.0006 0.0005 0.213 
HNCO -0.0003 0.0002 0.153 -0.0006 0.0006 0.354 -0.0002 <0.0001 0.000 -0.0006 <0.0001 0.000 -0.0013 0.0008 0.091 
HNFI -0.0009 0.0002 0.000 0.0010 0.0008 0.231 -0.0011 <0.0001 0.000 -0.0178 <0.0001 0.000 -0.0015 0.0009 0.107 
HNPK -0.0002 0.0001 0.076 -0.0033 0.0005 0.000 -0.0004 <0.0001 0.000 0.0001 <0.0001 0.000 -0.0010 0.0003 0.003 
HNNU -0.0001 0.0001 0.403 -0.0009 0.0003 0.003 -0.0009 <0.0001 0.000 -0.0001 <0.0001 0.000 -0.0005 0.0004 0.169 
HNFE -0.0004 0.0002 0.127 0.0056 0.0013 0.000 -0.0011 <0.0001 0.000 -0.0019 <0.0001 0.000 0.0006 0.0006 0.280 
HNWL <0.0001 0.0001 0.886 -0.0035 0.0008 0.000 0.0001 <0.0001 0.000 -0.0006 <0.0001 0.000 0.0013 0.0004 0.001 
HNWG 0.0001 0.0001 0.063 -0.0012 0.0004 0.006 0.0003 <0.0001 0.000 -0.0004 <0.0001 0.000 0.0012 0.0003 0.000 
Female -0.0045 0.0106 0.671 0.1739 0.0324 0.000 0.0398 0.0001 0.000 0.0291 0.0008 0.000 0.0799 0.0356 0.025 
Age -0.0008 0.0004 0.043 0.0015 0.0021 0.468 -0.0001 <0.0001 0.000 0.0007 <0.0001 0.000 -0.0022 0.0016 0.185 
Probability (constant) 1.7280 0.2565 0.000 0.5257 0.3090 0.089    -1.3532 0.1775 0.000    
/lns -3.3359 0.0801 0.000 -3.0249 0.1533 0.000 -9.3988 0.2156 0.000 -6.5865 0.1233 0.000 -1.8746 0.0788 0.000 
Sigma 0.0356 0.0028  0.0486 0.0074  0.0001 <0.0001  0.0014 0.0002  0.1534 0.0121  
Probability 0.6765 0.0592  0.2033 0.0517  0.1202 0.0242  0.2053 0.0290  0.7946 0.0290  
Goodness-of-fit statistics                
AIC -504.67         -203.65      
BIC -283.49         -50.53      
MAE 0.0689         0.1022      
RMSE 0.1167         0.1375       
Mean 0.892         0.796      
SD 0.073         0.162      
Min 0.640         0.151      
Max 0.993         0.985      
Below 0 0; 0%         0; 0%      
Ceiling 1 0; 0%         0; 0%      
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; HNOM: opening mouth; HNSS: 
sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding tube; HNWL: weight loss; HNWG: weight gain. AIC: Akaike Information Criterion; BIC:  Bayesian 
Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SD: standard deviation; SE: standard error. 
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Figure 4.4 Scatterplots of observed versus predicted EQ-5D-5L for ALDVM models 
using QLQ-C30. 
 
 
 
 
Figure 4.5 Scatterplots of observed versus predicted EQ-5D-5L for ALDVM models 
using QLQ-H&N35. 
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4.4 Discussion 
This study mapped QLQ-C30 and H&N35 scales/items to EQ-5D-5L utilities in HNC 
patients, using data collected within the ongoing HETeCo trial. This is the first mapping 
study linking EQ-5D (either -3L or -5L) to QLQ-C30 (and H&N35) in HNC. The 
HERC database (version 6.0, last updated in January 2017) [165] [238] [239] currently 
includes 144 mapping studies that predict EQ-5D utilities from any disease-specific 
tool. Among them, 22 are related to cancer and 15 map from QLQ-C30. Moreover, 
PubMed was also searched using as keywords “mapping”, “EORTC”, “EQ-5D” and 
“cancer” to avoid missing any recent publication. In total, 15 articles mapping QLQ-
C30 onto EQ-5D in cancer were identified. Among them, only the most recent [226] 
predicts utility scores for the 5-level version, and none addresses HNC. However, as 
described in Chapter III, one study [195] maps the EQ-5D-3L from the UWQOL 
Questionnaire (UW QOL v4) collected from a cohort of HNC patients shortly after 
treatment using OLS regression with forward stepwise selection (p<0.05).  
In this chapter, three different techniques which are being favoured by the most recent 
mapping literature [63] [220] [226] have been tested. Overall, the linear mixed-effects 
and the multi-component ALDVM models outperform the random-effects Tobit models 
in terms of AIC/BIC goodness-of-fit measures, and therefore are considered for more 
detailed analyses; moreover, as observed in a previous study on breast cancer [237], 
mapping the general questionnaire (QLQ-C30) provides a better fit than using the 
cancer-specific module (H&N35) irrespective of the model’s specification.  
In linear-mixed models, a few recurrent significant QLQ-C30 scores are observed: 
physical functioning, which is composed by five items largely corresponding to the first 
three EQ-5D dimensions (mobility, self-care, and usual activity), emotional functioning 
which can relate to the anxiety/depression dimension of EQ-5D, and pain, resembling 
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the pain/discomfort dimension. Global health status, which is a 2-item scale 
synthesizing the self-percieved patient’s health and HRQoL, can be interpreted as a 
general metrics resembling EQ-5D utility. Other symptom scales/items such as nausea 
and vomiting or financial difficulties that show a significant impact of EQ-5D-5L utility 
are harder to interpret. Similarly, in models using H&N35, pain clearly corresponds 
with pain/discomfort, while trouble with social contacts and felt ill can be interpreted as 
parts of the anxiety/depression domain. It is not surprising instead that the coefficients 
of cognitive functioning, fatigue, and insomnia are never statistically significant across 
the models, since the use of EQ-5D in cancer has been recently questioned for not 
including dimensions related to ‘cognition’, ‘sleep’, and especially ‘vitality’, which has 
been found to be significant in determining HRQoL [38].  
This study presents a few limitations. First, the sample size is small (97 patients, 
225/226 paired observations in models using QLQ-C30/-H&N35), thus affecting the 
precision of the estimated coefficients, especially for the more complex mixture models, 
which were limited to three components as a maximum. In the recent systematic review 
by Dakin [238], only 15% of the algorithms mapping to EQ-5D had less than 200 
observations, and an equivalent proportion between 200 and 500. Thus, a re-evaluation 
of these models using a larger sample at the end of the trial is scheduled. Additionally, 
the limited number of observations prevented splitting the database by QLQ-C30/-
H&N35 levels, to verify how the goodness-of-fit varies according to disease severity 
[234] [237]. Second, some caution should be adopted in using these algorithms, since it 
is well known that RCTs tend to recruit healthier patients than those usually observed in 
routine practice [234]. Moreover, data used for this mapping are collected from patients 
who have successfully completed their curative treatment(s) for primary cancer and, 
thus, are likely to be healthier than the overall HNC patients’ population; their HRQoL 
measures, indeed, are overall quite high. Thus, using these mapping coefficients might 
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lead to biased QALY estimates in cost-utility models assessing novel interventions for 
patients with other characteristics or at different treatment stages. Moreover, all models 
tend to over/under predict EQ-5D at the extremes of the distribution, thus potentially 
affecting QALY results for seriously ill and end-of-life patients and, conversely, less 
severe ones. Third, unexpected significant positive coefficients were obtained for 
constipation, weight loss and weight gain, which are symptom scales calculated from 
QLQ-C30 and H&N35 responses. However, none of the studies retrieved from the 
literature have perfectly intuitive signs for the full sets of independent variables. Such 
counterintuitive signs for coefficients could be attributable to unknown relationships 
between QLQ-C30/-H&N35 scales/items within the regression models [237]. 
Moreover, these specific symptoms might also be interpreted in a positive sense for 
oncological patients, who often suffer from lack of appetite, diarrhoea, and cachexia 
[240]. Fourth, additional EQ-5D-5L country value sets are being added to the literature, 
as documented by frequent updates of the EuroQol website; thus, the list of seven tariff 
sets explored in this study cannot be considered exhaustive. Similarly, the selected 
regression techniques do not cover the whole spectrum of models proposed by the most 
recent literature. For example, Khan et al. suggested a non-linear beta binomial 
regression as a promising alternative that has shown an improved fit compared to 
traditional censored regression (e.g. Tobit) in modelling EQ-5D-5L data. This 
technique, indeed, can easily model skewed and multimodal data bound on a 0 to 1 
interval (although any range is suitable by applying an appropriate data transformation 
into 0-1) [216] [226]. Moreover, the small number of available EQ-5D-5L profiles in 
the study sample prevented the application of more advanced techniques such as 
indirect methods for mapping. Among them, response mapping fits separate ordinal (or 
multinomial) logistic regression models to each of the five EQ-5D dimensions; 
thereafter, the expected utility value is calculated analytically using coefficients from 
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any preference-based algorithm [215] [220], thus overcoming the issue of country-
specific mapping functions that are frequently available in the literature. However, the 
criterion of at least 10 observations for the smallest category usually applies to response 
mapping [215] and is not satisfied by the current database, which contains far less than 
10 observations for levels 4 and 5 in each EQ-5D dimension (except for the usual 
activities dimension, level 4). 
4.5 Conclusions 
The developed functions are useful to obtain utility values in HNC clinical studies not 
collecting preference-based HRQoL data. Of the 1,815 HNC studies identified on 
ClinicalTrials.gov (accessed in November 2017), which is a database of privately and 
publicly funded clinical studies conducted worldwide, only 16 reported EQ-5D as an 
outcome measure, while QLQ-C30 and H&N35 (together or as stand-alone 
questionnaires) were adopted by 53 clinical trials; thus, studies using EORTC 
questionnaires only could obtain HSUVs by applying the algorithms presented in this 
chapter in order to perform trial-based cost-utility analyses. Moreover, since QLQ-C30 
data were modelled alone, this study can inform also cost-utility analyses in other 
cancer types; however, the generalizability of the developed functions to a different 
cancer dataset should be carefully evaluated since, even for the same cancer, 
oncological patients vary widely in age, gender, and disease severity [219]. 
Additionally, models are developed using alternative value sets for selected countries, 
thus future researchers can select the preferred one according to the geographical area 
where the study is conducted. According to the most recent guidelines [153] [220], re-
estimation of mapping results in an alternative dataset or other forms of evaluation (e.g. 
cross-sample validation) are not routinely required, especially for studies using small 
databases. However, the assessment of the algorithms’ external validity in a larger 
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sample of HNC data may be of interest. Overall, the ALDVMM appears as a promising 
technique to model EQ-5D-5L data for mapping purposes, although the limited size of 
the database prevented the application of multi-component models for the full set of 
country tariffs. Further research is encouraged on this topic, as new country algorithms 
are being developed to value EQ-5D-5L and made progressively available on the 
EuroQol website. An Italian value set is particularly warranted for this study, since data 
are collected from HNC patients in Italy. 
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5 THE USE OF INTENSIVE RADIOLOGICAL 
ASSESSMENTS IN ROUTINE SURVEILLANCE AFTER 
TREATMENT FOR HEAD AND NECK CANCER: AN 
ECONOMIC EVALUATION  
5.1 Introduction 
HNC is a major public issue worldwide that causes significant morbidity and mortality 
despite clinical advances in diagnosis and treatment [241]. As anticipated in Chapter I, 
in Europe alone, around 143,000 people are diagnosed and more than 68,000 die each 
year because of the disease [17]. The incidence in Italy is about 16 cases per 100,000, 
half of whom are aged between 50 and 70; the male-female ratio is around 6:1 [3] [6]. 
Despite the routine introduction of combined-modality treatment, the 5-year overall 
survival rate is 40% to 60%, varying by age, cancer site and disease stage [1] [6] [61]. 
When diagnosed at a locally advanced stage, HNC tends to recur, with up to 50% of 
patients developing loco-regional or metastatic recurrences in the first few years after 
treatment depending on site [10] [25] [61] [242] [243] [244]; additionally, a constant 
rate of 2-3% per year of second primaries is observed [21] [22].  
A few patients with loco-regional recurrences or second primaries can be salvaged by a 
potentially curative treatment with a possibility of long-term survival but a significant 
chance of treatment-related toxicity and intra-operative mortality [16] [17] [61]. Surgery 
is traditionally considered the treatment of choice for patients with a resectable loco-
regional recurrence or a second primary and sufficiently good health status. In the last 
decade, high-dose re-irradiation has also shown reasonable improvements in loco-
regional control and overall survival although at the expense of high, potentially life-
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threatening toxicities (e.g. carotid rupture, fistula, bleeding) [25] [245]. Unfortunately, 
most recurrent patients are only suitable for palliative treatment that, in addition to best 
supportive care, usually includes systemic treatment with a combination of 
chemotherapeutics [26] [246]. The prognosis for patients with recurrent or metastatic 
disease not eligible for surgery or re-irradiation is very poor, with a median overall 
survival of around 10 months under the standard scheme of platinum-based 
chemotherapy plus cetuximab (i.e. an epidermal growth factor receptor – directed 
monoclonal antibody) [242] [247].  
As extensively argued in Chapter I, a follow-up program is essential in the first few 
years after primary treatment to identify potentially curable relapses. However, there is 
no consensus in the medical community around the optimum timing of visits and 
number of radiological assessments to be carried out in this phase. Published 
recommendations are mostly based on retrospective studies and expert opinions, and 
clinical practice varies across countries, hospitals, and individual specialists [16] [32]. 
In particular, the added value of an intensive radiological assessment over a scheme 
based on self-reported symptoms (e.g. increased local pain, difficulty in swallowing, 
development of a new lump in the neck or other local symptoms) has not yet been 
confirmed in any prospective randomized study.  
The research question for this study originated from the HETeCo trial [33], although 
most of the data are retrieved from other sources and combined in a model-based 
framework. This chapter, indeed, presents an exploratory model assessing the cost-
effectiveness of the two strategies under evaluation in the ongoing RCT, where an 
intensive follow-up with frequent radiological investigations (including MRI, CT, and 
PET scans) is compared with minimal, symptom-based surveillance. A secondary 
objective is to identify the extent to which further collection of data from the trial is 
valuable for reducing the uncertainties that inevitably affect the model. The analyses 
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have been reported according to the CHEERS requirements for economic evaluations 
[73] (Table A5.1). 
5.2 Methods 
A decision-analytic Markov model is developed to assess the long-term health and 
economic consequences of the two strategies compared in the HETeCo trial. The model 
is populated using data from a variety of sources, including a retrospective study [248] 
conducted at the NCI (Milan, Italy) to replicate the pattern of cancer recurrences 
detected in the model; this study also acted as hypothesis generator for the trial. 
Additional parameters are obtained from the medical literature and expert opinion. The 
cost analysis is conducted from the perspective of a major Italian region (i.e. 
Lombardy). 
5.2.1 Clinical studies 
Full details regarding the HETeCo trial are reported in the protocol [33] and in Chapter 
I. Briefly, patients with a diagnosis of clinical or pathological stage III-IV squamous 
HNC in the oral cavity, oropharynx, larynx, or hypopharynx and without evidence of 
disease six months (± 1) after having received radiotherapy with curative intent (alone 
or with systemic therapy or in postoperative setting) are randomly allocated to one of 
two follow-up programs. The primary objective of the trial is to compare the two-year 
health outcomes and costs arising from two different surveillance schemes after primary 
treatment for HNC. Secondary objectives include the assessment of the number of 
potentially salvageable recurrences or second primaries, the cause-specific survival, and 
the overall survival in the two study groups.  
The trial plans to randomize 330 patients (i.e. 165 per arm) to two alternative 
surveillance schemes. The non-intensive follow-up (arm A), designed according to the 
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NCCN guidelines [34], comprises a few outpatient visits depending on cancer subsite. 
At each visit, patients receive both physical and fibre optic endoscopic examinations; 
laboratory tests including complete blood count and renal, hepatic, and thyroid function 
are performed once a year. Radiological assessment through MRI or CT is performed 
within six months of completion of treatment and thereafter only at the occurrence of 
new signs or symptoms. Patients are instructed how to recognize signs or symptoms of 
disease recurrence and contacted by phone between visits to monitor any health changes 
that might be related to cancer recurrence.  
The alternative strategy (arm B) is a more intensive follow-up where outpatient visits 
are performed similarly to arm A, including fibre optic endoscopic examinations and 
laboratory tests. Imaging (MRI or CT) tests are scheduled for all patients twice a year in 
the first two years and annually in the third and fourth years. The choice between MRI 
and CT is made in accordance with institutional policies, but MRI is preferred for all 
subsites except for laryngeal cancer. PET scans are performed annually in the first three 
years in patients aged ≥50 years and with a smoking history of ≥20 pack/years.  
Before starting the trial, a retrospective study was conducted at the NCI where the 
medical charts of 326 patients affected by stage III or IV HNC without evidence of 
disease 6 months after being treated with chemo-radiotherapy between 1998 to 2010 
were reviewed [248]. According to the hospital’s guidelines, all patients were enrolled 
in a 5-year follow-up program of outpatient visits and radiological examinations (i.e. 
MRI, CT, and PET), with frequency decreasing over time. In total, 113 patients (35%) 
were diagnosed with a recurrence or a second tumour. Specifically, 38 out of 113 (34%) 
cases presented loco-regional recurrences, 44 (39%) distant metastases and 31 (27%) 
second primary tumours; most recurrent patients (84%) were diagnosed during the first 
3 years of follow-up.  
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5.2.2 Model structure 
Figure 5.1 Markov state-transition diagram.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend. A hypothetical cohort of 1,000 62-year-old patients (i.e. mean age of the trial population) enter 
the model in the no evidence of disease (NED) state after the end of primary treatment. The individuals 
move between the health states based on a set of monthly transition probabilities. The symbol * indicates 
a temporary state, i.e. patients are not allowed to stay more than 1 cycle-month. 
A Markov state-transition model (Figure 5.1) with mutually exclusive health states is 
developed to predict the lifelong costs and effects from the two follow-up strategies 
under investigation in the HETeCo trial. The choice of model was informed by a 
systematic literature review of economic evaluation studies in cancer follow-up 
(Chapter II) and previously published health economic models in HNC [157] [249]. 
Most of the reviewed studies, indeed, developed a Markov model to conduct cost-
effectiveness analyses, whereas only few chose a discrete event simulation (DES) 
approach, which is not considered for this study due to the current unavailability of 
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individual-level patient data from the HETeCo trial to calibrate the model [85] [86]. 
Additionally, extensive discussions were conducted at the NCI with clinical experts 
including a medical oncologist, a radiotherapist, and a surgeon. The choice of 
classifying the model’s health states based on the type of secondary treatment 
administered instead of the type of cancer relapse diagnosed (i.e. loco-regional 
recurrence, distant metastasis or second primary) was agreed with the clinicians and 
justified by more meaningful health and economic consequences being associated with 
alternative treatment options. The clinical opinion was particularly relevant to identify 
two alternative paths within the model for surgically treated and re-irradiated recurrent 
patients, respectively. All the clinical experts involved in this study approved the final 
model structure. 
The model simulates the experience of a hypothetical cohort of 1,000 patients after 
being treated for primary stage III-IV HNC; mean age and gender ratio are 
representative of the patients enrolled in the trial (until May 2016). All patients enter the 
model free of disease six months after curative treatment for primary cancer and move 
through the different health states according to a set of transition probabilities. 
Recurrent patients are divided based on the intent of the treatment received (i.e. 
potentially curative or palliative); patients treated with curative intent are assigned to 
‘surgery’ or ‘re-irradiation’ states to capture the different costs and outcomes arising 
from the two therapeutic options. Patients without progression remain in the ‘no 
evidence of disease’ health states; the final, absorbing state is ‘death’. The cycle length 
of the model is one month with a lifetime horizon. Utility values ranging from 0 (death) 
to 1 (perfect health) and costs are applied to the time spent in each health state. The 
model is run until the whole cohort (i.e. >99%) dies to estimate differences in life 
expectancy (i.e. LYG), quality-adjusted life expectancy (i.e. QALYs) and long-term 
costs associated with the two follow-up schemes.  
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5.2.3 State-transition matrix 
Table 5.1 reports the clinical parameters derived from the published literature, 
unpublished data, and expert opinion; Table 5.2 presents the state-transition matrix with 
monthly transition probabilities between states, which are mainly derived from a 
combination of clinical parameters. Using the information from the retrospective study 
[248], the overall risk of relapse (i.e. local-regional recurrences, metastases and second 
primaries) is estimated at 29% in the first 3 years and 6% in the last two years of 
follow-up; 80% of the curable relapses undergo surgery and the remaining 20% are 
treated with re-irradiation. This recurrence risk is broadly similar to that reported by a 
recent study [244], which estimated the proportion of disease events (i.e. recurrence or 
death) to be 38% at 36 months. The proportion of potentially salvageable recurrences 
during follow-up in the study arm A (25%) is derived from the literature [250], while 
the percentage in group B (50%) is a clinical assumption of the HETeCo trial, which is 
intended to test whether a more intensive radiological assessment could detect a higher 
rate of salvageable relapses. In both groups, a 3% annual risk of second primary 
tumours is assumed from the 6th year onwards [21] [22], 47% of which are considered 
as curable [248]. As a simplification, all second primaries are hypothesized to affect the 
head and neck region in the model, disregarding other cancer localizations such as lung 
and oesophagus, and surgery is considered the only potentially curative treatment for 
second primaries. The ‘potentially curative treatment’ state is assumed temporary, 
meaning that each patient can only remain in it for one cycle. Indeed, the average length 
of hospitalization after salvage surgery has been reported as 30 days [251]. Up to 5% of 
the patients undergoing each salvage treatment (i.e. surgery or re-irradiation) are 
expected to die for causes related to re-treatment [252] [253]. The risk of relapsing after 
secondary treatment is estimated at 3% monthly, based on published studies [251] [253] 
[254]. These studies report almost the same value for salvage surgery and re-irradiation; 
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moreover, this parameter is consistent with the 0.009 weekly (i.e. 0.034 monthly) 
adopted by a previous cost-effectiveness model in HNC in Italy [157]. Any recurrence 
(or second primary) beyond the first is assumed to be treated with palliative intent only 
[192]. Patients receiving palliative chemotherapy are assumed to have a median survival 
of 10 months, corresponding to a 1-year overall survival of around 43% (equivalent to a 
6.6% monthly mortality) [247] [255]; this value is comparable with the data reported by 
a review study [25] translated into a monthly probability (i.e. 6.8%). In each health state 
patients also experience a general risk of dying for reasons other than HNC; mortality 
rates for 5-year age groups divided by gender are obtained from official statistics for 
Lombardy [256]; a weighted monthly risk of dying is calculated by using the male-
female ratio existing among the first 60 patients enrolled in the trial. Annual probability 
values reported in the literature are transformed into monthly probabilities using the 
appropriate formula linking probabilities and rates: p = 1-exp(-r*t) where p is 
probability, r is rate and t is the time expressed in months or years [257]. 
Table 5.1 Clinical parameters. 
 Value Distribution Source 
Male proportion 0.87 Beta  α=52 β=8 HETeCo trial* 
% of laryngeal cancer (requiring CT 
instead of MRI) 
0.22 Beta  α=13 β=47 HETeCo trial* 
% of patients receiving PET (arm B) 0.57 Beta  α=34 β=26 HETeCo trial* 
Recurrence risk over follow-up (5 
years) 
0.35 Beta  α=113 β=213 [248] 
% recurrences in the first 3 years 0.84 Beta  α=15.2 β=2.9 [248] 
Ratio surgery/re-irradiation 80:20 Beta  α=19.2 β=4.8 Clinical opinion 
Potentially curable relapses (arm A) 0.25 Beta  α=74.8 β=224.3 [250] 
Potentially curable relapses (arm B) 0.50 Beta α=49.5 β=49.5 Clinical opinion 
Annual risk of second primaries (6th 
year onwards) 
0.03 Beta α=97.0 β=3135.4 [21] [248] 
Potentially curable second primaries 
(6th year onwards) 
0.47 Beta α=15 β=16 [248] 
% of patients receiving home-based 
palliative care 
0.135 Beta α=20,985 β=134,461 [258] 
% of patients admitted to the 
hospital in the last month of life 
0.78 Beta α=8,947 β=2,523 [259] 
* Trial preliminary data (n=60 patients). HETeCo: Health and Economic Outcomes of Two Different Follow Up 
Strategies in Effectively Cured Advanced Head and Neck Cancer; MRI: magnetic resonance imaging; CT: computed 
tomography; PET: positron emission tomography; RCT: randomized controlled trial. 
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Table 5.2 State-transition matrix.  
Monthly transition probabilities (from/to) Value Distribution Source 
NED (after primary treatment) 
Years 1st-3rd  
NED (after primary treatment) 1-others **    
Salvageable recurrence (surgery) A: 0.0019 **   [248]; Clinical 
opinion B: 0.0038 
Salvageable recurrence (re-irradiation) A: 0.0005 **   [248]; Clinical 
opinion B: 0.0010 
Non-salvageable recurrence (chemotherapy/palliative 
care) 
A: 0.0072 **   [248]; Clinical 
opinion B: 0.0048 
Death (for other causes) * 0.0032 Fixed   [256] 
NED (after primary treatment) 
Years 4th -5th  
NED (after primary treatment) 1-others **   [248]; Clinical 
opinion 
Salvageable recurrence (surgery) A: 0.0005 **   [248]; Clinical 
opinion B: 0.0010 
Salvageable recurrence (re-irradiation) A: 0.0001 **   [248]; Clinical 
opinion B: 0.0002 
Non-salvageable recurrence (chemotherapy/palliative 
care) 
A: 0.0018 **   [248]; Clinical 
opinion B: 0.0012 
Death (for other causes) * 0.0032 Fixed   [256] 
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Table 5.2 (cont.) State-transition matrix.  
Monthly transition probabilities (from/to) Value Distribution Source 
NED (after primary treatment) 
From the 6th year onwards 
NED (after primary treatment) 1-others **    
Salvageable recurrence (surgery) 0.0012 **   [248] 
Non-salvageable recurrence (chemotherapy/palliative 
care) 
0.0013 **   [248] 
Death (for other causes) 0.0032 Fixed   [256] 
Salvageable recurrence (surgery) NED (after salvage surgery) 1-others **    
Treatment-related death 0.0380 Beta α=10 β=251 [252] 
Death (for other causes) * 0.0032 [256] 
Salvageable recurrence (re-irradiation) NED (after re-irradiation) 1-others **    
Treatment-related death 0.0490 Beta α=2 β=39 [253] 
Death (for other causes) 0.0032 Fixed   [256] 
NED (after salvage surgery) NED (after salvage surgery) 1-others **    
Non-salvageable recurrence (chemotherapy/palliative 
care) 
0.0300  α=26 β=13 [251] 
Death (for other causes) * 0.0032 Fixed   [256] 
NED (after re-irradiation) NED (after re-irradiation) 1-others **    
Non-salvageable recurrence (chemotherapy/palliative 
care) 
0.0300  α=0.03 β=0.90 [253] 
Death (for other causes) * 0.0032 Fixed    
Non-salvageable recurrence 
(chemotherapy/palliative care) 
Non-salvageable recurrence (chemotherapy/palliative 
care) 
1-others **    
Death from HNC 0.0660 Beta α=93.3 β=1,320.8 [247] [255] 
Death (for other causes) * 0.0032 Fixed   [256] 
* The death rate is reported only for the age group 60-64 years corresponding to the age when the model starts. **These parameters are obtained from a combination of other values; thus, distributions 
are assigned to original values only. HETeCo: Health and Economic Outcomes of Two Different Follow Up Strategies in Effectively Cured Advanced Head and Neck Cancer; HNC: head and neck 
cancer; NED: no evidence of disease. 
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5.2.4 Health state utility values 
The utility parameters are summarized in Table 5.3 and, since the HETeCo trial does 
not collect HRQoL measures after the patient is diagnosed with recurrence, mainly 
identified by a systematic literature review of HSUVs in HNC (Chapter III). An average 
utility value for the ‘no evidence of disease’ state (i.e. study recruitment time) is 
calculated from the EQ-5D-5L trial data using the English value set [227], in the 
absence of an Italian value set; the same value (i.e. 0.85) is confirmed by a cross-
sectional study [186] recruiting a comparable population (i.e. HNC patients with a 
follow-up of at least 6 months after curative radiotherapy). Utility values for re-
treatment health states are retrieved from a Canadian study [155] using the standard 
gamble technique to elicit preferences from the public; the value for the “non-
salvageable recurrence” state also corresponds to that adopted (i.e. 0.33) by another 
HNC model study [157]. The utility parameter for the ‘no evidence of disease’ state 
after salvage surgery (i.e. 0.62) comes from a study [172] of HNC patients with no 
evidence of disease three months after completion of treatment and using several 
measurement methods, including EQ-5D; the same value is applied to patients treated 
with re-irradiation.  
Table 5.3 Utility parameters. 
Health state Value Distribution Source 
NED (after primary treatment) 0.85 Beta α=1337.1 β=236.0 HETeCo trial *; 
[186] 
Salvageable recurrence (surgery) 0.57 Beta α=348.7 β=263.1 [155] 
Salvageable recurrence (re-irradiation) 0.57 Beta α=348.7 β=263.1 [155] 
NED (after salvage surgery) 0.62 Beta α=22.2 β=13.6 [172] 
NED (after re-irradiation) 0.62 Beta α=22.2 β=13.6 Assumption 
Non-salvageable recurrence 
(chemotherapy/palliative care) 
0.34 Beta α=190.4 β=369.6 [155] 
Death 0.00 Fixed   Assumption 
* Trial preliminary data (n=60 patients). NED: no evidence of disease; HETeCo: Health and Economic Outcomes of 
Two Different Follow Up Strategies in Effectively Cured Advanced Head and Neck cancer. 
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5.2.5 Cost data 
The cost analysis is conducted using a top-down approach from the perspective of the 
Lombardy regional healthcare system and thus includes only direct medical costs. Data 
on costs (not publicly available) are from Diagnosis-Related Groups (DRGs) and other 
regional tariffs (year 2016) for hospital admissions, specialist visits, radiological exams, 
laboratory tests and outpatient treatment regimens (Table 5.4). The cost of each follow-
up program (A or B) performed in the ‘no evidence of disease’ state is calculated for 5 
years (i.e. standard length of HNC follow-up in Italy and abroad), according to the 
description provided in the trial protocol in terms of healthcare resources consumption. 
An average monthly cost of around €12 is estimated for follow-up A, while two 
different monthly costs (€92 up to the 3rd year and €15 from the 4th year onwards) are 
estimated for follow-up B, recognizing that most radiological assessments are 
performed during the first three years. Using data from the first 60 patients enrolled in 
the trial, the cost of CT and MRI scans is weighted by the proportion of laryngeal and 
non-laryngeal cancers, respectively, while the PET cost is considered only for heavy 
smokers (i.e. ≥20 pack/years) aged more than 50. No surveillance costs are assumed 
from the 6th year onwards (Table 5.5). Patients surviving the ‘potentially curative 
treatment’ states are assumed to be monitored within a program of physical 
investigations resembling the less intensive scheme (arm A) with the primary objective 
of managing any re-treatment side effects. Since patients enter the ‘no evidence of 
disease’ state three months after salvage treatment at different times in the model, the 
monthly cost of this “secondary” follow-up is weighted by the proportion of people 
actually receiving the intervention at each cycle. The cost of salvage surgery is valued 
according to DRG 49 (i.e. major head and neck surgery). Re-irradiation is assumed to 
be prescribed as a cycle of intensity modulated radiation therapy (IMRT) sessions over 
a 5-week period (approximated at one month in the model) based on current practice in 
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Lombardy. Each re-irradiation cycle (≥5 sessions) is reimbursed at €10,000 and 
includes any specialist visit or examination that might be performed during the 
treatment. The standard platinum-based chemotherapy supplemented with 5-
fluoraouracil (5FU) and cetuximab is used for recurrences treated with palliative intent 
[247]. Monthly administration of cisplatin+5FU and weekly administration of 
cetuximab until one month before death is assumed in the model based on expert 
opinion. The average monthly cost of chemotherapy for the ‘palliatively treated 
recurrence’ state takes account of the higher drug dosage during the first administration 
of cetuximab. In Lombardy, the reimbursement of high cost chemotherapeutics, such as 
cetuximab, comprises the drug acquisition cost on behalf of the hospital plus a fixed 
tariff (MAC01) covering a preliminary specialist visit, laboratory exams and the drug 
administration. Additionally, an average cost of dying from HNC is assigned to each 
patient entering the ‘palliatively treated recurrence’ state calculated from published cost 
data for Italy according to the estimated consumption of formal end-of-life care (i.e. 
home-based assistance and hospital care). In detail, the proportion of terminally ill 
cancer patients receiving palliative care at home is estimated at 13.5% [258] at a cost of 
€2,100 [260]. Moreover, 78% of cancer patients [259] are assumed to be hospitalized in 
the last month of life at a cost of €4,000 [261]. The cost of alternative services (e.g. 
hospice and nursing home) is disregarded since it applies to less than 10% in Italy 
[258]. Monthly cost values for all model health states are reported in Table 5.6. 
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Table 5.4 Unit costs (€, 2016). 
 Value Code Source 
Treatments    
Major head and neck surgery 5,444 DRG 49 Regional tariff  
Intensity modulated radiation therapy, including computed 
tomography (more than 5 sessions) 
10,000 92.29.L Regional tariff 
Administration of high-cost chemotherapeutics (including 
specialist visits and laboratory tests) 
44.00 MAC01 Regional tariff 
Cetuximab (100 mg) * 153.56  File F 
Cisplatin (50 mg) * 5.09  Local charge 
5-Fluorouracil (500 mg) * 1.72  Local charge 
Home-based palliative care (100 days) 2,100  [260] 
Hospital admissions one month before death 4,000**  [261] 
Imaging    
Computed tomography of head and neck with contrast 159.93 87.03.1/8 Regional tariff 
Magnetic resonance imaging of head and neck with 
contrast 
238.87 88.91.7 Regional tariff 
Positron emission tomography (brain) 1,081.86 92.11.7 Regional tariff 
Specialist visits    
First visit 22.50 89.7B.6 Regional tariff 
Control visit 17.90 89.01.F Regional tariff 
Laboratory tests    
Blood cell count 4.05 90.62.2 Regional tariff 
Urea 1.70 90.44.1 Regional tariff 
Creatinine blood test 1.70 90.16.3 Regional tariff 
Sodium 1.70 90.40.4 Regional tariff 
Potassium 1.70 90.37.4 Regional tariff 
Calcium 1.70 90.11.4 Regional tariff 
Aspartate aminotransferase 1.70 90.09.2 Regional tariff 
Alanine aminotransferase 1.70 90.04.5 Regional tariff 
Bilirubin 1.70 90.10.4 Regional tariff 
Alkaline phosphatase 1.70 90.23.5 Regional tariff 
Thyrotropin 8.40 90.42.1 Regional tariff 
Free thyroxin 9.50 90.42.3 Regional tariff 
Other    
Phone call (cost/minute) 0.10  Telecom Italia 
* Drug costs are value-added tax (VAT) excluded. ** This value is approximated from a graph. DRG: diagnosis-
related group; MAC: macro ambulatory activity of high complexity. 
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Table 5.5 5-year follow-up costs in the HETeCo trial arms (A and B). 
  Follow-up (arm A) Follow-up (arm B) 
 Unit cost 
(€) 
Quantity  
(5 years) 
Total cost  
(€, 5 year) 
Quantity  
(3 years) 
Quantity  
(2 years) 
Total cost  
(€, 3 years) 
Total cost  
(€, 2 years) 
Total cost  
(€, 5 years) 
Specialist visit (first) 22.5 1 22.50 1 0 22.50 0.00 22.50 
Specialist visit (control) 17.9 14 250.60 10 4 179.00 71.60 250.60 
Blood cell count 4.05 6 24.30 4 2 16.20 8.10 24.30 
Urea 1.7 6 10.20 4 2 6.80 3.40 10.20 
Creatinine blood test 1.7 6 10.20 4 2 6.80 3.40 10.20 
Sodium 1.7 6 10.20 4 2 6.80 3.40 10.20 
Potassium 1.7 6 10.20 4 2 6.80 3.40 10.20 
Calcium 1.7 6 10.20 4 2 6.80 3.40 10.20 
Aspartate aminotransferase 1.7 6 10.20 4 2 6.80 3.40 10.20 
Alanine aminotransferase 1.7 6 10.20 4 2 6.80 3.40 10.20 
Alkaline phosphatase 1.85 6 11.10 4 2 7.40 3.70 11.10 
Bilirubin 1.7 6 10.20 4 2 6.80 3.40 10.20 
Thyrotropin 8.4 6 50.40 4 2 33.60 16.80 50.40 
Free thyroxin 9.5 6 57.00 4 2 38.00 19.00 57.00 
CT (% larynx*) 159.93 1 (0.22) 35.18 5 (0.22) 1 (0.22) 175.92 35.18 211.11 
MRI (% all other subsites*) 238.87 1 (0.78) 186.32 5 (0.78) 1 (0.78) 931.59 186.32 1117.91 
Phone call** 0.10/min 10 10.00 0 0 0 0  
PET (% ≥50 years and ≥20 pack/years*) 1081.86 0 0 3 (0.57) 0 1849.98 0 1849.98 
Total    729.00   3308.60 367.90 3676.50 
Total (monthly)   12.15   91.91 15.33 61.27 
*Trial preliminary data (n=60 patients). ** Each call is assumed to last 10 minutes. MRI: magnetic resonance imaging; CT: computed tomography; PET: positron emission tomography.  
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Table 5.6 Health state description and monthly costs. 
Health state Description Cost (€) 
NED (after primary treatment): 
follow-up A 
5-year follow-up program based on NCCN guidelines. Frequency of outpatient visits depending on 
cancer subsite. Laboratory tests performed once a year. Loco-regional imaging (MRI/CT*) performed 
within six months after treatment end and then recommended only at the occurrence of new signs or 
symptoms. Inter-visit phone calls to monitor patient’s symptomatology. 
12.1 
No costs from the 6th year onwards 
NED (after primary treatment): 
follow-up B 
Alternative 5-year follow-up program. Frequency of outpatient visits depending on cancer subsite. 
Laboratory tests performed once a year. Loco-regional imaging (MRI/CT*) requested two times/year 
in the first two years and once/year in the third and fourth years. PET scan performed yearly in the 
first three years only in high-risk patients (≥50 years and ≥20 pack/years). 
Up to the 3rd year: 91.9 
From the 4th year: 15.3 
No costs from the 6th year onwards 
Salvageable recurrence (surgery) Major head and neck surgical intervention with excision of tumour and surrounding tissues. Hospital 
stay of around one month. 
5,444 
 
Salvageable recurrence (re-irradiation) Intensity-modulated radiation therapy with curative intent five days a week for 5-6 weeks. 10,000 
NED (after salvage surgery/re-
irradiation) 
Same program described in NED (after primary treatment), follow-up A 12.1 
No costs from the 6th year onwards 
Non-salvageable recurrence 
(chemotherapy/palliative care) 
Combined treatment of platinum-based chemotherapy plus 5-fluorouracil (once a month) and 
cetuximab (once a week) administered up to one month before death. 
End-of-life care consisting in home-based palliative care and hospital admissions during the last 
month of life. 
Chemotherapy (1st month): 
3,720.0 
Chemotherapy: (2nd month 
onwards): 3,263.9 
(Average) monthly cost: 3,063.3** 
End-of-life care***: 3,403.5 
*MRI is preferred for all HNC subsites except for larynx. **The average monthly cost for chemotherapy (including administration) is calculated based on an average stay of 14 months in the “non-
salvageable recurrence” state. A gamma distribution (α=100; β=30.6) is assigned to the obtained value (€3,063.3).  ***End-of-life care cost is calculated as 13.5%*2,100+78%*4,000= €3,403.5 over a 
3-month period and assigned to all patients entering the “non-salvageable recurrence” state. MRI: magnetic resonance imaging; CT: computed tomography; PET: positron emission tomography; NCCN: 
National Comprehensive Cancer Network; NED: no evidence of disease.  
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5.2.6 Cost-effectiveness analysis 
Health outcomes (i.e. LYG and QALYs gained) and total costs are combined into an 
ICER= 
𝐶𝑜𝑠𝑡 𝐵−𝐶𝑜𝑠𝑡𝐴
LYsB−LYsA
) and ICUR = 
𝐶𝑜𝑠𝑡 𝐵−𝐶𝑜𝑠𝑡𝐴
QALYsB−QALYsA
 to represent the incremental cost 
of achieving one unit of health outcome when an intensive follow-up strategy (arm B) 
replaces a less intensive one (arm A). The ICUR obtained is compared with the range of 
€25,000-€40,000 [262] recommended by the Italian Health Economics Association to 
assess the cost-effectiveness of healthcare interventions. All costs and outcomes are 
discounted at 3% (converted to 0.247% monthly) following the same guidelines and 
expressed in Euro (€) 2016.  
5.2.7 One-way sensitivity analysis 
One-way sensitivity analyses explore the robustness of the base-case results by varying 
some key model parameters one at a time. First, the cost of salvage surgery is varied 
between €5,280.68 and €5,607.32 according to the hospital type as reported by official 
tariffs for Lombardy. Second, the annual discount factor for costs and outcomes is 
increased up to 3.5%, as recommended by NICE [263]. Third, the risk of overall relapse 
during follow-up is increased up to 50%, as reported by other studies [10]. Fourth, 
treatment-related mortality is set at zero reflecting a study [251] which reported no 
perioperative deaths in patients undergoing salvage surgery, although the sample size is 
very small (i.e. 41 patients) compared to the study used in the base case scenario 
(n=261) [252]. Similarly, the risk of dying because of re-irradiation-related toxicities is 
set equal to the lowest (i.e. 0%) and the highest (i.e. 11%) values from studies on IMRT 
and systematically reported in a review [26]. An intensive program of radiological 
assessments after a salvage treatment is not justifiable by any survival gains in case of a 
second recurrence; therefore, the base-case analysis applies the less intensive program 
cost to the ‘no evidence of disease’ state after surgery or re-irradiation. The impact of 
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this assumption is explored by assuming that patients have the same follow-up 
intervention (A or B) received in the ‘no evidence of disease’ state after primary 
treatment. 
5.2.8 Two-way sensitivity analysis 
A two-way sensitivity analysis is performed to assess the simultaneous effect of varying 
the proportion of salvageable recurrences in arm A and in arm B, with all else 
unchanged in the model. Cost-effectiveness is determined with respect to the Italian 
thresholds of €25,000 and €40,000 per QALY [262]. This analysis is important because 
of the uncertainty surrounding this parameter based on published literature and clinical 
opinion and not yet confirmed by the ongoing RCT.  
5.2.9 Probabilistic sensitivity analysis 
A probabilistic sensitivity analysis (PSA) is performed using Monte Carlo simulation 
with 5,000 random iterations from the distributions assigned to the model parameters. 
This is only undertaken for the ICUR, since a stated threshold for the cost per LYG is 
not available. A beta distribution is chosen for transition probabilities and utility values. 
If count data are not available, beta distributions are fitted using the ‘methods of 
moments’ based on the mean value and standard errors reported in the studies [257]. If 
neither standard error is available, a variance equal to 10% of the mean is arbitrarily 
assumed. No distributions are assigned to the cost values based on official tariffs (e.g. 
salvage surgery). However, when the cost assigned to a health state is obtained through 
a combination of different items, the proportion of users (e.g. patients receiving home-
care palliative care) is varied using a beta distribution or the cost itself (e.g. the cost of 
palliative chemotherapy) is varied using a gamma distribution. A cost-effectiveness 
scatterplot illustrates the uncertainty surrounding the base-case ICUR; cost-
effectiveness acceptability curves (CEACs) are also calculated to quantify the 
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probability that the more intensive follow-up (i.e. arm B) would be deemed cost-
effective at different threshold values. 
5.2.10 Expected value of perfect information 
The decisions based on existing information are inevitably uncertain, and this 
uncertainty can lead to the ‘wrong’ decision being made; in the present study, this 
would mean the adoption of a follow-up program that is not cost-effective in HNC. The 
expected value of perfect information (EVPI) represents the ‘value’ of obtaining perfect 
knowledge of the ‘true’ values of all parameters used in a model. In other words, it can 
be interpreted as the maximum amount the decision-maker is willing to pay to obtain 
perfect information [249]. Based on the non-parametric approach presented by Briggs et 
al. [257] and Oostenbrink et al. [264], the per patient EVPI is calculated as the 
difference between the expected net monetary benefit (NMB) with perfect information 
and the NMB under the current condition of uncertainty. Thereafter, since information 
is a non-rival public good, the population EVPI is calculated for the total number of 
potential beneficiaries of reducing the model’s uncertainty. The total number of incident 
HNC cases is estimated at 13,000 yearly in Italy [265] and 60% of them are locally 
advanced patients treated with combined modality therapy [17]; of these, about 10% 
recur locally or distantly shortly after treatment [266]; thus, around 7000 patients are 
estimated to be free of disease for at least six months and enter a regular follow-up 
program. The population EVPI is discounted at 3% on annual basis over a 10-year 
period (i.e. the expected lifetime of the programs under evaluation) [126]. 
The decision model is implemented in Microsoft Excel 2013 with the support of 
@RISK software (Palisade Corp) for the sensitivity analyses. 
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5.3 Results 
5.3.1 Base-case analysis 
The cost-effectiveness results are presented in Table 5.7. The extra-cost per patient 
enrolled in the more intensive follow-up (arm B) is €1,903 compared to the less 
intensive option (arm A). At the same time, the addition of routine radiological 
investigations leads to an increase of 0.10 QALYs and 0.15 LYG per patient. Thus, the 
ICUR results in €19,951 per QALY gained and the ICER in €13,123 per LYG.  
Table 5.7 Cost-effectiveness results (base-case analysis). 
 Costs 
(€) * 
Incremental 
costs (€) 
QALYs* Incremental 
QALYs 
LYs* Incremental 
LYs (LYG) 
ICUR 
(€) 
ICER 
(€) 
Follow-
up A 
16,895  5.36  6.61    
Follow-
up B 
18,798 1,903 5.45 0.10 6.75 0.15 19,951 13,123 
*Costs and outcomes (QALYs, LYs) are reported per patient. LYs: life years; LYG: life years gained; ICER: 
incremental cost-effectiveness ratio; ICUR: incremental cost-utility ratio; QALYs: quality-adjusted life years. 
 
5.3.2 Sensitivity analyses 
In univariate sensitivity analysis (Table 5.8), the ICUR is most sensitive to the overall 
risk of recurrence over the 5-year follow-up. Specifically, the recurrence risk is 
inversely proportional to the incremental cost per QALY, falling to €11,737 (ICER: 
€7,718) using a 50% value as reported by some studies [10] [243] and rising to €40,228 
(ICER: €26,468) at the lowest risk of 20%. Other variables including secondary 
treatment-related mortality, cost of head and neck surgery and discounting have a 
limited effect on the results.  
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Table 5.8 One-way sensitivity analysis. 
 ICUR (€) ICER (€) 
Discount rate  
3.0% (base-case) 
3.5%* (NICE, [263])  
 
19,951 
19,985 
 
13,123 
13,179 
Risk of recurrences (over the 5-year follow-up) 
20% 
30% 
35% (base-case) 
40% 
50% 
 
40,228 
24,474 
19,951 
16,544 
11,737 
 
26,468 
16,100 
13,123 
10,881 
7,718 
Treatment-related mortality (salvage surgery) 
0% [251] 
3.8% (base-case) 
5% [267] 
 
20,011 
19,951 
19,931 
 
13,052 
13,123 
13,147 
Treatment-related mortality (re-irradiation) [26] 
0%  
4.9% (base-case) 
11% 
 
19,971 
19,951 
19,925 
 
13,099 
13,123 
13,154 
Salvage surgery (cost, €) 
5,281 (hospitals without emergency department) 
5,444 (base-case) 
5,607 (hospital with emergency department) 
 
19,849 
19,951 
20,052 
 
13,056 
13,123 
13,190 
Cost in ‘no evidence of disease’ state after salvage treatment (arm B) 
12.1 (base-case) 
91.9 (up to year 3th) and 15.3 (from the 4th year) 
 
19,951 
22,480 
 
13,123 
14,787 
*corresponding to 0.287% monthly. ICER: incremental cost-effectiveness ratio; ICUR: incremental cost-utility ratio; 
NICE: National Institute for Health and Care Excellence. 
 
Figure 5.2 presents the two-way sensitivity analysis (full details of the results are 
reported in Table 5.9). As expected, the cost-effectiveness of the intensive follow-up 
(arm B) increases with the positive difference between the “curability” of recurrences 
detected in arm B and arm A, respectively, reaching a maximum value of €6,330/QALY 
(€4,163/LYG) when this parameter is equal to 0.7 in arm B and 0.1 in arm A and a 
minimum value of €113,354/QALY (€74,561/LYG) when the difference between the 
two “curability” rates is only 0.05. 
 
 
 
 
 
155 
 
Figure 5.2 Two-way sensitivity analysis of the proportion of potentially salvageable 
recurrences (or second primaries) detected over the 5-year follow-up.  
 
Legend: areas in dark grey represent the cost-effectiveness regions where the ICURs fall under the (upper and lower) 
thresholds recommended by Italian guidelines (i.e. the intensive follow-up is cost-effective compared to the less 
intensive one). 
 
Table 5.9 Two-way sensitivity analysis of the proportion of potentially salvageable 
recurrences (or second primaries) detected over the 5-year follow-up. 
L
es
s 
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e 
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 (
a
rm
 A
) 
Intensive follow-up (arm B) 
ICER 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 
0.10 16,963 13,123 10,563 8,735 7,363 6,297 5,443 4,745 4,163 
0.15 23,363 16,963 13,123 10,563 8,735 7,363 6,297 5,443 4,745 
0.20 36,162 23,363 16,963 13,123 10,563 8,735 7,363 6,297 5,443 
0.25 74,561 36,162 23,363 16,963 13,123* 10,563 8,735 7,363 6,297 
0.30  74,561 36,162 23,363 16,963 13,123 10,563 8,735 7,363 
0.35 -79,033  74,561 36,162 23,363 16,963 13,123 10,563 8,735 
0.40 -40,635 -79,033  74,561 36,162 23,363 16,963 13,123 10,563 
L
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s 
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e 
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w
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p
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a
rm
 A
) 
Intensive follow-up (arm B) 
ICUR 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 
0.10 25,789 19,951 16,059 13,279 11,194 9,573 8,275 7,214 6,330 
0.15 35,518 25,789 19,951 16,059 13,279 11,194 9,573 8,275 7,214 
0.20 54,977 35,518 25,789 19,951 16,059 13,279 11,194 9,573 8,275 
0.25 113,354 54,977 35,518 25,789 19,951* 16,059 13,279 11,194 9,573 
0.30  113,354 54,977 35,518 25,789 19,951 16,059 13,279 11,194 
0.35 -120,154  113,354 54,977 35,518 25,789 19,951 16,059 13,279 
0.40 -61,777 -120,154  113,354 54,977 35,518 25,789 19,951 16,059 
*Bold values correspond to the base-case results. ICER: incremental cost-effectiveness ratio; ICUR: incremental 
cost-utility ratio. 
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In the cost-effectiveness plane (Figure 5.3), most ICURs (72%) are to the right of the 
€40,000 threshold, suggesting that a more intensive follow-up (arm B) might represent a 
cost-effective option compared to a less intensive one (arm A). Even considering the 
lowest bound of the willingness-to-pay for Italy (i.e. €25,000), the intensive follow-up 
is cost-effective in more than 50% of simulations. None of the simulations fall in the 
left side of the graph (i.e. negative difference in QALYs); thus, under the model’s 
assumptions, the more intensive follow-up (arm B) is always more effective than the 
symptom-driven surveillance (arm A). The CEAC (Figure 5.4) reports the probability of 
the intensive follow-up being cost-effective at different thresholds; at a willingness-to-
pay equal to zero almost 5% of the simulations report a cost-saving result. 
Figure 5.3 Cost-effectiveness plane with Monte Carlo simulations (5,000 runs).  
 
Legend: the lines represent, respectively, the upper (€40,000) and lower (€25,000) cost-effectiveness 
thresholds for Italy; each dot represents one ICUR resulting from the 5,000 Monte Carlo simulations; 
points to the right of the straight lines are considered cost-effective. 
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Figure 5.4 Cost-effectiveness acceptability curve (CEAC). 
 
Legend: the probability of the intensive follow-up (arm B) to be cost-effective is plotted against the 
willingness-to-pay per QALY. 
 
5.3.3 Expected value of perfect information 
The PSA shows that at the threshold of €40,000 (€25,000) per QALY the probability of 
the more intensive follow-up to be cost-effective over the less intensive one is equal to 
0.72 (0.55); thus, a considerable uncertainty exists in making decisions using the 
currently available data. The EVPI reveals that the value of undertaking additional 
research is worth €298.10 and €449.12 per patient at the higher (i.e. €40,000) and lower 
(i.e. €25,000) cost-effectiveness thresholds for Italy, respectively. This results in a 
population EVPI of around €20 million (about €30 million at the lowest threshold). The 
population EVPI using different cost-effectiveness thresholds is reported in Figure 5.5; 
the decision uncertainty (and, therefore, the EVPI) reaches a peak at around €20,000, 
and then slowly decrease at higher cost-effectiveness ratios. If the population EVPI 
exceeds the expected cost of additional research (performing the HETeCo trial costs at 
least €200,000), then it is potentially valuable to conduct further research in this area. 
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Figure 5.5 Expected value of perfect information (EVPI). 
 
Legend: the expected value of perfect information (EVPI) at population level is shown at different 
threshold values for Italy. 
 
5.4 Discussion 
5.4.1 Synthesis of results 
In a time of financial constraints, economic evaluations are increasingly used to inform 
decisions about the efficient allocation of healthcare resources. In cancer care, these 
methods have been mainly applied to evaluate drug treatments, while less evidence has 
been generated for other interventions such as screening, medical devices, surgical 
treatments, and follow-up programs [57]. There is no agreement on a common follow-
up strategy in HNC across the guidelines proposed by the different cancer associations 
worldwide. Among them, the NCCN guidelines do not recommend routine imaging in 
the absence of symptoms [34]. Whereas, clinical practice in Italy usually involves 
regular radiological assessments over the post-treatment period, thus resulting in more 
intensive programs. The addition of routine MRI, CT and PET scans to the scheduled 
clinical examinations might increase the detection accuracy of recurrent HNC in 
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patients, especially the asymptomatic ones. However, the effectiveness (and cost-
effectiveness) of these more intensive follow-up schemes has never been shown with 
rigorous methods. 
Although RCTs provide valuable information for cost-effectiveness analyses, especially 
in terms of relative intervention effects, their observation periods are usually shorter 
than the required time horizon to estimate incremental costs and effects. Thus, model-
based economic evaluations are increasingly being performed using data other than 
from trials [268]. Models present the advantage of gathering information from a variety 
of sources and explicitly accounting for the uncertainty associated with input 
parameters. For example, modelling gives decision-makers the ability to change 
parameters to examine how outcomes vary under different policy or clinical scenarios. 
Several methods have been developed to quantify uncertainty in decision models. First, 
the results of Monte Carlo simulations can be plotted in a cost-effectiveness plane with 
incremental outcomes (e.g. QALYs) measured on the horizontal axis and incremental 
costs on the vertical axis; alternatively, the CEAC illustrates the probability that the 
intervention is acceptable for a range of cost-effectiveness thresholds. Second, the EVPI 
reports the highest value of undertaking further research to resolve the uncertainty 
surrounding the decision at different levels of the cost-effectiveness threshold [269]. 
The current model explores the potential costs and outcomes in terms of QALYs and 
survival gains of two alternative follow-up programs in HNC, corresponding to the arms 
of an ongoing RCT. However, the trial was mainly used to generate a research question, 
while most of the data to populate the model were obtained from other sources. In this 
model, more intensive follow-up is cost-effective with a cost per QALY gained of 
€19,951. In the PSA, more than two-thirds of the simulations are below the willingness-
to-pay of €40,000 and, at this threshold value, the EVPI is equal to around €300 per 
patient (€20 million at population level in Italy). Moreover, the two-way sensitivity 
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analysis shows that a difference in the proportion of potentially salvageable recurrences 
of about 0.15 between the two programs is sufficient to obtain an acceptable ICUR for 
arm B. The intermediate results can be compared with data reported in the literature. For 
example, the 5-year survival is equal to 58% and 60.5% in arm A and arm B, 
respectively, which is consistent with the epidemiological data [1] [6] [61]. Moreover, 
recurrent patients treated only with palliative intent spend an average 13-14 months in 
this state, which is aligned with the median overall survival (i.e. 10 months) reported by 
Vermorken [247], by assuming a positive skewness of the survival time distribution due 
to the presence of long survivors.  
5.4.2 Comparison with other studies 
In Chapter II, a systematic literature review of economic evaluations of post-treatment 
programs in oncology is presented. Some of the studies retrieved [82] [99] [126] [130] 
reported very high ICURs for intensive surveillance compared to less intensive options, 
whilst others [87] [96] [119] [127] concluded that the standard follow-up was cost-
effective compared to a simplified one; in other cases, [85] [86] the cost-effectiveness of 
the intensive program depended on the patient’s characteristics. The only study dealing 
with HNC follow-up [112] compared interventions differing only for the contact mode 
between patients and healthcare professionals (i.e. web-chat vs. traditional phone calls), 
and the time horizon was too short (i.e. 6 months) to capture meaningful endpoints. 
Thus, an economic evaluation study comparing follow-up programs of different 
intensity over a lifetime horizon was still lacking in the HNC literature.  
Since no relevant HNC studies were retrieved from this systematic search, and most of 
the studies do not report the incremental costs per QALY or LYG, comparisons with 
other economic evaluations in cancer follow-up are not straightforward. However, in 
this model, the incremental cost per salvageable recurrence detected is equal to €20,249, 
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which is perfectly coincident with the value reported (i.e. £18,077) by a modelling study 
comparing an intensive versus a standard surveillance for colorectal cancer in UK [113]. 
Moreover, the estimated EVPI per patient is broadly similar to one reported in a model-
based cost-utility analysis comparing strategies with different imaging methods in lung 
cancer follow-up (i.e. €282 per patient) [126]. 
5.4.3 Limitations 
This study presents a few limitations. As a modelling study, the analysis inevitably 
represents a simplification of the real world. Furthermore, as common in Markov 
models, the model has no memory, meaning that the probability of moving to future 
states (e.g. from ‘palliatively treated recurrence’ to ‘death’) only depends on the present 
state and not on the sequence of events (i.e. no evidence of disease, salvage surgery or 
re-irradiation) which preceded it. 
Second, there is no consensus regarding several of the model parameters. The risk of 
recurrence over the follow-up period varies in the literature between 20% and 50%. 
Based on a retrospective review of HNC patients undergoing a 5-year follow-up in Italy 
[248], a 35% risk of overall relapse (i.e. loco-regional and distant recurrences and 
second primaries) is assumed, 84% of which occur in the first 3 years. Another 
retrospective study, conducted in Norway, reports a similar figure (31% in 3 years) 
[270]. The rate of curability of loco-regional recurrences or second primaries according 
to different follow-up schemes has never been assessed in any comparative study; thus, 
the parameters used in this model (i.e. 50% vs. 25%) are based on previous literature 
[250] and clinical assumptions. The thirty-day postoperative mortality (i.e. 3.8%) is 
estimated from a single large study [252] which analysed the main causes of death in 
patients undergoing head and neck surgery. A comparable surgery-related mortality (i.e. 
5%) is reported by a review article [267]. Similarly, treatment-related death following 
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re-irradiation is reported at 5% using data from a single study [253] but representing an 
‘average’ effect estimate across the values reported in a recent review [26].  
Third, cancer-related deaths are assumed to occur only during the active disease and 
patients without any cancer relapse after (primary or salvage) treatments experience the 
same risk of dying as the general population at the same age. However, an extra-
mortality risk for HNC survivors has been shown by previous studies [271], mainly due 
to chronic liver disease and suicide. The model does not explore different ages at which 
patients can enter the ‘no evidence of disease’ state; the average age of 62 in the RCT is 
consistent with most studies reporting 60-65 years old HNC patients in the post-
treatment follow-up or secondary treatment phases. Moreover, overall mortality is 
reported by 5-year age intervals in official statistics for Italy, thus varying this 
parameter in the sensitivity analysis would not significantly affect the results. 
Fourth, the model does not account for any second primary sites other than the head and 
neck region, such as lung, oesophagus and colon as reported by previous studies [24] 
[248] [272]. Related to this, the HETeCo trial protocol is currently under review, with a 
low dose chest CT being included annually in heavy smokers according to the lung 
cancer screening NCCN guidelines [273]. Moreover, the possibility of a combined 
salvage treatment (e.g. surgery followed by re-irradiation), as reported in the literature 
[274] [275], is disregarded, as well as the use of radiotherapy with palliative intent 
[276] in recurrent HNC. Additionally, any re-treatment failures other than death, such as 
non-fatal toxicities leading to hospitalization or further treatments [26] [277] or residual 
disease after re-treatment, are considered in the analyses.  
Fifth, this study does not account for patient’s anxiety and discomfort in undergoing 
intensive radiological investigations, nor the potential toxicities related to the use of 
PET and CT, which may reduce the cost-effectiveness of the intensive follow-up. 
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Moreover, the risk of false-positive imaging leading to further investigations or 
unnecessary treatments [248] [278] is not considered. The model represents an “ideal” 
post-treatment scenario where delays in performing visits and exams, and non-
attendance at the recommended appointments on behalf of the patients are disregarded, 
although they clearly occur in clinical practice. 
On the cost side, the analysis is conducted from the perspective of the Lombardy 
regional healthcare system; thus, the cost-effectiveness results might change if 
reimbursement tariffs of other Italian regions are adopted. However, these differences 
are expected to be minimal since the ICER and ICUR calculated using the national tariff 
fixed by the Ministry of Health (and to which Regions must abide in establishing their 
reimbursement tariffs) for the most expensive items in the model (i.e. head and neck 
surgery, CT, MRI, brain PET) are €12,265 and €18,647, respectively; IMRT has not 
been included yet in the national tariff set [279]. The study results are less generalizable 
to other countries, where clinical practice and healthcare costs may differ more 
considerably. Moreover, cost-effectiveness thresholds vary from country to country; for 
example, in an analogous economic evaluation study conducted in the Netherlands and 
comparing different follow-up strategies in lung cancer, the threshold was set at 
€80,000 per QALY gained [126], which is twice that recommended by Italian 
guidelines [262].  
Furthermore, the analysis considers only direct healthcare costs, thus disregarding 
patient’s out-of-pocket costs (e.g. for frequent travel to the hospitals) and indirect costs 
(e.g. productivity losses due to travel time) that may be relevant during follow-up and 
salvage treatments. The cost of informal care by relatives and friends is expected to be 
considerable during the terminal disease stages; a survey on Italian cancer patients in 
their last three months of life estimated that 91% of them were cared for at home, but 
only 14% received assistance from domiciliary palliative care personnel [258].  
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Deterministic and probabilistic sensitivity analyses explore the robustness of the base-
case results to deal with the inevitable modelling assumptions. A two-way sensitivity 
analysis evaluates the joint effect of varying the curability rate of recurrent events in 
arm A and arm B, since robust estimates of these parameters, representing the relative 
intervention effect, will only be available upon completion of the HETeCo trial. 
However, owing to the ICUR being considerably less than the cost-effectiveness 
threshold, it is unlikely that study conclusions would change even under alternative 
scenarios not evaluated in this study.  
5.5 Conclusions 
Until now, no comparative study has assessed the superiority of follow-up schemes 
using intensive radiological examinations over symptom-driven surveillance in HNC, in 
terms of clinical effectiveness and cost-effectiveness. This study presents an exploratory 
model to investigate alternative strategies for monitoring patients after completion of 
treatments for primary cancer from a health economics perspective, showing that an 
intensive surveillance scheme may well be cost-effective in Italy. Further research is 
needed to check these results in empirical studies or real-world settings, and a definite 
answer awaits, at a minimum, the completion of the HETeCo trial. The results are also 
influenced by the choice of the analysis’s perspective; for example, using 
epidemiological and cost data from other European countries might yield alternative 
results in terms of ICER/ICUR and EVPI. The health and economic benefits of risk-
adapted follow-up schemes based on clinical or demographic factors may also be 
assessed in future studies. 
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6 ELICITING PREFERENCES FOR CLINICAL FOLLOW-
UP IN HEAD AND NECK CANCER PATIENTS USING 
BEST-WORST SCALING  
6.1 Introduction 
As reported in previous chapters, a follow-up program is essential shortly after the 
completion of treatment for HNC in order to identify potentially curable relapses. 
However, the optimal timing of visits and radiological assessments following treatment 
is debated by oncologists. Published recommendations are mostly informed by 
retrospective studies, expert opinions, and clinical practice rather than trial-based 
evidence [16] [32]. Until now, no consensus has been reached on the most appropriate 
follow-up modalities and timing in HNC patients. In addition to this clinical 
uncertainty, the patient’s perspective has traditionally been neglected in designing 
cancer programs and elaborating clinical guidelines, whilst considering individual 
preferences might improve the feasibility, acceptability, and effectiveness of healthcare 
interventions [280].  
Stated preference (discrete choice) techniques are a form of conjoint analysis which has 
been applied to a variety of settings to measure preferences for both market and non-
market goods. This technique differs from the revealed preference method which uses 
observed data on actual choices made by individuals to measure preferences. The 
discrete choice technique relies on respondents making choices over hypothetical 
scenarios, which are described by a set of attributes and levels generated from an 
experimental design; in its original version, respondents are asked to choose the ‘best’ 
alternative within a set of two (or more) scenarios [281]. The use of stated preference 
methods was introduced in the early 1990s to value aspects of healthcare beyond health 
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outcomes and has been growing in recent years [282] [283] [284]. However, as for 
economic evaluations, limited evidence is available yet about preferences elicitation in 
oncological post-treatment surveillance.  
The objective of this study is to quantify preferences for post-treatment surveillance in a 
large sample of patients treated for primary HNC, within the framework of the ongoing 
HETeCo trial which inspired the thesis.  
6.2 Methods 
This study used BWS to elicit patient’s preferences for different aspects of follow-up 
after primary treatment for HNC. 
6.2.1 Experimental design 
The BWS choice experiment is a type of stated preference technique that is becoming 
increasingly popular in health economics. There exist three types of BWS studies in the 
literature, which differ in terms of the complexity of the alternatives under evaluation: 
the object case (case 1), the profile case (case 2), and the multi-profile case (case 3) 
[285]. The first is used to obtain the ‘best’ and ‘worst’ options within a list of items, 
which are not divided into levels and could be otherwise evaluated using a rating scale. 
Conversely, the second and third are considered as alternatives to traditional DCEs in 
which respondents evaluate one (case 2) or several (case 3) profiles at a time [285] 
[286]; as in DCEs, indeed, these methods require the identification of key elements (i.e. 
the attributes) each of which is split into two or more levels to create a series of 
scenarios described by different attribute-level combinations. However, instead of 
selecting a single profile in a choice set of two or more, in BWS (case 2) participants are 
asked to indicate which attribute-level they consider to be the ‘best’ and which to be the 
‘worst’ (i.e. the ‘BW pair’) within each scenario. In the multi-profile case, respondents 
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are required to choose the best profile, as well as the worst one, in each choice set. In 
other words, in BWS, participants choose ‘the pair that exhibits the largest perceptual 
difference on an underlying continuum of interest’ [287] [288]. The present study used 
the profile case (case 2), which has been primarily applied in healthcare [285]; case 2, 
indeed, is particularly suitable in eliciting preferences for alternative features of a 
healthcare service but avoiding the complexity of case 3 that requires evaluation of 
multiple profiles at the same time.      
The analysis was limited to the process-related aspects of the follow-up [289], as 
clinical outcomes of post-treatment surveillance in HNC are still under debate in the 
scientific community and under evaluation in the HETeCo trial. Relevant attributes and 
levels were established from literature review and expert opinion. In detail, common 
databases (PubMed and EMBASE) were searched using key terms such as “cancer” 
AND “follow up” AND “discrete choice experiment” (OR “best worst”) in title/abstract 
in order to identify studies that assessed patient’s preferences around post-treatment 
programs in oncology using stated preference methods. Moreover, the choice of 
attributes and levels was influenced by the features distinguishing the two surveillance 
strategies under investigation in the HETeCo trial to quantify the patient’s preferences 
for each of them and inform about the ‘value’ of these programs beyond effectiveness 
and cost-effectiveness, as traditionally defined.  
Interviews with six patients during routine hospital visits were used to refine 
terminology and evaluate the comprehension and the acceptability of the BWS 
instrument. 
6.2.2 Literature review 
The few studies retrieved from the literature and quantifying preferences for cancer 
follow-up using state preference techniques are reported in Table 6.1. In details, two 
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binary DCE studies [290] [291] explored women’s preferences for breast cancer follow-
up services in the Netherlands and Australia, respectively. Face-to-face contacts were 
strongly preferred to telephone ones and a more intensive program of visits (every 3-6 
months) was preferred over the less intensive options; moreover, women liked to be 
followed-up by a medical specialist and at specialized breast cancer clinics. A further 
binary experiment [292] recently carried out in Scotland for different types of cancer 
showed that survivors had a strong preference to see a consultant during a face-to-face 
appointment when receiving follow-up care. Lastly, a BWS study of post-treatment 
surveillance for soft tissue sarcoma in the UK concluded that patients typically preferred 
visits routinely consisting of a clinical examination and a chest X-ray, and secondary 
care- rather than general practice-based programs [293]. 
6.2.3 Questionnaire development 
The preliminary work descripted so far allowed to eventually identify four attributes 
(from A to D): frequency and setting (hospital or mixed with primary care) of physical 
investigations; frequency of radiological assessments (MRI or CT); frequency (and 
eligibility) of PET scans; telephone calls to monitor the occurrence of new symptoms. 
Levels (from 0 to 2) were presented in order of increasing intensity of care and 
resources consumption for each attribute and connected to descriptions of the two 
HETeCo trial strategies (Table 6.2).  
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Table 6.1 Previous studies using stated preference techniques in cancer follow-up. 
First 
author 
(year) 
Country Technique Attributes (Levels) Main findings 
Cancer Sample 
size 
Murchie 
(2016) 
[292] 
Scotland DCE - Healthcare provider (consultant; registrar/trainee doctor; general practitioner; 
specialist nurse) 
- Continuity of care (yes; no) 
- Contact mode (face-to-face at hospital; face-to-face at general practitioner; 
telephone; videoconferencing/webcam/skype) 
- Duration of appointments (5 min, 10 min, 20 min, 30 min) 
- Frequency of appointments (every: 3, 6, 9, 12 months) 
- Length of follow-up (1 year; 2 years; 5 years; 10 years) 
- Counselling (no counselling; individual counselling; group counselling; family 
counselling) 
- Additional services (no additional services; personalized information pack; advice 
on complementary medicine; dietary advice) 
Respondents overall preferred 
continuous, 
face-to-face consultant-led 
follow-up; they may accept 
non-consultant follow-up if 
compensated with changes 
elsewhere, notably greater 
continuity of care. 
Various 
(melanoma, 
breast, prostate, 
and colorectal) 
668 
Damery 
(2014) 
[293] 
England BWS - Length of follow-up (5 years; 10 years; lifelong) 
- Frequency of visits (every: 3; 6; 12 months) 
- Type of investigations (clinical examinations; clinical examinations and x-ray; 
clinical examinations and MRI/CT scan) 
- Healthcare provider (general practitioner; specialist hospital nurse; specialist 
hospital doctor) 
Patients typically prefer 
appointments routinely 
consisting of clinical 
examination and chest X-ray, 
and for follow-up to remain in 
secondary care rather than 
general practice. 
Soft tissue 
sarcoma 
132 
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Table 6.1 (cont.) Previous studies eliciting patients’ preferences in cancer follow-up using stated preference techniques. 
First 
author 
(year) 
Country Technique Attributes (Levels) Main findings 
Cancer Sample 
size 
Bessen 
(2014) 
[290] 
Australia DCE - Healthcare provider (breast physician; general practitioner; breast cancer 
nurse) 
- Frequency of visits (every: 6; 9; 12 months) 
- Location (hospital clinic; general practice; local breast cancer follow-up 
clinic) 
- Contact mode (face-to-face; telephone; alternate between face-to-face and 
telephone) 
- Drop-in clinics (treatment side effects clinic; psychosocial support clinic; 
secondary prevention clinic) 
In the absence of specialist 
follow-up, the most preferred 
scenario is a face-to-face local 
breast cancer follow-up clinic 
held every 6 months and led by a 
breast physician. 
Breast 722 
Kimman 
(2010) 
[291] 
Netherlands DCE - Educational group program (yes; no) 
- Frequency of visits (every: 3; 4; 6; 12 months) 
- Waiting time (minutes) (5; 30; 60; 90 minutes) 
- Contact mode (face-to-face; telephone) 
- Healthcare provider (medical specialist; breast care nurse/nurse practitioner; 
general practitioner; breast care nurse and medical specialist) 
The medical specialist is the most 
preferred to perform the follow-
up, but a combination of medical 
specialist and breast cancer nurse 
alternating is also acceptable to 
patients. Face-to-face contact is 
strongly preferred to telephone 
contact. Follow-up visits every 
three months are preferred over 
visits every four, six, or 12 
months. 
Breast 331 
BWS: best-worst scaling; CT: computed tomography; DCE: discrete choice experiment; MRI: magnetic resonance imaging. 
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Table 6.2 Attributes and levels (in relation to the HETeCo trial arms). 
Attributes Levels RCT 
Frequency (and setting) of physical 
(and larynx/pharynx endoscopic) 
investigations (A) 
0. Every 2-3 months for 3 years (primary 
care-based follow-up for 2 more years)  
Neither 
1. Every 2-3 months for 2 years, every 5-6 
months for 3 more years 
Both 
arms 
2. Every 2-3 months for 5 years Neither 
Frequency of MRI/CT scans (B) 0. Only at the occurrence of new 
symptoms 
Neither 
1. One examination only at the beginning 
of follow-up (later only at occurrence of 
new symptoms) 
Arm A 
2. Once or twice a year Arm B 
Frequency (and eligibility) of PET 
scans (C) 
0. No PET scan during follow-up Arm A 
1. Yearly PET scan only for high-risk 
patients (≥50 years and heavy smokers) 
Arm B 
2. Yearly PET scan for all patients Neither 
Telephone calls to monitor occurrence 
of new symptoms (D) 
0. No inter-visit calls from the hospital  Arm B 
1. Inter-visit calls by the nurse  Arm A 
2. Inter-visit calls by the oncologist Neither 
CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography. 
A balanced study design was adopted in which each study attribute (K=4) had the same 
number of levels (LK = 3). If an alternative contains K attributes, there are K (K-1) = 4 
(4-1) = 12 possible BW pairs the participant can choose within each scenario. As a full 
factorial design generating all possible attribute-level combinations (34 = 81 scenarios) 
was not feasible, a subset of 9 orthogonal scenarios (fractional factorial, main-effects 
design) was derived using the Hann and Shapiro catalogue, Master Plan 3 [294]. The 
total number of BW pairs in the orthogonal design was 108 (12∙9). This sub-group of 
selected scenarios preserved the properties of orthogonality (i.e. each attribute-level 
appears an equal number of times in combination with all other attribute-levels) and 
balance (i.e. each level within an attribute appears an equal number of times) (Table 
6.3) [283] [295].  
Table 6.3 Orthogonal scenarios. 
 Attributes 
Level A B C D All 
0 3 3 3 3 12 
1 3 3 3 3 12 
2 3 3 3 3 12 
All 9 9 9 9 36 
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By using an orthogonal design instead of a full factorial one, it is possible to avoid 
potential bias resulting from scenarios where, for example, all attributes are at the “top” 
or at the “bottom” level, as suggested by other authors [296]. Moreover, the two 
attribute-level combinations representing, respectively, the less intensive (i.e. arm A) 
and the more intensive (i.e. arm B) surveillance strategies in the HETeCo trial were 
purposely included among the nine orthogonal scenarios to subsequently calculate their 
overall utility based on the BWS data analysis. 
The original questionnaire in Italian (and an English translation) is provided in the 
appendix (Annexes A6.1-2). 
6.2.4 Recruitment and setting 
Inclusion criteria for the experiment were broader than for the HETeCo trial. Patients 
aged 18 years and over, with a diagnosis of HNC in any anatomical site (except for the 
skin) in the last 5 years, who had completed any curative treatment at the NCI in Milan 
were eligible to participate. Patients were excluded if they were unable to comply with 
the study in the opinion of the clinical investigators, or they could not provide their 
informed consent. Moreover, this study excluded patients who underwent minor surgery 
for early stage cancer and subsequently did not attend a regular follow-up program in a 
multidisciplinary setting, i.e. with the contemporary presence of the head and neck 
surgeon, the radiation oncologist, and the medical oncologist. At the NCI, the routine 
follow-up program consists of outpatient visits every 2-3 months for the first 2 years 
after the end of treatment, then every 5-6 months for 3 more years. Radiological 
evaluations with MRI/CT scan are performed once 3 months after the end of treatment, 
then annually. PET is requested only in the case of doubtful imaging; no scheduled 
inter-visit contact is planned during the follow-up period. 
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The study was described to a consecutive sample of eligible patients during a routine 
follow-up appointment. Patients were reassured that responses to the questionnaire 
would not affect the care they were receiving at the hospital [297]. Those who agreed to 
participate were asked to sign a consent form and received the survey. Socio-
demographic and clinical information were collected for each study participant. The 
questionnaire included a short rationale for the study and an explanation of the task 
required. After completing the BWS survey, patients were asked to answer some 
questions regarding their experience in performing the task. The experiment was 
approved by the NCI Ethical Committee in March 2015 and subsequently carried out as 
a cross-sectional survey between May and October of the same year.  
6.2.5 Statistical analysis 
Data on patients’ characteristics were summarized through descriptive statistics; 
categorical variables were presented as percentages while continuous variables were 
presented as means and standard deviations. In regression analyses, missing 
demographic data were imputed using logical rules and information from related 
variables or, whenever this approach was not feasible, the most common value (i.e. the 
mode) [298]. Missing BW responses were imputed with the items most frequently 
selected as best and worst respectively within each scenario. The number of times each 
item was chosen as ‘best’ or ‘worst’ by the study participants was calculated. A best-
minus-worst score was calculated by subtracting the number of times a feature was 
chosen as worst from the number of times it was chosen as best [280] [297]. 
Regression analysis was performed using a conditional logit model (clogit command in 
Stata) with cluster-adjusted (robust) standard errors [299]. BW pairs were treated as 
single variables and plotted as one data point at the individual level [293]. For each 
possible pair, the attribute-level was coded as 1 for the best and -1 for the worst; all 
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remaining attribute-levels were coded as 0. An example of data reporting is provided for 
one choice set scenario (i.e. A2B0C0D0, scenario 4) presented in the experiment (Table 
6.4).  
Table 6.4 Dataset example.  
Patient Scenario Pair Choice A0 A1 A2 B0 B1 B2 C0 C1 C2 D0 D1 D2 
1 1 1 0 0 0 1 -1 0 0 0 0 0 0 0 0 
1 1 2 0 0 0 1 0 0 0 -1 0 0 0 0 0 
1 1 3 1 0 0 1 0 0 0 0 0 0 -1 0 0 
1 1 4 0 0 0 -1 1 0 0 0 0 0 0 0 0 
1 1 5 0 0 0 -1 0 0 0 1 0 0 0 0 0 
1 1 6 0 0 0 -1 0 0 0 0 0 0 1 0 0 
1 1 7 0 0 0 0 1 0 0 -1 0 0 0 0 0 
1 1 8 0 0 0 0 1 0 0 0 0 0 -1 0 0 
1 1 9 0 0 0 0 0 0 0 1 0 0 -1 0 0 
1 1 10 0 0 0 0 0 0 0 -1 0 0 1 0 0 
1 1 11 0 0 0 0 -1 0 0 1 0 0 0 0 0 
1 1 12 0 0 0 0 -1 0 0 0 0 0 1 0 0 
 
The dependent variable took the value of 1 for the BW pair selected and 0 otherwise. In 
order to avoid a saturated model, the attribute-level that showed the lowest utility was 
used as the reference level; the omitted item took the value of zero on the utility scale 
and all estimates of the model were interpreted in relation to that. Therefore, each 
attribute-level can be positioned on an underlying preference scale (0; +∞) starting with 
the reference item [285] [300]. Statistically significant coefficients indicated the 
importance of the attribute-level in determining overall utility [301]. 
A covariate-adjusted analysis was also performed to investigate sub-group preferences 
according to socio-demographic and clinical characteristics. A conditional logit model 
was run as previously described; however, interaction factors between selected 
covariates and choice outcomes (i.e. attribute-levels) were also added as independent 
variables [299]. In this model, interaction coefficients represent the additional utility of 
each attribute-level for the covariate [280]. A preliminary univariate regression analysis 
was performed to identify the demographic variables to be included in the final 
covariate-adjusted model as those displaying significant interaction terms (p<0.05). 
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Variables with three (or more) categories in the questionnaire were dichotomized to 
increase the sample size within each group. Two age classes were generated around the 
median value (59 years) [280]. With regards to the clinical variables, the number of 
treatments received (i.e. one vs. more than one) was chosen as a ‘proxy’ of disease 
severity that, according to the clinicians involved in the study, might influence patient’s 
preferences in follow-up; the time from the end of treatments was equally considered 
clinically relevant. Any other clinical information was disregarded in this analysis. A 
covariate-adjusted regression was also separately run using the patient-reported 
difficulty level in performing the BWS task as an interaction factor. To run all 
covariate-adjusted models, additional columns with socio-demographic variables were 
added to the original database (Table 6.4). 
Lastly, following the approach of a previous study [302], an overall utility for each 
hypothetical follow-up scheme deriving from the experiment was obtained by summing 
up the level coefficients from conditional logit regression. 
All data were analysed using Stata version 14 (Stata Corp, 2015). 
6.3 Results  
6.3.1 Sample characteristics 
A total of 162 consecutive patients who met the inclusion criteria were approached to 
participate in the survey; however, sixteen declined resulting in a response rate of 90%. 
Three questionnaires were excluded from data analysis, as they were not completed 
correctly or in full. Therefore, the final sample comprised 143 patients, of whom 74% 
were male. Socio-demographic and clinical features of the participants are presented in 
Table 6.5. The mean age of participants was 57.6 (±12.1) years and more than one third 
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of patients were retired (34.2%). The great majority of patients (85.3%) lived with 
family and 64.3% less than 100 km from the hospital.  
A variety of primary tumour diagnoses were observed in the sample, with the most 
common being oropharyngeal (38.4%), nasopharyngeal (28.0%) and laryngeal cancer 
(11.2%), mostly in a locally advanced stage (III and IV; 93.7%). Most patients (38.5%) 
received a combination of chemotherapy and radiation as primary treatment for HNC, 
or chemotherapy followed by the combined therapy (30.0%). Participants were equally 
distributed according to time since the end of treatments as follows: ≤2 years, 51.0%; 
>2 years, 49.0%.  
6.3.2 Best and worst choice counts 
Frequency counts provide summary estimates of best and worst choices made by 
participants (Table 6.6). Of a total of 2,574 expected BW responses, only 12 (0.5%) 
were missing and imputed as previously explained. The highest ranked attribute-level 
was “physical investigations performed every 2-3 months for 2 years, then every 5-6 
months for 3 more years”. The lowest rated feature is less clearly identifiable. 
According to the best-minus-worst score, the lowest valued attribute-level was “inter-
visit calls by the nurse” to monitor patient’s health status. “No PET scan during follow-
up” was the item least frequently chosen as “best”, while “primary care-based follow-up 
during the last 2 years” was that most often indicated as “worst”.  
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Table 6.5 Sample’s characteristics. 
Variable Class Frequency 
  N % 
Socio-demographic data 
Gender Male 106 74.1 
 Female 37 25.9 
Age (years)  Mean (±SD) 57.6 ± 12.1 
Age at diagnosis (years)  Mean (±SD) 54.9 ± 12.3 
Employment status Full-time employed 42 29.4 
 Part-time employed 8 5.6 
 Self-employed 28 19.6 
 Retired 49 34.2 
 Unemployed 7 4.9 
 Other  7 4.9 
 Missing 2 1.4 
Educational level Primary School 46 32.1 
 Secondary School 57 39.9 
 University 25 17.5 
 Post-University 9 6.3 
 Missing 6 4.2 
Living status Alone 15 10.5 
 With family 122 85.3 
 Missing 6 4.2 
Distance from home (Km) <100 92 64.3 
 100-500 15 10.5 
 >500 33 23.1 
 Missing 3 2.1 
Clinical data 
Site of primary tumour Oropharynx 55 38.4 
 Nasopharynx 40 28.0 
 Larynx 16 11.2 
 Oral cavity 12 8.4 
 Sino nasal cavity 5 3.5 
 Salivary glands 4 2.8 
 Other  11 7.7 
Grade of primary tumour Early stage 9 6.3 
 Locally advanced 134 93.7 
HPV status of disease Positive 47 32.9 
 Negative 10 7.0 
 Not applicable 86 60.1 
Treatment(s)  CTRT 55 38.5 
 CT + CTRT 40 30.0 
 Surgery + RT 13 9.1 
 Surgery + CTRT 12 8.4 
 RT 9 6.3 
 CT + RT 4 2.8 
 Other  10 7.0 
Number of treatments 1 66 46.1 
 2 71 49.7 
 3 or 4 6 4.2 
Time from treatment end ≤2 years 73 51.0 
 >2 years 70 49.0 
CT: chemotherapy; CTRT: combined chemo-radiotherapy; HPV: human papilloma virus; RT: radiotherapy; SD: standard deviation. 
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Table 6.6 Frequency of best and worst selections across scenarios. 
Attribute Level Best Worst Best- 
Worst 
Frequency (and setting) of 
physical (and larynx/pharynx 
endoscopic) investigations 
Every 2-3 months for 3 years (primary 
care-based follow-up for 2 more years)  
109 194 -85 
Every 2-3 months for 2 years, every 5-6 
months for 3 more years 
345 14 331 
Every 2-3 months for 5 years 278 35 243 
Frequency of MRI/CT scans  Only at the occurrence of new symptoms 64 120 -56 
One examination only at the beginning of 
follow-up (later only at occurrence of new 
symptoms) 
61 111 -50 
Once or twice a year 182 16 166 
Frequency (and eligibility) of 
PET scans 
No PET scan during follow-up 7 167 -160 
Yearly PET scan only for high-risk 
patients (≥50 years and heavy smokers) 
74 78 -4 
Yearly PET scan for all patients 103 84 19 
Telephone calls to monitor 
occurrence of new symptoms  
No inter-visit calls from the hospital  9 172 -163 
Inter-visit calls by the nurse  21 185 -164 
Inter-visit calls by the oncologist 34 111 -77 
CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography. 
6.3.3 Conditional logistic regression analysis 
The logistic regression results are presented in Table 6.7. The attribute-level with the 
lowest utility coefficient was “not performing any PET scan during follow-up” and was 
assumed as the reference level. The regression coefficients of BW pairs show the 
additional utility of each attribute-level over the reference case. As already observed in 
frequency counts, the feature showing the highest utility was “physical investigations 
performed every 2-3 months for 2 years and every 5-6 months for 3 more years”. A 
more intensive frequency of visits (“every 2-3 months for 5 years”) ranked second, and 
“MRI/CT scan performed once or twice a year” ranked third. In contrast, the attribute-
levels with the lowest utility were “follow-up based at primary care during the last 2 
years”, “inter-visit calls by the nurse” and “no inter-visit calls from the hospital” in that 
order; however, none of them was statistically significant compared to the reference 
level. For each individual attribute, the distance between the most and the least 
preferred levels is an indication of the relative importance of that attribute to 
respondents [285] [300]. In this survey, the “frequency and setting of physical and 
larynx/pharynx endoscopic investigations” is the item with the largest difference 
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between level coefficients (2.482 i.e. 2.523 minus 0.041) and, thus, the greatest impact 
on patients’ utilities.  
Table 6.7 Utility coefficients from paired conditional logistic regression analysis. 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and larynx/pharynx 
endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years) 
0.041 0.194 0.834 -0.340  0.422 
Every 2-3 months for 2 years, every 5-6 months for 3 
more years 
2.523 0.115 <0.001 2.297  2.749 
Every 2-3 months for 5 years 2.155 0.141 <0.001 1.877  2.432 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms 0.526 0.112 <0.001 0.3055  0.746 
One examination only at the beginning of follow-up 
(later only at occurrence of new symptoms) 
0.565 0.122 <0.001 0.326 0.804 
Once or twice a year 1.885 0.099 <0.001 1.691  2.079 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  - - - - - 
Yearly PET scan only for high-risk patients (≥50 years 
and heavy smokers) 
0.962 0.109 <0.001 0.748 1.176 
Yearly PET scan for all patients 1.111 0.138 <0.001 0.840 1.382 
Telephone calls to monitor occurrence of new symptoms      
No inter-visit calls from the hospital  0.092 0.093 0.322 -0.091 0.276 
Inter-visit calls by the nurse  0.087 0.112 0.439 -0.133 0.307 
Inter-visit calls by the oncologist 0.601 0.115 <0.001 0.375 0.826 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
6.3.4 Covariate-adjusted regression analysis 
Table 6.8 provides results from the conditional logistic regression analysis after 
adjusting for selected clinical and demographic data. Educational level (more educated 
i.e. university, post-university =1; less educated i.e. primary school, secondary school 
=0), employment status (employed i.e. full-time employed, part-time employed, self-
employed =1; not employed i.e. retired, unemployed, other =0), living status (with 
family=1; alone =0), time in follow-up (>2 years =1; ≤2 years =0) and number of 
treatments (≥1 i.e. 2, 3 or 4 =1; one only =0) which displayed significant interactions in 
univariate regression analysis (Tables A6.1-8) were included in the final model. 
Conversely, no significant interaction coefficients were found with respect to age 
(age≥59 =1; age<59 =0), gender (female =1; male =0) and distance from home (≥100 
km =1; <100 km =0).  
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Table 6.8 Utility coefficients from covariate-adjusted conditional logistic regression 
analysis. 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and larynx/pharynx 
endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based follow-up for 
2 more years)  
0.178 0.935 0.849 -1.654 2.010 
Every 2-3 months for 2 years, every 5-6 months for 3 more 
years  
2.303 0.494 <0.001 1.336 3.271 
Every 2-3 months for 5 years  1.810 0.600 0.003 0.634 2.985 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.382 0.467 0.414 -0.534 1.297 
One examination only at the beginning of follow-up (later only 
at occurrence of new symptoms)  
0.392 0.383 0.306 -0.359 1.142 
Once or twice a year  1.590 0.492 0.001 0.625 2.556 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.556 0.317 0.079 -1.177 0.064 
Yearly PET scan only for high-risk patients (≥50 years and 
heavy smokers)  
0.631 0.457 0.167 -0.264 1.527 
Yearly PET scan for all patients  0.877 0.516 0.089 -0.134 1.887 
Telephone calls to monitor occurrence of new symptoms       
No inter-visit calls from the hospital  -0.164 0.331 0.621 -0.813 0.486 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.414 0.269 0.124 -0.113 0.941 
Interactions (Educational level)      
Frequency (and setting) of physical (and larynx/pharynx 
endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based follow-up for 
2 more years)  
1.700 0.559 0.002 0.605 2.795 
Every 2-3 months for 2 years, every 5-6 months for 3 more 
years  
0.285 0.383 0.458 -0.467 1.036 
Every 2-3 months for 5 years  0.472 0.397 0.235 -0.306 1.250 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.081 0.300 0.786 -0.507 0.670 
One examination only at the beginning of follow-up (later only 
at occurrence of new symptoms)  
-0.214 0.293 0.465 -0.788 0.360 
Once or twice a year  0.756 0.339 0.026 0.092 1.420 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up 0.757 0.263 0.004 0.240 1.273 
Yearly PET scan only for high-risk patients (≥50 years and 
heavy smokers)  
0.372 0.264 0.159 -0.146 0.891 
Yearly PET scan for all patients  0.342 0.412 0.407 -0.466 1.150 
Telephone calls to monitor occurrence of new symptoms       
No inter-visit calls from the hospital  0.337 0.251 0.180 -0.156 0.829 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.157 0.213 0.461 -0.261 0.576 
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Table 6.8 (cont.) Utility coefficients from covariate-adjusted conditional logistic 
regression analysis. 
Attribute-level Coeff. SE p-value 95% CI 
Interactions (Job)      
Frequency (and setting) of physical (and larynx/pharynx 
endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based follow-up for 
2 more years)  
-0.132 0.418 0.752 -0.951 0.688 
Every 2-3 months for 2 years, every 5-6 months for 3 more 
years  
0.652 0.278 0.019 0.106 1.198 
Every 2-3 months for 5 years  0.755 0.321 0.019 0.126 1.384 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.654 0.271 0.016 0.124 1.185 
One examination only at the beginning of follow-up (later only 
at occurrence of new symptoms)  
0.338 0.266 0.203 -0.183 0.860 
Once or twice a year  0.741 0.255 0.004 0.241 1.240 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.164 0.225 0.464 -0.276 0.605 
Yearly PET scan only for high-risk patients (≥50 years and 
heavy smokers)  
0.463 0.252 0.067 -0.031 0.957 
Yearly PET scan for all patients  0.418 0.329 0.205 -0.228 1.063 
Telephone calls to monitor occurrence of new symptoms       
No inter-visit calls from the hospital  0.412 0.211 0.051 -0.002 0.827 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.063 0.185 0.732 -0.299 0.425 
Interactions (Living status)      
Frequency (and setting) of physical (and larynx/pharynx 
endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based follow-up for 
2 more years)  
0.400 0.820 0.626 -1.209 2.008 
Every 2-3 months for 2 years, every 5-6 months for 3 more 
years  
0.352 0.498 0.480 -0.624 1.327 
Every 2-3 months for 5 years  0.465 0.586 0.427 -0.683 1.613 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.077 0.394 0.846 -0.696 0.850 
One examination only at the beginning of follow-up (later only 
at occurrence of new symptoms)  
0.450 0.309 0.146 -0.156 1.056 
Once or twice a year  0.181 0.471 0.700 -0.742 1.105 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.732 0.282 0.009 0.180 1.284 
Yearly PET scan only for high-risk patients (≥50 years and 
heavy smokers)  
0.134 0.395 0.735 -0.640 0.908 
Yearly PET scan for all patients  0.578 0.490 0.238 -0.382 1.538 
Telephone calls to monitor occurrence of new symptoms       
No inter-visit calls from the hospital  0.066 0.302 0.826 -0.526 0.659 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.337 0.213 0.114 -0.081 0.756 
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Table 6.8 (cont.) Utility coefficients from covariate-adjusted conditional logistic 
regression analysis. 
Attribute-level Coeff. SE p-value 95% CI 
Interactions (Time in follow-up)      
Frequency (and setting) of physical (and larynx/pharynx 
endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based follow-up for 
2 more years)  
-0.870 0.404 0.031 -1.662 -0.079 
Every 2-3 months for 2 years, every 5-6 months for 3 more 
years  
-0.466 0.251 0.063 -0.958 0.025 
Every 2-3 months for 5 years  -0.452 0.298 0.129 -1.035 0.131 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  -0.197 0.256 0.442 -0.700 0.306 
One examination only at the beginning of follow-up (later only 
at occurrence of new symptoms)  
-0.136 0.252 0.590 -0.631 0.359 
Once or twice a year  -0.592 0.238 0.013 -1.058 -0.125 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.481 0.223 0.031 -0.919 -0.043 
Yearly PET scan only for high-risk patients (≥50 years and 
heavy smokers)  
-0.239 0.243 0.326 -0.716 0.238 
Yearly PET scan for all patients  -0.764 0.311 0.014 -1.374 -0.154 
Telephone calls to monitor occurrence of new symptoms       
No inter-visit calls from the hospital  -0.361 0.192 0.061 -0.739 0.016 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  -0.649 0.173 <0.001 -0.988 -0.309 
Interactions (Number of treatments)      
Frequency (and setting) of physical (and larynx/pharynx 
endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based follow-up for 
2 more years)  
-0.805 0.421 0.056 -1.632 0.021 
Every 2-3 months for 2 years, every 5-6 months for 3 more 
years  
-0.490 0.241 0.042 -0.962 -0.017 
Every 2-3 months for 5 years  -0.672 0.282 0.017 -1.225 -0.119 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  -0.492 0.267 0.066 -1.016 0.032 
One examination only at the beginning of follow-up (later only 
at occurrence of new symptoms)  
-0.675 0.253 0.008 -1.171 -0.180 
Once or twice a year  -0.306 0.236 0.196 -0.770 0.158 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.404 0.221 0.068 -0.838 0.030 
Yearly PET scan only for high-risk patients (≥50 years and 
heavy smokers)  
-0.132 0.244 0.588 -0.612 0.347 
Yearly PET scan for all patients  -0.487 0.310 0.116 -1.095 0.121 
Telephone calls to monitor occurrence of new symptoms       
No inter-visit calls from the hospital  -0.050 0.188 0.789 -0.419 0.319 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.081 0.175 0.643 -0.261 0.423 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
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The interpretation of regression results is facilitated through the example of education. 
There were statistically significant differences between education groups with respect to 
three of the four attributes in the experiment. The total utility of “MRI/CT scan 
performed once or twice a year” for highly educated patients is the sum of the attribute-
level coefficient (1.590) and its interaction term coefficient with educational level 
(0.756), which gives 2.346. The corresponding utility for less educated people is the 
coefficient without interaction (1.590). Thus, it is possible to infer that all patients like a 
more intensive radiological investigations program; however, this preference is stronger 
for those with more education. Furthermore, highly educated patients are more likely to 
prefer a primary care-based follow-up than those with a lower education level. The total 
utility of this item, indeed, is equal to 1.878 for the former, while not significantly 
different from the reference value for the latter (0.178). The last significant interaction 
is with “no PET scan during follow-up”; the overall utility for more educated patients is 
0.201 whilst not significantly different from zero for the less educated ones.  
In a similar way, it is possible to calculate separate utilities for different groups of 
patients according to the remaining four covariates selected within the univariate 
analysis.  
6.3.5 Scenario’s utilities 
The calculation of scenario’s utilities consisted in summing up the coefficients for each 
attribute-level combination resulting from the (unadjusted) conditional logit model in 
the overall sample. The same approach can be used to obtain utilities for specific 
subgroups using results from the covariate-adjusted model. By summing the level 
coefficients taken one at a time within each attribute, the most preferred hypothetical 
scenario (overall utility: 6.120) across the sample would be a hospital-based follow-up 
with frequency of visits decreasing over time (i.e. every 2-3 months for 2 years, every 5-
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6 months for the next 3 years), radiological assessments (i.e. MRI/CT) performed once 
or twice a year, yearly PET scan for all patients (irrespective of individual risk of 
recurrences) and inter-visit calls by the oncologist to monitor the occurrence of new 
symptoms. On the contrary, the least desirable option is a mixed hospital-/primary care-
based surveillance with MRI/CT scan performed only at the occurrence of new 
symptoms, no PET scan scheduled during follow-up period and inter-visit calls by the 
nurse to check the patient’s health (scenario utility: 0.654). 
Among the nine scenarios included in the experiment (i.e. the fractional factorial design, 
Annexes A6.1-2), the utilities associated with the two follow-up programs (i.e. arm A 
and arm B) under evaluation in the HETeCo trial are of interest. The one corresponding 
to arm B of the trial (scenario 3) obtains the highest utility (i.e. 5.462) in the overall 
sample, whilst the estimated utility for the less intensive follow-up (arm A, scenario 2) 
is substantially lower (i.e. 3.175). The lowest valued scenario (i.e. 1.616) is the one with 
primary-care based physical investigations during the last two program years, 
radiological assessments (MRI/CT) performed only at the occurrence of new symptoms, 
yearly PET scan only for high-risk patients and inter-visit calls by the nurse to monitor 
the occurrence of new symptoms (Table 6.9).  
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Table 6.9 Utilities of the survey scenarios (including the HETeCo trial arms). 
 Attribute-levels Coefficient Utility 
S
C
E
N
A
IO
 1
 Physical (and larynx/pharynx endoscopic) examinations every 2-3 months 
for the first 2 years and every 5-6 months for the last 3 years 
2.523 
4.761 
Radiological assessments (MRI/CT) only at the occurrence of new 
symptoms 
0.526 
Yearly PET scan for all patients (irrespective of age or other risk factors) 1.111 
Inter-visits call by the oncologist to monitor new symptoms occurrence 0.601 
S
C
E
N
A
R
IO
 2
 
(A
R
M
 A
) 
Physical (and larynx/pharynx endoscopic) examinations every 2-3 months 
for the first 2 years and every 5-6 months for the last 3 years 
2.523 
3.175 
One radiological assessment (MRI/CT) only at the beginning of follow-up 
(later only at occurrence of new symptoms) 
0.565 
No PET scan during follow-up 0.000 
(ref.) 
Inter-visits call by the nurse to monitor new symptoms occurrence 0.087 
S
C
E
N
A
R
IO
 3
 
(A
R
M
 B
) 
Physical (and larynx/pharynx endoscopic) examinations every 2-3 months 
for the first 2 years and every 5-6 months for the last 3 years 
2.523 
5.462 
Radiological examinations (MRI/CT) once or twice a year 1.885 
Yearly PET scan only for high-risk patients (≥ 50 years and heavy 
smokers) 
0.962 
No inter-visit calls from the hospital to monitor new symptoms occurrence 0.092 
S
C
E
N
A
R
IO
 4
 
Physical (and larynx/pharynx endoscopic) examinations every 2-3 months 
for 5 years 
2.155 
2.773 
Radiological assessments (MRI/CT) only at the occurrence of new 
symptoms 
0.526 
No PET scan during follow-up 0.000 
(ref.) 
No inter-visit calls from the hospital to monitor new symptoms occurrence 0.092 
S
C
E
N
A
R
IO
 5
 
Physical (and larynx/pharynx endoscopic) examinations every 2-3 months 
for 5 years 
2.155 
4.283 
One radiological assessment (MRI/CT) only at the beginning of follow-up 
(later only at occurrence of new symptoms) 
0.565 
Yearly PET scan only for high-risk patients (≥ 50 years and heavy 
smokers) 
0.962 
Inter-visits call by the oncologist to monitor new symptoms occurrence 0.601 
S
C
E
N
A
R
IO
 
6
 
Physical (and larynx/pharynx endoscopic) examinations every 2-3 months 
for 5 years 
2.155 
5.238 Radiological examinations (MRI/CT) once or twice a year 1.885 
Yearly PET scan for all patients (irrespective of age or other risk factors) 1.111 
Inter-visits call by the nurse to monitor new symptoms occurrence 0.087 
S
C
E
N
A
R
IO
 7
 
Physical (and larynx/pharynx endoscopic) examinations every 2-3 months 
for 3 years. Primary care-based follow-up for the last 2 years. 
0.041 
1.616 
Radiological assessments (MRI/CT scan) only at the occurrence of new 
symptoms 
0.526 
Yearly PET scan only for high-risk patients (≥ 50 years and heavy 
smokers) 
0.962 
Inter-visits call by the nurse to monitor new symptoms occurrence 0.087 
S
C
E
N
A
R
IO
 8
 Physical (and larynx/pharynx endoscopic) examinations every 2-3 months 
for 3 years. Primary care-based follow-up for the last 2 years. 
0.041 
1.809 
One radiological assessment (MRI/CT scan) only at the beginning of 
follow-up (later only at occurrence of new symptoms) 
0.565 
Yearly PET scan for all patients (irrespective of age or other risk factors) 1.111 
No inter-visit calls from the hospital to monitor new symptoms occurrence 0.092 
S
C
E
N
A
R
IO
 9
 Physical (and larynx/pharynx endoscopic) examinations every 2-3 months 
for 3 years. Primary care-based follow-up for the last 2 years. 
0.041 
2.527 
Radiological examinations (MRI/CT scan) once or twice a year 1.885 
No PET scan during follow-up 0.000 
(ref.) 
Inter-visits call by the oncologist to monitor new symptoms occurrence 0.601 
CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography. 
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6.3.6 Patients’ evaluation of the experiment 
Table 6.10 presents data on patients’ self-reported difficulties in understanding and 
completing the questionnaire. The average compilation time was 9.2 (± 3.1) minutes. 
Nearly half of the participants rated the BWS task very easy to perform (i.e. level 1; 
45.4%) and did not need any support from healthcare professionals or family members 
(44.7%). More than one-third (37.1%) reported no difficulties during completion among 
the options available; “understanding the task” was the most common difficulty (21.7%) 
followed by “length of the questionnaire” (6.3%) and “technical/scientific language” 
(5.6%). A further 14% indicated other difficulties mainly related to indecision in 
selecting the BW pair and the feeling that scenarios were too repetitive. The difficulty 
level (i.e. equal to 1 (low)=0; >1=1) used as interaction factor with BW attribute-levels 
did not yield any significant results (p<0.05) in univariate regression analysis, 
suggesting that its impact on participants’ responses was negligible (Tables A6.9). 
Table 6.10 Self-reported difficulties in performing the exercise. 
  N % 
Completion time ≤ 5 minutes 33 23.1 
 5-10 minutes 87 60.8 
 > 10 minutes 14 9.8 
 Missing 9 6.3 
Difficulty level 1 (low) 65 45.4 
 2 28 19.6 
 3 32 22.4 
 4 8 5.6 
 5 (high) 7 4.9 
 Missing 3 2.1 
Support needed (e.g. nurse, 
caregiver) 
Yes 63 44.1 
 No 64 44.7 
 Missing 16 11.2 
Main difficulty None 53 37.1 
 Length of the questionnaire 9 6.3 
 Understanding the task 31 21.7 
 Technical/scientific language 8 5.6 
 Other 20 14.0 
 Missing 22 15.3 
 
187 
 
6.4 Discussion 
Few studies have explored patient’s preferences for delivery of post-treatment cancer 
programs and even fewer have attempted to derive utility estimates from them. A non-
systematic literature review identified a total of four studies using stated preference 
techniques, of which only one adopts the BWS methodology and none addresses HNC; 
overall, these studies confirm that patients tend to prefer an intensive hospital-based 
post-treatment surveillance including frequent face-to-face visits with specialized 
doctors and radiological examinations. 
A further study [280] adopting the BWS methodology was identified even if not strictly 
related to follow-up but addressing a symptom supporting care intervention in lung 
cancer patients after completion of first line therapies. With respect to HNC, a non-DCE 
survey only on patients’ view of their follow-up regimen was conducted in UK. The 
study revealed that most patients felt their follow-up visits too frequent and were in 
favour of a less intensive, symptom-driven follow-up [303].  
The BWS method is argued to have several advantages over traditional DCEs [280] 
[300]. First, respondents are provided with profiles one by one rather than two (or more) 
at a time; thus, BWS is considered less cognitively demanding for participants [288] 
[296] [299] [301]. These expectations were confirmed in this study by the self-reported 
judgement on the choice task, which was graded as simple and quick by the majority of 
respondents. Moreover, BWS may elicit more information than traditional DCEs, as 
respondents make choices within profiles rather than between profiles; in particular, in 
BWS a single attribute-level combination acts as benchmark, instead of a whole 
scenario. In this way, it is possible to calculate utility coefficients for each item in the 
experiment, which may be useful in evaluating different elements of a healthcare 
service [288] [296] [299] [301]. Lastly, profile-based (case 2) BWS was selected in 
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preference to the traditional binary DCE because, in a life-threatening condition like 
HNC, it was anticipated that patients would always select the option which they thought 
would maximize survival and consequently less information would be generated on how 
other attribute/levels are valued. 
This study is the first stated preference survey of HNC follow-up and, in Italy, of any 
cancer surveillance. The survey aimed at providing insights into patients’ views on post-
treatment monitoring in this cancer population using BWS methodology. Moreover, a 
covariate-adjusted analysis was performed to investigate socio-demographic or clinical 
characteristics related to the choice of attribute-levels. It was not surprising to find that 
patients’ preferences for HNC follow-up were generally aligned with the scheme 
currently adopted by NCI where the study was conducted. This tendency has been 
described as the ‘lure of the familiar’ [293], meaning that individuals are likely to stick 
with they have already experienced, even if potentially unsatisfactory. Participants in 
this study revealed clear preferences for follow-up to remain in secondary care, even 
during the last phases of the program. Intensive radiological examinations (once or 
twice a year) were strongly preferred. Inter-visit telephone calls were generally disliked, 
especially when performed by healthcare professionals other than medical doctors. 
These results are in contrast with those found by a previous study on patients’ 
preferences in HNC follow-up [303]; however, that survey was conducted in a different 
geographical setting (highly deprived areas of London) and without relying on stated 
preference methods. Differences in preferences according to individual characteristics 
were also found. Overall, highly educated patients were more likely to prefer primary-
care based follow-up and intensive MRI/CT radiological investigations but avoiding 
PET scan. Patients with a job tended to prefer more frequent visits to the hospital but no 
inter-visit calls, while those living with family revealed a stronger preference for not 
performing any PET scan during follow-up. Patients two years (or more) following 
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treatment expressed a lower utility for more intensive MRI/CT investigations and were 
keener to avoid inter-visit telephone calls with their clinicians. Patients who had 
received more than one treatment option (e.g. surgery followed by radiotherapy) were 
less keen to accept a symptom-driven radiological surveillance and to travel frequently 
to the hospital for physical investigations. Conversely to a previous study [280], no 
differences were found in age or gender with regards to preferences for delivering a 
post-treatment intervention in cancer care; however, the program under evaluation was 
considerably different. In terms of hypothetical follow-up utilities, the experiments 
showed an overall preference for more intensive scenarios, including arm B of the 
ongoing HETeCo trial. 
This study has a number of limitations. First, the data collection was restricted to only 
one centre that, due to some distinctive features (i.e. high specialization, commitment to 
research, innovative technologies), may not be representative of a typical cancer clinic 
in Italy. Moreover, patients attending the NCI, especially those coming from afar, are 
likely to be more educated, wealthy or health conscious than the general HNC 
population. However, the NCI is the leading centre of the HETeCo trial with experience 
in cancer follow-up research, and the referral to a single centre reduced bias related to 
different ways of administering the survey and providing support during the completion 
of the questionnaire. Second, the cognitive ability of each participant with respect to 
completing the task was not evaluated, and on some occasions the patient was supported 
by an accompanying person. Moreover, the attribute-level descriptions were sometimes 
long, included multiple concepts and involved technical terms. Nevertheless, given the 
very low number (n=3) of questionnaires excluded from the analysis and the limited 
self-reported difficulties, it is likely that the task was feasible for most participants; 
moreover, regression analyses did not show any significant interactions between BW 
choices and difficulty level. The final limitations concern the restricted range of 
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hypothetical follow-up programs that can be valued owing to the small number of 
attributes-levels and the assumption of no interaction between BWS items. However, 
the small number of items included in the experiment, as well as the use of a small 
factorial main-effects design (i.e. 9 out of 81 scenarios), was justified by feasibility 
considerations. 
6.5 The use of best-worst scaling utilities for health economic 
comparison: fact or fiction? 
The interest in collecting information regarding patient’s preferences in healthcare using 
rigorous stated preference methods is confirmed by the increasing number of studies 
that can be found in the health economics literature; a recent study reported 53 BWS 
applications in health and healthcare [304]. Until now, DCEs have been mainly applied 
to elicit patient’s preferences and quantify trade-off among alternative treatments 
described by hypothetical scenarios. However, there is little guidance on how 
DCE/BWS preference and cost data can be combined in cost-effectiveness analysis to 
inform healthcare decisions [289].  
Conversely to HSUVs derived from EQ-5D (and other generic HRQoL measures) or 
direct techniques (e.g. SG and TTO), which range between 0 (death) and 1 (perfect 
health), there exist no standard scales on which DCE-based utilities are measured [289]. 
In this chapter, utilities for each attribute-level are obtained from a conditional logit 
model (clogit in Stata), which calculates them by summing up the number of times each 
item is selected as best or worst [301]. In theory, BWS-derived utility coefficients can 
vary between zero (i.e. the reference case representing the lowest valued item) and +∞. 
However, the highest utility obtained in the (unadjusted) conditional logit model is 
2.523, corresponding to the most preferred item of the experiment (i.e. a hospital-based 
program of physical investigations with frequency decreasing over time). A similar 
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study [293] quantifying preferences for soft tissue sarcoma follow-up using BWS and 
conditional logit regression obtained utilities confined in a comparable range (0; 2.503).  
BWS studies can be classified into two main categories according to their area of 
application, i.e. evaluation of HSUVs/HRQoL and evaluation of healthcare 
interventions. In the first case, profiles are derived from different combinations of 
responses to a HRQoL questionnaire (e.g. EQ-5D-5L identifies a total of 3,125 unique 
health state profiles) and regression analyses furnish utility coefficients for each 
attribute-level combination (e.g. mobility, level 2). Few examples are available in the 
BWS literature; among them, Ratcliffe et al. [302] obtained HSUVs from the Child 
Health Utility-9D (CHU9D), which is a newly developed generic preference-based 
instrument to measure HRQoL in children and adolescents. In this study, utility 
coefficients from conditional logit regression are rescaled onto the 0-1 range of HSUVs 
and summed up to generate utilities for each possible health state defined by the 
CHU9D. This study presents the feasibility of BWS approach to evaluate HSUVs for 
QALY calculation and cost-utility analyses, although further research is needed to 
explore the advantages and limitations of this approach. 
The way of combining utility estimates from the second group of BWS studies (i.e. 
those assessing preferences for healthcare interventions) and costs for economic 
evaluation remains unclear. In 2006, McIntosh [305] proposes an initial framework to 
perform cost-benefit analyses using DCE-derived utilities. A subsequent study from 
Benning and colleagues [289] presents a methodology to combine individual-specific 
preference data obtained from a traditional (binary) DCE with cost data to inform about 
the cost-effectiveness of customized care compared to standardized care. A more recent 
study [284] attempts to incorporate patients’ preferences into an economic evaluation 
and compare results with the standard cost per QALY approach using data from a RCT; 
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two other studies [306] [307] included DCE within a trial, but without collecting 
comparable QALY data. 
A simpler strategy can be used here to allow a cost-utility comparison of follow-up 
programs (A vs. B) under investigation in the HETeCo trial combining scenario utilities 
from the BWS experiment (Table 6.9) and the programs’ 5-year cost estimates 
calculated in Chapter V (Table 5.5), as shown in Table 6.11. 
Table 6.11 Cost-utility comparison using the survey results. 
 Costs (€) Δ costs (€) BWS utility Δ BWS 
utility 
Δ costs (€)/Δ BWS 
utility 
Follow-up A 729.0  3.175   
Follow-up B 3,676.5 2,947.5 5.462 2.287 1,288.8 
 
This approach presents several limitations mainly related to the interpretation of results. 
First, there exists no standard scale for DCE utilities, thus they can be compared within 
the same experiment only, and not across different studies. Second, conversely to 
traditional cost-utility analyses where country-specific guidelines exist to state the value 
of a QALY gained, this approach does not furnish a decision rule (i.e. a threshold) to 
state the cost-effectiveness of an intervention compared to the others in case differences 
in costs and utilities are both positive or negative (i.e. non-dominant comparisons). 
Third, in DCE/BWS surveys, the patient is rarely asked to value health-related aspects, 
but more frequently process-related aspects of an intervention (e.g. frequency of 
radiological imaging), although it is not stated how this information should be 
considered in medical decision-making and allocation of healthcare budgets [38]. 
Moreover, some authors argue that ‘value’ should depend on ‘outcome’ and not on the 
‘process’ of care that led to the outcome achievement [35]. Forth, utilities derived from 
DCEs/BWS experiments are generally obtained from cross-sectional surveys, thus 
preventing long-term comparison of costs and effects. These limitations suggest that 
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currently no valuable alternative can replace the cost per QALY approach, which still 
represents the milestone of cost-utility comparisons in healthcare.  
6.6 Conclusions 
In recent years, there has been growing interest in using preference elicitation methods 
to inform health policy and medical decision-making. Incorporating patient’s 
preferences into the treatment and follow-up strategies may help in tailoring healthcare 
to the patient and increasing adherence to treatment [18]. In HNC follow-up, patients 
seem to be reassured by a regular follow-up with scheduled imaging and expertise of 
specialists, as already reported in other experiences [308]. The present study highlighted 
patients’ limited interest in alternative ways of delivering post-treatment services, such 
as symptom-driven surveillance, telephone monitoring or non-specialist follow-up. 
Healthcare professionals (e.g. general practitioners or nurses) other than specialist 
doctors were probably considered not skilled enough to conduct cancer follow-up. 
There might be a resistance to change from established to new types of service without 
adequate reassurance from the clinicians. In particular, patients with less education may 
benefit least from a patient-initiated follow-up owing to difficulties in understanding 
medical instructions. Overall, there is a need for improved communication for cancer 
patients to evaluate consciously the post-treatment phase and to promote self-managed 
symptoms monitoring [309]. Patients likely prefer intensive radiological assessment 
because of fear of disease recurrence; however, tests should be performed for clinical 
reasons and not (only) for patient’s reassurance. The long-term effects associated with 
frequent and prolonged radiological scans should also be considered. In this regard, 
more efforts should be spent in order to identify the most cost-effective follow-up 
scheme in HNC, thus providing the scientific community and patients with evidence-
based programs. The HETeCo trial comparing health and economic outcomes in this 
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setting is ongoing and, in terms of patient’s preferences, the analysis presented in this 
chapter seems to advantage the more intensive follow-up scheme (arm B). Finally, 
differences in preferences were found according to the intensity of treatments received 
and the time already spent in follow-up; these results might justify a provision of 
different surveillance schemes based on these clinical variables, as already suggested by 
guidelines in the field [20]. Similarly, inter-visit calls appear to be more valuable in the 
initial phases of the follow-up than in the final ones, when patients may feel more 
confident of beating cancer. 
Overall, this study provided useful insights into individual preferences for several 
aspects of post-treatment surveillance in HNC in Italy. Additional elements might be 
explored in the future, such as the level of scientific evidence, co-payment for extra-
investigations and late side effects of intensive investigations. Currently, there is 
evidence of heterogeneity in preferences with respect to a limited number of patient’s 
characteristics. More research also considering the costs of different follow-up regimens 
is required to justify the provision of customized follow-up programs in HNC patients. 
From a methodological perspective, further research is needed to evaluate the feasibility 
of incorporating preferences information into traditional economic evaluations. 
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7 DISCUSSION AND CONCLUSIONS  
7.1 Introduction 
This thesis values follow-up programs in HNC from a health economic perspective. 
Post-treatment surveillance is recognized to be a valuable service in oncology, although 
the best way of monitoring patients after the primary treatment is completed is often 
uncertain. In HNC, several guidelines exist, although most of them are based on routine 
practice or expert opinion. Additionally, the clinical studies present conflicting results 
about the appropriate frequency of radiological investigations that should be prescribed 
in the post-treatment phase [20]. In Italy, follow-up is usually quite intensive, according 
to the recommendations of national scientific societies and individual cancer centres 
initiatives. However, the added ‘value’ of intensive follow-up programs has never been 
proved with rigorous methods. 
More generally, what is ‘value’ in healthcare and, especially, in oncology, is still 
debated in the literature. The QALY is a measure of health effectiveness that is widely 
used to inform the allocation of healthcare resources. In the traditional QALY approach, 
value is assessed in terms of preference or desirability for a given health state [36]. 
Several HTA agencies, including NICE in England, have endorsed the QALY as a 
standard measure to promote comparability in cost-utility analyses across different 
disease areas and treatments. However, the measurement of QALY as a ‘proxy’ of value 
in cancer poses some challenges reported in a recent paper by Devlin and Lorgelly [38]. 
The authors highlight that an overall survival estimate is required to calculate QALYs, 
whilst oncology trials rarely continue for long enough to capture that; thus, modelling 
has become an unavoidable approach to conduct cost-utility analyses in many cancers 
that have become chronic diseases. Moreover, as a measure combining length and 
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quality of life, the QALY requires utility weights that are infrequently directly available 
from clinical studies, where cancer-specific HRQoL tools, not provided with a 
preference-based algorithm, are usually preferred. Thus, “mapping” is growing in 
popularity to obtain HSUVs from non-preference-based measures. In addition, the 
QALY concept endorses the preference for a given health state, expressed as HSUV, 
but formally disregards preferences for the process of care; although information on 
patients’ desires are increasingly recognized as important for policy-makers, there is 
little consensus on how HTA can incorporate these data alongside QALYs [38]. 
In oncology, a few alternative value frameworks [51] [52] [53] [54] [55] have recently 
been developed, with the intent of evaluating cancer drugs through a set of meaningful 
attributes. Much emphasis is given to safety and clinical efficacy, whilst HRQoL and 
patients’ preferences are usually not included or given much weight. Most of these 
tools, indeed, have been developed by referring to RCTs only, thus disregarding the 
evidence generated by other study types. Moreover, there is no agreement across the 
different frameworks regarding which dimensions should be considered, and how they 
should be incorporated and weighted into the tool [56]. Lastly, aiming at specifically 
evaluating cancer pharmaceuticals, these frameworks do not allow a value comparison 
across different types of healthcare interventions. Thus, despite some limitations 
recognized in the literature, the cost per QALY remains central to value comparisons in 
healthcare and is endorsed by the main body of this thesis. Since it is not established 
how to enlarge the definition of QALY to incorporate additional elements of ‘value’ 
such as patients’ preferences, these are explored in an independent piece of work. 
This PhD thesis consists of a series of chapters, some of which have already been 
published as research papers. A synthesis of the main findings from each chapter is 
reported in the following section. Thereafter, a broader discussion of the thesis’s 
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limitations, its contributions to research and policy implications, and areas for future 
research are presented. 
7.2 Main findings 
➢ Chapter II. For the purposes of this thesis, the first task is to systematically 
verify the absence of economic evaluation studies in the HNC follow-up. The 
search is then extended to all cancer types to learn about the methodology and 
the findings in evaluating any surveillance programs in oncology. This work 
results in an independent piece of work, but also provides key insights for the 
model-based economic evaluation performed later in the thesis. In synthesis, 
following the PRISMA statement [72], a systematic literature search was 
undertaken for studies published, in a first instance, since 2000 until the end of 
2014, and subsequently updated until June 2017. The inclusion criteria imply 
selection of full economic evaluations of any type (i.e. cost-effectiveness, cost-
utility, cost-benefit, cost-minimization, cost-consequences) assessing follow-up 
programs in adult cancer patients who have successfully completed the primary 
treatment. The original systematic review, published in Expert Review of 
Pharmacoeconomics & Outcomes Research in October 2015, includes 39 
articles [310]; the updated review identifies 14 additional studies, for a total of 
53 studies included in the thesis’s chapter. Several types of follow-up 
interventions are compared in the included studies, but the attention of this thesis 
is focussed on those comparing programs of different ‘intensity’, defined as 
either increased frequency of standard examinations or add-on of new diagnostic 
procedures. Overall, most economic evaluations discourage the adoption of 
intensive surveillance, which turns out to be not cost-effective compared to 
minimal programs. Greater heterogeneity is observed in more recent studies 
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(published after 2014), with some showing a favourable cost-effectiveness 
profile for less intensive programs, and others recommending instead the more 
intensive ones. However, some of the results are reported as incremental cost per 
recurrence detected, which are not comparable with standard cost-effectiveness 
thresholds; moreover, the added value of an early diagnosis of cancer relapse is 
related to the availability of secondary treatments that are able to increase the 
quantity (and quality) of life. Thus, intermediate outcomes (e.g. increased 
detection of recurrences) are of limited value in the absence of an established 
relationship with final outcomes (i.e. survival). Other studies are cost-
consequence analyses reporting significantly lower costs for less intensive 
options but no significant differences in clinical outcomes, mainly expressed as 
recurrence detection rates; even in these cases, a cost-effectiveness ratio is 
unavailable for comparison with country-specific thresholds. Quality scoring of 
the included studies is performed using the 24-item CHEERS checklist [73], 
with 31 (out of 53) papers being classified as ‘high quality’ studies, and rigour 
of economic evaluations improving over time. However, some critical issues 
emerge also from the most recent studies, including the wide use of intermediate 
outcomes, the short analysis timeframe preventing estimation of the final 
survival endpoint, and a limited use of cost-effectiveness and cost-utility 
analyses combining costs and outcomes in a ratio comparable with other disease 
areas. Moreover, whilst the original literature search confirms the absence of 
published economic evaluations in HNC follow-up until 2014, a study 
examining HNC is found by updating the search; however, this study compares 
a web-based follow-up to a standard telephone-based one in a cost-consequences 
framework and over a short period. Thus, there is still a research need for a 
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sound cost-utility analysis assessing the value of follow-up involving alternative 
programs of radiological investigations with a lifetime horizon. 
➢ Chapter III. The availability of HSUVs is essential for model-based economic 
evaluations using QALYs. In this thesis, utility parameters are required for post-
treatment health states composing the Markov state-transition model presented 
in Chapter V; thus, a systematic review of HSUVs in HNC is carried out and 
gives rise to an independent research paper, published in Health and Quality of 
Life Outcomes in September 2017 [311]. In brief, common electronic databases 
(PubMed, EMBASE, the Cochrane Library) are searched using a combination of 
relevant free-text terms. Other searches are conducted in the Tufts Cost-
Effectiveness Analysis Registry and the School of Health and Related Research 
Health Utilities Database (ScHARRHUD) specifically containing health 
utilities, in addition to the HERC database of mapping studies. Studies are 
considered for inclusion if reporting original HSUVs obtained through 
established techniques including direct methods (i.e. TTO and SG), MAUIs (e.g. 
EQ-5D), and ‘mapping’. The studies are qualitatively assessed using a list of 
criteria provided by recent guidelines on the topic [160]. Overall, a total of 28 
studies qualify for data extraction and 346 unique HSUVs are retrieved from 
them. Three studies obtain utility values using mapping functions, but only one 
presents an original algorithm with HNC data. The remaining 25 studies are 
almost equally distributed between those using direct and indirect (i.e. MAUIs) 
techniques; EQ-5D is the most frequently adopted tool among MAUIs. A few 
critical elements are identified in reviewing these studies, including small 
sample sizes, limited reporting of missing values (and methods for dealing with 
missingness), and poor description of patients’ characteristics, especially in 
studies addressing HNC together with other cancer types. Moreover, most 
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studies elicit HSUVs during treatment or in the post-treatment disease-free state, 
whilst limited evidence is available for more advanced stages including the 
recurrent and terminal ones. 
➢ Chapter IV. This chapter presents a mapping study providing a set of algorithms 
to obtain EQ-5D-5L utility values from a widely used HNC-specific HRQoL 
tool (i.e. EORTC QLQ-C30 with H&N35 module) which is being administered 
regularly to the patients in the ongoing HETeCo trial. The EQ-5D-5L responses 
obtained from a sample of patients currently enrolled in the RCT are valued 
using the currently available tariff sets (i.e. England, Netherlands, Canada, 
Uruguay, Korea, Japan, China) reported on the EuroQol website (last updated on 
18th April 2017). Three different techniques are applied including a linear 
mixed-effects model, random-effects Tobit, and ALDVMM; all the developed 
models consider that multiple observations from each patient are likely to be 
correlated. Separate models for QLQ-C30 and H&N35 scales/items are 
developed and backward selection applied to identify the significant variables 
(p<0.05). Overall, HNC patients in follow-up report a substantial HRQoL 
impairment, especially caused by insomnia, fatigue, dry mouth, sticky saliva, 
and financial problems. The average EQ-5D-5L utility value ranges between 
0.786 and 0.905 according to the country set adopted; these values are aligned 
with a study [186] retrieved by the systematic review (Chapter III) and enrolling 
patients with similar characteristics. In models using the core set of questions 
(QLQ-C30), which are applicable to all cancer types, the scales/items 
significantly affecting the EQ-5D-5L utility are global health status, physical 
functioning, emotional functioning, nausea and vomiting, pain, constipation, 
diarrhoea, and financial difficulties; among the H&N35 scales/items, the most 
significant variables are pain (localised in the head and neck region), trouble 
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with social contacts, and felt ill. Some of these variables correspond to the EQ-
5D dimensions, such as physical functioning with dimensions 1-3 (mobility, 
self-care, usual activities), pain with dimension 4 (pain/discomfort), and 
emotional functioning with dimension 5 (anxiety/depression). Overall, the linear 
random-effects and the multi-component ALDVM models show comparable 
goodness-of-fit in terms of AIC/BIC statistics, although the latter provide more 
precise estimates for the poorest health states; models using QLQ-C30 perform 
better than those using H&N35 for all the tariff sets adopted. 
➢ Chapter V. The ‘core’ of the thesis is an exploratory cost-utility analysis of two 
alternative follow-up strategies in HNC, which coincide with the arms of the 
ongoing HETeCo trial. Since the clinical trial is expected to be completed by 
2020, it generated a research question only, while the analyses are conducted in 
a modelling framework. Briefly, a Markov model with mutually exclusive health 
states is developed to predict the lifetime outcomes and costs of an intensive 
follow-up (corresponding to arm B in the trial) as conceived by the clinical 
investigators compared to a less intensive, symptom-driven surveillance (arm A) 
based on the NCCN guidelines. A variety of sources are used to inform the 
model structure and parameters, including the trial protocol, published and 
unpublished literature, and expert opinion; the systematic review reported in 
Chapter III provides the utility parameters, except for the ‘no evidence of 
disease’ state, whose value is derived from preliminary trial data. In the base-
case analysis, the more intensive follow-up results in an incremental cost per 
QALY of €19,951, which is below the recommended €40,000/QALY threshold 
for Italy [262], and its cost-effectiveness is confirmed in sensitivity analyses. 
The key efficacy parameters in the model (i.e. the proportion of potentially 
salvageable recurrences in the two groups) are particularly uncertain, being 
202 
 
derived from published studies and clinical opinion pending completion of the 
trial. The value of undertaking additional research is estimated at around €300 
per patient using the EVPI technique. Although this work is only exploratory, it 
suggests that an intensive follow-up program is likely to be a valuable option 
from a healthcare system perspective in Italy. The model’s findings are poorly 
comparable with those identified by the systematic literature review presented in 
Chapter II, since most reviewed studies are cost-consequences analyses not 
reporting the ratio between incremental costs and incremental outcomes or 
expressing results in terms of cost per recurrence detected. A couple of studies 
[82] [99] performing a model-based cost-utility comparison of intensive versus 
less intensive programs obtained higher ICURs than in this thesis, but even these 
results are scarcely comparable due to different cancer sites and programs’ 
specifications. A research paper based on this work has been published in 
European Journal of Cancer in April 2018 [312]. 
➢ Chaper VI. This work reports the findings of a BWS experiment carried out 
during summer 2015 at the NCI (Milan) and published in Value in Health in 
June 2017 [313]. This study represents the first experiment of this type in HNC 
follow-up, and the second one in cancer follow-up in general, after that 
published by Damery et al [293]. It investigates patients’ preferences for several 
aspects of post-treatment surveillance using a stated preference technique. A 
balanced study design (i.e. four attributes, three levels each) is built and nine 
orthogonal scenarios (from a total of 81) are presented to a sample of patients 
currently in follow-up after being treated for primary HNC. The choice of 
attributes and levels for the experiment is informed by the features 
distinguishing arm A and arm B in the ongoing HETeCo trial. For each scenario 
reported in the BWS survey, participants are required to indicate the “best” and 
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the “worst” attribute-level combination (the ‘BW pair’). Responses are analysed 
through descriptive statistics and conditional logit regression; a covariate-
adjusted model is also estimated to investigate sub-group preferences according 
to socio-demographic and clinical characteristics. The study findings reveal a 
general preference towards a follow-up program like the one already 
experienced at the NCI, a phenomenon that has been described in the literature 
as the ‘lure of the familiar’ [293]. In the overall sample, indeed, the item 
obtaining the highest utility coefficient is a program of physical examinations 
resembling that already performed at the NCI, whilst the one showing the lowest 
utility is not performing any PET scan during follow-up. In addition, patients 
typically dislike ways of delivering follow-up other than specialist-led visits, 
such as symptom-driven, telephone or primary care-based surveillance. These 
findings are broadly consistent with previous studies adopting stated preference 
techniques in other cancer types and reporting general preferences for follow-up 
to remain in secondary care and to include frequent face-to-face appointments 
and radiological examinations. The covariate-adjusted analyses reveal little 
evidence of preference heterogeneity, although some patient-specific variables 
(i.e. education level, employment and living status, time already spent in follow-
up and number of treatments received) are significantly associated with the 
choice of BW items; conversely, age and gender have no significant effect on 
preferences. By summing the attribute-level coefficients resulting from the 
(unadjusted) conditional logit model, the scenario corresponding to arm B in the 
HETEcO trial obtains the highest utility in the overall sample, thus suggesting 
an alignment between elicited preferences and cost-effectiveness results 
(Chapter V) in HNC follow-up.  
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7.3 Limitations 
The different studies comprising this thesis present some limitations that have been 
extensively described in the corresponding chapters. Here, a discussion of the overall 
weaknesses of the thesis is provided. The original thesis’s research question was 
generated from a multicentre RCT that was to be completed by 2017. However, the 
study experienced severe delays, mainly due to a reluctance to participate on behalf of 
patients who are used to receive a quite intensive follow-up at Italian hospitals, broadly 
like that scheduled for arm B, and are afraid to be assigned to the symptom-driven one 
(arm A). Moreover, the clinical study faced some logistical and resource constraints that 
hampered the work at individual centres. Due to this slow recruitment process, more 
centres have joined the study over time, and the deadline for its completion has been 
delayed to 2020.  
This issue mainly affected two chapters of this thesis. In Chapter IV, a limited number 
of observations were available to conduct the mapping exercise, thus affecting the 
precision of model estimates, and hindering the use of alternative regression techniques 
(e.g. response mapping). Moreover, the data collected at different time points were 
pooled together, thus preventing a longitudinal study design that considers also the visit 
number, and not only the patient, as a cluster variable. Therefore, it is likely that this 
paper will be updated once more patients are recruited to the RCT. 
In Chapter V, the original idea was to perform an RCT-based economic evaluation over 
a 3-year period, corresponding to the trial length, with a subsequent extrapolation of 
lifetime outcomes and costs based on the trial’s results using established survival 
analysis techniques. In the absence of adequate clinical information from the trial, the 
economic evaluation of the two follow-up strategies was performed instead using 
alternative data sources. The proportion of potentially salvageable recurrences that is 
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detected by the two alternative surveillance schemes, which represents a key parameter 
in the model, was retrieved from previous studies and the assumptions reported in the 
HETeCo trial protocol. Thus, an empirical confirmation of this data upon the trial 
completion is of interest.  
Further limitations concern the two systematic literature reviews that are included in 
this thesis. In the first review (Chapter II), only the main databases (i.e. PubMed, 
EMBASE, and the Cochrane Library) were searched, despite there being others (e.g. 
EconLit) could also have been considered. In the second review (Chapter III), more 
databases were searched, including some specifically aimed at collecting HSUVs; 
however, a broad unpublished literature might be available on this topic that was 
disregarded. Additionally, in both reviews, the range of keywords was limited to those 
most frequently adopted in the field, thus potentially excluding studies using alternative 
terms (e.g. ‘monitoring’ instead of ‘follow-up’ or ‘surveillance’). 
7.4 Contributions to research 
Despite their limitations, each chapter (from II to VI) contributes to fill some 
knowledge “gaps” around different aspects defining the ‘value’ of follow-up programs 
in HNC. The two systematic reviews (Chapters II and III) provide a comprehensive and 
critical synthesis of relevant studies to inform the development of future research 
projects in HNC follow-up; moreover, they test the suitability of the available 
guidelines (i.e. the CHEERS checklist [73] and a set of recommendations from 
Papaioannou et al. [160]) to provide a quality scoring of the available literature. The 
mapping chapter (Chapter IV) is a technical work that furnishes a set of mapping 
functions to generate HSUVs in studies where only cancer-specific instruments (i.e. 
EORTC QLQ-C30 and H&N35) are collected. Moreover, the study represents a 
knowledge advancement in the recent mapping literature by exploring alternative 
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modelling techniques to the traditional linear regression, and a range of EQ-5D-5L 
value sets. The model presented in Chapter V adopts the well-established technique of 
cost per QALY to explore the value of using intensive radiological investigations in 
HNC follow-up. More intensive follow-up was shown to potentially increase patient’s 
overall survival and quality-adjusted survival and be good ‘value for money’ for a 
regional healthcare system in Italy; moreover, conducting additional research in this 
field can be worthwile according to the EVPI analysis. This chapter, despite intrinsic 
limitations related to the unavailability of reliable efficacy parameters, fills a relevant 
knowledge “gap” in HNC literature where no economic evaluations comparing 
surveillance programs of different intensity were available to date. Lastly, the BWS 
study (Chapter VI) explores the topic of patients’ preferences that has received limited 
attention from health economics and HTA decision-making so far. The work also tests 
the suitability of a survey instrument, the BWS, which has been applied much less often 
than the better-known binary DCE. The analysis of self-reported difficulties by the 
patients confirms that BWS is a quick and easy tool for eliciting patients’ preferences in 
vulnerable people like cancer patients.  
7.5 Policy implications 
Cost-effectiveness analyses are increasingly used to inform policy-makers about the 
efficient allocation of limited healthcare resources. This is particularly true in countries 
where health services are largely tax-financed, such as Italy, and healthcare expenditure 
is growing dramatically over time. In oncology, these methods have been mainly 
applied to drug treatments such as chemotherapy and radiotherapy, whilst much less 
evidence is available for non-pharmaceutical interventions including population 
screening, surgery, medical devices, and follow-up programs [57]. This thesis has the 
merit of stimulating a scientific debate around the topic of post-treatment surveillance in 
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cancer and can inform health and policy decision-making in several ways. The 
systematic review of economic evaluations in cancer follow-up (Chapter II) is useful to 
oncologists and policy-makers who wish to update surveillance programs in their 
organizations or countries based on scientific evidence. The quality assessment based 
on the CHEERS checklist allows identification of the most reliable evaluations. 
However, the search identified only one study [112] related to HNC and adopting a too 
short horizon to capture meaningful clinical outcomes. Thus, the first economic 
evaluation of follow-up interventions in this cancer population has been provided by 
this thesis (Chapter V). The cost-effectiveness model’s results revealed that intensive 
follow-up with frequent radiological assessments (MRI, CT, PET) over time is likely to 
generate a quality-adjusted (and -unadjusted) survival gain at acceptable additional cost 
compared to less intensive, symptom-driven surveillance. In sensitivity analyses, a 
difference of 0.15 in ‘curability’ between arm B and arm A of the HETeCo trial is 
estimated to be sufficient for obtaining the cost-effectiveness of the more intensive 
intervention. Moreover, the healthcare costs of HNC follow-up have not been deeply 
studied yet [23]. In Chapter V, an estimate of 5-year costs associated to the two 
alternative surveillance strategies is provided, with details on resource consumption and 
cost items for the Lombardy region, which may represent a useful template to cost other 
follow-up programs in Italy and elsewhere. These results can influence the healthcare 
planning and financing in the next few years, as well as the clinical practice, at least in 
Italy.  
Discrete choice preference methods, including BWS, allow analysis of innovative 
policies and complex interventions with multiple features [281]; moreover, they have a 
potential to contribute to an efficient allocation of scarce resources, although their role 
in the healthcare decision process has not yet been codified. DCE studies may be useful 
to account for trade-offs among different aspects of cancer care and to subsequently 
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prioritise and rank interventions from a patient’s perspective. Overall, the awareness of 
patients’ preferences and expectations can improve the adherence to the existing 
programs, incentivise their improvement or replacement, and strengthen the doctor-
patient relationship. Although this thesis does not provide data on adherence to follow-
up, the clinicians involved in this study report skipped appointments and poor 
compliance with physician’s recommendations, especially during the later years of 
surveillance.  
7.6 Future research 
This thesis contributes to the literature on the health economic aspects of HNC follow-
up. However, additional areas might be explored in the future, using this work as a 
starting point. The first systematic review (Chapter II) highlights the need for sound 
economic evaluations in any cancer follow-up, since the studies published so far present 
some methodological weaknesses, mainly related to the use of intermediate endpoints. 
Moreover, the studies mostly address common neoplasms such as breast, colorectal, and 
cervical, whilst other cancers, including HNC, received much less attention. The 
updated search conducted in June 2017 identified many new studies published in a 
limited time, thus carrying on this review work over the years would be valuable to 
collect systematically and to synthesize new evidence in the field. 
Additionally, the area of health-related utility assessment in HNC deserves further 
attention, since the collection of HSUVs (Chapter III) retrieved only few data for 
recurrent and palliative stages, when patients are likely to be too sick and unable to self-
complete questionnaires or take part in TTO/SG tasks. Thus, future research on HSUVs 
elicitation techniques that allows, for example, a systematic involvement of the 
caregiver or healthcare professionals, or the use of user-friendly mobile-app 
technologies to administer EQ-5D directly to the patient, might be further explored in 
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this cancer population. Moreover, additional work is needed in the mapping area to 
derive reliable functions to convert the most common HNC-specific questionnaires, 
including the FACT-H&N, into utility values that are usable in economic evaluation 
studies, and to establish the most efficient regression techniques for this task. As new 
EQ-5D-5L tariff sets are available, the development of model functions using 
algorithms other than those already included in the Chapter IV should be explored.  
More research in needed also on the clinical effectiveness of alternative follow-up 
programs, which is essential to inform cost-utility analyses such as that reported in 
Chapter V. Until now, no prospective studies have been conducted on the topic, and the 
evidence generated from experimental trials is completely lacking [20]. Thus, as 
confirmed by the EVPI results, RCTs beyond the one mentioned in this thesis are 
strongly encouraged to understand the impact of varying follow-up intensity on 
patient’s survival and QALYs. Moreover, even in publicly funded healthcare systems 
such as Italy, the private expenditure and indirect costs over the course of the disease 
might be substantial in cancer; this issue is particularly relevant in HNC, where most 
patients have traditionally belonged to middle-low socioeconomic groups [19]. Thus, 
future economic evaluations of HNC follow-up programs might consider a broader 
societal perspective. Cost-effectiveness analysis of follow-up strategies stratified by risk 
of recurrences and cancer site is a further research opportunity, since different post-
treatment patterns have been identified according to age, smoking status and positivity 
or negativity to HPV. Lastly, how the use of mapped utility values, instead of original 
ones, impacts on QALY calculation and, consequently, on cost-utility analyses results 
might be addressed in future research. 
In the BWS study (Chapter VI), the preference analysis is limited to the process-related 
aspects of the follow-up, as clinical outcomes are still uncertain and under investigation 
in the RCT. Additional elements might be considered in future studies, such as the 
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survival gains, the toxicities related to intensive radiological surveillance, the level of 
scientific evidence, and co-payments for additional investigations. Moreover, how HTA 
should systematically consider patients’ preferences alongside the traditional QALY 
approach remains largely understudied [284]. The next, challenging step is combining 
BWS estimates with program costs to inform healthcare decisions about ‘customised 
care’, which has been defined as healthcare tailored on a patient-by-patient basis and 
has the potential to achieve cost-effectiveness when many individuals prefer a less 
expensive program over a more intensive one [289]. 
7.7 Conclusions 
The number of people living with cancer has increased substantially over time and is 
expected to grow further given advancements in medical and surgical treatment, 
diagnostic tools, and an aging population [314]. After being treated for their primary 
cancer, patients usually enter a program of post-treatment follow-up which may last for 
several years. Routine surveillance is aimed at detecting recurrences, metastases or 
second primaries at the earliest opportunity to administer potentially salvage treatments; 
however, these schemes often lack a sound scientific base and may impose a significant 
economic burden to healthcare systems and societies [32]. In HNC, recent advances in 
primary treatments and rising incidence of HPV-related cancers are likely to increase 
the number of patients who complete the standard 5-year follow-up. 
Until now, post-treatment follow-up in oncology has received little attention, since most 
of the research efforts have been oriented towards the development of effective anti-
cancer therapies. This “gap” is particularly evident for some malignancies like HNC. 
This thesis contributes to the current debate around post-treatment surveillance in HNC, 
by taking advantage of the collaboration with an HNC oncology department located at 
the NCI in Milan, Italy. Moreover, in conducting the BWS experiment, the candidate 
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had the opportunity to hear the patients’ ‘voice’, who could value the main features 
making up a follow-up program in HNC. She has also been invited to join a focus group 
organized by the Italian Association of Medical Oncology (AIOM) and involving 
several healthcare professionals with the objective to standardise the follow-up practices 
in HNC on the national territory based on sound clinical and economic evidence. Other 
stakeholders including policy-makers, patients’ representatives, caregivers, and 
pharmaceutical companies might contribute to this emerging discussion in the future. 
The first RCT is ongoing in Italy and it is hoped that many other studies, with a range of 
designs, will be carried out in Italy and elsewhere on this topic. However, a relevant 
step forward in the knowledge of HNC follow-up has been taken with this thesis. 
 
 
 
 
 
 
 
 
 
 
 
212 
 
REFERENCES  
[1]  B. J. Braakhuis, C. R. Leemans e O. Visser, «Incidence and survival trends of head and 
neck squamous cell carcinoma in the Netherlands between 1989 and 2011,» Oral Oncol, 
vol. 50, pp. 670-75, 2014.  
[2]  G. Gatta, L. Botta, M. J. Sánchez, L. A. Anderson, D. Pierannunzio, L. Licitra e the 
EUROCARE Working Group, «Prognoses and improvement for head and neck cancers 
diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study,» Eur J 
Cancer, vol. 51, pp. 2130-43, 2015.  
[3]  Associazione Italiana di Oncologia Medica (AIOM), «Linee guida per i tumori della testa 
e del collo.,» 2013. [Online]. Available: www.aiom.it. 
[4]  A. Karligkiotis, N. Machouchas, C. Bozzo, A. Melis, A. Cossu, M. Budroni e et al., 
«Head and neck cancer epidemiology in North Sardinia, Italy,» Acta Medica Mediterr, 
vol. 30, n. 1, pp. 41-7, 2014.  
[5]  AIRTUM Working Group, «I tumori in Italia. Rapporto 2016. La sopravvivenza dei 
pazienti oncologici in Italia.,» 2017. [Online]. Available: 
www.epiprev.it/materiali/2017/EP2/AIRTUM_2017_full.pdf. 
[6]  Associazione Italiana Registro Tumori (AIRTUM); Associazione Italiana Oncologia 
Medica (AIOM), «I numeri del cancro in Italia 2015,» 2015. [Online]. Available: 
http://www.registri-tumori.it/PDF/AIOM2015/I_numeri_del_cancro_2015.pdf. 
[7]  ISTAT, «Il consumo di alcol in Italia. Anno 2016.,» 2017. [Online]. Available: 
https://www.istat.it/it/files/2017/04/Consumo_alcol_in_Italia_2016.pdf?title=Consumo+
di+alcol++-+12%2Fapr%2F2017+-+Testo+integrale+e+nota+metodologica.pdf. 
[8]  EpiCentro, «Rapporto nazionale Passi 2011: abitudine al fumo.,» 2011. [Online]. 
Available: http://www.epicentro.iss.it/passi/rapporto2011/FumoAttivo.asp. 
[9]  S. Marur e A. A. Forastiere, «Head and neck squamous cell carcinoma: update on 
epidemiology, diagnosis and treatment,» Mayo Clin Proc, vol. 91, n. 3, pp. 386-96, 2016.  
[10]  D. A. de Andrade e J. P. Machiels, «Treatment options for patients with recurrent or 
metastatic squamous cell carcinoma of the head and neck, who progress after platinum-
based chemotherapy,» Curr Opin Oncol, vol. 24, pp. 211-7, 2012.  
[11]  O. Guntinas-Lichius, T. G. Wendt, N. Kornetzky, J. Buentzel, D. Esser, D. Böger e et al., 
«Trends in epidemiology and treatment and outcome for head and neck cancer: A 
population-based long-term analysis from 1996 to 2011 of the Thuringian cancer 
registry,» Oral Oncol, vol. 50, pp. 1157-64, 2014.  
 
 
 
213 
 
[12]  K. A. Price e E. E. Cohen, «Current treatment options for metastatic head and neck 
cancer,» Curr Treat Options Oncol, vol. 13, pp. 35-46, 2012.  
[13]  E. Wissinger, I. Griebsch, J. Lungershausen, T. Foster e C. L. Pashos, «The economic 
burden of head and neck cancer: A systematic literature review,» Pharmacoeconomics, 
vol. 32, n. 9, pp. 865-82, 2014.  
[14]  M. A. Tejani, R. B. Cohen e R. Mehra, «The contribution of cetuximab in the treatment 
of recurrent and/or metastatic head and neck cancer,» Biologics, vol. 4, pp. 173-85, 2010.  
[15]  L. Sweeny, E. L. Rosenthal, L. Clemons, T. M. Stevens, E. R. McIntosh e W. R. Carroll, 
«Outcomes after surgical salvage for recurrent oropharyngeal squamous cell carcinoma,» 
Oral Oncol, vol. 60, pp. 118-24, 2016.  
[16]  A. Kawecki e R. Krajewski, «Follow-up in patients treated for head and neck cancer,» 
Memo, vol. 7, pp. 87-91, 2014.  
[17]  J. B. Vermorken e P. Specenier, «Optimal treatment for recurrent/metastatic head and 
neck cancer,» Ann Oncol, vol. 21, n. 7, pp. vii252-61, 2010.  
[18]  J. A. de Souza e T. Y. Seiwert, «A value framework in head and neck cancer,» Am Soc 
Clin Oncol Educ Book, pp. e304-9, 2014.  
[19]  H. J. Lu e P. M. Chang, «How to treat recurrent/metastatic head and neck cancer: the 
economic issue in real-world practice,» Curr Med Res Opin, vol. 33, n. 4, pp. 779-80, 
2017.  
[20]  F. De Felice, D. Musio e V. Trombolini, «Follow-up in head and neck cancer: a 
management dilemma,» Adv Otolaryngol, 2015.  
[21]  K. S. Choe, D. J. Haraf, A. Solanki, E. E. Cohen, T. Y. Seiwert, K. M. Stenson e et al., 
«Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary 
head and neck cancer treated with concurrent chemotherapy and reirradiation,» Cancer, 
vol. 117, n. 20, pp. 4671-8, 2011.  
[22]  D. Posch, H. Fuchs, G. Kornek, A. Grah, J. Pammer, M. B. Aretin e et al., «Docetaxel 
plus cetuximab biweekly is an active regimen for the first line treatment of patients with 
recurrent/metastatic head and neck cancer,» Sci Rep, vol. 6, pp. 1-7, 2016.  
[23]  N. Denaro, M. C. Merlano e E. G. Russi, «Follow-up in head and neck cancer: do more 
does it mean do better? A systematic review and our proposal based on our experience,» 
Clin Exp Otorhinolaryngol, vol. 9, n. 4, pp. 287-97, 2016.  
[24]  J. H. González-Botas, P. V. Vázquez e C. V. Barro, «Second primary tumours in head 
and neck cancer,» Acta Otorrinolaringol Esp, vol. 67, n. 3, pp. 123-9, 2016.  
 
[25]  A. S. Ho, D. H. Kraus, I. Ganly, N. Y. Lee, J. P. Shah e L. G. Morris, «Decision making 
in the management of recurrent head and neck cancer,» Head Neck, vol. 36, n. 1, pp. 144-
51, 2014.  
214 
 
[26]  P. Strojan, J. Corry, A. Eisbruch, J. B. Vermorken, W. M. Mendenhall e A. W. Lee, 
«Recurrent and second primary squamous cell carcinoma of the head and neck: when and 
how to reirradiate,» Head Neck, vol. 37, n. 1, pp. 134-50, 2015.  
[27]  S. J. Wong, D. E. Heron, K. Stenson, D. C. Ling e J. A. Vargo, «Locoregional recurrent 
or second primary head and neck cancer: management strategies and challenges,» Am 
Soc Clin Oncol Educ Book, vol. 35, pp. e284-92, 2016.  
[28]  A. Pagh, T. Vedtofte, C. D. Lynggaard, N. Rubek, M. Lonka, J. Johansen e et al., «The 
value of routine follow-up after treatment for head and neck cancer: A National Survey 
from DAHANCA,» Acta Oncol, vol. 52, n. 2, pp. 277-84, 2013.  
[29]  M. Piemonte e M. G. Rugiu, «Il follow-up dei tumori maligni della testa e del collo. 
Quaderni monografici di aggiornamento,» 2013. [Online]. Available: 
https://www.aooi.it/contents/attachment/c11/QMA_31_2013.pdf. 
[30]  F. De Felice, M. de Vincentiis, V. Valentini, D. Musio, S. Mezi, L. Lo Mele e et al., 
«Follow-up program in head and neck cancer,» Crit Rev Oncol Hematol, vol. 113, pp. 
151-5, 2017.  
[31]  S. J. Wang, «Surveillance radiologic imaging after treatment of oropharyngeal cancer: a 
review,» World J Surg Oncol, vol. 13, pp. 1-6, 2015.  
[32]  K. Manikantan, S. Khode, R. C. Dwivedi, R. Palav, C. M. Nutting, P. Rhys-Evans e et 
al., «Making sense of post-treatment surveillance in head and neck cancer: when and 
what to follow-up,» Cancer Treat Rev, vol. 35, pp. 744-53, 2009.  
[33]  Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy), «Health and economic 
outcomes of two different follow-up strategies in effectively cured advanced head and 
neck cancer (HETeCo),» [Online]. Available: 
https://clinicaltrials.gov/ct2/show/NCT02262221. [Consultato il giorno 2016]. 
[34]  D. G. Pfister, S. Spencer, D. M. Brizel, B. Burtness, P. M. Busse, J. J. Caudell e et al., 
«Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology,» J 
Natl Compr Canc Netw, vol. 12, n. 10, pp. 1454-87, 2014.  
[35]  M. E. Porter, «What is value in healthcare?,» N Engl J Med, vol. 363, n. 26, pp. 2477-81, 
2010.  
[36]  M. C. Weinstein, G. Torrance e A. McGuire, «QALYs: the basics,» Value Health, vol. 
12, n. 1, pp. S5-9, 2009.  
[37]  B. H. Goulart, «Value: the next frontier in cancer care,» Oncologist, vol. 21, n. 6, pp. 
651-3, 2016.  
 
[38]  N. J. Devlin e P. K. Lorgelly, «QALYs as a measure of value in cancer,» J Cancer 
Policy, vol. 11, pp. 19-25, 2017.  
[39]  M. Garau, K. K. Shah, A. R. Mason, Q. Wang, A. Towse e M. F. Drummond, «Using 
QALYs in cancer,» Pharmacoeconomics, vol. 29, n. 8, pp. 673-85, 2011.  
215 
 
[40]  R. Llewellyn-Bennett, L. Bowman e R. Bulbulia, «Post-trial follow-up methodology in 
large randomized controlled trials: a systematic review protocol,» Syst Rev, vol. 5, n. 1, 
pp. 1-7, 2016.  
[41]  S. Michiels, E. D. Saad e M. Buyse, «Progression-Free Survival as a Surrogate for 
Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors,» 
Drugs, vol. 77, n. 7, pp. 713-9, 2017.  
[42]  P. M. Rothwell, «Factors that can affect the external validity of randomised controlled 
trials,» PLoS Clin Trials, vol. 1, n. 1, pp. 1-5, 2006.  
[43]  U. A. Matulonis, A. M. Oza, T. W. Ho e J. A. Ledermann, «Intermediate clinical 
endpoints: a bridge between progression-free survival and overall survival in ovarian 
cancer trials,» Cancer, vol. 121, n. 11, pp. 1737-46, 2015.  
[44]  A. E. Attema e W. B. Brouwer, «On the (not so) constant proportional trade-off in TTO,» 
Qual Life Res, vol. 19, n. 4, pp. 489-97, 2010.  
[45]  P. Dolan, G. Kavetsos e A. Tsuchiya, «Sick but satisfied: the impact of life and health 
satisfaction on choice between health scenarios,» J Health Econ, vol. 32, n. 4, pp. 708-
14, 2013.  
[46]  S. Dixon, L. Longworth and A. Wailoo, “Assessing technologies at the end of life: a 
review of empirical evidence,” 2009. [Online]. Available: 
http://scharr.dept.shef.ac.uk/nicedsu/wp-content/uploads/sites/7/2016/03/DSU-EOL-lit-
review.FINAL_.pdf. 
[47]  R. Grieve, M. Grishchenko e J. Cairns, «SF-6D versus EQ-5D: reasons for differences in 
utility scores and impact on reported cost-utility,» Eur J Health Econ, vol. 10, pp. 15-23, 
2009.  
[48]  D. N. Lakdawalla, J. A. Romley, Y. Sanchez, J. R. Maclean, J. R. Penrod e T. Philipson, 
«How cancer patients value hope and the implications for cost-effectiveness assessments 
of high-cost cancer therapies,» Health Aff (Millwood), vol. 31, n. 4, pp. 676-82, 2012.  
[49]  M. Collins e N. Latimer, «NICE's end of life criteria: who gains, who loses?,» BMJ, vol. 
346, 2013.  
 
[50]  J. E. Brazier, S. Dixon e J. Ratcliffe, «The role of patient preferences in cost-
effectiveness analysis: a conflict of values?,» Pharmacoeconomics, vol. 27, n. 9, pp. 705-
12, 2009.  
[51]  L. E. Schnipper, N. E. Davidson, D. S. Wollins, D. W. Blayney, A. P. Dicker, P. A. Ganz 
e et al., «Updating the American Society of Clinical Oncology Value Framework: 
Revisions and Reflections in Response to Comments Received,» J Clin Oncol, vol. 34, n. 
24, pp. 2925-34, 2016.  
 
 
 
216 
 
[52]  N. I. Cherny, R. Sullivan, U. Dafni, J. M. Kerst, A. Sobrero, C. Zielinski e et al., «A 
standardised, generic, validated approach to stratify the magnitude of clinical benefit that 
can be anticipated from anti-cancer therapies: the European Society for Medical 
Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS),» Ann Oncol, vol. 26, n. 
8, pp. 1547-73, 2015.  
[53]  R. W. Carlson e E. Jonasch, «NCCN Evidence Blocks,» J Natl Compr Canc Netw, vol. 
14, n. 5, pp. 616-9, 2016.  
[54]  R. Nelson, «New abacus calculates price of cancer drug based on value,» Medscape, 
2015. [Online]. Available: http://www.medscape.com/viewarticle/847755. 
[55]  L. Pizzi, «The Institute for Clinical and Economic Review and its growing influence on 
the US healthcare,» Am Health Drug Benefits, vol. 9, n. 1, pp. 9-10, 2016.  
[56]  J. Maervoet, P. Moise e S. Naidoo, «Overview and comparison of frameworks for the 
valuation of oncology drugs,» in ISPOR 21st Annual International Meeting, Washington, 
DC, USA, 2016.  
[57]  M. Barbieri, H. L. Weatherly, R. Ara, H. Basarir, M. Sculpher, R. Adams e et al., «What 
is the quality of economic evaluations of non-drug therapies? A systematic review and 
critical appraisal of economic evaluations of radiotherapy for cancer,» Appl Health Econ 
Health Policy, vol. 12, pp. 497-510, 2014.  
[58]  I. Boutron, L. Guittet, C. Estellat, D. Moher, A. Hróbjartsson e P. Ravaud, «Reporting 
methods of blinding in randomized trials assessing nonpharmacological treatments,» 
PLoS Med, vol. 4, n. 2, pp. 370-80, 2007.  
[59]  A. Lanfranconi, L. Pylkkänen, S. Deandrea, A. Bramesfeld, D. Lerda, L. Neamtiu e et al., 
«Intensive follow-up for women with breast cancer: review of clinical, economic and 
patient's preference domains through evidence to decision framework,» Health Qual Life 
Outcomes, vol. 15, n. 1, pp. 1-18, 2017.  
[60]  C. Jackson, J. Stevens, S. Ren, N. Latimer, L. Bojke, A. Manca e et al., «Extrapolating 
survival from randomized trials using external data: a review of methods,» Med Decis 
Making, vol. 37, n. 4, pp. 377-90, 2017.  
[61]  Y. Schenker, R. M. Arnold, J. E. Bauman, D. E. Heron e J. T. Johnson, «An enhanced 
role for palliative care in the multidisciplinary approach to high-risk head and neck 
cancer,» Cancer, vol. 122, n. 3, pp. 340-3, 2016.  
[62]  S. H. Kim, M. W. Jo, H. J. Kim e J. H. Ahn, «Mapping EORTC QLQ-C30 onto EQ-5D 
for the assessment of cancer patients,» Health Qual Life Outcomes, vol. 10, pp. 1-6, 
2012.  
[63]  E. R. Marriott, G. van Hazel, P. Gibbs e A. J. Hatswell, «Mapping EORTC-QLQ-C30 to 
EQ-5D-3L in patients with colorectal cancer,» J Med Econ, vol. 20, n. 2, pp. 193-9, 2017. 
  
217 
 
[64]  D. Rowen, J. Brazier, T. Young, S. Gaugris, B. M. Craig, M. T. King e et al., «Deriving a 
preference-based measure for cancer using the EORTC QLQ-C30,» Value Health, vol. 
14, n. 5, pp. 721-31, 2011.  
[65]  R. A. Lewis, R. D. Neal, N. H. Williams, B. France, M. Hendry, D. Russell e et al., 
«Follow-up of cancer in primary care versus secondary care: systematic review,» Br J 
Gen Pract, vol. 59, n. 564, pp. e234-47, 2009.  
[66]  R. Dickinson, S. Hall, J. E. Sinclair, C. Bond e P. Murchie, «Using technology to deliver 
cancer follow-up: a systematic review,» BMC Cancer, vol. 14, pp. 1-16, 2014.  
[67]  M. Jeffery, B. E. Hickey e P. N. Hider, «Follow-up strategies for patients treated for non-
metastatic colorectal cancer (Review),» Cochrane Libr, vol. 1, pp. 1-37, 2007.  
[68]  S. Pita-Fernández , M. Alhayek-Ai , C. González-Martín , B. López-Calviño, T. Seoane-
Pillado e S. Pértega-Díaz, «Intensive follow-up strategies improve outcomes in 
nonmetastatic colorectal cancer patients after curative surgery: a systematic review and 
meta-analysis,» Ann Oncol, vol. 26, n. 4, pp. 644-56, 2015.  
[69]  A. Digonnet, M. Hamoir, G. Andry, M. J. Haigentz, R. P. Takes, C. E. Silver e et al., 
«Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma,» 
Eur Arch Otorhinolaryngol, vol. 270, n. 5, pp. 1569-80, 2013.  
[70]  V. Nama, A. Nordin e A. Bryant, «Patient-reported outcome measures for follow-up after 
gynecological cancer treatment (Review),» Cochrane Libr, vol. 11, pp. 1-15, 2013.  
[71]  C. Robertson, S. K. Arcot Ragupathy, C. Boachie, J. M. Dixon, C. Fraser, R. Hernández 
e et al., «The clinical effectiveness and cost-effectiveness of different surveillance 
mammography regimens after the treatment for primary breast cancer: systematic 
reviews registry database analyses and economic evaluation,» Health Technol Assess, 
vol. 15, n. 34, pp. 1-322, 2011.  
[72]  D. Moher, L. Shamseer, M. Clarke, D. Ghersi, A. Liberati, M. Petticrew e et al., 
«Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-
P) 2015 statement,» Syst Rev, vol. 4, n. 1, pp. 1-9, 2015.  
[73]  D. Husereau, M. Drummond, S. Petrou, C. Carswell, D. Moher, D. Greenberg e et al., 
«Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--
explanation and elaboration: a report of the ISPOR Health Economic Evaluation 
Publication Guidelines Good Reporting Practices Task Force,» Value Health, vol. 16, n. 
2, pp. 231-50, 2013.  
[74]  L. G. Gordon e D. Rowell, «Health system costs of skin cancer and cost-effectiveness of 
skin cancer prevention and screening: a systematic review,» Eur J Cancer Prev, vol. 24, 
pp. 141-9, 2015.  
[75]  S. Maru, J. Byrnes, M. J. Carrington, S. Stewart e P. A. Scuffham, «Systematic review of 
trial-based analyses reporting the economic impact of heart failure management programs 
compared with usual care,» Eur J Cardiovasc Nurs, vol. 15, n. 1, pp. 82-90, 2016.  
218 
 
[76]  C. Mihalopoulos e M. L. Chatterton, «Economic evaluations of interventions designed to 
prevent mental disorders: a systematic review,» Early Interv Psychiatry, vol. 9, n. 2, pp. 
85-92, 2015.  
[77]  S. J. Palfreyman e P. W. Stone, «A systematic review of economic evaluations assessing 
interventions aimed at preventing or treating pressure ulcers,» Int J Nurs Stud, vol. 52, n. 
3, pp. 769-88, 2015.  
[78]  B. Almog, R. Gamzu, J. Bornstein, I. Levin, O. Fainaru, J. Niv e et al., «Clinical and 
economic benefit of HPV-load testing in follow-up and management of women postcone 
biopsy for CIN2-3,» Br J Cancer, vol. 89, n. 1, pp. 109-12, 2003.  
[79]  K. A. Armstrong, J. L. Semple e P. C. Coyte, «Replacing ambulatory surgical follow-up 
visits with mobile app home monitoring: modeling cost-effective scenarios,» J Med 
Internet Res, vol. 16, n. 9, pp. 1-34, 2014.  
[80]  S. A. Assoumou, K. H. Mayer, L. Panther, B. P. Linas e J. Kim, «Cost-effectiveness of 
surveillance strategies after treatment for high-grade anal dysplasia in high-risk patients,» 
Sex Transm Dis, vol. 40, n. 4, pp. 298-303, 2013.  
[81]  K. M. Augestad, J. Norum, S. Dehof, R. Aspevik, U. Ringberg, T. Nestvold e et al., 
«Cost-effectiveness and quality of life in surgeon versus general practitioner-organised 
colon cancer surveillance: a randomised controlled trial,» BMJ Open, vol. 3, n. 4, pp. 1-
15, 2013.  
[82]  P. Auguste, P. Barton, C. Meads, C. Davenport, S. Malysiak, M. Kowalska e et al., 
«Evaluating PET-CT in routine surveillance and follow-up after treatment for cervical 
cancer: a cost-effectiveness analysis,» BJOG, vol. 121, n. 4, pp. 464-76, 2014.  
[83]  J. M. Baena-Cañada, P. Ramírez-Daffós, C. Cortés-Carmona, P. Rosado-Varela, J. Nieto-
Vera e E. Benítez-Rodríguez, «Follow-up of long-term survivors of breast cancer in 
primary care versus specialist attention,» Fam Pract, vol. 30, n. 5, pp. 525-32, 2013.  
[84]  K. Beaver, W. Hollingworth, R. McDonald, G. Dunn, D. Tysver-Robinson, L. Thomson 
e et al., «Economic evaluation of a randomized clinical trial of hospital versus telephone 
follow-up after treatment for breast cancer,» Br J Surg, vol. 96, n. 12, pp. 1406-15, 2009.  
 
[85]  T. Bessen e J. Karnon, «A patient-level calibration framework for evaluating surveillance 
strategies: a case study of mammographic follow-up after early breast cancer,» Value 
Health, vol. 17, pp. 669-78, 2014.  
[86]  T. Bessen, D. M. Keefe e J. Karnon, «Does one size fit all? Cost utility analyses of 
alternative mammographic follow-up schedules, by risk of recurrence,» Int J Technol 
Assess Health Care, vol. 31, n. 5, pp. 281-8, 2015.  
[87]  F. Borie, C. Combescure, J. P. Daurès, B. Trétarre e B. Millat, «Cost-effectiveness of two 
follow-up strategies for curative resection of colorectal cancer: comparative study using a 
Markov model,» World J Surg, vol. 28, n. 6, pp. 563-9, 2004.  
 
 
219 
 
[88]  V. M. Coupé, J. Berkhof, R. H. Verheijen e C. J. Meijer, «Cost-effectiveness of human 
papillomavirus testing after treatment for cervical intraepithelial neoplasia,» BJOG, vol. 
114, n. 4, pp. 416-24, 2007.  
[89]  D. Coyle, E. Grunfeld, K. Coyle, G. Pond, J. A. Julian e M. N. Levine, «Cost 
effectiveness of a survivorship care plan for breast cancer survivors,» J Oncol Pract, vol. 
10, n. 2, pp. e86-e92, 2014.  
[90]  I. Cromwell, M. Gaudet, S. J. Peacock e C. Aquino-Parsons, «Cost-effectiveness analysis 
of anal cancer screening in women with cervical neoplasia in British Columbia, Canada,» 
BMC Health Serv Res, vol. 16, pp. 1-10, 2016.  
[91]  S. Damude, J. E. Hoekstra-Weebers, A. B. Francken, S. Ter Meulen, E. Bastiaannet e H. 
J. Hoekstra, «The MELFO-Study: prospective, randomized, clinical trial for the 
evaluation of a stage-adjusted reduced follow-up schedule in cutaneous melanoma 
patients-results after 1 year,» Ann Surg Oncol, vol. 23, n. 9, pp. 2762-71, 2016.  
[92]  V. Dansk, P. U. Malmström, M. Bläckberg e M. Malmenäs, «Hexaminolevulinate 
hydrochloride blue-light flexible cystoscopy in the detection and follow-up of 
nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in 
Sweden,» Future Oncol, vol. 12, n. 8, pp. 1025-38, 2016.  
[93]  P. Das, A. K. Ng, C. C. Earle, P. M. Mauch e K. M. Kuntz, «Computed tomography 
screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-
effectiveness analysis,» Ann Oncol, vol. 17, n. 5, pp. 785-93, 2006.  
[94]  E. W. de Bekker-Grob, M. N. van der Aa, E. C. Zwarthoff, M. J. Eijkemans, B. W. van 
Rhijn, T. H. van der Kwast e et al., «Non-muscle-invasive bladder cancer surveillance for 
which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective 
alternative?,» BJU Int, vol. 104, n. 1, pp. 41-7, 2009.  
[95]  J. D. Emery, M. Jefford, M. King, D. Hayne, A. Martin, J. Doorey e et al., «ProCare 
Trial: a phase II randomized controlled trial of shared care for follow-up of men with 
prostate cancer,» BJU Int, vol. 119, n. 3, pp. 381-9, 2017.  
 
[96]  F. S. Erenay, O. Alagoz, R. Banerjee, A. Said e R. R. Cima, «Cost-effectiveness of 
alternative colonoscopy surveillance strategies to mitigate metachronous colorectal 
cancer incidence,» Cancer, vol. 122, n. 16, pp. 2560-70, 2016.  
[97]  F. Forni, G. Ferrandina, F. Deodato, G. Macchia, A. G. Morganti, D. Smaniotto e et al., 
«Squamous cell carcinoma antigen in follow-up of cervical cancer treated with 
radiotherapy: evaluation of cost-effectiveness,» Int J Radiat Oncol Biol Phys, vol. 69, n. 
4, pp. 1145-9, 2007.  
[98]  S. Gilbert, K. R. Reid, M. Y. Lam e D. Petsikas, «Who should follow up lung cancer 
patients after operation?,» Ann Thorac Surg, vol. 69, n. 6, pp. 1696-700, 2000.  
 
 
 
220 
 
[99]  B. A. Guadagnolo, R. S. Punglia, K. M. Kuntz, P. M. Mauch e A. K. Ng, «Cost-
effectiveness analysis of computerized tomography in the routine follow-up of patients 
after primary treatment for Hodgkin's disease,» J Clin Oncol, vol. 24, n. 25, pp. 4116-22, 
2006.  
[100]  C. Hassan, P. J. Pickhardt, A. Zullo, E. Di Giulio, A. Laghi, D. H. Kim e et al., «Cost-
effectiveness of early colonoscopy surveillance after cancer resection,» Dig Liver Dis, 
vol. 41, n. 12, pp. 881-5, 2009.  
[101]  N. Hatam, N. Ahmadloo, M. Vazirzadeh, A. Jafari e M. Askarian, «Cost-effectiveness of 
intensive vs. standard follow-up models for patients with breast cancer in Shiraz, Iran,» 
Asian Pac J Cancer Prev, vol. 17, n. 12, pp. 5309-14, 2016.  
[102]  F. Helgesen, S. O. Andersson, O. Gustafsson, E. Varenhorst, B. Gobén, S. Carnock e et 
al., «Follow-up of prostate cancer patients by on-demand contacts with a specialist nurse: 
a randomized study,» Scand J Urol Nephrol, vol. 34, n. 1, pp. 55-61, 2000.  
[103]  U. R. Hengge, A. Wallerand, A. Stutzki e N. Kockel, «Cost-effectiveness of reduced 
follow-up in malignant melanoma,» J Dtsch Dermatol Ges, vol. 5, n. 10, pp. 898-907, 
2007.  
[104]  A. M. Kamat, J. A. Karam, H. B. Grossman, A. K. Kader, M. Munsell e C. P. Dinney, 
«Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs 
while maximizing sensitivity,» BJU Int, vol. 108, n. 7, pp. 1119-23, 2011.  
[105]  M. S. Kent, P. Korn, J. L. Port, P. C. Lee, N. K. Altorki e R. J. Korst, «Cost effectiveness 
of chest computed tomography after lung cancer resection: a decision analysis model,» 
Ann Thorac Surg, vol. 80, n. 4, pp. 1215-22, 2005.  
[106]  M. L. Kimman, C. D. Dirksen, A. C. Voogd, P. Falger, B. C. Gijsen, M. Thuring e et al., 
«Economic evaluation of four follow-up strategies after curative treatment for breast 
cancer: results of an RCT,» Eur J Cancer, vol. 47, n. 8, pp. 1175-85, 2011.  
[107]  I. Koinberg, G. B. Engholm, A. Genell e L. Holmberg, «A health economic evaluation of 
follow-up after breast cancer surgery: results of an rct study,» Acta Oncol, vol. 48, n. 1, 
pp. 99-104, 2009.  
[108]  R. Kokko, M. Hakama e K. Holli, «Follow-up cost of breast cancer patients with 
localized disease after primary treatment: a randomized trial,» Breast Cancer Res Treat, 
vol. 93, n. 3, pp. 255-60, 2005.  
[109]  A. Lanceley, C. Berzuini, M. Burnell, S. Gessler, S. Morris, A. Ryan e et al., «Ovarian 
cancer follow-up: a preliminary comparison of 2 approaches,» Int J Gynecol Cancer, vol. 
27, n. 1, pp. 59-68, 2017.  
[110]  R. Legood, M. Smith, J. B. Lew, R. Walker, S. Moss, H. Kitchener e et al., «Cost 
effectiveness of human papillomavirus test of cure after treatment for cervical 
intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study,» 
BMJ, vol. 345, pp. 1-10, 2012.  
221 
 
[111]  W. Lu, M. J. Greuter, M. Schaapveld, K. M. Vermeulen, T. Wiggers e G. H. de Bock, 
«Safety and cost-effectiveness of shortening hospital follow-up after breast cancer 
treatment,» Br J Surg, vol. 99, n. 9, pp. 1227-33, 2012.  
[112]  K. X. Lyu, J. Zhao, B. Wang, G. X. Xiong, W. Q. Yang, Q. H. Liu e et al., «Smartphone 
application WeChat for clinical follow-up of discharged patients with head and neck 
tumors: a randomized controlled trial,» Chin Med J (Engl), vol. 129, n. 23, pp. 2816-23, 
2016.  
[113]  D. A. Macafee, D. K. Whynes e J. H. Scholefield, «Risk-stratified intensive follow up for 
treated colorectal cancer - realistic and cost saving?,» Colorectal Dis, vol. 10, n. 3, pp. 
222-30, 2008.  
[114]  J. Melnikow, S. Kulasingam, C. Slee, L. J. Helms, M. Kuppermann, S. Birch e et al., 
«Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and 
cost-effectiveness,» Obstet Gynecol, vol. 116, n. 5, pp. 1158-70, 2010.  
[115]  J. Monteil, A. Vergnenègre, F. Bertin, F. Dalmay, S. Gaillard, F. Bonnaud e et al., 
«Randomized follow-up study of resected NSCLC patients: conventional versus 18F-DG 
coincidence imaging,» Anticancer Res, vol. 30, n. 9, pp. 3811-6, 2010.  
[116]  S. Moore, J. Corner, J. Haviland, M. Wells, E. Salmon, C. Normand e et al., «Nurse led 
follow up and conventional medical follow up in management of patients with lung 
cancer: randomised trial,» BMJ, vol. 325, n. 7373, pp. 1-7, 2002.  
[117]  B. G. Ok, Y. S. Ji, Y. H. Ko e P. H. Song, «Usefulness of urine cytology as a routine 
work-up in the detection of recurrence in patients with prior non-muscle-invasive bladder 
cancer: practicality and cost-effectiveness,» Korean J Urol, vol. 55, n. 10, pp. 650-5, 
2014.  
[118]  A. Oltra, A. Santaballa, B. Munárriz, M. Pastor e J. Montalar, «Cost-benefit analysis of a 
follow-up program in patients with breast cancer: a randomized prospective study,» 
Breast J, vol. 13, n. 6, pp. 571-4, 2007.  
 
[119]  N. T. Phippen, L. J. Havrilesky, J. C. Barnett, C. A. Hamilton, M. P. Stany e W. J. 
Lowery, «Does Routine Posttreatment PET/CT Add Value to the Care of Women With 
Locally Advanced Cervical Cancer?,» Int J Gynecol Cancer, vol. 26, n. 5, pp. 944-50, 
2016.  
[120]  S. Polinder, E. M. Verschuur, P. D. Siersema, E. J. Kuipers e E. W. Steyerberg, «Cost 
comparison study of two different follow-up protocols after surgery for oesophageal 
cancer,» Eur J Cancer, vol. 45, n. 12, pp. 2110-5, 2009.  
[121]  G. B. Secco, R. Fardelli, D. Gianquinto, P. Bonfante, E. Baldi, Ravera G e et al., 
«Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a 
prospective, randomized and controlled trial,» Eur J Surg Oncol, vol. 28, n. 4, pp. 418-
23, 2002.  
 
 
222 
 
[122]  A. Siddika, D. Tolia-Shah, T. E. Pearson, N. G. Richardson e A. H. Ross, «Remote 
surveillance after colorectal cancer surgery: an effective alternative to standard clinic-
based follow-up,» Colorectal Dis, vol. 17, n. 10, pp. 870-5, 2015.  
[123]  E. Strand, I. Nygren, L. Bergkvist e K. Smedh, «Nurse or surgeon follow-up after rectal 
cancer: a randomized trial,» Colorectal Dis, vol. 13, n. 9, pp. 999-1003, 2011.  
[124]  A. I. Tergas, L. J. Havrilesky, A. N. Fader, S. R. Guntupalli, W. K. Huh, L. S. Massad e 
et al., «Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance 
for cervical cancer,» Gynecol Oncol, vol. 130, n. 3, pp. 421-5, 2013.  
[125]  C. W. Tzeng, D. E. Abbott, S. B. Cantor, J. B. Fleming, J. E. Lee, P. W. Pisters e et al., 
«Frequency and intensity of postoperative surveillance after curative treatment of 
pancreatic cancer: a cost-effectiveness analysis,» Ann Surg Oncol, vol. 20, n. 7, pp. 2197-
203, 2013.  
[126]  J. van Loon, J. P. Grutters, R. Wanders, L. Boersma, A. M. Dingemans, G. Bootsma e et 
al., «18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical 
radiotherapy with or without chemotherapy: an economic evaluation,» Eur J Cancer, vol. 
46, n. 1, pp. 110-9, 2010.  
[127]  C. J. Verberne, T. Wiggers, I. Grossmann, G. H. de Bock e K. M. Vermeulen, «Cost-
effectiveness of a carcinoembryonic antigen (CEA) based follow-up programme for 
colorectal cancer (the CEA Watch trial),» Colorectal Dis, vol. 18, n. 3, pp. O91-6, 2016.  
[128]  E. M. Verschuur, E. W. Steyerberg, H. W. Tilanus, S. Polinder, M. L. Essink-Bot, K. T. 
Tran e et al., «Nurse-led follow-up of patients after oesophageal or gastric cardia cancer 
surgery: a randomised trial,» Br J Cancer, vol. 100, pp. 70-6, 2009.  
[129]  A. Visser, H. W. van Laarhoven, P. H. Govaert, M. S. Schlooz, L. Jansen, T. van Dalen e 
et al., «Group medical consultations in the follow-up of breast cancer: a randomized 
feasibility study,» J Cancer Surviv, vol. 9, n. 3, pp. 450-61, 2015.  
 
[130]  J. X. Wu, C. E. Beni, K. A. Zanocco, C. Sturgeon e M. W. Yeh, «Cost-effectiveness of 
long-term every three-year versus annual postoperative surveillance for low-risk 
papillary thyroid cancer,» Thyroid, vol. 25, n. 7, pp. 797-803, 2015.  
[131]  M. J. Edelman, F. J. Meyers e D. Siegel, «The utility of follow-up testing after curative 
cancer therapy. A critical review and economic analysis,» J Gen Intern Med, vol. 12, n. 
5, pp. 318-31, 1997.  
[132]  N. Hex e C. Bartlett, «Cost-effectiveness of follow-up services for childhood cancer 
survivors outside the cancer setting,» Curr Opin Support Palliat Care, vol. 7, n. 3, pp. 
314-7, 2013.  
[133]  M. Yang, D. S. Patel, W. Tufail e A. M. Issa, «The quality of economic studies of cancer 
pharmacogenomics: a quantitative appraisal of the evidence,» Expert Rev Pharmacoecon 
Outcomes Res, vol. 13, n. 5, pp. 597-611, 2013.  
 
 
223 
 
[134]  M. F. Drummond e T. O. Jefferson, «Guidelines for authors and peer reviewers of 
economic submissions to the BMJ,» BMJ, vol. 313, pp. 275-83, 1996.  
[135]  P. J. Neumann, S. J. Goldie e M. C. Weinstein, «Preference-based measures in economic 
evaluation in health care,» Annu Rev Public Health, vol. 21, pp. 587-611, 2000.  
[136]  S. E. Wolowacz, A. Briggs, V. Belozeroff, P. Clarke, L. Doward, R. Goeree e et al., 
«Estimating health-state utility for economic models in clinical studies: an ISPOR Good 
Research Practices Task Force Report,» Value Health, vol. 19, n. 6, pp. 704-19, 2016.  
[137]  A. A. Rashidi, A. H. Anis e C. A. Marra, «Do visual analogue scale (VAS) derived 
standard gamble (SG) utilities agree with Health Utilities Index utilities? A comparison 
of patient and community preferences for health status in rheumatoid arthritis patients,» 
Health Qual Life Outcomes, vol. 4, pp. 1-10, 2006.  
[138]  A. G. Witney, G. J. Treharne, M. Tavakoli, A. C. Lyons, K. Vincent, D. L. Scott e et al., 
«The relationship of medical, demographic and psychosocial factors to direct and indirect 
health utility instruments in rheumatoid arthritis,» Rheumatology (Oxford), vol. 45, n. 8, 
pp. 975-81, 2006.  
[139]  P. Dolan e M. Sutton, «Mapping visual analogue scale health state valuations onto 
standard gamble and time trade-off values,» Soc Sci Med, vol. 44, n. 10, pp. 1519-30, 
1997.  
[140]  S. J. Whitehead e S. Ali, «Health outcomes in economic evaluation: the QALY and 
utilities,» Br Med Bull, vol. 96, n. 1, pp. 5-21, 2010.  
[141]  P. Krabbe, The measurement of health and health status, Academic Press, 2016.  
[142]  M. W. Post, «Definitions of quality of life: what has happened and how to move on,» Top 
Spinal Cord Inj Rehabil, vol. 20, n. 3, pp. 167-80, 2014.  
[143]  W. Wiedermann e U. Frick, «Using surveys to calculate disability-adjusted life-year,» 
Alcohol Res, vol. 35, n. 2, pp. 128-33, 2013.  
[144]  A. E. Attema, Y. Edelaar-Peeters, M. M. Versteegh e E. A. Stolk, «Time trade-off: one 
methodology, different methods,» Eur J Health Econ, vol. 14, n. Suppl 1, pp. S53-64, 
2013.  
[145]  J. Richardson, M. A. Khan, A. Iezzi e A. Maxwell, «Comparing and explaining 
differences in the magnitude, content, and sensitivity of utilities predicted by the EQ-5D, 
SF-6D, HUI 3, 15D, QWB, and AQoL-8D multiattribute utility instruments,» Med Decis 
Making, vol. 35, n. 3, pp. 276-91, 2015.  
[146]  A. Beaudet, J. Clegg, P. O. Thuresson, A. Lloyd e P. McEwan, «Review of utility values 
for economic modeling in type 2 diabetes,» Value Health, vol. 17, n. 4, pp. 462-70, 2014. 
 
  
224 
 
[147]  European Network for Health Techmology Assessment (EUnetHTA), «Methods for 
health economic evaluations - A guideline based on current practices in Europe,» May 
2015. [Online]. Available: http://www.eunethta.eu/wp-
content/uploads/2018/03/Methods_for_health_economic_evaluations.pdf. 
[148]  Y. Hao, V. Wolfram e J. Cook, «A structured review of health utility measures and 
elicitation in advanced/metastatic breast cancer,» Clinicoecon Outcomes Res, vol. 8, pp. 
293-303, 2016.  
[149]  K. S. Boye, L. S. Matza, D. H. Feeny, J. A. Johnston, L. Bowman e J. B. Jordan, 
«Challenges to time trade-off utility assessment methods: when should you consider 
alternative approaches?,» Expert Rev Pharmacoecon Outcomes Res, vol. 14, n. 3, pp. 
437-50, 2014.  
[150]  J. Horsman, W. Furlong, D. Feeny e G. Torrance, «The health utilities index (HUI®): 
concepts, measurement properties and applications,» Health Qual Life Outcomes, vol. 1, 
pp. 1-13, 2003.  
[151]  B. Button, «Quality of well-being (QWB) scale,» in Encyclopedia of Quality of Life and 
Well-Being Research, Springer, Dordrecht, 2014.  
[152]  G. Hawthorne, J. Richardson e R. Osborne, «The assessment of quality of life (AQoL) 
instrument: a psychometric measure of health-related quality of life,» Qual Life Res, vol. 
8, n. 3, pp. 209-24, 1999.  
[153]  A. J. Wailoo, M. Hernandez-Alava, A. Manca, A. Mejia, J. Ray, B. Crawford e et al., 
«Mapping to estimate health-state utility from non-preference-based outcome measures: 
an ISPOR Good Practices for Outcomes Research Task Force Report,» Value Health, 
vol. 20, n. 1, pp. 18-27, 2017.  
[154]  L. Longworth e D. Rowen, «Mapping to obtain EQ-5D utility values for use in NICE 
health technology assessments,» Value Health, vol. 16, n. 1, pp. 202-10, 2013.  
 
[155]  S. M. Szabo, R. L. Dobson, B. M. Donato, G. L'Italien, S. J. Hotte e A. R. Levy, «The 
quality-of-life impact of head and neck cancer: preference values from the Canadian 
general public,» Health Outcomes Res Med, vol. 3, n. 1, pp. e11-23, 2012.  
[156]  M. B. Hannouf, C. Sehgal, J. Q. Cao, J. D. Mocanu, E. Winquist e G. S. Zaric, «Cost-
effectiveness of adding cetuximab to platinum-based chemotherapy for first line 
treatment of recurrent or metastatic head and neck cancer,» PLoS One, vol. 7, n. 6, pp. 1-
9, 2012.  
[157]  N. L. Liberato, C. Rognoni, S. Rubrichi, S. Quaglini, M. Marchetti, T. Gorlia e et al., 
«Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and 
neck cancer: a cost-utility analysis,» Ann Oncol, vol. 23, n. 7, pp. 1825-32, 2012.  
[158]  Y. Komatsuzaki, P. Gramegna, J. M. Stephens, M. F. Botteman, C. L. Pashos e A. 
Redaelli, «Preferences and utilities of health outcomes and treatments associated with 
head and neck cancer: a systematic review,» Am J Cancer, vol. 5, n. 1, pp. 27-34, 2006.  
225 
 
[159]  C. J. Sampson, J. C. Tosh, C. P. Cheyne, D. Broadbent e M. James, «Health state utility 
values for diabetic retinopathy: protocol for a systematic review and meta-analysis,» Syst 
Rev, vol. 4, pp. 1-6, 2015.  
[160]  D. Papaioannou, J. Brazier e S. Paisley, «Systematic searching and selection of health 
state utility values from the literature,» Value Health, vol. 16, pp. 686-95, 2013.  
[161]  K. Jeong e J. Cairns, «Systematic review of health state utility values for economic 
evaluation of colorectal cancer,» Health Econ Rev, vol. 6, n. 1, pp. 1-10, 2016.  
[162]  A. Gheorghe, G. Moran, H. Duffy, T. Roberts, T. Pinkney e M. Calvert, «Health utility 
values associated with surgical site infection: a systematic review,» Value Health, vol. 
18, n. 8, pp. 1126-37, 2015.  
[163]  «CEA Registry,» 2016. [Online]. Available: 
http://healtheconomics.tuftsmedicalcenter.org/cear4/home.aspx. 
[164]  «ScHARRHUD Health Utilities Database,» 2016. [Online]. Available: 
https://www.scharrhud.org/. 
[165]  H. Dakin, «Review of studies mapping from quality of life or clinical measures to EQ-
5D: an online database,» Health Qual Life Outcomes, vol. 11, pp. 1-6, 2013.  
[166]  Health Economics Research Centre (HERC), University of Oxford, «HERC database of 
mapping studies, Version 5.0,» [Online]. Available: 
http://www.herc.ox.ac.uk/downloads/herc-database-of-mapping-studies. 
[167]  J. Smith-Palmer, J. P. Bae, K. S. Boye, K. Norrbacka, B. Hunt e W. J. Valentine, 
«Evaluating health-related quality of life in type 1 diabetes: a systematic literature review 
of utilities for adults with type 1 diabetes,» Clinicoecon Outcomes Res, vol. 8, pp. 559-
71, 2016.  
[168]  G. W. Torrance, D. Feeny e W. Furlong, «Visual analog scales: do they have a role in the 
measurement of preferences for health states?,» Med Decis Mak, vol. 21, n. 4, pp. 329-
34, 2001.  
[169]  J. E. Fincham, «Response rates and responsiveness for surveys, standards, and the 
journal,» Am J Pharm Educ, vol. 72, n. 2, pp. 1-3, 2008.  
[170]  N. Linendoll, T. Saunders, R. Burns, J. D. Nyce, K. B. Wendell, A. M. Evens e et al., 
«Health-related quality of life in Hodgkin lymphoma: a systematic review,» Health Qual 
Life Outcomes, vol. 14, n. 1, pp. 1-14, 2016.  
[171]  A. Marcellusi, A. Capone, G. Favato, F. S. Mennini, G. Baio, K. Haeussler e et al., 
«Health utilities lost and risk factors associated with HPV-induced diseases in men and 
women: the HPV Italian collaborative study group,» Clin Ther, vol. 37, n. 1, pp. 156-67, 
2015.  
 
 
226 
 
[172]  C. W. Noel, D. J. Lee, Q. Kong, W. Xu, C. Simpson, D. Brown e et al., «Comparison of 
health state utility measures in patients with head and neck cancer,» JAMA Otolaryngol 
Head Neck Surg, vol. 141, n. 8, pp. 696-703, 2015.  
[173]  E. L. Conway, K. C. Farmer, W. J. Lynch, G. L. Rees, G. Wain e J. Adams, «Quality of 
life valuations of HPV-associated cancer health states by the general population,» Sex 
Transm Infect, vol. 88, n. 7, pp. 517-21, 2012.  
[174]  D. W. Hamilton, J. E. Bins, P. McMeekin, A. Pedersen, N. Steen, A. De Soyza e et al., 
«Quality compared to quantity of life in laryngeal cancer: A time trade-off study,» Head 
Neck, vol. 38, n. Suppl 1, pp. E631-7, 2016.  
[175]  C. S. Hollenbeak, V. J. Lowe e B. C. Stack, «The cost-effectiveness of 
fluorodeoxyglucose 18-F positron emission tomography in the N0 neck,» Cancer, vol. 
92, n. 9, pp. 2341-8, 2001.  
[176]  V. Jalukar, G. F. Funk, A. J. Christensen, L. H. Karnell e P. J. Moran, «Health states 
following head and neck cancer treatment: patient, health-care professional, and public 
perspectives,» Head Neck, vol. 20, n. 7, pp. 600-8, 1998.  
[177]  J. Ringash, D. A. Redelmeier, B. O'Sullivan e A. Bezjak, «Quality of life and utility in 
irradiated laryngeal cancer patients,» Int J Radiat Oncol Biol Phys, vol. 47, n. 4, pp. 875-
81, 2000.  
[178]  M. H. Weiss, L. B. Harrison e R. S. Isaacs, «Use of decision analysis in planning a 
management strategy for the stage N0 neck,» Arch Otolaryngol Head Neck, vol. 120, n. 
7, pp. 699-702, 1994.  
[179]  J. R. de Almeida, N. L. Villanueva, A. J. Moskowitz, B. A. Miles, M. S. Teng, A. Sikora 
e et al., «Preferences and utilities for health states after treatment for oropharyngeal 
cancer: transoral robotic surgery versus definitive (chemo)radiotherapy,» Head Neck, vol. 
36, n. 7, pp. 923-33, 2014.  
[180]  H. A. Llewellyn-Thomas, H. J. Sutherland e E. C. Thiel, «Do patients' evaluations of a 
future health state change when they actually enter that state?,» Med Care, vol. 31, n. 11, 
pp. 1002-12, 1993.  
[181]  J. van der Donk, P. C. Levendag, A. J. Kuijpers, F. H. Roest, J. D. Habbema, C. A. 
Meeuwis e et al., «Patient participation in clinical decision-making for treatment of T3 
laryngeal cancer: a comparison of state and process utilities,» J Clin Oncol, vol. 13, n. 9, 
pp. 2369-78, 1995.  
[182]  E. Del Barco Morillo, R. Mesía, J. C. Adansa Klain, S. Vázquez Fernández, J. Martínez-
Galán, M. Pastor Borgoñon e et al., «Phase II study of panitumumab and paclitaxel as 
first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-
03/VECTITAX study,» Oral Oncol, vol. 62, pp. 54-9, 2016.  
 
 
 
227 
 
[183]  N. Ouattassi, N. Benmansour, S. El Fakir, C. Nejjari e M. N. Alami, «Translation and 
validation of EORTC QLQ-H&N 35 into Moroccan Arabic for ENT head and neck 
cancer patients in Morocco,» Eur Arch Otorhinolaryngol, vol. 273, n. 9, pp. 2727-34, 
2016.  
[184]  C. Parrilla, A. Minni, H. Bogaardt, G. F. Macri, M. Battista, R. Roukos e et al., 
«Pulmonary rehabilitation after total laryngectomy: a multicenter time-series clinical trial 
evaluating the Provox XtraHME in HME-Naïve patients,» Ann Otol Rhinol Laryngol, 
vol. 124, n. 9, pp. 706-13, 2015.  
[185]  S. N. Rogers, R. D. Miller, K. Ali, A. B. Minhas, H. F. Williams e D. Lowe, «Patients' 
perceived health status following primary surgery for oral and oropharyngeal cancer,» Int 
J Oral Maxillofac Surg, vol. 35, n. 10, pp. 913-9, 2006.  
[186]  B. L. Ramaekers, M. A. Joore, J. P. Grutters, P. van den Ende, J. Jong, R. Houben e et 
al., «The impact of late treatment-toxicity on generic health-related quality of life in head 
and neck cancer patients after radiotherapy,» Oral Oncol, vol. 47, n. 8, pp. 768-74, 2011.  
[187]  A. S. Pickard, R. Jiang, H. W. Lin, S. Rosenbloom e D. Cella, «Using patient-reported 
outcomes to compare relative burden of cancer: EQ-5D and functional assessment of 
cancer therapy-general in eleven types of cancer,» Clin Ther, vol. 38, n. 4, pp. 769-77, 
2016.  
[188]  M. T. Truong, Q. Zhang, D. I. Rosenthal, M. List , R. Axelrod, E. Sherman e et al., 
«Quality of life and performance status from a substudy conducted within a prospective 
phase 3 randomized trial of concurrent accelerated radiation plus cisplatin with or 
without cetuximab for locally advanced head and neck carcinoma: NRG Oncology 
Radiatio,» Int J Radiat Oncol Biol Phys, vol. 97, n. 4, pp. 687-99, 2017.  
[189]  T. M. Govers, W. H. Schreuder, W. M. Klop, J. P. Grutters, M. M. Rovers, M. A. Merkx 
e et al., «Quality of life after different procedures for regional control in oral cancer 
patients: cross-sectional survey,» Clin Otolaryngol, vol. 41, n. 3, pp. 228-33, 2016.  
 
[190]  L. Pottel, M. Lycke, T. Boterberg, H. Pottel, L. Goethals, F. Duprez e et al., «G-8 
indicates overall and quality-adjusted survival in older head and neck cancer patients 
treated with curative radio-chemotherapy,» BMC Cancer, vol. 15, pp. 1-11, 2015.  
[191]  K. Aro, L. Bäck, V. Loimu, K. Saarilahti, S. Rogers, H. Sintonen e et al., «Trends in the 
15D health-related quality of life over the first year following diagnosis of head and neck 
cancer,» Eur Arch Otorhinolaryngol, vol. 273, n. 8, pp. 2141-50, 2016.  
[192]  K. M. Higgins, «What treatment for early-stage glottic carcinoma among adult patients: 
CO2 endolaryngeal laser excision versus standard fractionated external beam radiation is 
superior in terms of cost utility?,» Laryngoscope, vol. 121, n. 1, pp. 116-34, 2011.  
[193]  E. E. Kent, A. Ambs, S. A. Mitchell, S. B. Clauser, A. W. Smith e R. D. Hays, «Health-
related quality of life in older adult survivors of selected cancers: data from the SEER-
MHOS linkage,» Cancer, vol. 121, n. 5, pp. 758-65, 2015.  
 
 
228 
 
[194]  V. Loimu, A. A. Mäkitie, L. J. Bäck, H. Sintonen, P. Räsänen, R. Roine e et al., «Health-
related quality of life of head and neck cancer patients with successful oncological 
treatment,» Eur Arch Otorhinolaryngol, vol. 272, n. 9, pp. 2415-23, 2015.  
[195]  K. K. Chan, A. R. Willan, M. Gupta e E. Pullenayegum, «Underestimation of 
uncertainties in health utilities derived from mapping algorithms involving health-related 
quality-of-life measures: statistical explanations and potential remedies,» Med Decis 
Mak, vol. 34, n. 7, pp. 863-72, 2014.  
[196]  A. Parthan, M. R. Posner, C. Brammer, P. Beltran e J. P. Jansen, «Cost utility of 
docetaxel as induction chemotherapy followed by chemoradiation in locally advanced 
squamous cell carcinoma of the head and neck,» Head Neck, vol. 31, n. 10, pp. 1255-62, 
2009.  
[197]  P. F. Krabbe, L. Peerenboom, B. S. Langenhoff e T. J. Ruers, «Responsiveness of the 
generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30,» 
Qual Life Res, vol. 13, n. 7, pp. 1247-53, 2004.  
[198]  J. B. Vermorken, E. Remenar, C. van Herpen, T. Gorlia, R. Mesia, M. Degardin, et al. e 
EORTC 24971/TAX 323 Study Group., «Cisplatin, fluorouracil, and docetaxel in 
unresectable head and neck cancer,» N Engl J Med, vol. 357, n. 17, pp. 1695-704, 2007.  
[199]  J. H. Yong, J. Beca, B. O'Sullivan, S. H. Huang, T. McGowan, P. Warde e et al., «Cost-
effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer,» Clin Oncol 
(R Coll Radiol), vol. 24, n. 7, pp. 532-8, 2012.  
[200]  M. B. Nichol, N. Sengupta e D. R. Globe, «Evaluating quality-adjusted life years: 
estimation of the health utility index (HUI2) from the SF-36,» Med Decis Mak, vol. 21, n. 
2, pp. 105-12, 2001. 
 
[201]  E. H. Pow, D. L. Kwong, A. S. McMillan, M. C. Wong, J. S. Sham, L. H. Leung e et al., 
«Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional 
radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized 
controlled clinical trial,» Int J Radiat Oncol Biol Phys, vol. 66, n. 4, pp. 981-91, 2006.  
[202]  J. Heiskanen, A. M. Tolppanen, R. P. Roine, J. Hartikainen, M. Hippeläinen, H. 
Miettinen e et al., «Comparison of EQ-5D and 15D instruments for assessing the health-
related quality of life in cardiac surgery patients,» Eur Heart J Qual Care Clin Outcomes, 
vol. 2, n. 3, pp. 193-200, 2016.  
[203]  T. Vainiola, V. Pettilä, R. P. Roine, P. Räsänen, A. M. Rissanen e H. Sintonen, 
«Comparison of two utility instruments, the EQ-5D and the 15D, in the critical care 
setting,» Intensive Care Med, vol. 36, n. 12, pp. 2090-3, 2010.  
[204]  L. Lunde, «Can EQ-5D and 15D be used interchangeably in economic evaluations? 
Assessing quality of life in post-stroke patients,» Eur J Health Econ, vol. 14, pp. 539-50, 
2013.  
 
 
229 
 
[205]  P. Vartiainen, P. Mäntyselkä, T. Heiskanen, N. Hagelberg, S. Mustola, H. Forssell e et 
al., «Validation of EQ-5D and 15D in the assessment of health-related quality of life in 
chronic pain,» Pain, vol. 158, n. 8, pp. 1577-85, 2017.  
[206]  D. Arnold, A. Girling, A. Stevens e R. Lilford, «Comparison of direct and indirect 
methods of estimating health state utilities for resource allocation: review and empirical 
analysis,» BMJ, vol. 339, pp. 1-8, 2009.  
[207]  S. L. Dennett, K. S. Boye e N. R. Yurgin, «The impact of body weight on patient utilities 
with or without type 2 diabetes: a review of the medical literature,» Value Health, vol. 
11, n. 3, pp. 478-86, 2008.  
[208]  C. M. McDonough e A. N. Tosteson, «Measuring preferences for cost-utility analysis: 
how choice of method may influence decision-making,» Pharmacoeconomics, vol. 25, n. 
2, pp. 93-106, 2007.  
[209]  J. Brazier e D. Rowen, «NICE DSU Technical Support Document 11: Alternatives to 
EQ-5D for Generating Health State Utility Values [Internet],» NICE Decision Support 
Unit Technical Support Documents, 2011. 
[210]  National Institute for Health and Care Excellence, «Position statement on use of the EQ-
5D-5L valuation set,» August 2017. [Online]. Available: 
https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-
technology-appraisal-guidance/eq5d5l_nice_position_statement.pdf. [Consultato il 
giorno August 2017]. 
 
[211]  P. M. Fayers, N. K. Aaronson, K. Bjordal, M. Groenvold, D. Curran, A. Bottomley e on 
behalf of the EORTC Quality of Life Group, The EORTC QLQ-C30 scoring manual, 3rd 
edition, Brussels: European Organization for Research and Treatment of Cancer 
(EORTC), 2001.  
[212]  M. A. Weitzner, C. A. Meyers, C. K. Gelke, K. S. Byrne, D. F. Cella e V. A. Levin, «The 
functional assessment of cancer therapy (FACT) scale. Development of a brain subscale 
and revalidation of the general version (FACT-G) in patients with primary brain tumors,» 
Cancer, vol. 75, n. 5, pp. 1151-61, 1995.  
[213]  R. Crott e A. Briggs, «Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-
5D patient preferences,» Eur J Health Econ, vol. 11, n. 4, pp. 427-34, 2010.  
[214]  L. McKenzie e M. van der Pol, «Mapping the EORTC QLQ C-30 onto the EQ-5D 
instrument: the potential to estimate QALYs without generic preference data,» Value 
Health, vol. 12, n. 1, pp. 167-71, 2009.  
[215]  L. Longworth, Y. Yang, T. Young, B. Mulhern, M. Hernández Alava, C. Mukuria e et 
al., «Use of generic and condition-specific measures of health-related quality of life in 
NICE decision-making: a systematic review, statistical modelling and survey,» Health 
Technol Assess, vol. 18, n. 9, pp. 1-224, 2014.  
 
 
230 
 
[216]  I. Khan e S. Morris, «A non-linear beta-binomial regression model for mapping EORTC 
QLQ- C30 to the EQ-5D-3L in lung cancer patients: a comparison with existing 
approaches,» Health Qual Life Outcomes, vol. 12, pp. 1-16, 2014.  
[217]  National Institute for Health and Care Excellence (NICE), «Guide to the methods of 
technology appraisal 2013,» 4 April 2013. [Online]. Available: 
https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-
appraisal-2013-pdf-2007975843781. 
[218]  T. A. Young, C. Mukuria, D. Rowen, J. E. Brazier e L. Longworth, «Mapping functions 
in health-related quality of life: mapping from two cancer-specific health-related quality-
of-life instruments to EQ-5D-3L,» Med Decis Making, vol. 35, n. 7, pp. 912-26, 2015.  
[219]  R. Crott, «Mapping algorithms from QLQ-C30 to EQ-5D utilities: no firm ground to 
stand on yet,» Expert Rev Pharmacoecon Outcomes Res, vol. 14, n. 4, pp. 569-76, 2014.  
[220]  A. Wailoo, M. Hernández, C. Philips, S. Brophy e S. Siebert, «Modeling health state 
utility values in ankylosing spondylitis: comparisons of direct and indirect methods,» 
Value Health, vol. 18, n. 4, pp. 425-31, 2015.  
[221]  S. Rathod, J. Livergant, J. Klein, I. Witterick e J. Ringash, «A systematic review of 
quality of life in head and neck cancer treated with surgery with or without adjuvant 
treatment,» Oral Oncol, vol. 51, n. 10, pp. 888-900, 2015.  
[222]  S. M. Parkar e M. N. Shah, «A relationship between quality-of-life and head and neck 
cancer: A systemic review,» South Asian J Cancer, vol. 4, n. 4, pp. 179-82, 2015.  
[223]  S. Dunne, O. Mooney, L. Coffey, L. Sharp, D. Desmond e C. Timon, «Psychological 
variables associated with quality of life following primary treatment for head and neck 
cancer: a systematic review of the literature from 2004 to 2015,» Psychooncology, vol. 
26, n. 2, pp. 149-60, 2017.  
[224]  S. Petrou, O. Rivero-Arias, H. Dakin, L. Longworth, M. Oppe e R. Froud, «Preferred 
reporting items for studies mapping onto preference-based outcome measures: the MAPS 
statement,» Int J Technol Assess Health Care, vol. 31, n. 4, pp. 230-5, 2015.  
[225]  S. Petrou, O. Rivero-Arias, H. Dakin, L. Longworth, M. Oppe, R. Froud e et al., 
«Preferred reporting items for studies mapping onto preference-based outcome measures: 
the MAPS statement,» Qual Life Res, vol. 25, n. 2, pp. 275-81, 2016.  
[226]  I. Khan, S. Morris, N. Pashayan, B. Matata, Z. Bashir e J. Maguirre, «Comparing the 
mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell 
lung cancer patients,» Health Qual Life Outcomes, vol. 14, pp. 1-15, 2016.  
[227]  N. J. Devlin, K. K. Shah, Y. Feng, B. Mulhern e B. van Hout, «Valuing health-related 
quality of life: An EQ-5D-5L value set for England,» Health Econ, vol. 27, n. 1, pp. 7-22, 
2018.  
 
 
231 
 
[228]  M. M. Versteegh, K. M. Vermeulen, S. M. Evers, G. A. de Wit, R. Prenger e E. A. Stolk, 
«Dutch tariff for the five-level version of EQ-5D,» Value Health, vol. 19, n. 4, pp. 343-
52, 2016.  
[229]  F. Xie, E. Pullenayegum, K. Gaebel, N. Bansback, S. Bryan, A. Ohinmaa, et al. e on 
behalf of the Canadian EQ-5D-5L Valuation Study, «A time trade-off-derived value set 
of the EQ-5D-5L for Canada,» Med Care, vol. 54, n. 1, pp. 98-105, 2016.  
[230]  F. Augustovski, L. Rey-Ares, V. Irazola, O. U. Garay, O. Gianneo, G. Fernández e et al., 
«An EQ-5D-5L value set based on Uruguayan population preferences,» Qual Life Res, 
vol. 25, n. 2, pp. 323-33, 2016.  
[231]  T. Shiroiwa, S. Ikeda, S. Noto, A. Igarashi, T. Fukuda, S. Saito e et al., «Comparison of 
value set based on DCE and/or TTO data: scoring for EQ-5D-5L health states in Japan,» 
Value Health, vol. 19, n. 5, pp. 648-54, 2016.  
[232]  S. H. Kim, J. Ahn, M. Ock, S. Shin, J. Park, N. Luo e et al., «The EQ-5D-5L valuation 
study in Korea,» Qual Life Res, vol. 25, n. 7, pp. 1845-52, 2016.  
[233]  N. Luo, G. Liu, M. Li, H. Guan, X. Jin e K. Rand-Hendriksen, «Estimating an EQ-5D-5L 
Value Set for China,» Value Health, vol. 20, n. 4, pp. 662-9, 2017.  
[234]  M. Hernández Alava, A. J. Wailoo e R. Ara, «Tails from the peak district: adjusted 
limited dependent variable mixture models of EQ-5D questionnaire health state utility 
values,» Value Health, vol. 15, n. 3, pp. 550-61, 2012.  
 
[235]  M. Hernández Alava e A. J. Wailoo, «Fitting adjusted limited dependent variable mixture 
models to EQ-5D,» The Stata Journal, vol. 15, n. 3, pp. 737-50, 2015.  
[236]  A. Wailoo, M. Hernandez-Alava e A. Escobar Martinez, «Modelling the relationship 
between the WOMAC Osteoarthritis Index and EQ-5D,» Health Qual Life Outcomes , 
vol. 12, pp. 1-6, 2014.  
[237]  E. J. Kim, S. K. Ko e H. Y. Kang, «Mapping the cancer-specific EORTC QLQ-C30 and 
EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients,» Qual 
Life Res, vol. 21, n. 7, pp. 1193-203, 2012.  
[238]  H. Dakin, L. Abel, R. Burns e Y. Yang, «Review and critical appraisal of studies 
mapping from quality of life or clinical measures to EQ-5D: an online database and 
application of the MAPS statement,» Health Qual Life Outcomes, vol. 16, n. 1, pp. 1-9, 
2018.  
[239]  Health Economics Research Centre (HERC), University of Oxford, «HERC database of 
mapping studies, Version 6.0,» 17 January 2017. [Online]. Available: 
https://www.herc.ox.ac.uk/downloads/herc-database-of-mapping-studies. 
[240]  H. Suzuki , A. Asakawa, H. Amitani, N. Nakamura e A. Inui, «Cancer cachexia—
pathophysiology and management,» J Gastroenterol, vol. 48, n. 5, pp. 574-594, 2013.  
 
 
232 
 
[241]  B. Gupta, N. W. Johnson e N. Kumar, «Global epidemiology of head and neck cancers: 
A continuing challenge,» Oncology, vol. 91, n. 1, pp. 13-23, 2016.  
[242]  J. Péron, V. Polivka, S. Chabaud, M. Poupart, P. Ceruse, A. Ramade e et al., «An 
effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: 
successive lines of active chemotherapeutic agents.,» BMC Cancer, vol. 14, pp. 1-8, 
2014.  
[243]  K. P. Pendleton e J. R. Grandis, «Cisplatin-based chemotherapy options for recurrent 
and/or metastatic squamous cell cancer of the head and neck,» Clin Med Insights Ther, 
vol. 2013, n. 5, 2013.  
[244]  K. Harrington, S. Temam, H. Mehanna, A. D'Cruz, M. Jain, I. D'Onofrio e et al., 
«Postoperative adjuvant lapatinib and concurrent chemoradiotherapy followed by 
maintenance lapatinib monotherapy in high-risk patients with resected squamous cell 
carcinoma of the head and neck: A phase III, randomized, double-blind, placebo-
controlled stu,» J Clin Oncol, vol. 33, n. 35, pp. 4202-9, 2015.  
[245]  R. Al-Wassia, S. Vakilian, C. Holly, K. Sultanem e G. Shenouda, «A retrospective study 
of head and neck re-irradiation for patients with recurrent or second primary head and 
neck cancer: the McGill University experience,» J Otolaryngol Head Neck Surg, vol. 44, 
pp. 1-8, 2015.  
[246]  T. Kurzweg, N. Möckelmann, S. Laban e R. Knecht, «Current treatment options for 
recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last 
year's literature,» Eur Arch Otorhinolaryngol, vol. 269, n. 10, pp. 2157-67, 2012.  
[247]  J. B. Vermorken, R. Mesia, F. Rivera, E. Remenar, A. Kawecki, S. Rottey e et al., 
«Platinum-based chemotherapy plus cetuximab in head and neck cancer,» N Engl J Med, 
vol. 359, n. 11, pp. 1116-27, 2008.  
[248]  M. Imbimbo, P. Bossi, P. Potepan, C. Fallai, G. Scaramellini, L. Locati e et al., «OC-039: 
surveillance of head and neck cancer (HNC) patients: clinical and radiological exams or 
symptom driven follow up?,» Radiother Oncol, vol. 106, n. Suppl 1, p. S16, 2013.  
[249]  V. P. Retèl, L. van der Molen, F. J. Hilgers, C. R. Rasch, A. A. L'Ortye, L. M. Steuten e 
et al., «A cost-effectiveness analysis of a preventive exercise program for patients with 
advanced head and neck cancer treated with concomitant chemo-radiotherapy,» BMC 
Cancer, vol. 11, pp. 1-9, 2011.  
[250]  S. Temam, E. Pape, F. Janot, P. Wibault, M. Julieron, A. Lusinchi e et al., «Salvage 
surgery after failure of very accelerated radiotherapy in advanced head-and-neck 
squamous cell carcinoma,» Int J Radiat Oncol Biol Phys, vol. 62, n. 4, pp. 1078-83, 
2005.  
[251]  M. E. Zafereo, M. M. Hanasono, D. I. Rosenthal, E. M. Sturgis, J. S. Lewin, D. B. 
Roberts e et al., «The role of salvage surgery in patients with recurrent squamous cell 
carcinoma of the oropharynx,» Cancer, vol. 115, n. 24, pp. 5723-33, 2009.  
 
 
233 
 
[252]  N. Penel, E. Y. Amela, Y. Mallet, D. Lefebvre, S. Clisant, A. Kara e et al., «A simple 
predictive model for postoperative mortality after head and neck cancer surgery with 
opening of mucosa,» Oral Oncol, vol. 43, n. 2, pp. 174-80, 2007.  
[253]  M. C. Biagioli, M. Harvey, E. Roman, L. E. Raez, A. H. Wolfson, S. Mutyala e et al., 
«Intensity-modulated radiotherapy with concurrent chemotherapy for previously 
irradiated, recurrent head and neck cancer,» Int J Radiat Oncol Biol Phys, vol. 69, n. 4, 
pp. 1067-73, 2007.  
[254]  D. J. Sher, R. I. Haddad, C. M. Norris, M. R. Posner, L. J. Wirth, L. A. Goguen e et al., 
«Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for 
recurrent or second primary head and neck cancer,» Cancer, vol. 116, n. 20, pp. 4761-8, 
2010.  
[255]  Y. W. Won, Y. H. Park, M. J. Ahn, I. G. Do, Y. H. Ko e K. Park, «A phase II study of 
combination chemotherapy with capecitabine and cisplatin in patients with metastatic or 
recurrent squamous cell carcinoma of the head and neck,» Ann Oncol, vol. 22, n. 2, pp. 
417-23, 2011.  
[256]  Istituto Nazionale di Statistica (ISTAT), «Tavole di mortalità per classi di età,» 2015. 
[Online]. Available: http://dati.istat.it/Index.aspx?DataSetCode=DCIS_MORTALITA1. 
[257]  A. Briggs, M. Sculpher e K. Claxton, Decision modelling for health economic evaluation 
(Handbooks in health economic evaluation), 1st edition, Oxford: Oxford University 
Press, 2006.  
 
[258]  M. Beccaro, M. Costantini, D. F. Merlo e I. S. Group, «Inequity in the provision of and 
access to palliative care for cancer patients. Results from the Italian survey of the dying 
of cancer (ISDOC),» BMC Public Health, vol. 7, pp. 1-13, 2007.  
[259]  D. Z. Louis, S. E. Hegarty, M. Leoni, R. De Palma, S. Varga e R. Melotti, «Variation in 
hospital utilization at the end of life for patients with cancer in the Emilia-Romagna 
region of Italy,» Tumori, vol. 102, n. 6, pp. 614-20, 2016.  
[260]  R. Pannuti, «Qualità di vita del malato terminale e sostenibilità delle cure palliative: 
l'integrazione tra sanità pubblica e privato sociale,» Evidence, vol. 7, n. 9, pp. 1-2, 2015.  
[261]  S. Francisci, S. Guzzinati, M. Mezzetti, E. Crocetti, F. Giusti, G. Miccinesi e et al., «Cost 
profiles of colorectal cancer patients in Italy based on individual patterns of care,» BMC 
Cancer, vol. 13, pp. 1-11, 2013.  
[262]  Gruppo di lavoro Associazione Italiana di Economia Sanitaria (AIES) coordinato da 
Giovanni Fattore, «Proposta di linee guida per la valutazione economica degli interventi 
sanitari in Italia,» Pharmacoeconomics Ital Res Articles , vol. 11, n. 2, pp. 83-93, 2009.  
[263]  P. J. Neumann, T. G. Ganiats, G. D. Sanders, L. B. Russell e J. E. Siegel, Cost-
effectiveness in health and medicine. 2nd ed, Oxford: Oxford University Press, 2017.  
 
 
234 
 
[264]  J. B. Oostenbrink, M. J. Al, M. Oppe e M. P. Rutten-van Mölken, «Expected value of 
perfect information: an empirical example of reducing decision uncertainty by 
conducting additional research,» Value Health, vol. 11, n. 7, pp. 1070-80, 2008.  
[265]  Associazione Italiana Registro Tumori (AIRTUM), «Italian cancer figures - Report 2015. 
Epithelial tumours of head and neck.,» 2015. [Online]. Available: http://www.registri-
tumori.it/PDF/AIRTUM2016/TUMORIRARI/AIRTUM_RARI_S001_headandneck.pdf. 
[266]  J. E. Leeman, J. Li, X. Pei, P. Venigalla, Z. S. Zumsteg, E. Katsoulakis e et al., «Patterns 
of treatment failure and postrecurrence outcomes among patients with locally advanced 
head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation 
techniques,» JAMA Oncol, vol. 3, n. 11, pp. 1487-94, 2017.  
[267]  P. R. Patel e J. K. Salama, «Reirradiation for recurrent head and neck cancer,» Expert 
Rev Anticancer Ther, vol. 12, n. 9, pp. 1177-89, 2012.  
[268]  M. Sculpher, «Clinical trials provide essential evidence, but rarely offer a vehicle for 
cost-effectiveness analysis,» Value Health, vol. 18, n. 2, pp. 141-2, 2015.  
[269]  G. R. Barton, A. H. Briggs e E. A. Fenwick, «Optimal cost-effectiveness decisions: the 
role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness 
acceptability frontier (CEAF), and the expected value of perfection information (EVPI),» 
Value Health, vol. 11, n. 5, pp. 886-97, 2008.  
 
[270]  M. E. Boysen, U. K. Zätterström e J. F. Evensen, «Self-reported symptoms to monitor 
recurrent head and neck cancer-analysis of 1,678 cases,» Anticancer Res, vol. 36, n. 6, 
pp. 2849-54, 2016.  
[271]  S. T. Massa, N. Osazuwa-Peters, K. M. Christopher, L. D. Arnold, M. Schootman, R. J. 
Walker e et al., «Competing causes of death in the head and neck cancer population,» 
Oral Oncol, vol. 65, pp. 8-15, 2017.  
[272]  A. V. Priante, E. C. Castilho e L. P. Kowalski, «Second primary tumors in patients with 
head and neck cancer,» Curr Oncol Rep, vol. 13, n. 2, pp. 132-7, 2011.  
[273]  D. E. Wood, E. Kazerooni, S. L. Baum, M. T. Dransfield, G. A. Eapen, D. S. Ettinger e et 
al., «Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines,» J 
Natl Compr Canc Netw, vol. 13, n. 1, pp. 23-34, 2015.  
[274]  A. S. Ho, Z. S. Zumsteg, A. Meyer, N. Riaz, R. Rahmati, D. H. Kraus e et al., «Impact of 
flap reconstruction on radiotoxicity after salvage surgery and reirradiation for recurrent 
head and neck cancer,» Ann Surg Oncol, vol. 23, n. Suppl 3, pp. 850-57, 2016.  
[275]  F. Janot, D. de Raucourt, E. Benhamou, C. Ferron, G. Dolivet, R. J. Bensadoun e et al., 
«Randomized trial of postoperative reirradiation combined with chemotherapy after 
salvage surgery compared with salvage surgery alone in head and neck carcinoma,» J 
Clin Oncol, vol. 26, n. 34, pp. 5518-23, 2008.  
 
 
235 
 
[276]  V. Paleri e C. G. Kelly, «Re-irradiation with concurrent chemotherapy in recurrent head 
and neck cancer: a decision analysis model based on a systematic review,» Clin 
Otolaryngol, vol. 33, n. 4, pp. 331-7, 2008.  
[277]  J. Cacicedo, A. Navarro, F. Alongi, A. Gómez de Iturriaga, O. Del Hoyo, E. Boveda e et 
al., «The role of re-irradiation of secondary and recurrent head and neck carcinomas. Is it 
a potentially curative treatment? A practical approach,» Cancer Treat Rev, vol. 40, n. 1, 
pp. 178-89, 2014.  
[278]  S. F. Huntington, J. Svoboda e J. A. Doshi, «Cost-effectiveness analysis of routine 
surveillance imaging of patients with diffuse large B-cell lymphoma in first remission,» J 
Clin Oncol, vol. 33, n. 13, pp. 1467-74, 2015.  
[279]  Ministero della Salute, «DECRETO 18 ottobre 2012. Remunerazione delle prestazioni di 
assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza 
post acuzie e di assistenza specialistica ambulatoriale,» 28 January 2013. [Online]. 
Available: http://www.gazzettaufficiale.it/eli/gu/2013/01/28/23/so/8/sg/pdf. 
[280]  A. Molassiotis, R. Emsley, D. Ashcroft, A. Caress, J. Ellis, R. Wagland e et al., 
«Applying Best-Worst scaling methodology to establish delivery preferences of a 
symptom supportive care intervention in patients with lung cancer,» Lung Cancer, vol. 
77, n. 1, pp. 199-204, 2012.  
 
[281]  R. L. Hicks, «A comparison of stated and revealed preference methods for fisheries,» in 
American Agricultural Economics Association. Annual Meeting, July 28-31, 2002., Long 
Beach (California), 2002.  
[282]  T. L. Mark e J. Swait, «Using stated preference and revealed preference modeling to 
evaluate prescribing decisions,» Health Econ, vol. 13, n. 6, pp. 563-73, 2004.  
[283]  F. Reed Johnson, E. Lancsar, D. Marshall, V. Kilambi, A. Mühlbacher, D. A. Regier e et 
al., «Constructing experimental designs for discrete-choice experiments: report of the 
ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force,» 
Value Health, vol. 16, n. 1, pp. 3-13, 2013.  
[284]  M. Tinelli, M. Ryan e C. Bond, «What, who and when? Incorporating a discrete choice 
experiment into an economic evaluation,» Health Econ Rev, vol. 6, n. 1, pp. 1-9, 2016.  
[285]  J. Marti, «A best-worst scaling survey of adolescents' level of concern for health and 
non-health consequences of smoking,» Soc Sci Med, vol. 75, n. 1, pp. 87-97, 2012.  
[286]  K. L. Cheung, B. F. Wijnen, I. L. Hollin, E. M. Janssen, J. F. Bridges, S. M. Evers e et 
al., «Using best-worst scaling to investigate preferences in health care,» 
Pharmacoeconomics, vol. 34, n. 12, pp. 1195-209, 2016.  
[287]  A. Flynn e J. J. Louviere, «Determining the appropriate response to evidence of public 
concern: the case of food safety,» J Public Policy Mark, vol. 11, pp. 12-25, 1992.  
[288]  T. N. Flynn, J. J. Louviere, T. J. Peters e J. Coast, «Best-worst scaling: What it can do for 
health care research and how to do it,» J Health Econ, vol. 26, n. 1, pp. 171-89, 2007.  
236 
 
[289]  T. M. Benning, M. L. Kimman, C. D. Dirksen, L. J. Boersma e B. G. Dellaert, 
«Combining individual-level discrete choice experiment estimates and costs to inform 
health care management decisions about customized care: the case of follow-up strategies 
after breast cancer treatment,» Value Health, vol. 15, n. 5, pp. 680-9, 2012.  
[290]  T. Bessen, G. Chen, J. Street, J. Eliott, J. Karnon, D. Keefe e et al., «What sort of follow-
up services would Australian breast cancer survivors prefer if we could no longer offer 
long-term specialist-based care? A discrete choice experiment,» Br J Cancer, vol. 110, n. 
4, pp. 859-67, 2014.  
[291]  M. L. Kimman, B. G. Dellaert, L. J. Boersma, P. Lambin e C. D. Dirksen, «Follow-up 
after treatment for breast cancer: one strategy fits all? An investigation of patient 
preferences using a discrete choice experiment,» Acta Oncol, vol. 49, n. 3, pp. 328-37, 
2010.  
[292]  P. Murchie, P. F. Norwood, M. Pietrucin-Materek, T. Porteous, P. C. Hannaford e M. 
Ryan, «Determining cancer survivors' preferences to inform new models of follow-up 
care,» Br J Cancer, vol. 115, n. 12, pp. 1495-503, 2016.  
 
[293]  S. Damery, M. Biswas, L. Billingham, P. Barton, H. Al-Janabi e R. Grimer, «Patient 
preferences for clinical follow-up after primary treatment for soft tissue sarcoma: a cross-
sectional survey and discrete choice experiment,» Eur J Surg Oncol, vol. 40, n. 12, pp. 
1655-61, 2014.  
[294]  G. Kocur, T. Adler, W. Hyman e B. Aunet, «Guide to forecasting travel demand with 
direct utility assessment,» 1981. 
[295]  W. J. Ungar, A. Hadioonzadeh, M. Najafzadeh, N. W. Tsao, S. Dell e L. D. Lynd, 
«Quantifying preferences for asthma control in parents and adolescents using best-worst 
scaling,» Respir Med, vol. 108, n. 6, pp. 842-51, 2014.  
[296]  D. Potoglou, P. Burge, T. Flynn, A. Netten, J. Malley, J. Forder e et al., «Best-worst 
scaling vs. discrete choice experiments: an empirical comparison using social care data,» 
Soc Sci Med, vol. 72, n. 10, pp. 1717-27, 2011.  
[297]  A. Ejaz, G. Spolverato, J. F. Bridges, N. Amini, Y. Kim e T. M. Pawlik, «Choosing a 
cancer surgeon: analyzing factors in patient decision making using a best-worst scaling 
methodology,» Ann Surg Oncol, vol. 21, n. 12, pp. 3732-8, 2014.  
[298]  A. Duhamel, M. C. Nuttens, P. Devos, M. Picavet e R. Beuscart, «A preprocessing 
method for improving data mining techniques. Application to a large medical diabetes 
database,» Stud Health Technol Inform, vol. 95, pp. 269-74, 2003.  
[299]  T. N. Flynn, J. J. Louviere, T. J. Peters e J. Coast, «Estimating preferences for a 
dermatology consultation using Best-Worst Scaling: comparison of various methods of 
analysis,» BMC Med Res Methodol, vol. 8, pp. 1-12, 2008.  
[300]  F. Severin, J. Schmidtke, A. Mühlbacher e W. H. Rogowski, «Eliciting preferences for 
priority setting in genetic testing: a pilot study comparing best-worst scaling and discrete-
choice experiments,» Eur J Hum Genet, vol. 21, n. 11, pp. 1202-8, 2013.  
237 
 
 
 
[301]  M. R. Franco, K. Howard, C. Sherrington, P. H. Ferreira, J. Rose, J. L. Gomes e et al., 
«Eliciting older people's preferences for exercise programs: a best-worst scaling choice 
experiment,» J Physiother, vol. 61, n. 1, pp. 34-41, 2015.  
[302]  J. Ratcliffe, E. Huynh, G. Chen, K. Stevens, J. Swait, J. Brazier e et al., «Valuing the 
Child Health Utility 9D: Using profile case best worst scaling methods to develop a new 
adolescent specific scoring algorithm,» Soc Sci Med, vol. 157, pp. 48-59, 2016.  
[303]  A. Trinidade, P. Kothari, Z. Andreou, R. J. Hewitt e P. O'Flynn, «Follow-up in head and 
neck cancer: patients' perspective,» Int J Health Care Qual Assur, vol. 25, n. 2, pp. 145-
9, 2012.  
[304]  A. C. Mühlbacher, A. Kaczynski, P. Zweifel e F. R. Johnson, «Experimental 
measurement of preferences in health and healthcare using best-worst scaling: an 
overview,» Health Econ Rev, vol. 6, n. 1, pp. 1-14, 2016.  
[305]  E. McIntosh, «Using discrete choice experiments within a cost-benefit analysis 
framework: some considerations,» Pharmacoeconomics, vol. 24, n. 9, pp. 855-68, 2006.  
[306]  S. Petrou e E. McIntosh, «Women's preferences for attributes of first-trimester 
miscarriage management: a stated preference discrete-choice experiment,» Value Health, 
vol. 12, n. 4, pp. 551-9, 2009.  
[307]  M. van der Pol, A. Shiell, F. Au, D. Jonhston e S. Tough, «Eliciting individual 
preferences for health care: a case study of perinatal care,» Health Expect, vol. 13, n. 1, 
pp. 4-12, 2010.  
[308]  R. A. Lewis, R. D. Neal, M. Hendry, B. France, N. H. Williams, D. Russell e et al., 
«Patients' and healthcare professionals' views of cancer follow-up: systematic review,» 
Br J Gen Pract, vol. 59, n. 564, pp. e248-59, 2009.  
[309]  G. Frew, A. Smith, B. Zutshi, N. Young, A. Aggarwal, P. Jones e et al., «Results of a 
quantitative survey to explore both perceptions of the purposes of follow-up and 
preferences for methods of follow-up delivery among service users, primary care 
practitioners and specialist clinicians after cancer treatment,» Clin Oncol (R Coll Radiol), 
vol. 22, n. 10, pp. 874-84, 2010.  
[310]  M. Meregaglia e J. Cairns, «Economic evaluations of follow-up strategies for cancer 
survivors: a systematic review and quality appraisal of the literature,» Expert Rev 
Pharmacoecon Outcomes Res, vol. 15, n. 6, pp. 913-29, 2015.  
[311]  M. Meregaglia e J. Cairns, «A systematic literature review of health state utility values in 
head and neck cancer,» Health Qual Life Outcomes, vol. 15, n. 1, pp. 1-13, 2017.  
[312]  M. Meregaglia, J. Cairns, L. Licitra e P. Bossi, «The use of intensive radiological 
assessments in routine surveillance after treatment for head and neck cancer: An 
economic evaluation,» Eur J Cancer, vol. 93, pp. 89-98, 2018.  
238 
 
 
 
[313]  M. Meregaglia, J. Cairns, S. Alfieri, F. Favales, D. Mazzitelli, E. Orlandi e et al., 
«Eliciting preferences for clinical follow-up in patients with head and neck cancer using 
best-worst scaling,» Value Health, vol. 20, n. 6, pp. 799-808, 2017.  
[314]  G. P. Guy, D. U. Ekwueme, K. R. Yabroff, E. C. Dowling, C. Li, J. L. Rodriguez e et al., 
«Economic burden of cancer survivorship among adults in the United States,» J Clin 
Oncol, vol. 31, n. 30, pp. 3749-57, 2013.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
239 
 
 
APPENDICES 
 
 
 
240 
 
APPENDIX TO CHAPTER 2 
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Table A2.1 (cont.) PRISMA 2009 checklist. 
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APPENDIX TO CHAPTER 3 
Table A3.1 Details of HSUVs reported by the studies (n=27). 
 
 
Author 
(year) 
Method 
Patient’s characteristics/ 
Health state description 
Group/Time point N Mean SD SE 95% CI Median Range IQR 
Aro (2016) 
[191] 
15D 
Patients receiving treatment (i.e. 
surgery, CRT, or combined modality 
treatment) and followed-up for at least 
12 months 
Baseline 214 0.872       
3 months 
All 198 0.839 0.114 
     no PEG 109 0.862  
PEG 88 0.810  
6 months 202 0.857       
12 months 214 0.852       
Chan 
(2014) 
[195] 
Mapping Patients after treatment for HNC 
Estimation 
sample 
Actual 
89 
0.821  0.03     
Predicted 0.821  0.02     
Validation 
sample 
Actual 
48 
0.801  0.02     
Predicted 0.791  0.01     
Conway 
(2012) 
[173] 
SG 
Oropharyngeal cancer stages II-III 
treated with ND and CRT/RT and/or 
surgery 
 99 0.58   0.53-0.63 0.65  0.45-0.75 
de 
Almeida 
(2014) 
[179] 
VAS 
Scenarios 
describing 
treatment 
modalities for 
oropharyngeal 
cancer 
TORS 
Healthy subjects 50 0.67   0.61-0.73    
Experts 9 0.82   0.75-0.89    
TORS + adjuvant 
XRT 
Healthy subjects 50 0.59   0.62-0.64    
Experts 9 0.60   0.48-0.72    
TORS + adjuvant 
CRT 
Healthy subjects 50 0.53   0.47-0.58    
Experts 9 0.45   0.33-0.57    
XRT 
Healthy subjects 50 0.54   0.49-0.60    
Experts 9 0.59   0.48-0.70    
CRT 
Healthy subjects 50 0.48   0.43-0.54    
Experts 9 0.42   0.29-0.54    
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Table A3.1 (cont.) Details of HSUVs reported by the studies (n=27). 
Author 
(year) 
Method 
Patient’s characteristics/ 
Health state description 
Group/Time point N Mean SD SE 95% CI Median Range IQR 
de Almeida 
(2014) 
[179] 
(cont.) 
SG 
Scenarios 
describing 
treatment 
modalities for 
oropharyngeal 
cancer  
TORS 
Healthy subjects 50 0.95   0.94-0.97    
Experts 9 0.99   0.97-1.00    
TORS + adjuvant 
XRT 
Healthy subjects 50 0.89   0.85-0.93    
Experts 9 0.97   0.94-1.00    
TORS + adjuvant 
CRT 
Healthy subjects 50 0.89   0.85-0.93    
Experts 9 0.94   0.91-0.97    
XRT 
Healthy subjects 50 0.91   0.87-0.94    
Experts 9 0.97   0.94-1.00    
CRT 
Healthy subjects 50 0.88   0.83-0.92    
Experts 9 0.93   0.88-0.97    
VAS 
Scenarios 
describing 
treatment-
related 
complications  
Temporary 
tracheostomy 
Healthy subjects 50 0.61   0.56-0.66    
Experts 9 0.53   0.44-0.62    
Permanent 
tracheostomy 
Healthy subjects 50 0.44   0.38-0.52    
Experts 9 -   -    
Temporary 
gastrostomy 
Healthy subjects 50 0.54   0.50-0.59    
Experts 9 0.46   0.29-0.62    
Permanent 
gastrostomy 
Healthy subjects 50 0.36   0.29-0.43    
Experts 9 -   -    
Pharyngocutaneous 
fistula 
Healthy subjects 50 0.53   0.47-0.60    
Experts 9 0.46   0.36-0.57    
Febrile neutropenia 
Healthy subjects 50 0.70   0.65-0.75    
Experts 9 0.77   0.63-0.91    
Oesophageal 
stenosis 
Healthy subjects 50 0.40   0.35-0.46    
Experts 9 0.38   0.22-0.53    
Osteoradionecrosis 
Healthy subjects 50 0.41   0.35-0.47    
Experts 9 0.44   0.33-0.55    
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Table A3.1 (cont.) Details of HSUVs reported by the studies (n=27). 
Author 
(year) 
Method 
Patient’s characteristics/ 
Health state description 
Group/Time point N Mean SD SE 95% CI Median Range IQR 
de 
Almeida 
(2014) 
[179] 
(cont.) 
SG 
Scenarios 
describing 
treatment-
related 
complications 
Temporary tracheostomy 
Healthy subjects 50 0.94   0.92-0.97    
Experts 9 0.98   0.96-0.99    
Permanent tracheostomy 
Healthy subjects 50 0.85   0.80-0.91    
Experts 9 -   -    
Temporary gastrostomy 
Healthy subjects 50 0.89   0.85-0.94    
Experts 9 0.98   0.96-0.99    
Permanent gastrostomy 
Healthy subjects 50 0.81   0.74-0.88    
Experts 9 -   -    
Pharyngocutaneous fistula 
Healthy subjects 50 0.89   0.85-0.94    
Experts 9 0.96   0.92-0.99    
Febrile neutropenia 
Healthy subjects 50 0.96   0.94-0.98    
Experts 9 0.99   0.98-1.00    
Oesophageal stenosis 
Healthy subjects 50 0.85   0.80-0.90    
Experts 9 0.96   0.94-0.98    
Osteoradionecrosis 
Healthy subjects 50 0.85   0.81-0.90    
Experts 9 0.96   0.93-0.99    
VAS 
Scenarios 
describing 
remission and 
recurrence 
Remission (after TORS) 
Healthy subjects 50 0.80   0.76-0.85    
Experts 9 0.87   0.81-0.94    
Remission (after TORS/adjuvant 
XRT or after XRT) 
Healthy subjects 50 0.75   0.70-0.79    
Experts 9 0.80   0.75-0.85    
Remission (after TORS/adjuvant 
CRT or after CRT) 
Healthy subjects 50 0.72   0.67-0.77    
Experts 9 0.68   0.55-0.80    
Local recurrence (requiring 
surgery) 
Healthy subjects 50 0.39   0.33-0.45    
Experts 9 0.45   0.29-0.62    
Local recurrence (requiring XRT) 
Healthy subjects 50 0.51   0.45-0.56    
Experts 9 0.41   0.27-0.55    
Regional recurrence (ND) 
Healthy subjects 50 0.68   0.62-0.74    
Experts 9 0.63   0.48-0.79    
Distant recurrence (CT) 
Healthy subjects 50 0.20   0.16-0.24    
Experts 9 0.18   0.12-0.24    
Terminal/palliative state (CT) 
Healthy subjects 50 0.14   0.10-0.18    
Experts 9 0.08   0.05-0.11    
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Table A3.1 (cont.) Details of HSUVs reported by the studies (n=27). 
Author 
(year) 
Method 
Patient’s characteristics/ 
Health state description 
Group/Time point N Mean SD SE 95% CI Median Range IQR 
de Almeida 
(2014) [179] 
(cont.) 
SG 
Scenarios 
describing 
remission and 
recurrence 
Remission (after TORS) 
Healthy subjects 50 0.96   0.94-0.98    
Experts 9 0.99   0.98-1.00    
Remission (after TORS/adjuvant 
XRT or XRT) 
Healthy subjects 50 0.95   0.93-0.98    
Experts 9 0.98   0.96-1.00    
Remission (after TORS/adjuvant 
CRT or CRT) 
Healthy subjects 50 0.95   0.92-0.98    
Experts 9 0.97   0.94-0.99    
Local recurrence (surgery) 
Healthy subjects 50 0.82   0.77-0.87    
Experts 9 0.92   0.87-0.97    
Local recurrence (XRT) 
Healthy subjects 50 0.88   0.84-0.91    
Experts 9 0.91   0.87-0.95    
Regional recurrence (ND) 
Healthy subjects 50 0.94   0.91-0.97    
Experts 9 0.97   0.94-0.99    
Distant recurrence (CT) 
Healthy subjects 50 0.57   0.50-0.64    
Experts 9 0.43   0.22-0.64    
Terminal/palliative state (CT) 
Healthy subjects 50 0.42   0.34-0.50    
Experts 9 0.31   0.11-0.51    
del Barco 
Morillo 
(2016) [182] 
EQ-5D 
Palliative CT for recurrent or metastatic HNC 
(untreatable by surgery or re-irradiation) 
Across all visits (every 8 
weeks) 
40     0.7 0.6-0.8  
Govers 
(2016) [189] 
EQ-5D 
(Dutch 
tariff) 
Early stage (I-
II) oral cavity 
cancer patient 
undergoing 
different 
diagnostic and 
treatment 
interventions 
WW 
All patients 26 0.804  0.04     
Group 1* 21 0.849  0.05     
Group 2** 20 0.826  0.05     
SLNB 
All patients 19 0.863  0.05     
Group 1 18 0.859  0.05     
Group 2 18 0.858  0.05     
SOHND 
All patients 104 0.834  0.02     
Group 1 86 0.841  0.02     
Group 2 53 0.849  0.03     
MRND 
All patients 25 0.794  0.04     
Group 1 20 0.800  0.05     
Group 2  -  -     
* Group 1: patients without previous mucosal malignancies, local recurrences, or second primary tumours in the HNC region. **Group 2: patients without previous mucosal malignancies, local recurrences, or second primary 
tumours and without adjuvant (chemo)radiotherapy in the HNC region. 
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Table A3.1 (cont.) Details of HSUVs reported by the studies (n=27). 
Author 
(year) 
Method 
Patient’s characteristics/ 
Health state description 
Group/Time point N Mean SD SE 95% CI Median Range IQR 
Hamilton 
(2016) [174] 
TTO 
Four vignettes 
describing the 
treatment 
process and 
outcome for 
advanced 
laryngeal 
cancer 
CRT, optimal outcome 
All participants 114 0.64       
Group 1* 71 0.70       
Group 2** 43 0.53       
CRT, outcome with 
complications 
All participants 114 0.31       
Group 1 71 0.37       
Group 2 43 0.22       
TL, optimal outcome 
All participants 114 0.57       
Group 1 71 0.55       
Group 2 43 0.59       
TL, outcome with 
complications 
All participants 114 0.33       
Group 1 71 0.34       
Group 2 43 0.22       
Higgins 
(2011) [192] 
HUI3 (health 
state A); 
adjustments 
of A score 
(other health 
states) 
Patients with 
complete 
response to 
treatment 
(XRT/CO2) 
and no 
evidence of 
active disease 
(health state A) 
A: alive with voice box 
entirely intact 
 
30 0.8718 
      
B: alive with part of the 
box intact  
- 0.706 
C: dead of disease - 0 
D: alive with 
recurrent/active disease 
- 0.307 
E: alive without voice 
box/TL 
- 0.366 
Hollenbeak 
(2001) [175] 
TTO 
Surgical 
patients 
Modified ND 
 
8 0.925 0.23      
Radiation plus modified 
ND 
8 0.913 0.18      
Radiation 8 0.875 0.44      
Radical ND 8 0.763 1.03      
Radiation plus radical 
ND 
8 0.675 1.3      
Kent (2015) 
[193] 
SF-6D/VR-
6D 
Patients after a diagnosis of oral cavity or 
pharyngeal cancer 
 580 0.69   0.68-0.70    
* Group 1: participants ranking CRT first in a previous exercise. ** Group 2: participants ranking TL first in a previous exercise.  
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Table A3.1 (cont.) Details of HSUVs reported by the studies (n=27). 
Author 
(year) 
Method 
Patient’s characteristics/ 
Health state description 
Group/Time point N Mean SD SE 95% CI Median Range IQR 
Llewellyn-
Thomas 
(1993) [180] 
TTO 
Larynx cancer patients 
eligible for a standard 
four-week RT regimen 
Mild* 
Mild** 
Time 1 
24 
0.721 26.2      
Time 2 0.735 23.5      
Moderate** 
Time 1 
36 
0.750 19.9      
Time 2 0.757 19.0      
Severe** 
Time 1 
6 
0.750 24.1      
Time 2 0.866 7.5      
Moderate* 
Mild** 
Time 1 
24 
0.629 26.9      
Time 2 0.571 26.4      
Moderate** 
Time 1 
36 
0.644 22.9      
Time 2 0.667 21.8      
Severe** 
Time 1 
6 
0.700 27.0      
Time 2 0.758 15.0      
Severe* 
Mild** 
Time 1 
24 
0.352 28.3      
Time 2 0.429 29.2      
Moderate** 
Time 1 
36 
0.344 25.3      
Time 2 0.381 26.7      
Severe** 
Time 1 
6 
0.233 22.7      
Time 2 0.408 39.0      
VAS 
Mild* 
Mild** 
Time 1 
24 
0.826 9.8      
Time 2 0.793 13.3      
Moderate** 
Time 1 
36 
0.793 16.0      
Time 2 0.744 13.7      
Severe** 
Time 1 
6 
0.775 13.9      
Time 2 0.783 10.0      
Moderate* 
Mild** 
Time 1 
24 
0.598 16.6      
Time 2 0.623 17.8      
Moderate** 
Time 1 
36 
0.559 20.9      
Time 2 0.532 17.8      
Severe** 
Time 1 
6 
0.647 17.4      
Time 2 0.615 14.0      
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Table A3.1 (cont.) Details of HSUVs reported by the studies (n=27). 
Author 
(year) 
Method 
Patient’s characteristics/ 
Health state description 
Group/Time point N Mean SD SE 95% CI Median Range IQR 
Llewellyn-
Thomas 
(1993) [180] 
(cont.) 
VAS (cont.) 
Larynx cancer patients 
eligible for a standard 
four-week RT regimen  
Severe* 
Mild** 
Time 1 
24 
0.266 24.3      
Time 2 0.276 25.3      
Moderate** 
Time 1 
36 
0.226 21.4      
Time 2 0.209 19.2      
Severe** 
Time 1 
6 
0.128 17.6      
Time 2 0.292 31.8      
Loimu 
(2015) [194] 
15D 
Newly diagnosed patients scheduled for 
receiving CRT 
Baseline 64 0.886 0.10      
3 months 54 0.829 0.12      
6 months 61 0.860 0.12      
12 months 64 0.862 0.14      
Marcellusi 
(2015) [171] 
TTO Patients with a confirmed diagnosis of 
HNC and time from (medical or 
surgical) treatment no longer than 20 
months 
All patients 79 0.69 0.30  0.62-0.75    
Males 62 0.70 0.32  0.62-0.78    
Females 17 0.64 0.21  0.54-0.74    
EQ-5D 
All patients 79 0.80 0.20      
Males 62 0.80 0.20      
Females 17 0.70 0.20      
Noel (2015) 
[172] 
SG 
Patients with a minimum of three 
months after completion of treatment 
(surgery or RT) and no evidence of 
recurrent disease 
All patients 100 0.91 0.17    0.2-1.0  
Primary surgery 54 0.93 0.17      
Salvage surgery 5 0.98 0.04      
Chemotherapy 13 0.92 0.10      
No chemotherapy 87 0.91 0.18      
Stage T1 or T2 47 0.95 0.13      
Stage T3 or T4 20 0.87 0.22      
Tracheotomy and/or 
feeding tube 
6 0.99 0.02      
No tracheotomy and/or 
feeding tube 
94 0.91 0.17      
Llewellyn-Thomas (1993): Mild/Moderate/Severe*: health state scenarios describing increasing levels of three radiation-induced disorders (i.e. mouth/throat pain, fatigue, inability to converse). Mild/Moderate/Severe**: end-of-
therapy groups as self-determined by the patients. Time 1/Time 2: outset/end of therapy. HSUVs are converted on a 0-1 scale (from a 0-100 one). 
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Table A3.1 (cont.) Details of HSUVs reported by the studies (n=27). 
Author 
(year) 
Method 
Patient’s characteristics/ 
Health state description 
Group/Time point N Mean SD SE 95% CI Median Range IQR 
Noel (2015) 
[172] 
(cont.) 
TTO 
Patients with a minimum of 
three months after 
completion of treatment 
(surgery or RT) and no 
evidence of recurrent 
disease  
All patients 100 0.94 0.14    0.3-1.0  
Primary surgery 54 0.95 0.13      
Salvage surgery 5 0.98 0.04      
Chemotherapy 13 0.99 0.03      
No chemotherapy 87 0.94 0.14      
Stage T1 or T2 47 0.96 0.09      
Stage T3 or T4 20 0.88 0.21      
Tracheotomy and/or feeding tube 6 0.91 0.12      
No tracheotomy and/or feeding tube 94 0.95 0.14      
VAS 
All patients 100 0.76 0.19    0.2-1.0  
Primary surgery 54 0.76 0.20      
Salvage surgery 5 0.48 0.13      
Chemotherapy 13 0.66 0.19      
No chemotherapy 87 0.77 0.18      
Stage T1 or T2 47 0.77 0.18      
Stage T3 or T4 20 0.70 0.20      
Tracheotomy and/or feeding tube 6 0.69 0.23      
No tracheotomy and/or feeding tube 94 0.76 0.19      
EQ-5D 
All patients 100 0.82 0.18    -0.07; 1.0  
Primary surgery 54 0.83 0.19      
Salvage surgery 5 0.62 0.17      
Chemotherapy 13 0.76 0.17      
No chemotherapy 87 0.83 0.18      
Stage T1 or T2 47 0.83 0.18      
Stage T3 or T4 20 0.83 0.09      
Tracheotomy and/or feeding tube 6 0.78 0.14      
No tracheotomy and/or feeding tube 94 0.82 0.18      
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Table A3.1 (cont.) Details of HSUVs reported by the studies (n=27). 
Author (year) Method 
Patient’s characteristics/ 
Health state description 
Group/Time point N Mean SD SE 95% CI Median Range IQR 
Noel (2015) 
[172] 
(cont.) 
HUI3 
Patients with a minimum of three 
months after completion of 
treatment (surgery or RT) and no 
evidence of recurrent disease  
All patients 100 0.75 0.25    -0.06; 1.0  
Primary surgery 54 0.78 0.22      
Salvage surgery 5 0.37 0.29      
Chemotherapy 13 0.57 0.38      
No chemotherapy 87 0.78 0.21      
Stage T1 or T2 47 0.80 0.21      
Stage T3 or T4 20 0.74 0.21      
Tracheotomy and/or 
feeding tube 
6 0.73 0.25      
No tracheotomy and/or 
feeding tube 
94 0.75 0.29      
Larynx 17 0.59       
Oropharynx 14 0.76       
Oral cavity 67 0.78       
Outtassi 
(2016) [183] 
EQ-5D 
Patients with a confirmed 
diagnosis of HNC 
 120 0.49 0.35      
Parrilla (2015) 
[184] 
EQ-5D 
Patients laryngectomized with a 
stable pulmonary situation with a 
minimum of 3 months after 
treatment 
Baseline (no HME) 30 0.84 0.14    0.44-1.00  
Week 2 (HME) 30 0.90 0.10    0.67-1.00  
Week 6 (HME) 30 0.93 0.09    0.68-1.00  
Week 12 (HME) 30 0.96 0.10    0.66-1.00  
Parthan (2009) 
[196] 
Mapping 
Patients with locally advanced 
inoperable HNC 
Stable  0.70     0.63-0.77*  
Progressive  0.67     0.60-0.74  
Response  0.79     0.71-0.87  
Pickard (2016) 
[187] 
EQ-5D 
(US tariff) 
Patients with advanced HNC after 
at least two cycles of CT 
 50 0.76 0.15      
* Uncertainty range: 2.5 percentile and 97.5 percentile. 
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Table A3.1 (cont.) Details of HSUVs reported by the studies (n=27). 
Author 
(year) 
Method 
Patient’s characteristics/ 
Health state description 
Group/Time point N Mean SD SE 95% CI Median Range IQR 
Pottel 
(2015) 
[190] 
EQ-5D 
(Belgian 
tariff) 
Patients aged ≥65 years, eligible 
for curative primary or adjuvant 
RT 
Baseline 
(before 
treatment) 
All 81     0.66  0.55-0.76 
Fit* -     0.76  0.66-0.76 
Vulnerable -     0.63  0.29-0.73 
Week 4 (mid-
therapy) 
All 81     0.42  0.26-0.73 
Fit -     0.66  0.39-0.76 
Vulnerable -     0.39  0.21-0.67 
2 months (end 
of treatment) 
All 81     0.66  0.29-0.76 
Fit -     0.74  0.66-0.76 
Vulnerable -     0.58  0.23-0.73 
5 months 
(follow-up) 
All 81     0.66  0.27-0.76 
Fit -     0.76  0.66-1.00 
Vulnerable -     0.66  0.19-0.76 
12 months  
All 81     0.64  0.00-0.76 
Fit -     0.76  0.64-1.00 
Vulnerable -     0.57  0.00-0.74 
24 months 
All 81     0.29  0.00-0.76 
Fit -     0.76  0.32-1.00 
Vulnerable -     0.00  0.00-0.66 
36 months 
All 81     0.00  0.00-0.67 
Fit -     0.66  0.00-1.00 
Vulnerable -     0.00  0.00-0.58 
* Fit/vulnerable patients: classification based on geriatric-8 (G-8) assessment at baseline. 
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Table A3.1 (cont.) Details of HSUVs reported by the studies (n=27). 
Author 
(year) 
Method 
Patient’s characteristics/ 
Health state description 
Group/Time point N Mean SD SE 95% CI Median Range IQR 
Ramaekers 
(2011) 
[186] 
EQ-5D (UK 
tariff) 
Patients with a follow-up of at least 
6 months after curative RT without 
evidence of recurrent disease 
All patients 396 0.850 0.18   -  - 
X0-D0 84 0.909 0.161   1.000  0.186 
X0-D1 18 0.841 0.144   0.796  0.275 
X1-D0 92 0.898 0.138   1.000  0.204 
X1-D1 68 0.829 0.175   0.814  0.275 
X1-D2 14 0.803 0.136   0.796  0.133 
X2-D0 15 0.846 0.177   0.850  0.275 
X2-D1 31 0.817 0.187   0.812  0.309 
X2-D2 40 0.763 0.213   0.778  0.311 
X2-D3(+) 16 0.758 0.234   0.796  0.363 
Ringash 
(2000) 
[177] 
TTO 
Irradiated laryngeal cancer patients 
who completed treatment at least 6 
months before 
All 112 0.914 0.156    0.25; 1.0  
Group 1* 84 0.878 0.174    0.25; 1.0  
Rogers 
(2006) 
[185] 
EQ-5D (UK 
tariff) 
Patients without evidence of 
disease after primary surgery for 
oral/oropharyngeal cancer  
 224 0.75  0.02   -0.18; 1.0  
Group 1: excluding patients who claimed they had or did not want perfect health. 
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Table A3.1 (cont.) Details of HSUVs reported by the studies (n=27). 
Author 
(year) 
Method 
Patient’s characteristics/ 
Health state description 
Group/Time point N Mean SD SE 95% CI Median Range IQR 
Szabo 
(2012) 
[155] 
 
SG 
Eight vignettes representing 
disease’s characteristics and ten 
describing treatment-related 
toxicities 
Loco-regional (larynx) 101 0.62  0.02 0.57-0.67 0.65 0.00-0.98 0.50-0.80 
Loco-regional (not larynx) 101 0.61  0.02 0.56-0.66 0.63 0.03-0.98 0.50-0.78 
Recurrent (not larynx) 101 0.57  0.02 0.52-0.62 0.58 0.03-0.98 0.50-0.78 
Recurrent (larynx) 101 0.56  0.02 0.51-0.61 0.55 0.00-0.98 0.45-0.73 
Metastatic (not larynx) 101 0.52  0.02 0.47-0.57 0.50 0.00-0.98 0.38-0.68 
Metastatic (larynx) 101 0.50  0.02 0.45-0.55 0.50 0.00-0.98 0.35-0.65 
Anaemia grade III/IV 49 0.47  0.03 0.40-0.54 0.50 0.00-0.98 0.30-0.65 
Haematological grade 
III/IV 
49 0.46  0.04 0.39-0.53 0.50 0.00-0.98 0.33-0.65 
Skin reactions grade I/II 52 0.45  0.04 0.37-0.52 0.50 0.03-0.98 0.24-0.58 
Peripheral neuropathy 
grade III/IV 
49 0.44  0.04 0.36-0.51 0.45 0.00-0.98 0.20-0.60 
Treatment cessation due to 
grade III/IV toxicity 
52 0.44  0.03 0.36-0.51 0.50 0.03-0.98 0.23-0.55 
Nausea/vomiting grade 
III/IV 
49 0.43  0.04 0.35-0.50 0.45 0.00-0.98 0.25-0.60 
Mucositis/stomatitis grade 
III/IV 
49 0.43  0.04 0.35-0.50 0.45 0.00-0.98 0.23-0.58 
Anorexia/weight loss grade 
III/IV 
52 0.40  0.04 0.33-0.47 0.48 0.00-0.98 0.18-0.50 
Skin reactions grade III/IV 52 0.37  0.04 0.30-0.44 0.43 0.00-0.98 0.14-0.50 
Post-progression (not 
larynx) 
101 0.34  0.02 0.29-0.39 0.38 0.00-0.98 0.08-0.50 
Post-progression (larynx) 101 0.34  0.02 0.29-0.39 0.38 0.00-0.98 0.08-0.50 
Hospitalization for grade 
III/IV toxicity 
52 0.33  0.04 0.26-0.40 0.36 0.00-0.98 0.05-0.50 
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Table A3.1 (cont.) Details of HSUVs reported by the studies (n=27). 
Author 
(year) 
Method 
Patient’s characteristics/ 
Health state description 
Group/Time point N Mean SD SE 95% CI Median Range IQR 
Truong 
(2016) 
[188] 
EQ-5D (US 
tariff) 
Untreated stage III or IV cancer 
patients enrolled on a RCT comparing 
radiation-cisplatin without cetuximab 
(CIS) or with cetuximab (CET/CIS) 
CIS 
Baseline 366 0.78 0.18   0.82 0.17-1.00 0.77-0.84 
3 months - 0.78 0.18   - - - 
12 months - 0.84 0.17   - - - 
CET/CIS 
Baseline 349 0.80 0.17   0.83 0.20-1.00 0.77-0.84 
3 months - 0.77 0.15   - - - 
12 months - 0.84 0.16   - - - 
van der 
Donk 
(1995) 
[181] 
TTO 
Scenarios 
describing the 
health state of 
patients treated 
for T3 
laryngeal 
cancer (state 
scenarios) 
RT 
Laryngeal cancer 10 0.70       
FOM cancer 10 0.72       
Healthy subjects 10 0.90       
Clinical experts 9 0.81       
Surgery 
Laryngeal cancer 10 0.65       
FOM cancer 10 0.64       
Healthy subjects 10 0.77       
Clinical experts 9 0.71       
SG 
RT 
Laryngeal cancer 10 0.61       
FOM cancer 10 0.83       
Healthy subjects 10 0.84       
Clinical experts 9 0.92       
Surgery 
Laryngeal cancer 10 0.62       
FOM cancer 10 0.63       
Healthy subjects 10 0.68       
Clinical experts 9 0.84       
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Table A3.1 (cont.) Details of HSUVs reported by the studies (n=27). 
Author 
(year) 
Method 
Patient’s characteristics/ 
Health state description 
Group/Time point N Mean SD SE 95% CI Median Range IQR 
van der 
Donk (1995) 
[181] 
(cont.) 
RS 
Scenarios 
describing the 
health state of 
patients treated 
for T3 laryngeal 
cancer (state 
scenarios) 
 
RT 
Laryngeal cancer 10 0.66       
FOM cancer 10 0.78       
Healthy subjects 10 0.68       
Clinical experts 9 0.78       
Surgery 
Laryngeal cancer 10 0.45       
FOM cancer 10 0.50       
Healthy subjects 10 0.47       
Clinical experts 9 0.57       
TTO 
Scenarios 
describing the 
health state of 
patients treated 
for T3 laryngeal 
cancer including 
temporary and 
permanent side 
effects, life 
expectancy, 
tumour 
recurrence rates, 
and probability 
of treatment 
outcomes 
(dynamic 
scenarios) 
RT 
Laryngeal cancer 10 0.66       
FOM cancer 10 0.62       
Healthy subjects 10 0.73       
Clinical experts 9 0.80       
Surgery 
Laryngeal cancer 10 0.62       
FOM cancer 10 0.61       
Healthy subjects 10 0.66       
Clinical experts 9 0.73       
SG 
RT 
Laryngeal cancer 10 0.65       
FOM cancer 10 0.70       
Healthy subjects 10 0.83       
Clinical experts 9 0.91       
Surgery 
Laryngeal cancer 10 0.71       
FOM cancer 10 0.66       
Healthy subjects 10 0.76       
Clinical experts 9 0.85       
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Table A3.1 (cont.) Details of HSUVs reported by the studies (n=27). 
Author 
(year) 
Method 
Patient’s characteristics/ 
Health state description 
Group/Time 
point 
N Mean SD SE 95% CI Median Range IQR 
van der 
Donk 
(1995) 
[181] 
(cont.) 
RS (VAS) 
Scenarios describing the health 
state of patients treated for T3 
laryngeal cancer including 
temporary and permanent side 
effects, life expectancy, tumour 
recurrence rates, and probability 
of treatment outcomes (dynamic 
scenarios) 
RT 
Laryngeal cancer 10 0.60       
FOM cancer 10 0.63       
Healthy subjects 10 0.64       
Clinical experts 9 0.69       
Clinical experts 9 0.55       
Surgery 
Laryngeal cancer 10 0.49       
FOM cancer 10 0.55       
Healthy subjects 10 0.52       
Clinical experts 9 0.55       
Weiss 
(1994) 
[178] 
TTO 
Stage N0 patients free of disease 
after different treatment options 
Observation 
 
3 1.0 
      
Neck dissection 3 0.97 
Radiotherapy 3 0.97 
Salvage surgery 
(successful) 
3 0.94 
Yong 
(2012) 
[199] 
Mapping Patients with early stage cancer 
IMRT 
Immediately after 
treatment 
 
0.810 
      
6 months  0.853 
12 months 0.925 
3DCRT 
Immediately after 
treatment 
0.810 
6 months  0.853 
12 months 0.868 
 
3DCRT: three dimensional conformal radiotherapy; CI: confidence interval; CO2: transoral CO2 laser excision; CRT: chemoradiotherapy; CT: chemotherapy; D: dysphagia; FOM: floor-of-the-mouth; 
HME: heat and moisture exchanger; HSUV: health state utility value; HUI3: Health Utility Index Mark 3; IMRT: intensity-modulated radiation therapy; IQR: interquartile range; MRND: modified 
radical neck dissection; NA: not available; ND: neck dissection; PEG: gastrostomy tube; RCT: randomized controlled trial; RS: rating scale; RT: radiotherapy; SE: standard error; SD: standard 
deviation; SG: standard gamble; SLNB: sentinel lymph node biopsy; SOHND: supraomohyoid neck dissection; TL: total laryngectomy; TORS: transoral robotic surgery; TTO: time trade-off; VAS: 
visual analogue scale; WW: watchful waiting; X: xerostomia; XRT: external radiation therapy.  
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APPENDIX TO CHAPTER 4 
Table A4.1 MAPS checklist of included items.   
Section/topic 
Item 
number 
Recommendation 
Reported on page 
number/line number 
Title and abstract 
Title 1 
Identify the report as a study mapping between outcome 
measures. State the source measure(s) and generic, 
preference-based target measure(s) used in the study 
Page 104 
Abstract 2 
Provide a structured abstract including, as applicable: 
objectives; methods, including data sources and their 
key characteristics, outcome measures used and 
estimation and validation strategies; results, including 
indicators of model performance; conclusions; and 
implications of key findings 
Not available 
Introduction 
Study 
rationale 
3 
Describe the rationale for the mapping study in the 
context of the broader evidence base 
Pages 104-106 
Study 
objective 
4 
Specify the research question with reference to the 
source and target measures used and the disease or 
population context of the study 
Page 106 
Methods 
Estimation 
sample 
5 
Describe how the estimation sample was identified, 
why it was selected, the methods of recruitment and 
data collection, and its location(s) or setting(s) 
Page 108 
External 
validation 
sample 
6 
If an external validation sample was used, the rationale 
for selection, the methods of recruitment and data 
collection, and its location(s) or setting(s) should be 
described 
Not applicable 
Source and 
target 
measures 
7 
Describe the source and target measures and the 
methods by which they were applied in the mapping 
study 
Pages 107-108 
Exploratory 
data analysis 
8 
Describe the methods used to assess the degree of 
conceptual overlap between the source and target 
measures 
Page 109 
Missing data 9 
State how much data were missing and how missing 
data were handled in the sample(s) used for the analyses 
Page 108 
Modelling 
approaches  
10 
Describe and justify the statistical model(s) used to 
develop the mapping algorithm 
Pages 109-111 
Estimation 
of predicted 
scores or 
utilities 
11 
Describe how predicted scores or utilities are estimated 
for each model specification 
Page 112 
Validation 
methods 
12 
Describe and justify the methods used to validate the 
mapping algorithm 
Not applicable 
Measures of 
model 
performance 
13 
State and justify the measure(s) of model performance 
that determine the choice of the preferred model(s) and 
describe how these measures were estimated and 
applied 
Page 112 
Source: Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, et al. PREFERRED REPORTING ITEMS FOR 
STUDIES MAPPING ONTO PREFERENCE-BASED OUTCOME MEASURES: THE MAPS STATEMENT. Int J Technol 
Assess Health Care. 2015; 31(4):230-5. 
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Table A4.1 (cont.) MAPS checklist of included items.   
Section/topic 
Item 
number 
Recommendation 
Reported on page 
number/line number 
Results 
Final sample 
size(s)  
14 
State the size of the estimation sample and any validation 
sample(s) used in the analyses (including both number of 
individuals and number of observations) 
Pages 112-115 
Descriptive 
information 
15 
Describe the characteristics of individuals in the sample(s) 
(or refer back to previous publications giving such 
information). Provide summary scores for source and 
target measures, and summarize results of analyses used to 
assess overlap between the source and target measures 
Pages 112-118; 
Tables 4.1-4.2-4.3-
4.4; Figure 4.1 
Model selection 16 
State which model(s) is(are) preferred and justify why 
this(these) model(s) was(were) chosen 
Pages 119-120 
Model 
coefficients 
17 
Provide all model coefficients and standard errors for the 
selected model(s). Provide clear guidance on how a user 
can calculate utility scores based on the outputs of the 
selected model(s) 
Tables 4.5-4.6-4.7-
4.8 
Uncertainty 18 
Report information that enables users to estimate standard 
errors around mean utility predictions and individual-level 
variability 
Not applicable 
Model 
performance 
and face validity 
19 
Present results of model performance, such as measures of 
prediction accuracy and fit statistics for the selected 
model(s) in a table or in the text. Provide an assessment of 
face validity of the selected model(s) 
Tables 4.5-4.6-4.7-
4.8; Figures 4.2-4.3-
4.4-4.5 
Discussion 
Comparisons 
with previous 
studies 
20 
Report details of previously published studies developing 
mapping algorithms between the same source and target 
measures and describe differences between the algorithms, 
in terms of model performance, predictions, and 
coefficients, if applicable 
Page 129 
Study 
limitations 
21 Outline the potential limitations of the mapping algorithm 
Pages 130-132 
Scope of 
applications 
22 
Outline the clinical and research settings in which the 
mapping algorithm could be used 
Page 132 
Other 
Additional 
information 
23 
Describe the source(s) of funding and non-monetary 
support for the study, and the role of the funder(s) in its 
design, conduct and report. Report any conflicts of interest. 
Not applicable 
Source: Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, et al. PREFERRED REPORTING ITEMS FOR 
STUDIES MAPPING ONTO PREFERENCE-BASED OUTCOME MEASURES: THE MAPS STATEMENT. Int J Technol 
Assess Health Care. 2015; 31(4):230-5. 
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Tables A4.2 Linear mixed-effects and random-effects Tobit models using QLQ-C30. 
Table A4.2 (A) Linear mixed-effects and random-effects Tobit models using QLQ-C30 (England). 
 Linear  Tobit 
 Full model Reduced model Full model Reduced model 
 Coefficient SE P Coefficient SE P Coefficient SE p Coefficient SE p 
Intercept 0.4537 0.1069 0.000 0.4050 0.0751 0.000 0.4492 0.1298 0.001 0.4422 0.0593 0.000 
GH 0.0009 0.0005 0.068 0.0011 0.0004 0.012 0.0012 0.0005 0.024 0.0013 0.0005 0.014 
PF 0.0034 0.0008 0.000 0.0034 0.0008 0.000 0.0035 0.0007 0.000 0.0034 0.0006 0.000 
RF 0.0004 0.0005 0.330    0.0005 0.0005 0.328    
EF 0.0011 0.0004 0.011 0.0012 0.0005 0.022 0.0013 0.0006 0.022 0.0010 0.0005 0.041 
CF -0.0003 0.0007 0.717    -0.0003 0.0006 0.570    
SF 0.0002 0.0003 0.565    0.0002 0.0004 0.591    
FA 0.0008 0.0006 0.235    0.0007 0.0005 0.215    
NV -0.0027 0.0013 0.035 -0.0027 0.0012 0.022 -0.0029 0.0010 0.005 -0.0024 0.0009 0.011 
PA -0.0007 0.0005 0.167    -0.0007 0.0005 0.118    
DY 0.0001 0.0004 0.855    0.0001 0.0004 0.728    
SL 0.0003 0.0003 0.302    0.0002 0.0004 0.493    
AP 0.0002 0.0004 0.546    0.0002 0.0004 0.541    
CO 0.0007 0.0004 0.080 0.0007 0.0002 0.006 0.0006 0.0004 0.107    
DI -0.0018 0.0010 0.078    -0.0018 0.0007 0.009 -0.0018 0.0007 0.008 
FI -0.0010 0.0003 0.001 -0.0008 0.0003 0.002 -0.0011 0.0003 0.002 -0.0011 0.0003 0.001 
Female 0.0143 0.0170 0.401    0.0218 0.0277 0.432    
Age -0.0010 0.0009 0.261    -0.0015 0.0011 0.171    
/sigma_u       0.0687 0.0122 0.000 0.0719 0.0110 0.000 
/sigma_e       0.0836 0.0062 0.000 0.0865 0.0059 0.000 
Rho       0.4030 0.1062  0.4085 0.0907  
AIC -411.79   -413.60   -230.34   -238.84   
BIC -343.55   -382.90   -162.10   -208.13   
MAE 0.0695   0.0698   0.0702   0.0693   
RMSE 0.0985   0.1012   0.0978   0.1012   
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; 
DY: dyspnoea; SL: insomnia; AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute 
Error; RMSE: Root Mean Square Error, SE: standard error. 
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Table A4.2 (B) Linear mixed-effects and random-effects Tobit models using QLQ-C30 (Netherlands). 
 Linear  Tobit 
 Full model Reduced model Full model Reduced model 
 Coefficient SE P Coefficient SE P Coefficient SE p Coefficient SE p 
Intercept 0.3416 0.1255 0.007 0.2859 0.0929 0.002 0.3390 0.1606 0.035 0.3283 0.0738 0.000 
GH 0.0013 0.0006 0.030 0.0014 0.0005 0.005 0.0016 0.0006 0.016 0.0017 0.0007 0.010 
PF 0.0038 0.0009 0.000 0.0037 0.0009 0.000 0.0040 0.0009 0.000 0.0037 0.0007 0.000 
RF 0.0006 0.0005 0.275    0.0006 0.0006 0.293    
EF 0.0015 0.0006 0.009 0.0016 0.0007 0.022 0.0017 0.0007 0.013 0.0013 0.0006 0.032 
CF -0.0003 0.0008 0.680    -0.0004 0.0007 0.552    
SF <0.0001 0.0004 0.942    0.0001 0.0005 0.864    
FA 0.0010 0.0007 0.183    0.0009 0.0007 0.187    
NV -0.0031 0.0015 0.038 -0.0030 0.0013 0.028 -0.0032 0.0012 0.009 -0.0026 0.0012 0.023 
PA -0.0009 0.0005 0.119    -0.0009 0.0006 0.130    
DY 0.0002 0.0005 0.710    0.0003 0.0005 0.627    
SL 0.0004 0.0004 0.228    0.0004 0.0004 0.411    
AP 0.0003 0.0005 0.572    0.0003 0.0005 0.548    
CO 0.0008 0.0004 0.081 0.0008 0.0003 0.010 0.0007 0.0005 0.130    
DI -0.0023 0.0012 0.062    -0.0022 0.0008 0.008 -0.0022 0.0008 0.007 
FI -0.0014 0.0004 0.000 -0.0011 0.0003 0.001 -0.0015 0.0004 0.001 -0.0014 0.0004 0.000 
Female 0.0195 0.0221 0.377    0.0278 0.0351 0.429    
Age -0.0013 0.0011 0.241    -0.0019 0.0014 0.165    
/sigma_u       0.0908 0.0152 0.000 0.0926 0.0138 0.000 
/sigma_e       0.1005 0.0075 0.000 0.1048 0.0073 0.000 
Rho       0.4494 0.1049  0.4387 0.0906  
AIC -323.26   -323.78   -149.16   -157.87   
BIC -255.02   -293.07   -80.93   -127.17   
MAE 0.0869   0.0883   0.0879   0.0862   
RMSE 0.1224   0.1256   0.1207   0.1243   
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; 
DY: dyspnoea; SL: insomnia; AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute 
Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.2 (C) Linear mixed-effects and random-effects Tobit models using QLQ-C30 (Canada). 
 Linear  Tobit 
 Full model Reduced model Full model Reduced model 
 Coefficient SE P Coefficient SE P Coefficient SE p Coefficient SE p 
Intercept 0.5232 0.0871 0.000 0.5628 0.0555 0.000 0.5172 0.1171 0.000 0.5471 0.0510 0.000 
GH 0.0009 0.0004 0.023 0.0009 0.0003 0.002 0.0012 0.0005 0.012 0.0012 0.0005 0.007 
PF 0.0032 0.0007 0.000 0.0028 0.0007 0.000 0.0034 0.0006 0.000 0.0029 0.0005 0.000 
RF 0.0005 0.0004 0.211    0.0005 0.0004 0.210    
EF 0.0006 0.0004 0.158    0.0008 0.0005 0.114    
CF -0.0005 0.0006 0.406    -0.0005 0.0005 0.286    
SF <0.0001 0.0002 0.852    0.0001 0.0004 0.827    
FA 0.0009 0.0005 0.111    0.0008 0.0005 0.094    
NV -0.0021 0.0012 0.066    -0.0023 0.0009 0.009 -0.0019 0.0008 0.020 
PA -0.0009 0.0004 0.027 -0.0011 0.0004 0.003 -0.0009 0.0004 0.026 -0.0010 0.0004 0.008 
DY <0.0001 0.0003 0.995    0.0001 0.0004 0.829    
SL 0.0004 0.0002 0.146    0.0003 0.0003 0.313    
AP 0.0002 0.0003 0.553    0.0002 0.0003 0.515    
CO 0.0006 0.0003 0.055 0.0006 0.0002 0.005 0.0006 0.0003 0.082 0.0006 0.0003 0.032 
DI -0.0018 0.0009 0.045 -0.0020 0.0009 0.026 -0.0018 0.0006 0.002 -0.0019 0.0006 0.001 
FI -0.0011 0.0003 0.000 -0.0009 0.0002 0.000 -0.0012 0.0003 0.000 -0.0011 0.0003 0.000 
Female 0.0130 0.0167 0.435    0.0191 0.0271 0.481    
Age -0.0011 0.0009 0.220    -0.0015 0.0011 0.150    
/sigma_u       0.0755 0.0103 0.000 0.0787 0.0096 0.000 
/sigma_e       0.0675 0.0049 0.000 0.0692 0.0048 0.000 
Rho       0.5559 0.0873  0.5640 0.0762  
AIC -470.50   -473.48   -284.78   -293.32   
BIC -402.27   -442.77   -216.55   -259.21   
MAE 0.0643   0.0653   0.0651   0.0649   
RMSE 0.0958   0.0997   0.0944   0.0984   
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; 
DY: dyspnoea; SL: insomnia; AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute 
Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.2 (D) Linear mixed-effects and random-effects Tobit models using QLQ-C30 (Uruguay). 
 Linear  Tobit 
 Full model Reduced model Full model Reduced model 
 Coefficient SE P Coefficient SE P Coefficient SE p Coefficient SE p 
Intercept 0.6878 0.0695 0.000 0.7288 0.0399 0.000 0.6846 0.0892 0.000 0.7172 0.0389 0.000 
GH 0.0007 0.0003 0.041 0.0007 0.0002 0.003 0.0009 0.0004 0.014 0.0010 0.0003 0.006 
PF 0.0020 0.0005 0.000 0.0018 0.0005 0.000 0.0022 0.0005 0.000 0.0020 0.0004 0.000 
RF 0.0005 0.0004 0.171    0.0005 0.0003 0.095    
EF 0.0002 0.0003 0.605    0.0003 0.0004 0.417    
CF -0.0003 0.0005 0.550    -0.0003 0.0004 0.439    
SF 0.0002 0.0002 0.208    0.0003 0.0003 0.368    
FA 0.0005 0.0004 0.174    0.0005 0.0004 0.217    
NV -0.0016 0.0008 0.055    -0.0017 0.0007 0.010 -0.0014 0.0006 0.021 
PA -0.0006 0.0003 0.081 -0.0008 0.0003 0.013 -0.0006 0.0003 0.049 -0.0007 0.0003 0.017 
DY 0.0002 0.0002 0.495    0.0002 0.0003 0.430    
SL 0.0001 0.0002 0.474    0.0001 0.0002 0.617    
AP 0.0002 0.0002 0.420    0.0002 0.0002 0.408    
CO 0.0005 0.0002 0.044 0.0005 0.0002 0.005 0.0004 0.0002 0.085 0.0005 0.0002 0.026 
DI -0.0011 0.0006 0.084 -0.0013 0.0006 0.030 -0.0011 0.0004 0.018 -0.0012 0.0004 0.005 
FI -0.0008 0.0002 0.000 -0.0007 0.0002 0.000 -0.0008 0.0002 0.000 -0.0008 0.0002 0.000 
Female 0.0138 0.0124 0.269    0.0183 0.0200 0.359    
Age -0.0007 0.0006 0.245    -0.0011 0.0008 0.182    
/sigma_u       0.0535 0.0081 0.000 0.0574 0.0075 0.000 
/sigma_e       0.0537 0.0040 0.000 0.0544 0.0038 0.000 
rho       0.4980 0.0969  0.5262 0.0825  
AIC -586.48   -590.39   -381.67   -390.66   
BIC -518.24   -559.69   -313.43   -356.54   
MAE 0.0477   0.0498   0.0477   0.0487   
RMSE 0.0704   0.0738   0.0697   0.0730   
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; 
DY: dyspnoea; SL: insomnia; AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute 
Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.2 (E) Linear mixed-effects and random-effects Tobit models using QLQ-C30 (South Korea). 
 Linear  Tobit 
 Full model Reduced model Full model Reduced model 
 Coefficient SE P Coefficient SE P Coefficient SE p Coefficient SE p 
Intercept 0.4707 0.0961 0.000 0.5110 0.0466 0.000 0.4734 0.1187 0.000 0.4863 0.0483 0.000 
GH 0.0010 0.0004 0.012 0.0012 0.0004 0.001 0.0012 0.0005 0.012 0.0015 0.0005 0.003 
PF 0.0028 0.0007 0.000 0.0030 0.0006 0.000 0.0029 0.0007 0.000 0.0032 0.0005 0.000 
RF 0.0006 0.0004 0.160    0.0006 0.0004 0.168    
EF 0.0006 0.0004 0.103    0.0008 0.0005 0.137    
CF -0.0004 0.0005 0.407    -0.0005 0.0005 0.368    
SF 0.0001 0.0002 0.577    0.0002 0.0004 0.659    
FA 0.0007 0.0006 0.210    0.0007 0.0005 0.200    
NV -0.0020 0.0011 0.061 -0.0018 0.0009 0.041 -0.0020 0.0010 0.032 -0.0019 0.0009 0.034 
PA -0.0006 0.0005 0.167    -0.0007 0.0004 0.138    
DY 0.0002 0.0003 0.653    0.0002 0.0004 0.602    
SL 0.0002 0.0002 0.391    0.0002 0.0003 0.596    
AP 0.0002 0.0003 0.442    0.0002 0.0003 0.510    
CO 0.0004 0.0003 0.195    0.0003 0.0003 0.346    
DI -0.0010 0.0006 0.088    -0.0010 0.0006 0.101    
FI -0.0009 0.0002 0.000 -0.0009 0.0002 0.000 -0.0010 0.0003 0.002 -0.0010 0.0003 0.000 
Female 0.0209 0.0161 0.194    0.0261 0.0248 0.291    
Age -0.0006 0.0009 0.504    -0.0010 0.0010 0.330    
/sigma_u       0.0593 0.0122 0.000 0.0618 0.0106 0.000 
/sigma_e       0.0793 0.0060 0.000 0.0833 0.0057 0.000 
rho       0.3586 0.1158     
AIC -455.30   -459.93   -242.36   -250.78   
BIC -387.07   -436.05   -174.13   -226.90   
MAE 0.0662   0.0671   0.0665   0.0680   
RMSE 0.0863   0.0895   0.0854   0.0892   
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; 
DY: dyspnoea; SL: insomnia; AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute 
Error; RMSE: Root Mean Square Error, SE: standard error. 
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Table A4.2 (F) Linear mixed-effects and random-effects Tobit models using QLQ-C30 (Japan). 
 Linear  Tobit 
 Full model Reduced model Full model Reduced model 
 Coefficient SE P Coefficient SE P Coefficient SE p Coefficient SE p 
Intercept 0.2735 0.1053 0.009 0.3203 0.0538 0.000 0.2740 0.1269 0.031 0.1870 0.0716 0.009 
GH 0.0014 0.0004 0.001 0.0014 0.0004 0.000 0.0016 0.0005 0.002 0.0019 0.0005 0.000 
PF 0.0038 0.0007 0.000 0.0035 0.0006 0.000 0.0039 0.0007 0.000 0.0042 0.0006 0.000 
RF 0.0005 0.0004 0.210    0.0005 0.0005 0.284    
EF 0.0016 0.0004 0.000 0.0013 0.0004 0.002 0.0018 0.0006 0.001 0.0018 0.0005 0.000 
CF -0.0004 0.0005 0.448    -0.0004 0.0006 0.435    
SF 0.0001 0.0003 0.589    0.0002 0.0004 0.627    
FA 0.0011 0.0006 0.050    0.0011 0.0005 0.050 0.0011 0.0005 0.037 
NV -0.0025 0.0011 0.023 -0.0021 0.0010 0.038 -0.0026 0.0010 0.010 -0.0025 0.0009 0.007 
PA -0.0005 0.0005 0.250    -0.0006 0.0005 0.232    
DY 0.0002 0.0004 0.556    0.0003 0.0004 0.490    
SL 0.0001 0.0003 0.622    0.0001 0.0004 0.808    
AP 0.0001 0.0003 0.759    0.0001 0.0004 0.767    
CO 0.0005 0.0003 0.146    0.0004 0.0004 0.237    
DI -0.0010 0.0006 0.089    -0.0011 0.0007 0.127    
FI -0.0008 0.0003 0.002 -0.0008 0.0002 0.001 -0.0009 0.0003 0.006 -0.0009 0.0003 0.002 
Female 0.0056 0.0190 0.768    0.0109 0.0269 0.686    
Age -0.0007 0.0009 0.407    -0.0011 0.0011 0.281    
/sigma_u       0.0665 0.0123 0.000 0.0679 0.0112 0.000 
/sigma_e       0.0827 0.0061 0.000 0.0854 0.0059 0.000 
rho       0.3925 0.1087  0.3878 0.0948  
AIC -426.59   -431.40   -224.75   -236.05   
BIC -358.35   -404.11   -156.52   -205.35   
MAE 0.0741   0.0745   0.0735   0.0752   
RMSE 0.0933   0.0949   0.0926   0.0945   
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; 
DY: dyspnoea; SL: insomnia; AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute 
Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.2 (G) Linear mixed-effects and random-effects Tobit models using QLQ-C30 (China). 
 Linear  Tobit 
 Full model Reduced model Full model Reduced model 
 Coefficient SE P Coefficient SE P Coefficient SE p Coefficient SE p 
Intercept 0.2412 0.1272 0.058 0.3730 0.0753 0.000 0.2356 0.1561 0.131 0.1670 0.0922 0.070 
GH 0.0017 0.0006 0.005 0.0016 0.0004 0.000 0.0020 0.0006 0.002 0.0021 0.0006 0.001 
PF 0.0051 0.0009 0.000 0.0045 0.0009 0.000 0.0053 0.0008 0.000 0.0052 0.0008 0.000 
RF 0.0006 0.0005 0.274    0.0006 0.0006 0.264    
EF 0.0013 0.0005 0.010    0.0015 0.0007 0.023 0.0012 0.0006 0.048 
CF -0.0006 0.0008 0.419    -0.0007 0.0007 0.338    
SF 0.0001 0.0004 0.720    0.0002 0.0005 0.708    
FA 0.0016 0.0007 0.031    0.0015 0.0006 0.024 0.0016 0.0006 0.011 
NV -0.0030 0.0016 0.054    -0.0032 0.0012 0.006 -0.0029 0.0011 0.007 
PA -0.0011 0.0006 0.045 -0.0016 0.0005 0.004 -0.0012 0.0006 0.039 -0.0013 0.0005 0.023 
DY 0.0001 0.0004 0.764    0.0002 0.0005 0.634    
SL 0.0003 0.0003 0.330    0.0002 0.0004 0.573    
AP 0.0002 0.0004 0.574    0.0003 0.0004 0.544    
CO 0.0008 0.0004 0.053 0.0007 0.0003 0.012 0.0007 0.0004 0.092 0.0008 0.0004 0.048 
DI -0.0017 0.0008 0.039 -0.0019 0.0008 0.012 -0.0016 0.0008 0.038 -0.0019 0.0008 0.016 
FI -0.0013 0.0003 0.000 -0.0012 0.0003 0.000 -0.0014 0.0004 0.001 -0.0014 0.0004 0.000 
Female 0.0054 0.0243 0.823    0.0130 0.0351 0.711    
Age -0.0012 0.0011 0.286    -0.0018 0.0014 0.200    
/sigma_u       0.0944 0.0139 0.000 0.0990 0.0129 0.000 
/sigma_e       0.0938 0.0069 0.000 0.0939 0.0065 0.000 
rho       0.5033 0.0942  0.5264 0.0824  
AIC -336.71   -336.13   -172.03   -182.49   
BIC -268.48   -305.43   -103.80   -141.55   
MAE 0.0895   0.0923   0.0900   0.0904   
RMSE 0.1248   0.1296   0.1233   0.1264   
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; 
DY: dyspnoea; SL: insomnia; AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute 
Error; RMSE: Root Mean Square Error; SE: standard error. 
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Tables A4.3 Linear mixed-effects and random-effects Tobit models using QLQ-H&N35. 
Table A4.3 (A) Linear mixed-effects and random-effects Tobit models using QLQ-H&N35 (England). 
 Linear  Tobit 
 Full model Reduced model Full model Reduced model 
 Coefficient SE P Coefficient SE P Coefficient SE p Coefficient SE p 
Intercept 0.9534 0.0609 0.000 0.9200 0.0118 0.000 1.0225 0.0885 0.000 0.9434 0.0172 0.000 
HNPA -0.0020 0.0006 0.002 -0.0020 0.0005 0.000 -0.0023 0.0006 0.000 -0.0023 0.0005 0.000 
HNSW <0.0001 0.0006 0.978    <0.0001 0.0006 0.943    
HNSE 0.0004 0.0004 0.296    0.0003 0.0004 0.482    
HNSP -0.0004 0.0005 0.359    -0.0004 0.0005 0.430    
HNSO 0.0004 0.0005 0.468    0.0004 0.0007 0.539    
HNSC -0.0027 0.0008 0.000 -0.0026 0.0006 0.000 -0.0029 0.0007 0.000 -0.0028 0.0005 0.000 
HNSX <0.0001 0.0005 0.978    -0.0001 0.0003 0.761    
HNTE -0.0003 0.0002 0.143    -0.0003 0.0003 0.249    
HNOM -0.0004 0.0003 0.237    -0.0005 0.0004 0.162    
HNDR 0.0003 0.0003 0.301    0.0004 0.0004 0.250    
HNSS -0.0001 0.0002 0.804    -0.0002 0.0004 0.575    
HNCO -0.0005 0.0004 0.210    -0.0006 0.0004 0.146    
HNFI -0.0013 0.0005 0.007 -0.0014 0.0005 0.004 -0.0013 0.0007 0.058 -0.0014 0.0007 0.043 
HNPK <0.0001 0.0002 0.963    -0.0001 0.0002 0.690    
HNNU -0.0003 0.0002 0.203    -0.0004 0.0002 0.054    
HNFE -0.0003 0.0003 0.416    -0.0003 0.0004 0.474    
HNWL 0.0004 0.0002 0.008    0.0005 0.0002 0.018    
HNWG 0.0002 0.0001 0.060    0.0003 0.0002 0.106    
Female 0.0379 0.0250 0.131    0.0478 0.0344 0.165    
Age -0.0006 0.0009 0.494    -0.0013 0.0013 0.336    
/sigma_u       0.0935 0.0127 0.000 0.1050 0.0119 0.000 
/sigma_e       0.0878 0.0062 0.000 0.0902 0.0060 0.000 
Rho       0.5314 0.0857  0.5755 0.0683  
AIC -357.22   -377.11   -174.87   -189.21   
BIC -278.96   -356.59   -96.61   -168.69   
MAE 0.0809   0.0847   0.0802   0.0824   
RMSE 0.1167   0.1252   0.1165   0.1253   
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; 
HNOM: opening mouth; HNSS: sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding tube; HNWL: weight loss; HNWG: weight gain. 
AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.3 (B) Linear mixed-effects and random-effects Tobit models using QLQ-H&N35 (Netherlands). 
 Linear  Tobit 
 Full model Reduced model Full model Reduced model 
 Coefficient SE P Coefficient SE P Coefficient SE p Coefficient SE p 
Intercept 0.9220 0.0738 0.000 0.8818 0.0141 0.000 1.0042 0.1078 0.000 0.9088 0.0209 0.000 
HNPA -0.0025 0.0007 0.001 -0.0024 0.0006 0.000 -0.0028 0.0007 0.000 -0.0028 0.0006 0.000 
HNSW -0.0002 0.0008 0.815    -0.0002 0.0008 0.784    
HNSE 0.0005 0.0005 0.275    0.0004 0.0005 0.455    
HNSP -0.0004 0.0005 0.508    -0.0004 0.0006 0.575    
HNSO 0.0004 0.0006 0.547    0.0004 0.0008 0.587    
HNSC -0.0033 0.0009 0.000 -0.0031 0.0007 0.000 -0.0035 0.0009 0.000 -0.0033 0.0006 0.000 
HNSX <0.0001 0.0006 0.984    -0.0001 0.0004 0.821    
HNTE -0.0003 0.0002 0.223    -0.0003 0.0003 0.365    
HNOM -0.0004 0.0004 0.312    -0.0005 0.0004 0.219    
HNDR 0.0005 0.0003 0.093    0.0007 0.0004 0.109    
HNSS -0.0002 0.0003 0.499    -0.0004 0.0004 0.389    
HNCO -0.0006 0.0005 0.283    -0.0006 0.0005 0.185    
HNFI -0.0017 0.0006 0.007 -0.0018 0.0006 0.003 -0.0016 0.0008 0.049 -0.0018 0.0008 0.033 
HNPK <0.0001 0.0002 0.938    -0.0001 0.0003 0.615    
HNNU -0.0004 0.0003 0.172    -0.0005 0.0002 0.051    
HNFE -0.0004 0.0004 0.304    -0.0004 0.0005 0.368    
HNWL 0.0006 0.0002 0.010    0.0007 0.0003 0.016    
HNWG 0.0003 0.0002 0.044    0.0004 0.0002 0.081    
Female 0.0493 0.0307 0.108    0.0608 0.0418 0.146    
Age -0.0008 0.0011 0.454    -0.0016 0.0016 0.313    
/sigma_u       0.1144 0.0153 0.000 0.1287 0.0145 0.000 
/sigma_e       0.1062 0.0076 0.000 0.1090 0.0073 0.000 
Rho       0.5372 0.0843  0.5821 0.0677  
AIC -274.37   -292.37   -100.17   -113.22   
BIC -196.11   -271.85   -21.91   -92.70   
MAE 0.0987   0.1031   0.0978   0.1018   
RMSE 0.1418   0.1520   0.1410   0.1519   
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; 
HNOM: opening mouth; HNSS: sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding tube; HNWL: weight loss; HNWG: weight gain. 
AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.3 (C) Linear mixed-effects and random-effects Tobit models using QLQ-H&N35 (Canada). 
 Linear  Tobit 
 Full model Reduced model Full model Reduced model 
 Coefficient SE p Coefficient SE P Coefficient SE p Coefficient SE p 
Intercept 0.9220 0.0609 0.000 0.8908 0.0097 0.000 0.9833 0.0845 0.000 0.9121 0.0157 0.000 
HNPA -0.0018 0.0005 0.001 -0.0017 0.0004 0.000 -0.0020 0.0005 0.000 -0.0020 0.0004 0.000 
HNSW -0.0001 0.0005 0.900    -0.0001 0.0006 0.861    
HNSE 0.0004 0.0004 0.278    0.0003 0.0004 0.452    
HNSP -0.0003 0.0004 0.533    -0.0002 0.0005 0.578    
HNSO 0.0002 0.0004 0.593    0.0003 0.0006 0.646    
HNSC -0.0025 0.0007 0.000 -0.0023 0.0006 0.000 -0.0026 0.0006 0.000 -0.0025 0.0005 0.000 
HNSX -0.0001 0.0004 0.830    -0.0002 0.0003 0.592    
HNTE -0.0002 0.0002 0.181    -0.0002 0.0002 0.326    
HNOM -0.0003 0.0003 0.252    -0.0005 0.0003 0.153    
HNDR 0.0004 0.0003 0.184    0.0005 0.0003 0.134    
HNSS <0.0001 0.0002 0.909    -0.0001 0.0003 0.778    
HNCO -0.0003 0.0004 0.369    -0.0004 0.0003 0.222    
HNFI -0.0013 0.0005 0.007 -0.0013 0.0004 0.002 -0.0013 0.0006 0.036 -0.0014 0.0006 0.025 
HNPK <0.0001 0.0002 0.968    -0.0001 0.0002 0.678    
HNNU -0.0002 0.0002 0.259    -0.0003 0.0002 0.086    
HNFE -0.0001 0.0003 0.667    -0.0002 0.0003 0.652    
HNWL 0.0004 0.0001 0.017    0.0004 0.0002 0.020    
HNWG 0.0002 0.0001 0.059    0.0003 0.0002 0.083    
Female 0.0351 0.0220 0.111    0.0433 0.0327 0.185    
Age -0.0007 0.0010 0.457    -0.0013 0.0013 0.313    
/sigma_u       0.0940 0.0113 0.000 0.1028 0.0107 0.000 
/sigma_e       0.0732 0.0052 0.000 0.0753 0.0050 0.000 
Rho       0.6221 0.0724  0.6509 0.0590  
AIC -412.22   -435.47   -225.28   -242.50   
BIC -333.96   -414.95   -147.02   -221.97   
MAE 0.0753   0.0776   0.0752   0.0747   
RMSE 0.1131   0.1201   0.1126   0.1203   
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; 
HNOM: opening mouth; HNSS: sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding tube; HNWL: weight loss; HNWG: weight gain. 
AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.3 (D) Linear mixed-effects and random-effects Tobit models using QLQ-H&N35 (Uruguay). 
 Linear  Tobit 
 Full model Reduced model Full model Reduced model 
 Coefficient SE p Coefficient SE P Coefficient SE p Coefficient SE p 
Intercept 0.9719 0.0448 0.000 0.9575 0.0081 0.000 1.0176 0.0606 0.000 0.9736 0.0115 0.000 
HNPA -0.0012 0.0004 0.002 -0.0011 0.0003 0.001 -0.0014 0.0004 0.000 -0.0014 0.0003 0.000 
HNSW -0.0001 0.0004 0.793    -0.0001 0.0004 0.777    
HNSE 0.0003 0.0002 0.310    0.0002 0.0003 0.521    
HNSP -0.0002 0.0003 0.562    -0.0002 0.0003 0.627    
HNSO 0.0001 0.0003 0.623    0.0002 0.0004 0.688    
HNSC -0.0019 0.0005 0.000 -0.0018 0.0004 0.000 -0.0020 0.0005 0.000 -0.0019 0.0003 0.000 
HNSX <0.0001 0.0003 0.986    <0.0001 0.0002 0.826    
HNTE -0.0001 0.0002 0.438    -0.0001 0.0002 0.403    
HNOM -0.0003 0.0002 0.123    -0.0004 0.0002 0.093    
HNDR 0.0003 0.0002 0.119    0.0004 0.0002 0.073    
HNSS 0.0001 0.0002 0.656    <0.0001 0.0002 0.965    
HNCO -0.0003 0.0003 0.271    -0.0004 0.0003 0.162    
HNFI -0.0009 0.0003 0.008 -0.0010 0.0003 0.003 -0.0009 0.0004 0.052 -0.0010 0.0005 0.030 
HNPK <0.0001 0.0001 0.817    -0.0001 0.0001 0.501    
HNNU -0.0002 0.0001 0.234    -0.0002 0.0001 0.085    
HNFE -0.0002 0.0002 0.345    -0.0002 0.0003 0.389    
HNWL 0.0003 0.0001 0.009    0.0004 0.0001 0.014    
HNWG 0.0001 0.0001 0.149    0.0002 0.0001 0.124    
Female 0.0253 0.0161 0.115    0.0314 0.0234 0.181    
Age -0.0004 0.0007 0.543    -0.0008 0.0009 0.361    
/sigma_u       0.0657 0.0084 0.000 0.0719 0.0080 0.000 
/sigma_e       0.0561 0.0040 0.000 0.0581 0.0039 0.000 
Rho       0.5781 0.0799  0.6044 0.0662  
AIC -541.55   -565.08   -332.90   -349.94   
BIC -463.29   -544.55   -254.64   -329.41   
MAE 0.0546   0.0560   0.0542   0.0534   
RMSE 0.0796   0.0848   0.0795   0.0850   
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; 
HNOM: opening mouth; HNSS: sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding tube; HNWL: weight loss; HNWG: weight gain. 
AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.3 (E) Linear mixed-effects and random-effects Tobit models using QLQ-H&N35 (South Korea). 
 Linear  Tobit 
 Full model Reduced model Full model Reduced model 
 Coefficient SE p Coefficient SE P Coefficient SE p Coefficient SE p 
Intercept 0.9002 0.0617 0.000 0.8721 0.0118 0.000 0.9561 0.0752 0.000 0.8959 0.0151 0.000 
HNPA -0.0017 0.0005 0.000 -0.0017 0.0004 0.000 -0.0019 0.0005 0.001 -0.0019 0.0005 0.000 
HNSW <0.0001 0.0005 0.996    <0.0001 0.0006 0.993    
HNSE 0.0003 0.0003 0.324    0.0003 0.0004 0.502    
HNSP -0.0003 0.0004 0.486    -0.0003 0.0005 0.572    
HNSO 0.0003 0.0004 0.544    0.0003 0.0006 0.647    
HNSC -0.0022 0.0006 0.000 -0.0022 0.0005 0.000 -0.0023 0.0007 0.000 -0.0023 0.0005 0.000 
HNSX -0.0001 0.0003 0.625    -0.0002 0.0003 0.480    
HNTE -0.0001 0.0002 0.489    -0.0001 0.0002 0.553    
HNOM -0.0005 0.0002 0.021    -0.0006 0.0003 0.050    
HNDR 0.0003 0.0003 0.242    0.0004 0.0003 0.217    
HNSS <0.0001 0.0002 0.843    -0.0002 0.0003 0.614    
HNCO -0.0005 0.0004 0.186    -0.0005 0.0004 0.139    
HNFI -0.0012 0.0004 0.003 -0.0013 0.0004 0.002 -0.0012 0.0006 0.062 -0.0012 0.0006 0.047 
HNPK -0.0001 0.0002 0.610    -0.0002 0.0002 0.401    
HNNU -0.0002 0.0002 0.297    -0.0003 0.0002 0.143    
HNFE -0.0001 0.0002 0.569    -0.0001 0.0004 0.701    
HNWL 0.0004 0.0001 0.008    0.0004 0.0002 0.031    
HNWG 0.0002 0.0001 0.145    0.0002 0.0002 0.182    
Female 0.0405 0.0200 0.043 0.0437 0.0209 0.036 0.0482 0.0294 0.102    
Age -0.0004 0.0009 0.668    -0.0009 0.0011 0.405    
/sigma_u       0.0761 0.0114 0.000 0.0892 0.0108 0.000 
/sigma_e       0.0827 0.0059 0.000 0.0836 0.0056 0.000 
Rho       0.4585 0.0924  0.5322 0.0740  
AIC -408.89   -431.10   -196.81   -213.03   
BIC -330.63   -407.16   -118.55   -192.51   
MAE 0.0730   0.0754   0.0732   0.0783   
RMSE 0.0991   0.1048   0.0987   0.1073   
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; 
HNOM: opening mouth; HNSS: sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding tube; HNWL: weight loss; HNWG: weight gain. 
AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.3 (F) Linear mixed-effects and random-effects Tobit models using QLQ-H&N35 (Japan). 
 Linear  Tobit 
 Full model Reduced model Full model Reduced model 
 Coefficient SE p Coefficient SE P Coefficient SE p Coefficient SE p 
Intercept 0.9232 0.0696 0.000 0.8735 0.0160 0.000 0.9870 0.0930 0.000 0.9045 0.0189 0.000 
HNPA -0.0016 0.0005 0.002 -0.0018 0.0005 0.000 -0.0018 0.0006 0.004 -0.0022 0.0005 0.000 
HNSW -0.0001 0.0006 0.834    -0.0001 0.0007 0.824    
HNSE 0.0001 0.0004 0.864    <0.0001 0.0004 0.927    
HNSP -0.0007 0.0005 0.195    -0.0007 0.0005 0.210    
HNSO 0.0002 0.0006 0.717    0.0002 0.0007 0.718    
HNSC -0.0022 0.0007 0.002 -0.0025 0.0005 0.000 -0.0023 0.0007 0.001 -0.0025 0.0005 0.000 
HNSX 0.0001 0.0003 0.663    0.0001 0.0003 0.832    
HNTE -0.0003 0.0002 0.154    -0.0003 0.0003 0.317    
HNOM -0.0008 0.0003 0.002 -0.0009 0.0003 0.001 -0.0010 0.0004 0.010 -0.0010 0.0004 0.006 
HNDR 0.0002 0.0003 0.370    0.0004 0.0004 0.330    
HNSS <0.0001 0.0003 0.998    -0.0001 0.0004 0.715    
HNCO -0.0005 0.0004 0.171    -0.0006 0.0004 0.153    
HNFI -0.0010 0.0005 0.027 -0.0012 0.0005 0.007 -0.0010 0.0007 0.140    
HNPK -0.0001 0.0002 0.750    -0.0001 0.0002 0.512    
HNNU -0.0003 0.0002 0.241    -0.0003 0.0002 0.105    
HNFE -0.0004 0.0004 0.263    -0.0004 0.0004 0.329    
HNWL 0.0004 0.0002 0.014 0.0004 0.0002 0.026 0.0005 0.0002 0.034    
HNWG 0.0004 0.0001 0.007 0.0003 0.0001 0.023 0.0005 0.0002 0.021    
Female 0.0140 0.0253 0.579    0.0216 0.0362 0.550    
Age -0.0007 0.0011 0.515    -0.0013 0.0014 0.347    
/sigma_u       0.1019 0.0132 0.000 0.1146 0.0125 0.000 
/sigma_e       0.0869 0.0063 0.000 0.0895 0.0060 0.000 
Rho       0.5786 0.0807  0.6212 0.0638  
AIC -356.22   -377.78   -159.06   -172.81   
BIC -277.96   -346.99   -80.80   -152.29   
MAE 0.0928   0.0973   0.0908   0.0985   
RMSE 0.1205   0.1253   0.1199   0.1304   
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; 
HNOM: opening mouth; HNSS: sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding tube; HNWL: weight loss; HNWG: weight gain. 
AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.3 (G) Linear mixed-effects and random-effects Tobit models using QLQ-H&N35 (China). 
 Linear  Tobit 
 Full model Reduced model Full model Reduced model 
 Coefficient SE p Coefficient SE P Coefficient SE p Coefficient SE P 
Intercept 0.9601 0.0830 0.000 0.9106 0.0182 0.000 1.0413 0.1169 0.000 0.9391 0.0230 0.000 
HNPA -0.0021 0.0007 0.002 -0.0023 0.0007 0.000 -0.0024 0.0007 0.001 -0.0027 0.0006 0.000 
HNSW -0.0001 0.0007 0.851    -0.0002 0.0008 0.817    
HNSE 0.0003 0.0005 0.591    0.0001 0.0005 0.821    
HNSP -0.0006 0.0006 0.354    -0.0006 0.0006 0.370    
HNSO 0.0002 0.0006 0.803    0.0002 0.0008 0.793    
HNSC -0.0033 0.0009 0.000 -0.0034 0.0008 0.000 -0.0034 0.0008 0.000 -0.0036 0.0006 0.000 
HNSX 0.0001 0.0004 0.791    <0.0001 0.0004 0.960    
HNTE -0.0003 0.0002 0.126    -0.0004 0.0003 0.255    
HNOM -0.0009 0.0004 0.018 -0.0009 0.0004 0.018 -0.0011 0.0004 0.017 -0.0011 0.0004 0.010 
HNDR 0.0003 0.0004 0.333    0.0005 0.0004 0.235    
HNSS 0.0002 0.0003 0.518    <0.0001 0.0004 0.905    
HNCO -0.0005 0.0005 0.296    -0.0007 0.0005 0.169    
HNFI -0.0014 0.0006 0.027 -0.0016 0.0006 0.006 -0.0014 0.0008 0.084 -0.0017 0.0008 0.039 
HNPK -0.0001 0.0002 0.623    -0.0002 0.0003 0.385    
HNNU -0.0003 0.0002 0.243    -0.0004 0.0002 0.110    
HNFE -0.0004 0.0005 0.463    -0.0004 0.0005 0.392    
HNWL 0.0005 0.0002 0.019 0.0005 0.0002 0.026 0.0006 0.0003 0.015 0.0006 0.0003 0.021 
HNWG 0.0005 0.0002 0.007 0.0004 0.0002 0.028 0.0006 0.0002 0.012 0.0005 0.0002 0.029 
Female 0.0231 0.0299 0.439    0.0330 0.0452 0.465    
Age -0.0009 0.0013 0.499    -0.0016 0.0018 0.349    
/sigma_u       0.1312 0.0154 0.000 0.1382 0.0145 0.000 
/sigma_e       0.0993 0.0070 0.000 0.1014 0.0068 0.000 
Rho       0.6359 0.0700  0.6501 0.0596  
AIC -273.52   -294.74   -109.41   -125.75   
BIC -195.26   -263.96   -31.15   -94.96   
MAE 0.1112   0.1150   0.1098   0.1114   
RMSE 0.1554   0.1611   0.1554   0.1617   
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; 
HNOM: opening mouth; HNSS: sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding tube; HNWL: weight loss; HNWG: weight gain. 
AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Tables A4.4 ALDVM models using QLQ-C30. 
Table A4.4 (A) ALDVM model using QLQ-C30 (England). 
 Coefficient SE P 
Component 1    
Intercept 0.8685 0.0039 0.000 
GH 0.0010 <0.0001 0.000 
PF -0.0001 <0.0001 0.000 
RF -0.0005 <0.0001 0.000 
EF 0.0007 <0.0001 0.000 
CF 0.0006 <0.0001 0.000 
SF -0.0003 <0.0001 0.000 
FA -0.0013 <0.0001 0.000 
NV 0.0005 <0.0001 0.000 
PA -0.0008 <0.0001 0.000 
DY -0.0011 <0.0001 0.000 
SL 0.0004 <0.0001 0.000 
AP -0.0002 <0.0001 0.000 
CO 0.0013 <0.0001 0.000 
DI 0.0012 <0.0001 0.000 
FI -0.0011 <0.0001 0.000 
Female 0.0398 0.0007 0.000 
Age -0.0012 <0.0001 0.000 
Component 2    
Intercept 0.3562 0.1514 0.019 
GH 0.0010 0.0007 0.144 
PF 0.0042 0.0009 0.000 
RF 0.0012 0.0007 0.082 
EF 0.0016 0.0005 0.003 
CF -0.0007 0.0007 0.290 
SF 0.0003 0.0005 0.551 
FA 0.0005 0.0007 0.541 
NV -0.0037 0.0018 0.034 
PA -0.0013 0.0006 0.044 
DY 0.0003 0.0005 0.552 
SL 0.0003 0.0004 0.487 
AP 0.0002 0.0005 0.701 
CO -0.0004 0.0003 0.271 
DI -0.0022 0.0009 0.018 
FI -0.0009 0.0004 0.017 
Female 0.0477 0.0217 0.028 
Age -0.0013 0.0010 0.211 
Probability (Component 1) 
Constant 
-1.6222 0.2222 0.000 
/lns_1 -7.0701 0.1472 0.000 
/lns_2 -2.2525 0.0872 0.000 
Sigma 1 0.0008 0.0001  
Sigma 2 0.1051 0.0092  
Probability (Component 1) 0.1649 0.0306  
Probability (Component 2) 0.8351 0.0306  
AIC -341.64   
BIC -208.59   
MAE 0.0666   
RMSE 0.0943   
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive 
functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; DY: dyspnoea; SL: insomnia; 
AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC:  
Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.4 (B) ALDVM model using QLQ-C30 (Netherlands). 
 Coefficient SE P 
Component 1    
Intercept 0.9311 0.0023 0.000 
GH 0.0003 <0.0001 0.000 
PF 0.0025 <0.0001 0.000 
RF 0.0002 <0.0001 0.000 
EF -0.0011 <0.0001 0.000 
CF -0.0008 <0.0001 0.000 
SF 0.0008 <0.0001 0.000 
FA -0.0049 <0.0001 0.000 
NV 0.0017 <0.0001 0.000 
PA -0.0017 <0.0001 0.000 
DY -0.0034 <0.0001 0.000 
SL 0.0006 <0.0001 0.000 
AP -0.0004 <0.0001 0.000 
CO 0.0001 <0.0001 0.000 
DI -0.0040 <0.0001 0.000 
FI 0.0005 <0.0001 0.000 
Female 0.0313 0.0004 0.000 
Age -0.0013 <0.0001 0.000 
Component 2    
Intercept 0.8319 0.0553 0.000 
GH 0.0009 0.0007 0.168 
PF -0.0008 0.0007 0.238 
RF -0.0002 0.0001 0.244 
EF 0.0013 0.0003 0.000 
CF 0.0005 0.0004 0.148 
SF -0.0008 0.0002 0.000 
FA 0.0002 0.0004 0.594 
NV -0.0009 0.0003 0.001 
PA -0.0003 0.0003 0.219 
DY -0.0007 0.0003 0.011 
SL -0.0013 0.0003 0.000 
AP 0.0006 0.0002 0.015 
CO 0.0002 0.0002 0.325 
DI -0.0002 0.0004 0.553 
FI -0.0003 0.0003 0.363 
Female -0.0090 0.0166 0.585 
Age -0.0005 0.0008 0.563 
Component 3    
Intercept -0.5478 0.3278 0.095 
GH 0.0034 0.0015 0.019 
PF 0.0087 0.0014 0.000 
RF 0.0022 0.0010 0.029 
EF 0.0054 0.0016 0.001 
CF -0.0010 0.0015 0.514 
SF -0.0014 0.0013 0.279 
FA 0.0036 0.0015 0.018 
NV -0.0117 0.0022 0.000 
PA -0.0012 0.0009 0.200 
DY 0.0034 0.0013 0.009 
SL 0.0016 0.0010 0.104 
AP 0.0008 0.0011 0.469 
CO -0.0003 0.0008 0.669 
DI -0.0026 0.0018 0.158 
FI -0.0028 0.0009 0.003 
Female 0.0634 0.0501 0.205 
Age -0.0014 0.0021 0.504 
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Table A4.4 (B) (cont.) ALDVM model using QLQ-C30 (Netherlands). 
 Coefficient SE P 
Probability (Component 1) 
Constant 
-1.4306 0.3064 0.000 
Probability (Component 2) 
Constant 
-0.2280 0.3213 0.478 
/lns_1 -9.9034 0.4471 0.000 
/lns_2 -3.7173 0.2172 0.000 
/lns_3 -2.0715 0.1109 0.000 
Sigma 1 <0.0001 <0.0001  
Sigma 2 0.0243 0.0053  
Sigma 3 0.1260 0.0140  
Probability (Component 1) 0.1175 0.0256  
Probability (Component 2) 0.3911 0.0689  
Probability (Component 3) 0.4913 0.0738  
AIC -383.64   
BIC -192.59   
MAE 0.0872   
RMSE 0.1196   
 
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive 
functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; DY: dyspnoea; SL: insomnia; 
AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC:  
Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.4 (C) ALDVM model using QLQ-C30 (Canada). 
 Coefficient SE P 
Component 1    
Intercept 0.7767 0.0412 0.000 
GH 0.0007 0.0003 0.043 
PF 0.0010 0.0002 0.000 
RF -0.0001 0.0001 0.252 
EF 0.0014 0.0002 0.000 
CF -0.0003 0.0001 0.018 
SF -0.0005 0.0002 0.024 
FA 0.0013 0.0002 0.000 
NV -0.0012 0.0002 0.000 
PA -0.0012 0.0001 0.000 
DY 0.0007 0.0002 0.000 
SL -0.0008 0.0002 0.000 
AP 0.0005 0.0001 0.000 
CO -0.0004 0.0001 0.000 
DI -0.0012 0.0002 0.000 
FI -0.0003 0.0002 0.212 
Female -0.0188 0.0054 0.001 
Age -0.0006 0.0005 0.215 
Component 2    
Intercept 0.3011 0.1806 0.095 
GH 0.0001 0.0005 0.789 
PF 0.0035 0.0011 0.001 
RF 0.0029 0.0008 0.000 
EF 0.0005 0.0006 0.422 
CF 0.0006 0.0006 0.355 
SF -0.0006 0.0005 0.200 
FA 0.0001 0.0008 0.926 
NV -0.0041 0.0014 0.003 
PA -0.0017 0.0008 0.028 
DY 0.0004 0.0006 0.478 
SL 0.0002 0.0003 0.507 
AP 0.0009 0.0005 0.071 
CO 0.0005 0.0003 0.115 
DI -0.0016 0.0010 0.099 
FI -0.0006 0.0004 0.174 
Female 0.0453 0.0210 0.031 
Age -0.0010 0.0010 0.330 
Probability (Component 1) 
Constant 
-0.4538 0.3152 0.150 
/lns_1 -4.3653 0.4044 0.000 
/lns_2 -2.5282 0.1004 0.000 
Sigma 1 0.0127 0.0051  
Sigma 2 0.0798 0.0080  
Probability (Component 1) 0.3884 0.0749  
Probability (Component 2) 0.6115 0.0749  
AIC -547.84   
BIC -414.78   
MAE 0.0624   
RMSE 0.0921   
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive 
functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; DY: dyspnoea; SL: insomnia; 
AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC:  
Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.4 (D) ALDVM model using QLQ-C30 (Uruguay). 
 Full model Reduced model 
 Coefficient SE P Coefficient SE P 
Component 1       
Intercept 0.6678 0.1005 0.000 0.6431 0.0563 0.000 
GH 0.0008 0.0004 0.051 0.0012 0.0004 0.001 
PF 0.0023 0.0006 0.000 0.0027 0.0006 0.000 
RF 0.0009 0.0004 0.047    
EF 0.0003 0.0003 0.311    
CF -0.0001 0.0005 0.757    
SF 0.0002 0.0002 0.454    
FA 0.0004 0.0005 0.353    
NV -0.0019 0.0008 0.023 -0.0016 0.0008 0.040 
PA -0.0010 0.0004 0.017 -0.0011 0.0005 0.020 
DY 0.0001 0.0003 0.637    
SL -0.0002 0.0003 0.448    
AP 0.0004 0.0003 0.124    
CO 0.0001 0.0002 0.738    
DI -0.0005 0.0007 0.464    
FI -0.0007 0.0002 0.005 -0.0007 0.0002 0.001 
Female 0.0375 0.0150 0.013 0.0373 0.0142 0.009 
Age -0.0013 0.0007 0.069    
/lns_1 -2.6205 0.0892 0.000 -2.5726 0.0898 0.000 
Sigma 1 0.0728 0.0065  0.0763 0.0069  
AIC -359.02   -362.34   
BIC -294.20   -335.05   
MAE 0.0428   0.0455   
RMSE 0.0638   0.0670   
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive 
functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; DY: dyspnoea; SL: insomnia; 
AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC:  
Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.4 (E) ALDVM model using QLQ-C30 (South Korea). 
 Full model Reduced model 
 Coefficient SE P Coefficient SE P 
Component 1       
Intercept 0.4606 0.1239 0.000 0.4554 0.0497 0.000 
GH 0.0014 0.0005 0.006 0.0017 0.0005 0.000 
PF 0.0029 0.0007 0.000 0.0034 0.0006 0.000 
RF 0.0008 0.0005 0.108    
EF 0.0008 0.0004 0.069    
CF -0.0003 0.0005 0.559    
SF 0.0002 0.0003 0.567    
FA 0.0006 0.0006 0.318    
NV -0.0021 0.0011 0.058    
PA -0.0010 0.0005 0.042 -0.0014 0.0005 0.011 
DY 0.0002 0.0004 0.673    
SL -0.0001 0.0003 0.704    
AP 0.0004 0.0003 0.215    
CO <0.0001 0.0003 0.961    
DI -0.0005 0.0007 0.423    
FI -0.0009 0.0003 0.005 -0.0009 0.0002 0.000 
Female 0.0417 0.0188 0.027 0.0390 0.0182 0.032 
Age -0.0012 0.0011 0.262    
/lns_1 -2.3405 0.0729 0.000 -2.3013 0.0736 0.000 
Sigma 1 0.0963 0.0070  0.1001 0.0074  
AIC -232.56   -241.32   
BIC -167.74   -217.44   
MAE 0.0655   0.0679   
RMSE 0.0835   0.0866   
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive 
functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; DY: dyspnoea; SL: insomnia; 
AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC:  
Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.4 (F) ALDVM model using QLQ-C30 (Japan). 
 Full model Reduced model 
 Coefficient SE P Coefficient SE P 
Component 1       
Intercept 0.2714 0.1365 0.047 0.2000 0.0637 0.002 
GH 0.0018 0.0005 0.001 0.0022 0.0005 0.000 
PF 0.0038 0.0008 0.000 0.0042 0.0008 0.000 
RF 0.0007 0.0005 0.160    
EF 0.0017 0.0005 0.000 0.0017 0.0004 0.000 
CF -0.0002 0.0005 0.699    
SF 0.0002 0.0004 0.499    
FA 0.0009 0.0006 0.129    
NV -0.0029 0.0012 0.016 -0.0026 0.0011 0.021 
PA -0.0010 0.0005 0.062    
DY 0.0002 0.0004 0.576    
SL -0.0004 0.0003 0.271    
AP 0.0003 0.0004 0.372    
CO 0.0001 0.0004 0.745    
DI -0.0005 0.0008 0.510    
FI -0.0007 0.0003 0.025 -0.0009 0.0003 0.006 
Female 0.0297 0.0206 0.150    
Age -0.0014 0.0011 0.210    
/lns_1 -2.2743 0.0693 0.000 -2.2276 0.0710 0.000 
Sigma 1 0.1029 0.0071  0.1078 0.0076  
AIC -212.02   -217.93   
BIC -147.20   -194.05   
MAE 0.0720   0.0746   
RMSE 0.0898   0.0939   
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive 
functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; DY: dyspnoea; SL: insomnia; 
AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC:  
Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.4 (G) ALDVM model using QLQ-C30 (China). 
 Coefficient SE P 
Component 1    
Intercept 0.7636 0.0480 0.000 
GH 0.0018 0.0004 0.000 
PF 0.0014 0.0005 0.008 
RF 0.0000 0.0001 0.517 
EF 0.0009 0.0004 0.026 
CF <0.0001 0.0001 0.939 
SF -0.0009 0.0001 0.000 
FA 0.0010 0.0002 0.000 
NV -0.0030 0.0003 0.000 
PA -0.0015 0.0004 0.000 
DY 0.0019 0.0003 0.000 
SL -0.0021 0.0003 0.000 
AP 0.0011 0.0001 0.000 
CO -0.0008 0.0001 0.000 
DI -0.0017 0.0002 0.000 
FI -0.0001 0.0001 0.642 
Female 0.0086 0.0213 0.687 
Age -0.0010 0.0006 0.120 
Component 2    
Intercept -0.2102 0.4200 0.617 
GH 0.0013 0.0010 0.201 
PF 0.0079 0.0021 0.000 
RF 0.0018 0.0009 0.039 
EF 0.0022 0.0009 0.018 
CF 0.0009 0.0010 0.396 
SF -0.0007 0.0006 0.219 
FA <0.0001 0.0014 0.977 
NV -0.0069 0.0027 0.010 
PA -0.0011 0.0014 0.401 
DY 0.0011 0.0012 0.358 
SL 0.0008 0.0006 0.213 
AP 0.0017 0.0008 0.035 
CO 0.0005 0.0005 0.360 
DI -0.0004 0.0011 0.732 
FI -0.0015 0.0005 0.001 
Female 0.0369 0.0301 0.220 
Age -0.0014 0.0017 0.435 
Component 3    
Intercept 1.0463 0.0032 0.000 
GH <0.0001 <0.0001 0.037 
PF <0.0001 <0.0001 0.657 
RF 0.0001 <0.0001 0.000 
EF 0.0001 <0.0001 0.000 
CF -0.0002 <0.0001 0.000 
SF 0.0003 <0.0001 0.000 
FA -0.0005 <0.0001 0.000 
NV -0.0052 <0.0001 0.000 
PA -0.0060 <0.0001 0.000 
DY -0.0026 <0.0001 0.000 
SL -0.0001 <0.0001 0.000 
AP -0.0008 <0.0001 0.000 
CO -0.0007 <0.0001 0.000 
DI -0.0043 <0.0001 0.000 
FI -0.0002 <0.0001 0.000 
Female -0.1055 0.0005 0.000 
Age -0.0002 <0.0001 0.000 
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Table A4.4 (G) (cont.) ALDVM model using QLQ-C30 (China). 
 Coefficient SE P 
Probability (Component 1) 
Constant 
0.4192 0.3344 0.210 
Probability (Component 2) 
Constant 
1.4316 0.2279 0.000 
/lns_1 -4.4991 0.4309 0.000 
/lns_2 -2.2115 0.0974 0.000 
/lns_3 -7.5695 0.1339 0.000 
Sigma 1 0.0111 0.0048  
Sigma 2 0.1095 0.0107  
Sigma 3 0.0005 0.0001  
Probability (Component 1) 0.2268 0.0561  
Probability (Component 2) 0.6241 0.0575  
Probability (Component 3) 0.1491 0.0273  
AIC -313.69   
BIC -112.40   
MAE 0.0856   
RMSE 0.1187   
GH: global health status; PF: physical functioning; RF: role functioning; EF: emotional functioning; CF: cognitive 
functioning; SF: social functioning; FA: fatigue; NV: nausea and vomiting; PA: pain; DY: dyspnoea; SL: insomnia; 
AP: appetite loss; CO: constipation; DI: diarrhoea; FI: financial problems. AIC: Akaike Information Criterion; BIC: 
Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Tables A4.5 ALDVM models using QLQ-H&N35. 
Table A4.5 (A) ALDVM model using QLQ-H&N35 (England). 
 Coefficient SE P 
Component 1    
Intercept 1.0587 0.0548 0.000 
HNPA -0.0038 0.0007 0.000 
HNSW -0.0004 0.0006 0.488 
HNSE 0.0002 0.0004 0.570 
HNSP -0.0002 0.0005 0.667 
HNSO 0.0003 0.0006 0.616 
HNSC -0.0035 0.0009 0.000 
HNSX 0.0009 0.0003 0.002 
HNTE <0.0001 0.0003 0.986 
HNOM -0.0005 0.0003 0.121 
HNDR -0.0002 0.0003 0.564 
HNSS <0.0001 0.0003 0.902 
HNCO -0.0008 0.0004 0.079 
HNFI -0.0012 0.0007 0.083 
HNPK -0.0005 0.0002 0.019 
HNNU -0.0002 0.0002 0.242 
HNFE -0.0003 0.0003 0.449 
HNWL 0.0005 0.0003 0.054 
HNWG 0.0004 0.0001 0.006 
Female 0.0407 0.0228 0.075 
Age -0.0012 0.0008 0.142 
Component 2    
Intercept 0.5542 0.0013 0.000 
HNPA -0.0009 <0.0001 0.000 
HNSW -0.0038 <0.0001 0.000 
HNSE 0.0024 <0.0001 0.000 
HNSP 0.0017 <0.0001 0.000 
HNSO 0.0072 <0.0001 0.000 
HNSC -0.0024 <0.0001 0.000 
HNSX -0.0017 <0.0001 0.000 
HNTE -0.0018 <0.0001 0.000 
HNOM 0.0010 <0.0001 0.000 
HNDR 0.0033 <0.0001 0.000 
HNSS -0.0016 <0.0001 0.000 
HNCO -0.0068 <0.0001 0.000 
HNFI -0.0049 <0.0001 0.000 
HNPK -0.0011 <0.0001 0.000 
HNNU -0.0037 <0.0001 0.000 
HNFE -0.0019 <0.0001 0.000 
HNWL 0.0027 <0.0001 0.000 
HNWG 0.0001 <0.0001 0.000 
Female 0.2872 0.0004 0.000 
Age 0.0020 <0.0001 0.000 
Component 3    
Intercept 0.9462 0.0019 0.000 
HNPA -0.0001 <0.0001 0.000 
HNSW 0.0001 <0.0001 0.000 
HNSE -0.0001 <0.0001 0.000 
HNSP 0.0006 <0.0001 0.000 
HNSO 0.0010 <0.0001 0.000 
HNSC -0.0023 <0.0001 0.000 
HNSX -0.0003 <0.0001 0.000 
HNTE 0.0007 <0.0001 0.000 
HNOM -0.0008 <0.0001 0.000 
HNDR -0.0003 <0.0001 0.000 
HNSS -0.0006 <0.0001 0.000 
HNCO -0.0010 <0.0001 0.000 
HNFI -0.0020 <0.0001 0.000 
HNPK 0.0005 <0.0001 0.000 
HNNU 0.0003 <0.0001 0.000 
283 
 
Table A4.5 (A) (cont.) ALDVM model using QLQ-H&N35 (England). 
 Coefficient SE P 
HNFE -0.0002 <0.0001 0.000 
HNWL <0.0001 <0.0001 0.000 
HNWG -0.0006 <0.0001 0.000 
Female -0.0394 0.0002 0.000 
Age -0.0005 <0.0001 0.000 
Probability (Component 1) 
Constant 
1.8421 0.2146 0.000 
Probability (Component 2) 
Constant 
-0.0618 0.3030 0.838 
/lns_1 -2.4564 0.0695 0.000 
/lns_2 -8.2578 0.1251 0.000 
/lns_3 -10.0190 0.3320 0.000 
Sigma 1 0.0857 0.0060  
Sigma 2 0.0003 <0.0001  
Sigma 3 <0.0001 <0.0001  
Probability (Component 1) 0.7648 0.0295  
Probability (Component 2) 0.1139 0.0233  
Probability (Component 3) 0.1212 0.0228  
AIC -566.40   
BIC -365.64   
MAE 0.0834   
RMSE 0.1133   
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social eating; HNSC: 
trouble with social contact; HNSX: less sexuality; HNTE: teeth; HNOM: opening mouth; HNSS: sticky saliva; HNCO: coughing; 
HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding tube; HNWL: weight loss; HNWG: weight 
gain. AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean 
Square Error; SE: standard error. 
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Table A4.5 (B) ALDVM model using QLQ-H&N35 (Netherlands). 
 Full model Reduced model 
 Coefficient SE p Coefficient SE P 
Component 1       
Intercept 1.0619 0.0927 0.000 0.9376 0.0228 0.000 
HNPA -0.0035 0.0008 0.000 -0.0037 0.0010 0.000 
HNSW -0.0003 0.0009 0.737    
HNSE 0.0007 0.0005 0.198    
HNSP <0.0001 0.0007 0.993    
HNSO 0.0020 0.0010 0.037    
HNSC -0.0059 0.0014 0.000 -0.0046 0.0011 0.000 
HNSX -0.0003 0.0007 0.625    
HNTE 0.0001 0.0003 0.847    
HNOM -0.0006 0.0004 0.126    
HNDR 0.0002 0.0004 0.533    
HNSS -0.0004 0.0004 0.343    
HNCO -0.0011 0.0007 0.118    
HNFI -0.0023 0.0010 0.022 -0.0026 0.0011 0.019 
HNPK -0.0007 0.0003 0.009 -0.0008 0.0003 0.017 
HNNU -0.0005 0.0003 0.141    
HNFE -0.0003 0.0004 0.409    
HNWL 0.0008 0.0003 0.018    
HNWG 0.0007 0.0003 0.013    
Female 0.1000 0.0354 0.005 0.1207 0.0408 0.003 
Age -0.0023 0.0014 0.106    
/lns_1 -1.8964 0.0963 0.000 -1.8170 0.1182 0.000 
Sigma 1 0.1501 0.0144  0.1625 0.0192  
AIC -65.57   -65.22   
BIC 9.29   -41.27   
MAE 0.0968   0.0995   
RMSE 0.1296   0.1411   
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social 
eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; HNOM: opening mouth; HNSS: 
sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding 
tube; HNWL: weight loss; HNWG: weight gain. AIC: Akaike Information Criterion; BIC: Bayesian Information 
Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.5 (C) ALDVM model using QLQ-H&N35 (Canada). 
 Coefficient SE P 
Component 1    
Intercept 0.8644 0.0200 0.000 
HNPA -0.0003 0.0003 0.282 
HNSW -0.0006 0.0006 0.352 
HNSE -0.0009 0.0002 0.000 
HNSP 0.0018 0.0003 0.000 
HNSO 0.0012 0.0002 0.000 
HNSC -0.0064 0.0004 0.000 
HNSX 0.0003 0.0001 0.021 
HNTE -0.0005 0.0002 0.003 
HNOM -0.0004 0.0002 0.047 
HNDR -0.0001 0.0003 0.844 
HNSS 0.0003 0.0002 0.106 
HNCO 0.0002 0.0002 0.321 
HNFI -0.0119 0.0006 0.000 
HNPK -0.0005 0.0001 0.001 
HNNU <0.0001 0.0001 0.828 
HNFE 0.0009 0.0003 0.000 
HNWL -0.0004 0.0001 0.000 
HNWG -0.0002 0.0001 0.083 
Female 0.0489 0.0113 0.000 
Age 0.0008 0.0003 0.010 
Component 2    
Intercept 0.9904 0.0171 0.000 
HNPA -0.0024 0.0003 0.000 
HNSW <0.0001 0.0002 0.797 
HNSE <0.0001 0.0001 0.783 
HNSP -0.0005 0.0002 0.023 
HNSO -0.0003 0.0003 0.291 
HNSC 0.0009 0.0003 0.007 
HNSX 0.0004 0.0001 0.002 
HNTE <0.0001 0.0001 0.861 
HNOM -0.0003 0.0001 0.018 
HNDR -0.0001 0.0001 0.386 
HNSS -0.0005 0.0002 0.004 
HNCO -0.0009 0.0002 0.000 
HNFI 0.0006 0.0004 0.124 
HNPK -0.0002 0.0001 0.003 
HNNU <0.0001 0.0001 0.592 
HNFE -0.0012 0.0001 0.000 
HNWL 0.0004 0.0001 0.000 
HNWG 0.0001 0.0001 0.050 
Female -0.0060 0.0074 0.413 
Age -0.0008 0.0003 0.007 
Component 3    
Intercept 0.5233 0.0915 0.000 
HNPA -0.0065 0.0009 0.000 
HNSW 0.0006 0.0005 0.205 
HNSE 0.0029 0.0004 0.000 
HNSP 0.0009 0.0010 0.359 
HNSO 0.0046 0.0011 0.000 
HNSC -0.0028 0.0003 0.000 
HNSX -0.0013 0.0005 0.013 
HNTE 0.0009 0.0004 0.021 
HNOM 0.0010 0.0005 0.040 
HNDR 0.0017 0.0009 0.067 
HNSS 0.0005 0.0003 0.089 
HNCO -0.0039 0.0005 0.000 
HNFI -0.0002 0.0003 0.579 
HNPK -0.0006 0.0002 0.004 
HNNU -0.0008 0.0002 0.000 
HNFE 0.0026 0.0003 0.000 
HNWL 0.0007 0.0005 0.159 
HNWG 0.0013 0.0003 0.000 
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Table A4.5 (C) (cont.) ALDVM model using QLQ-H&N35 (Canada). 
 Coefficient SE P 
Female 0.1885 0.0374 0.000 
Age 0.0002 0.0007 0.727 
Probability (Component 1) 
Constant 
0.7863 0.2810 0.005 
Probability (Component 2) 
Constant 
0.9643 0.2808 0.001 
/lns_1 -3.5098 0.1262 0.000 
/lns_2 -3.8609 0.0964 0.000 
/lns_3 -3.5452 0.1148 0.000 
Sigma 1 0.0299 0.0038  
Sigma 2 0.0210 0.0020  
Sigma 3 0.0289 0.0033  
Probability (Component 1) 0.3773 0.0515  
Probability (Component 2) 0.4508 0.0540  
Probability (Component 3) 0.1719 0.0361  
AIC -535.52   
BIC -304.14   
MAE 0.0758   
RMSE 0.1097   
 
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social 
eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; HNOM: opening mouth; HNSS: 
sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding 
tube; HNWL: weight loss; HNWG: weight gain. AIC: Akaike Information Criterion; BIC: Bayesian Information 
Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.5 (D) ALDVM model using QLQ-H&N35 (Uruguay). 
 Coefficient SE P 
Component 1    
Intercept 1.0471 0.0282 0.000 
HNPA -0.0010 0.0003 0.000 
HNSW 0.0001 0.0002 0.718 
HNSE -0.0003 0.0002 0.095 
HNSP 0.0002 0.0002 0.390 
HNSO 0.0005 0.0003 0.067 
HNSC -0.0008 0.0005 0.102 
HNSX <0.0001 0.0001 0.898 
HNTE 0.0001 0.0001 0.142 
HNOM -0.0008 0.0001 0.000 
HNDR 0.0001 0.0001 0.668 
HNSS -0.0002 0.0002 0.200 
HNCO -0.0003 0.0002 0.153 
HNFI -0.0009 0.0002 0.000 
HNPK -0.0002 0.0001 0.076 
HNNU -0.0001 0.0001 0.403 
HNFE -0.0004 0.0002 0.127 
HNWL <0.0001 0.0001 0.886 
HNWG 0.0001 0.0001 0.063 
Female -0.0045 0.0106 0.671 
Age -0.0008 0.0004 0.043 
Component 2    
Intercept 0.8676 0.1005 0.000 
HNPA -0.0031 0.0012 0.010 
HNSW 0.0036 0.0008 0.000 
HNSE 0.0053 0.0006 0.000 
HNSP -0.0067 0.0012 0.000 
HNSO 0.0014 0.0006 0.018 
HNSC 0.0015 0.0008 0.069 
HNSX -0.0015 0.0004 0.000 
HNTE -0.0019 0.0006 0.002 
HNOM 0.0007 0.0006 0.207 
HNDR 0.0028 0.0008 0.000 
HNSS -0.0036 0.0009 0.000 
HNCO -0.0006 0.0006 0.354 
HNFI 0.0010 0.0008 0.231 
HNPK -0.0033 0.0005 0.000 
HNNU -0.0009 0.0003 0.003 
HNFE 0.0056 0.0013 0.000 
HNWL -0.0035 0.0008 0.000 
HNWG -0.0012 0.0004 0.006 
Female 0.1739 0.0324 0.000 
Age 0.0015 0.0021 0.468 
Component 3    
Intercept 0.9980 <0.0001 0.000 
HNPA -0.0012 <0.0001 0.000 
HNSW 0.0005 <0.0001 0.000 
HNSE -0.0004 <0.0001 0.000 
HNSP -0.0005 <0.0001 0.000 
HNSO -0.0002 <0.0001 0.000 
HNSC -0.0012 <0.0001 0.000 
HNSX -0.0001 <0.0001 0.000 
HNTE -0.0001 <0.0001 0.000 
HNOM 0.0001 <0.0001 0.000 
HNDR -0.0001 <0.0001 0.000 
HNSS -0.0002 <0.0001 0.000 
HNCO -0.0002 <0.0001 0.000 
HNFI -0.0011 <0.0001 0.000 
HNPK -0.0004 <0.0001 0.000 
HNNU -0.0009 <0.0001 0.000 
HNFE -0.0011 <0.0001 0.000 
HNWL 0.0001 <0.0001 0.000 
HNWG 0.0003 <0.0001 0.000 
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Table A4.5 (D) ALDVM model using QLQ-H&N35 (Uruguay). 
 Coefficient SE P 
Female 0.0398 0.0001 0.000 
Age -0.0001 <0.0001 0.000 
Probability (Component 1) 
Constant 
1.7280 0.2565 0.000 
Probability (Component 2) 
Constant 
0.5257 0.3090 0.089 
/lns_1 -3.3359 0.0801 0.000 
/lns_2 -3.0249 0.1533 0.000 
/lns_3 -9.3988 0.2156 0.000 
Sigma 1 0.0356 0.0028  
Sigma 2 0.0486 0.0074  
Sigma 3 0.0001 <0.0001  
Probability (Component 1) 0.6765 0.0592  
Probability (Component 2) 0.2033 0.0517  
Probability (Component 3) 0.1202 0.0242  
AIC -504.67   
BIC -283.49   
MAE 0.0689   
RMSE 0.1167   
 
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social 
eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; HNOM: opening mouth; HNSS: 
sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding 
tube; HNWL: weight loss; HNWG: weight gain. AIC: Akaike Information Criterion; BIC: Bayesian Information 
Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.5 (E) ALDVM model using QLQ-H&N35 (South Korea). 
 Full model Reduced model 
 Coefficient SE P Coefficient SE P 
Component 1       
Intercept 0.9865 0.0786 0.000 0.9135 0.0178 0.000 
HNPA -0.0024 0.0006 0.000 -0.0025 0.0007 0.000 
HNSW <0.0001 0.0006 0.954    
HNSE 0.0005 0.0004 0.189    
HNSP <0.0001 0.0005 0.915    
HNSO 0.0009 0.0006 0.145    
HNSC -0.0038 0.0009 0.000 -0.0031 0.0007 0.000 
HNSX -0.0003 0.0004 0.416    
HNTE <0.0001 0.0002 0.883    
HNOM -0.0006 0.0003 0.032    
HNDR 0.0001 0.0003 0.751    
HNSS -0.0001 0.0003 0.837    
HNCO -0.0007 0.0005 0.112    
HNFI -0.0016 0.0006 0.009 -0.0017 0.0007 0.013 
HNPK -0.0005 0.0002 0.006 -0.0006 0.0002 0.019 
HNNU -0.0003 0.0002 0.208    
HNFE -0.0001 0.0002 0.675    
HNWL 0.0006 0.0002 0.009    
HNWG 0.0004 0.0002 0.034    
Female 0.0758 0.0240 0.002 0.0863 0.0286 0.003 
Age -0.0013 0.0011 0.255    
/lns_1 -2.2163 0.0757 0.000 -2.1486 0.0791 0.000 
Sigma 1 0.1090 0.0082  0.1166 0.0092  
AIC -172.09   -178.06   
BIC -97.23   -154.12   
MAE 0.0712   0.0753   
RMSE 0.0936   0.1001   
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social 
eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; HNOM: opening mouth; HNSS: 
sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding 
tube; HNWL: weight loss; HNWG: weight gain. AIC: Akaike Information Criterion; BIC: Bayesian Information 
Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.5 (F) ALDVM model using QLQ-H&N35 (Japan). 
 Full model Reduced model 
 Coefficient SE P Coefficient SE P 
Component 1       
Intercept 1.0271 0.0866 0.000 0.9079 0.0254 0.000 
HNPA -0.0026 0.0007 0.000 -0.0029 0.0008 0.000 
HNSW <0.0001 0.0008 0.981    
HNSE 0.0004 0.0005 0.449    
HNSP -0.0003 0.0006 0.588    
HNSO 0.0015 0.0008 0.075 0.0015 0.0007 0.028 
HNSC -0.0044 0.0011 0.000 -0.0046 0.0010 0.000 
HNSX -0.0002 0.0004 0.628    
HNTE <0.0001 0.0003 0.962    
HNOM -0.0009 0.0004 0.014 -0.0010 0.0004 0.006 
HNDR <0.0001 0.0003 0.937    
HNSS -0.0002 0.0004 0.610    
HNCO -0.0009 0.0005 0.101    
HNFI -0.0017 0.0008 0.028 -0.0018 0.0008 0.027 
HNPK -0.0007 0.0002 0.002 -0.0008 0.0003 0.002 
HNNU -0.0003 0.0003 0.178    
HNFE -0.0001 0.0004 0.713    
HNWL 0.0006 0.0003 0.027    
HNWG 0.0006 0.0002 0.005 0.0005 0.0002 0.019 
Female 0.0626 0.0283 0.027 0.0775 0.0322 0.016 
Age -0.0017 0.0013 0.178    
/lns_1 -2.0621 0.0682 0.000 -2.0217 0.0705 0.000 
Sigma 1 0.1272 0.0087  0.1324 0.0093  
AIC -119.68   -129.03   
BIC -44.82   -94.83   
MAE 0.0864   0.0899   
RMSE 0.1100   0.1144   
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social 
eating; HNSC: trouble with social contact; HNSX: less sexuality; HNTE: teeth; HNOM: opening mouth; HNSS: 
sticky saliva; HNCO: coughing; HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding 
tube; HNWL: weight loss; HNWG: weight gain. AIC: Akaike Information Criterion; BIC: Bayesian Information 
Criterion; MAE: Mean Absolute Error; RMSE: Root Mean Square Error; SE: standard error. 
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Table A4.5 (G) ALDVM model using QLQ-H&N35 (China). 
 Coefficient SE P 
Component 1    
Intercept 0.9966 0.0024 0.000 
HNPA -0.0021 <0.0001 0.000 
HNSW 0.0019 <0.0001 0.000 
HNSE -0.0003 <0.0001 0.000 
HNSP 0.0013 <0.0001 0.000 
HNSO <0.0001 <0.0001 0.925 
HNSC -0.0012 <0.0001 0.000 
HNSX -0.0008 <0.0001 0.000 
HNTE 0.0001 <0.0001 0.000 
HNOM -0.0020 <0.0001 0.000 
HNDR 0.0003 <0.0001 0.000 
HNSS -0.0020 <0.0001 0.000 
HNCO -0.0006 <0.0001 0.000 
HNFI -0.0178 <0.0001 0.000 
HNPK 0.0001 <0.0001 0.000 
HNNU -0.0001 <0.0001 0.000 
HNFE -0.0019 <0.0001 0.000 
HNWL -0.0006 <0.0001 0.000 
HNWG -0.0004 <0.0001 0.000 
Female 0.0291 0.0008 0.000 
Age 0.0007 <0.0001 0.000 
Component 2    
Intercept 1.0846 0.1082 0.000 
HNPA -0.0035 0.0011 0.002 
HNSW 0.0003 0.0012 0.778 
HNSE 0.0010 0.0006 0.128 
HNSP -0.0009 0.0009 0.320 
HNSO 0.0025 0.0011 0.023 
HNSC -0.0075 0.0016 0.000 
HNSX -0.0003 0.0007 0.610 
HNTE -0.0001 0.0004 0.798 
HNOM -0.0010 0.0005 0.040 
HNDR -0.0007 0.0004 0.085 
HNSS 0.0006 0.0005 0.213 
HNCO -0.0013 0.0008 0.091 
HNFI -0.0015 0.0009 0.107 
HNPK -0.0010 0.0003 0.003 
HNNU -0.0005 0.0004 0.169 
HNFE 0.0006 0.0006 0.280 
HNWL 0.0013 0.0004 0.001 
HNWG 0.0012 0.0003 0.000 
Female 0.0799 0.0356 0.025 
Age -0.0022 0.0016 0.185 
Probability (Component 1) 
Constant 
-1.3532 0.1775 0.000 
/lns_1 -6.5865 0.1233 0.000 
/lns_2 -1.8746 0.0788 0.000 
Sigma 1 0.0014 0.0002  
Sigma 2 0.1534 0.0121  
Probability (Component 1) 0.2053 0.0290  
Probability (Component 2) 0.7946 0.0290  
AIC -203.65   
BIC -50.53   
MAE 0.1022   
RMSE 0.1375    
HNPA: pain; HNSW: swallowing; HNSE: senses problems; HNSP: speech problems; HNSO: trouble with social eating; HNSC: 
trouble with social contact; HNSX: less sexuality; HNTE: teeth; HNOM: opening mouth; HNSS: sticky saliva; HNCO: coughing; 
HNFI: felt ill; HNPK: pain killers; HNNU: nutritional supplements; HNFE: feeding tube; HNWL: weight loss; HNWG: weight 
gain. AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; MAE: Mean Absolute Error; RMSE: Root Mean 
Square Error; SE: standard error. 
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APPENDIX TO CHAPTER 5 
Table A5.1 CHEERS checklist - items to include when reporting economic evaluations 
of health interventions. 
Section/item Item No Recommendation Reported on page No 
Title and abstract 
Title 1 Identify the study as an economic evaluation or use more 
specific terms such as “cost-effectiveness analysis”, and 
describe the interventions compared. 
Page 134 
Abstract 2 Provide a structured summary of objectives, perspective, 
setting, methods (including study design and inputs), 
results (including base case and uncertainty analyses), 
and conclusions. 
Not available 
Introduction 
Background and 
objectives 
3 Provide an explicit statement of the broader context for 
the study. 
Pages 134-135 
Present the study question and its relevance for health 
policy or practice decisions. 
Page 135 
Methods 
Target population and 
subgroups 
4 Describe characteristics of the base case population and 
subgroups analysed, including why they were chosen. 
Page 136 
Setting and location 5 State relevant aspects of the system(s) in which the 
decision(s) need(s) to be made. 
Page 136 
Study perspective 6 Describe the perspective of the study and relate this to the 
costs being evaluated. 
Pages 145-146 
Comparators 7 Describe the interventions or strategies being compared 
and state why they were chosen. 
Pages 136-137 
Time horizon 8 State the time horizon(s) over which costs and 
consequences are being evaluated and say why 
appropriate. 
Page 138 
Discount rate 9 Report the choice of discount rate(s) used for costs and 
outcomes and say why appropriate. 
Page 150 
Choice of health 
outcomes 
10 Describe what outcomes were used as the measure(s) of 
benefit in the evaluation and their relevance for the type 
of analysis performed. 
Page 150 
Measurement of 
effectiveness 
11a Single study-based estimates: Describe fully the design 
features of the single effectiveness study and why the 
single study was a sufficient source of clinical 
effectiveness data. 
Not applicable 
11b Synthesis-based estimates: Describe fully the methods 
used for identification of included studies and synthesis 
of clinical effectiveness data. 
Pages 140-141 
Measurement and 
valuation of 
preference-based 
outcomes 
12 If applicable, describe the population and methods used 
to elicit preferences for outcomes. 
Page 144 
Estimating resources 
and costs 
13a Single study-based economic evaluation: Describe 
approaches used to estimate resource use associated with 
the alternative interventions. Describe primary or 
secondary research methods for valuing each resource 
item in terms of its unit cost. Describe any adjustments 
made to approximate to opportunity costs. 
Not applicable 
13b Model-based economic evaluation: Describe approaches 
and data sources used to estimate resource use associated 
with model health states. Describe primary or secondary 
research methods for valuing each resource item in terms 
of its unit cost. Describe any adjustments made to 
approximate to opportunity costs. 
Pages 145-146 
Currency, price date, 
and conversion 
14 Report the dates of the estimated resource quantities and 
unit costs. Describe methods for adjusting estimated unit 
costs to the year of reported costs if necessary. Describe 
methods for converting costs into a common currency 
base and the exchange rate. 
Page 150 
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Table A5.1 (cont.) CHEERS checklist - items to include when reporting economic 
evaluations of health interventions. 
Section/item Item No Recommendation Reported on page No 
Choice of model 15 Describe and give reasons for the specific type of 
decision-analytical model used. Providing a figure to 
show model structure is strongly recommended. 
Pages 138-139;  
Figure 5.1 
Assumptions 16 Describe all structural or other assumptions 
underpinning the decision-analytical model. 
Pages 139-141; 145-146 
Analytical methods 17 Describe all analytical methods supporting the 
evaluation. This could include methods for dealing 
with skewed, missing, or censored data; extrapolation 
methods; methods for pooling data; approaches to 
validate or make adjustments (such as half cycle 
corrections) to a model; and methods for handling 
population heterogeneity and uncertainty. 
Pages 150-152 
Results 
Study parameters 18 Report the values, ranges, references, and, if used, 
probability distributions for all parameters. Report 
reasons or sources for distributions used to represent 
uncertainty where appropriate. Providing a table to 
show the input values is strongly recommended. 
Tables 5.1-5.2-5.3-5.4 
Incremental costs 
and outcomes 
19 For each intervention, report mean values for the 
main categories of estimated costs and outcomes of 
interest, as well as mean differences between the 
comparator groups. If applicable, report incremental 
cost-effectiveness ratios. 
Tables 5.5-5.6-5.7;  
Page 153 
Characterising 
uncertainty 
20a Single study-based economic evaluation: Describe 
the effects of sampling uncertainty for the estimated 
incremental cost and incremental effectiveness 
parameters, together with the impact of 
methodological assumptions (such as discount rate, 
study perspective). 
Not applicable 
20b Model-based economic evaluation: Describe the 
effects on the results of uncertainty for all input 
parameters, and uncertainty related to the structure of 
the model and assumptions. 
Tables 5.8-5.9 
Figures 5.2-5.3-5.4-5.5 
Pages 153-157 
Characterising 
heterogeneity 
21 If applicable, report differences in costs, outcomes, 
or cost-effectiveness that can be explained by 
variations between subgroups of patients with 
different baseline characteristics or other observed 
variability in effects that are not reducible by more 
information. 
Not applicable 
Discussion 
Study findings, 
limitations, 
generalisability, and 
current knowledge 
22 Summarise key study findings and describe how they 
support the conclusions reached. Discuss limitations 
and the generalisability of the findings and how the 
findings fit with current knowledge. 
Pages 158-164 
Other 
Source of funding 23 Describe how the study was funded and the role of 
the funder in the identification, design, conduct, and 
reporting of the analysis. Describe other non-
monetary sources of support. 
Not applicable 
Conflicts of interest 24 Describe any potential for conflict of interest of study 
contributors in accordance with journal policy. In the 
absence of a journal policy, we recommend authors 
comply with International Committee of Medical 
Journal Editors recommendations. 
No conflict of interest 
Source: Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 
statement. Value Health. 2013; 16(2): e1-5. 
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APPENDICES TO CHAPTER 6 
Annex A6.1 BWS questionnaire. 
                                                                                                                                                                                                                          
 
 
 
Patients’ preferences analysis in clinical follow-
up after treatment for head and neck cancer 
 
(March 2015)  
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QUESTIONNAIRE ON SOCIO-DEMOGRAPHIC AND CLINICAL 
CHARACTERISTICS 
Name                                         Surname                                       Compilation date  
Socio-demographic data  
Sex  M 
 F 
Age (years)  
Age at cancer diagnosis (years)  
Employment status  Full-time employed 
 Part-time employed 
 Self-employed 
 Retired 
 Unemployed 
 Other (specify)………………….. 
Educational level  Primary School 
 Secondary School 
 University 
 Post-University (Master, PhD) 
Living status  With family 
 Alone 
 Other (specify)……………….….. 
Distance from home (Km)  < 100 Km 
 100-500 Km 
 > 500 Km 
Enrolment in HETeCo  
trial?1   Yes 
  No 
Clinical data  
Site of primary tumour  Oral cavity 
 Oropharynx 
 Larynx 
 Hypopharynx 
 Nasopharynx 
 Salivary glands 
 Other (specify) ……….................. 
Grade of primary tumour  Early stage 
 Locally advanced 
 Metastatic or recurrent 
HPV (Human Papilloma Virus)  Positive 
 Negative 
Treatment received (multiple answers are possible)  Surgery 
 Radiotherapy 
 Chemotherapy 
 Palliative chemotherapy 
 Other (specify)……………........... 
How long has the patient completed the treatment?  Less than 1 year 
 Between 1 and 3 years 
 More than 3 years 
Participation in educational groups (e.g. for 
smoking/alcohol cessation) 
 Yes 
 No 
1 “Health and Economic Outcomes of two different follow-up strategies in Effectively Cured Advances Head and 
Neck Cancer” 
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QUESTIONNAIRE ON PATIENTS’ PREFERENCES 
BACKGROUND 
Follow up programmes after curative cancer treatment are mainly designed at identifying 
disease recurrences or second primaries at an early stage in order to put in practice effective 
rescue treatments. Evidence shows that most recurrences for head and neck cancer (HNC) 
occur in the first 2 years after treatment. Secondary follow-up aims are the management of 
treatment-related long-term complications and provision of physical rehabilitation and 
emotional support.  
The optimum follow-up regime in HNC in terms of health gains achievable is still controversial, 
and an intensive follow-up may produce either reassurance or anxiety for patients. The aim of 
this survey is to assess the patient acceptability of different follow-up strategies following 
curative treatment for locally advanced HNC. Information about individual preferences are 
highly valuable as they can help clinicians to design more tailored follow-up programmes, 
increasing patient satisfaction and potentially achieving financial savings. 
DESCRIPTION 
The 9 scenarios presented in the questionnaire refer to a hypothetical 5-year follow-up 
programme for patients previously treated for HNC. The scenarios are obtained from a 
statistical combination of follow-up attributes and levels listed in the table below. 
Attributes Levels 
Frequency of physical (and 
larynx/pharynx endoscopic) 
investigations 
• Every 2-3 months for 3 years (primary care-
based follow-up for the last 2 years)  
• Every 2-3 months for 2 years, every 5-6 
months for other 3 years 
• Every 2-3 months for 5 years 
Frequency of radiological 
investigations: MRI/CT scan  
• Only at the occurrence of new symptoms 
• One examination only at the beginning of 
follow-up (later only at occurrence of new 
symptoms) 
• Once or twice a year 
Frequency of radiological 
investigations: PET scan  
• No PET scan during follow-up 
• Yearly PET scan only for high-risk patients (≥ 
50 years and heavy smokers) 
• Yearly PET scan for all patients 
Telephone calls to monitor new 
symptoms occurrence 
• No inter-visit calls from the hospital  
• Inter-visit calls by the nurse  
• Inter-visit calls by the oncologist  
Legend: MRI: Magnetic Resonance Imaging; CT: Computed Tomography; PET: Positron emission tomography. 
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INSTRUCTIONS 
For each scenario reported in the questionnaire, please indicate two aspects you do value ‘best’ 
and ‘worst’ respectively, with reference to a hypothetical follow-up programme for patients 
previously treated for HNC. In responding to the survey, please think all aspects that affect your 
life during the post-treatment period (e.g. need for reassurance, concerns for radiological 
assessments, travel expenditures to attend follow-up visits). 
Example. 
MOST 
PREFERRED 
 LEAST 
PREFERRED 
√ Physical (and larynx/pharynx endoscopic) examinations 
every 2-3 months for 5 years 
 
 One radiological assessment (MRI/CT scan) only at the 
beginning of follow-up (later only at occurrence of new 
symptoms) 
 
 Yearly PET scan only for high-risk patients (≥ 50 years and 
heavy smokers) 
√ 
 Inter-visits call by the oncologist to monitor new symptoms 
occurrence 
 
Legend: MRI: Magnetic Resonance Imaging; CT: Computed Tomography; PET: Positron emission tomography. 
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SCENARIO 1  
MOST 
PREFERRED 
 LEAST 
PREFERRED 
 Physical (and larynx/pharynx endoscopic) examinations 
every 2-3 months for the first 2 years and every 5-6 months 
for the last 3 years 
 
 Radiological assessments (MRI/CT scan) only at the 
occurrence of new symptoms 
 
 Yearly PET scan for all patients (irrespective of age or other 
risk factors) 
 
 Inter-visits call by the oncologist to monitor new symptoms 
occurrence 
 
Legend: MRI: Magnetic Resonance Imaging; CT: Computed Tomography; PET: Positron emission tomography. 
 
SCENARIO 2  
MOST 
PREFERRED 
 LEAST 
PREFERRED 
 Physical (and larynx/pharynx endoscopic) examinations 
every 2-3 months for the first 2 years and every 5-6 months 
for the last 3 years 
 
 One radiological assessment (MRI/CT scan) only at the 
beginning of follow-up (later only at occurrence of new 
symptoms) 
 
 No PET scan during follow-up  
 Inter-visits call by the nurse to monitor new symptoms 
occurrence 
 
Legend: MRI: Magnetic Resonance Imaging; CT: Computed Tomography; PET: Positron emission tomography. 
 
SCENARIO 3  
MOST 
PREFERRED 
 LEAST 
PREFERRED 
 Physical (and larynx/pharynx endoscopic) examinations 
every 2-3 months for the first 2 years and every 5-6 months 
for the last 3 years 
 
 Radiological examinations (MRI/CT scan) once or twice a 
year 
 
 Yearly PET scan only for high-risk patients (≥ 50 years and 
heavy smokers) 
 
 No inter-visit calls from the hospital to monitor new 
symptoms occurrence 
 
Legend: MRI: Magnetic Resonance Imaging; CT: Computed Tomography; PET: Positron emission tomography. 
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SCENARIO 4  
MOST 
PREFERRED 
 LEAST 
PREFERRED 
 Physical (and larynx/pharynx endoscopic) examinations 
every 2-3 months for 5 years 
 
 Radiological assessments (MRI/CT scan) only at the 
occurrence of new symptoms 
 
 No PET scan during follow-up  
 No inter-visit calls from the hospital to monitor new 
symptoms occurrence 
 
Legend: MRI: Magnetic Resonance Imaging; CT: Computed Tomography; PET: Positron emission tomography. 
 
SCENARIO 5  
MOST 
PREFERRED 
 LEAST 
PREFERRED 
 Physical (and larynx/pharynx endoscopic) examinations 
every 2-3 months for 5 years 
 
 One radiological assessment (MRI/CT scan) only at the 
beginning of follow-up (later only at occurrence of new 
symptoms) 
 
 Yearly PET scan only for high-risk patients (≥ 50 years and 
heavy smokers) 
 
 Inter-visits call by the oncologist to monitor new symptoms 
occurrence 
 
Legend: MRI: Magnetic Resonance Imaging; CT: Computed Tomography; PET: Positron emission tomography. 
 
SCENARIO 6  
MOST 
PREFERRED 
 LEAST 
PREFERRED 
 Physical (and larynx/pharynx endoscopic) examinations 
every 2-3 months for 5 years 
 
 Radiological examinations (MRI/CT scan) once or twice a 
year 
 
 Yearly PET scan for all patients (irrespective of age or other 
risk factors) 
 
 Inter-visits call by the nurse to monitor new symptoms 
occurrence 
 
Legend: MRI: Magnetic Resonance Imaging; CT: Computed Tomography; GP: General Practitioner; PET: Positron 
emission tomography. 
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SCENARIO 7  
MOST 
PREFERRED 
 LEAST 
PREFERRED 
 Physical (and larynx/pharynx endoscopic) examinations 
every 2-3 months for 3 years. Primary care-based follow-up 
for the last 2 years. 
 
 Radiological assessments (MRI/CT scan) only at the 
occurrence of new symptoms 
 
 Yearly PET scan only for high-risk patients (≥ 50 years and 
heavy smokers) 
 
 Inter-visits call by the nurse to monitor new symptoms 
occurrence 
 
Legend: MRI: Magnetic Resonance Imaging; CT: Computed Tomography; GP: General Practitioner; PET: Positron 
emission tomography. 
SCENARIO 8  
MOST 
PREFERRED 
 LEAST 
PREFERRED 
 Physical (and larynx/pharynx endoscopic) examinations 
every 2-3 months for 3 years. Primary care-based follow-up 
for the last 2 years. 
 
 One radiological assessment (MRI/CT scan) only at the 
beginning of follow-up (later only at occurrence of new 
symptoms) 
 
 Yearly PET scan for all patients (irrespective of age or other 
risk factors) 
 
 No inter-visit calls from the hospital to monitor new 
symptoms occurrence 
 
Legend: MRI: Magnetic Resonance Imaging; CT: Computed Tomography; GP: General Practitioner; PET: Positron 
emission tomography. 
SCENARIO 9  
MOST 
PREFERRED 
 LEAST 
PREFERRED 
 Physical (and larynx/pharynx endoscopic) examinations 
every 2-3 months for 3 years. Primary care-based follow-up 
for the last 2 years. 
 
 Radiological examinations (MRI/CT scan) once or twice a 
year 
 
 No PET scan during follow-up  
 Inter-visits call by the oncologist to monitor new symptoms 
occurrence 
 
Legend: MRI: Magnetic Resonance Imaging; CT: Computed Tomography; GP: General Practitioner; PET: Positron 
emission tomography. 
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CONCLUSION 
The questionnaire ends here! We thank you for taking part in the study and kindly ask 
you to give us a feedback about it.  
1. How much did you take to fill in the whole questionnaire?                                  
minutes 
 
2. From 1 (easy) to 5 (difficult), how do you value the task of answering questions? 
 
 
 
3. Did you need the help from someone (e.g. caregiver, doctor, nurse) to reply the 
questions?  
 Yes         No 
4. What is the main difficulty you experienced in answering the questionnaire? 
 Length of the questionnaire 
 Understanding the task 
 Technical/scientific language 
 Other …………………………………………………… 
 
5. Comments: 
……………………………………………………………………………………
……………………………………………………………………………………
……………………………………………………………………………………
……………………………………………………………………………………
…………………………………………………………………………………… 
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Annex A6.2 BWS questionnaire (original Italian version). 
 
                                                                                                                                                                                                    
 
 
 
 
 
 
 
Analisi delle preferenze dei pazienti in follow-up 
clinico post-trattamento per tumore testa-collo 
 
 (marzo 2015) 
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DATI SOCIO-DEMOGRAFICI E CLINICI  
 
Nome                                          Cognome                                              Data di compilazione   
 
Dati socio-demografici  
(compilazione da parte del paziente) 
 
Sesso  M 
 F 
Età (anni)  
Età alla diagnosi di tumore (anni)  
Stato occupazionale  Lavoratore dipendente a tempo 
pieno 
 Lavoratore dipendente part-time 
 Lavoratore autonomo 
 Pensionato/a 
 Disoccupato/a 
 Altro (specificare).……………… 
Livello di istruzione  Licenza elementare 
 Diploma di scuola media inferiore 
 Diploma di scuola media superiore 
 Laurea 
 Post-laurea 
Situazione abitativa  In famiglia 
 Da solo/a 
 Altro (specificare) ………………. 
Distanza dell’INT2 dalla propria abitazione (Km)  < 100 Km 
 100-500 Km 
 > 500 Km 
Dati clinici 
(compilazione da parte del medico) 
 
Il paziente partecipa anche allo studio HETeCo?1  Si 
 No 
Sede del tumore primario  Cavità orale 
 Orofaringe 
 Laringe 
 Ipofaringe 
 Rinofaringe 
 Ghiandole salivari 
 Altro (specificare) ………........ 
Grado del tumore primario  Fase iniziale 
 Localmente avanzato 
 Metastatico o recidivante 
HPV (Human Papilloma Virus)  Positivo 
 Negativo 
Trattamenti ricevuti (più risposte possibili)  Chirurgia 
 Radioterapia 
 Chemioterapia 
 Chemioterapia palliativa 
 Altro (specificare) 
…………………........ 
Da quanto tempo il paziente ha ultimato i trattamenti?  Meno di 1 anno 
 Tra 1 e 3 anni 
 Più di 3 anni 
Il paziente partecipa a percorsi terapeutici (es. per 
abbandono del fumo o alcol)? 
 Si 
 No 
1 “Health and Economic Outcomes of two different follow-up strategies in Effectively Cured Advanced Head and Neck Cancer”  
2 Istituto Nazionale dei Tumori 
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QUESTIONARIO SULLE PREFERENZE DEI PAZIENTI 
 
INTRODUZIONE 
I programmi di follow-up* a seguito del trattamento per il cancro hanno lo scopo di 
identificare recidive della malattia o nuovi tumori in una fase sufficientemente precoce 
per mettere in atto efficaci terapie di salvataggio. La maggior parte delle recidive di 
neoplasia del distretto ‘testa-collo’ si verificano nei primi 2 anni dopo il trattamento. 
Obiettivi secondari del follow-up sono la gestione delle complicanze a lungo termine 
del trattamento, la riabilitazione fisica e il supporto psicologico al paziente e alla sua 
famiglia.  
 
La scelta della strategia ottimale di follow-up in termini di guadagni di salute per il 
paziente è ancora controversa. Allo stesso tempo, non si conosce se un follow-up 
intensivo causi più rassicurazione o ansia nei pazienti. Scopo della presente ricerca è 
quello di stimare le preferenze riguardo a diversi aspetti del follow-up a seguito di 
trattamento curativo per tumore ‘testa-collo’. Le preferenze soggettive sono sempre più 
importanti in ambito clinico per programmare interventi sanitari personalizzati, 
aumentare la soddisfazione dei pazienti e ottimizzare l’impiego di risorse economiche. 
 
* Follow-up: programma di visite di controllo ed esami diagnostici che segue il periodo di cura (chemioterapia o 
radioterapia) 
 
DESCRIZIONE 
  
I 9 scenari presentati nel questionario fanno riferimento a ipotetici programmi di 
follow-up, di durata quinquennale (5 anni), per pazienti precedentemente trattati per 
tumore del distretto ‘testa-collo’. Gli scenari sono ottenuti da una combinazione 
statistica di attributi e livelli del follow-up elencati nella tabella sottostante. 
 
Attributi Livelli 
Frequenza visite mediche (con 
esame endoscopico di 
faringe/laringe) 
• Ogni 2-3 mesi per 3 anni (follow-up presso il 
medico di base per i restanti 2 anni) 
• Ogni 2-3 mesi per 2 anni, ogni 5-6 mesi per i 
restanti 3 anni 
• Ogni 2-3 mesi per 5 anni 
Frequenza esami radiologici 
(RM/TAC) 
• Solo all’occorrenza di nuovi sintomi 
• Un solo esame radiologico all’inizio del follow-
up (in seguito, solo all’occorrenza di nuovi 
sintomi) 
• Una o due volte l’anno 
Frequenza esami radiologici (PET) • Nessuna PET durante il follow-up 
• PET annuale solo per pazienti ad alto rischio di 
recidive di malattia (per età e/o abitudine al 
fumo) 
• PET annuale per tutti i pazienti 
(indipendentemente da età o fattori di rischio) 
Telefonate per monitorare 
l’insorgenza di nuovi sintomi 
• Nessuna telefonata periodica dall’ospedale 
• Telefonate dall’infermiere tra una visita e l’altra 
• Telefonate dallo specialista oncologo tra una 
visita e l’altra 
Legenda: RM: Risonanza Magnetica; TAC: Tomografia assiale computerizzata; PET: Tomografia a emissione di 
positroni. 
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ISTRUZIONI 
Per ciascun scenario, La preghiamo di indicare le due caratteristiche che Lei valuta 
come “migliore” e “peggiore” rispettivamente, come da esempio. Nel compilare le 
risposte, La invitiamo a riflettere sugli aspetti che caratterizzano maggiormente la Sua 
vita a seguito del trattamento per il tumore (es. bisogno di rassicurazioni, inquietudine 
per gli esami radiologici, spese di viaggio per recarsi alle visite di follow-up). 
 
ESEMPIO 
OPZIONE 
MIGLIORE 
 OPZIONE 
PEGGIORE 
√ Visite mediche (con esame endoscopico di 
faringe/laringe) ogni 2-3 mesi per 5 anni 
 
 Un solo esame radiologico (RM/TAC) all’inizio 
del follow-up (e in seguito, solo all’occorrenza 
di nuovi sintomi) 
 
 PET annuale solo per pazienti ad alto rischio di 
recidive di malattia (per età e/o abitudine al 
fumo) 
√ 
 Telefonate dallo specialista oncologo per 
monitorare l’insorgenza di nuovi sintomi tra una 
visita e l’altra 
 
Legenda: RM: Risonanza Magnetica; TAC: Tomografia assiale computerizzata; PET: Tomografia a emissione di 
positroni. 
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SCENARIO 1  
OPZIONE 
MIGLIORE 
 OPZIONE 
PEGGIORE 
 Visite mediche (con esame endoscopico di faringe e 
laringe) ogni 2-3 mesi per 2 anni, ogni 5-6 mesi per i 
restanti 3 anni 
 
 Esami radiologici (RM/TAC) solo all’occorrenza di 
nuovi sintomi 
 
 PET annuale per tutti i pazienti (indipendentemente 
da età o fattori di rischio) 
 
 Telefonate dallo specialista oncologo per monitorare 
l’insorgenza di nuovi sintomi tra una visita e l’altra 
 
Legenda: RM: Risonanza Magnetica; TAC: Tomografia assiale computerizzata; PET: Tomografia a emissione di 
positroni. 
 
 
SCENARIO 2  
OPZIONE 
MIGLIORE 
 OPZIONE 
PEGGIORE 
 Visite mediche (con esame endoscopico di faringe e 
laringe) ogni 2-3 mesi per 2 anni, ogni 5-6 mesi per 
i restanti 3 anni 
 
 Un solo esame radiologico (RM/TAC) all’inizio del 
follow-up (e in seguito, solo all’occorrenza di nuovi 
sintomi) 
 
 Nessuna PET durante il follow-up  
 Telefonate dall’infermiere per monitorare 
l’insorgenza di nuovi sintomi tra una visita e l’altra 
 
Legenda: RM: Risonanza Magnetica; TAC: Tomografia assiale computerizzata; PET: Tomografia a emissione di 
positroni. 
 
 
SCENARIO 3  
OPZIONE 
MIGLIORE 
 OPZIONE 
PEGGIORE 
 Visite mediche (con esame endoscopico di faringe e 
laringe) ogni 2-3 mesi per 2 anni, ogni 5-6 mesi per 
i restanti 3 anni 
 
 Esami radiologici (RM/TAC) una o due volte 
all’anno 
 
 PET annuale solo per pazienti ad alto rischio di 
recidive di malattia (per età e/o abitudine al fumo) 
 
 Nessuna telefonata dall’ospedale per monitorare 
l’insorgenza di nuovi sintomi tra una visita e l’altra 
 
Legenda: RM: Risonanza Magnetica; TAC: Tomografia assiale computerizzata; PET: Tomografia a emissione di 
positroni. 
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SCENARIO 4  
OPZIONE 
MIGLIORE 
 OPZIONE 
PEGGIORE 
 Visite mediche (con esame endoscopico di faringe e 
laringe) ogni 2-3 mesi per 5 anni 
 
 Esami radiologici (RM/TAC) solo all’occorrenza di 
nuovi sintomi  
 
 Nessuna PET durante il follow-up  
 Nessuna telefonata dall’ospedale per monitorare 
l’insorgenza di nuovi sintomi tra una visita e l’altra 
 
Legenda: RM: Risonanza Magnetica; TAC: Tomografia assiale computerizzata; PET: Tomografia a emissione di 
positroni. 
 
 
SCENARIO 5  
OPZIONE 
MIGLIORE 
 OPZIONE 
PEGGIORE 
 Visite mediche (con esame endoscopico di faringe e 
laringe) ogni 2-3 mesi per 5 anni 
 
 Un solo esame radiologico (RM/TAC) all’inizio del 
follow-up (e in seguito, solo all’occorrenza di nuovi 
sintomi) 
 
 PET annuale solo per pazienti ad alto rischio di 
recidive di malattia (per età e/o abitudine al fumo) 
 
 Telefonate dallo specialista oncologo per 
monitorare l’insorgenza di nuovi sintomi tra una 
visita e l’altra 
 
Legenda: RM: Risonanza Magnetica; TAC: Tomografia assiale computerizzata; PET: Tomografia a emissione di 
positroni. 
 
 
SCENARIO 6  
OPZIONE 
MIGLIORE 
 OPZIONE 
PEGGIORE 
 Visite mediche (con esame endoscopico di faringe e 
laringe) ogni 2-3 mesi per 5 anni 
 
 Esami radiologici (RM/TAC) una o due volte 
all’anno  
 
 PET annuale per tutti i pazienti (indipendentemente 
da età o fattori di rischio) 
 
 Telefonate dall’infermiere per monitorare 
l’insorgenza di nuovi sintomi tra una visita e l’altra 
 
Legenda: RM: Risonanza Magnetica; TAC: Tomografia assiale computerizzata; PET: Tomografia a emissione di 
positroni. 
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SCENARIO 7 
OPZIONE 
MIGLIORE 
 OPZIONE 
PEGGIORE 
 Visite mediche (con esame endoscopico di faringe e 
laringe) ogni 2-3 mesi per 2 anni. Follow-up presso 
il medico di base per i restanti 2 anni. 
 
 Esami radiologici (RM/TAC) solo all’occorrenza di 
nuovi sintomi  
 
 PET annuale solo per pazienti ad alto rischio di 
recidive di malattia (per età e/o abitudine al fumo) 
 
 Telefonate dall’infermiere per monitorare 
l’insorgenza di nuovi sintomi tra una visita e l’altra 
 
Legenda: RM: Risonanza Magnetica; TAC: Tomografia assiale computerizzata; PET: Tomografia a emissione di 
positroni. 
 
 
SCENARIO 8  
OPZIONE 
MIGLIORE 
 OPZIONE 
PEGGIORE 
 Visite mediche (con esame endoscopico di faringe e 
laringe) ogni 2-3 mesi per 2 anni. Follow-up presso 
il medico di base per i restanti 2 anni. 
 
 Un solo esame radiologico (RM/TAC) all’inizio del 
follow-up (e in seguito, solo all’occorrenza di nuovi 
sintomi) 
 
 PET annuale per tutti i pazienti (indipendentemente 
da età o fattori di rischio) 
 
 Nessuna telefonata dall’ospedale per monitorare 
l’insorgenza di nuovi sintomi tra una visita e l’altra 
 
Legenda: RM: Risonanza Magnetica; TAC: Tomografia assiale computerizzata; PET: Tomografia a emissione di 
positroni. 
 
SCENARIO 9  
OPZIONE 
MIGLIORE 
 OPZIONE 
PEGGIORE 
 Visite mediche (con esame endoscopico di faringe 
e laringe) ogni 2-3 mesi per 2 anni. Follow-up 
presso il medico di base per i restanti 2 anni. 
 
 Esami radiologici (RM/TAC) una o due volte 
all’anno  
 
 Nessuna PET durante il follow-up  
 Telefonate dallo specialista oncologo per 
monitorare l’insorgenza di nuovi sintomi tra una 
visita e l’altra 
 
Legenda: RM: Risonanza Magnetica; TAC: Tomografia assiale computerizzata; PET: Tomografia a emissione di 
positroni. 
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CONCLUSIONE 
 
Il questionario è terminato! La ringraziamo per aver preso parte allo studio e Le 
chiediamo la cortesia di fornirci una Sua valutazione a riguardo. 
 
6. Quanto tempo ha impiegato per compilare l’intero questionario?                     
minuti 
 
7. Da 1 (facile) a 5 (difficile), come valuta il compito di rispondere alle domande?  
 
 
 
 
8. Per rispondere alle domande, ha avuto bisogno dell’aiuto di qualcuno (es. 
parente, infermiere, medico)? 
 
 Si        No 
 
9. Qual è la principale difficoltà che ha incontrato nel compilare le risposte? 
 
 Lunghezza del questionario 
 Comprensione dell’esercizio richiesto 
 Linguaggio tecnico/scientifico 
 Altro 
.................................................................................................................................
. 
 
10. Eventuali commenti: 
 
……………………………………………………………………………………
……………………………………………………………………………………
……………………………………………………………………………………
……………………………………………………………………………………
…………………………………………………………………………………… 
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Tables A6.1-9 Utility coefficients from covariate-adjusted univariate conditional 
logistic regression analyses. 
Table A6.1 Utility coefficients from covariate-adjusted univariate conditional logistic 
regression analysis (gender: female=1; male=0). 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
  
 
   
Every 2-3 months for 3 years (primary care-
based follow-up for 2 more years)  
0.122 0.259 0.639 -0.387 0.630 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
2.466 0.142 <0.001 2.188 2.745 
Every 2-3 months for 5 years  2.158 0.165 <0.001 1.834 2.482 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.459 0.146 0.002 0.171 0.746 
One examination only at the beginning of 
follow-up (later only at occurrence of new 
symptoms)  
0.512 0.144 <0.001 0.228 0.795 
Once or twice a year  1.821 0.135 <0.001 1.556 2.086 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.088 0.136 0.518 -0.354 0.178 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.925 0.142 <0.001 0.646 1.204 
Yearly PET scan for all patients  1.084 0.181 <0.001 0.729 1.440 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  -0.029 0.108 0.787 -0.241 0.183 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.551 0.104 <0.001 0.347 0.755 
Interactions (Gender)      
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-
based follow-up for 2 more years)  
-0.608 0.427 0.154 -1.446 0.229 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
-0.089 0.298 0.766 -0.673 0.496 
Every 2-3 months for 5 years  -0.329 0.373 0.377 -1.060 0.401 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  -0.072 0.282 0.798 -0.625 0.481 
One examination only at the beginning of 
follow-up (later only at occurrence of new 
symptoms) 
-0.125 0.288 0.664 -0.690 0.440 
Once or twice a year  -0.070 0.304 0.817 -0.665 0.525 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.003 0.238 0.991 -0.463 0.469 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
-0.184 0.262 0.483 -0.698 0.330 
Yearly PET scan for all patients  -0.220 0.328 0.503 -0.862 0.423 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  0.139 0.221 0.530 -0.294 0.572 
Inter-visit calls by the nurse - - - - - 
Inter-visit calls by the oncologist  -0.141 0.194 0.467 -0.521 0.239 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
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Table A6.2 Utility coefficients from covariate-adjusted univariate conditional logistic 
regression analysis (age≥59 =1; age<59 =0). 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-
based follow-up for 2 more years)  
-0.169 0.268 0.530 -0.695 0.358 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
2.490 0.150 <0.001 2.196 2.785 
Every 2-3 months for 5 years  2.039 0.207 <0.001 1.634 2.444 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.505 0.163 0.002 0.185 0.824 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.371 0.172 0.030 0.035 0.708 
Once or twice a year  1.944 0.175 <0.001 1.601 2.286 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.134 0.152 0.378 -0.431 0.163 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.844 0.169 <0.001 0.513 1.175 
Yearly PET scan for all patients  0.936 0.198 <0.001 0.547 1.325 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  0.090 0.117 0.442 -0.140 0.320 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.619 0.132 <0.001 0.361 0.877 
Interactions (Age)      
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-
based follow-up for 2 more years)  
0.245 0.424 0.563 -0.585 1.076 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
-0.094 0.251 0.706 -0.586 0.397 
Every 2-3 months for 5 years  0.069 0.301 0.820 -0.521 0.658 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  -0.126 0.250 0.614 -0.617 0.364 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms) 
0.212 0.250 0.396 -0.278 0.702 
Once or twice a year  -0.284 0.244 0.245 -0.763 0.195 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.093 0.225 0.679 -0.348 0.534 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.066 0.240 0.783 -0.405 0.537 
Yearly PET scan for all patients  0.178 0.303 0.557 -0.416 0.772 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  -0.165 0.188 0.380 -0.532 0.203 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  -0.204 0.176 0.247 -0.549 0.141 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
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Table A6.3 (A) Utility coefficients from covariate-adjusted univariate conditional logistic 
regression analysis (employed (full-time employed, part-time employed, self-employed) =1; not 
employed (retired, unemployed, other) =0) using missing imputation. 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
-0.169 0.312 0.588 -0.781 0.443 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
2.078 0.195 <0.001 1.695 2.460 
Every 2-3 months for 5 years  1.620 0.232 <0.001 1.166 2.074 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.070 0.190 0.714 -0.303 0.443 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms) 
0.285 0.189 0.131 -0.085 0.655 
Once or twice a year  1.348 0.176 <0.001 1.003 1.693 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.272 0.161 0.092 -0.588 0.044 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers) 
0.598 0.188 0.002 0.229 0.967 
Yearly PET scan for all patients  0.761 0.228 0.001 0.314 1.209 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  -0.251 0.158 0.113 -0.562 0.059 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.472 0.138 0.001 0.202 0.743 
Interactions (Employment)      
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
0.218 0.426 0.609 -0.617 1.054 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
0.703 0.246 0.004 0.221 1.185 
Every 2-3 months for 5 years  0.863 0.296 0.004 0.283 1.444 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.708 0.250 0.005 0.219 1.198 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.365 0.253 0.148 -0.130 0.861 
Once or twice a year  0.859 0.236 <0.001 0.397 1.322 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.343 0.225 0.128 -0.098 0.784 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.529 0.240 0.028 0.058 1.001 
Yearly PET scan for all patients  0.504 0.305 0.099 -0.095 1.102 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  0.474 0.192 0.013 0.098 0.851 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.073 0.178 0.681 -0.276 0.423 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
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Table A6.3 (B) Utility coefficients from covariate-adjusted univariate conditional logistic 
regression analysis (employed (full-time employed, part-time employed, self-employed) =1; not 
employed (retired, unemployed, other) =0) using complete case analysis. 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
-0.087 0.321 0.786 -0.716 0.542 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
2.084 0.201 <0.001 1.690 2.479 
Every 2-3 months for 5 years  1.673 0.231 <0.001 1.220 2.126 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.075 0.196 0.700 -0.309 0.460 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.297 0.193 0.124 -0.081 0.676 
Once or twice a year  1.358 0.174 <0.001 1.016 1.700 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.267 0.164 0.105 -0.589 0.055 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.604 0.192 0.002 0.226 0.981 
Yearly PET scan for all patients  0.787 0.232 0.001 0.332 1.242 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  -0.222 0.162 0.169 -0.539 0.095 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.459 0.140 0.001 0.184 0.733 
Interactions (Employment)      
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
0.136 0.433 0.753 -0.712 0.984 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
0.696 0.251 0.006 0.205 1.188 
Every 2-3 months for 5 years  0.810 0.296 0.006 0.231 1.390 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.703 0.254 0.006 0.205 1.201 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.353 0.256 0.168 -0.149 0.855 
Once or twice a year  0.850 0.235 <0.001 0.390 1.310 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.338 0.227 0.137 -0.107 0.783 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.523 0.244 0.032 0.046 1.001 
Yearly PET scan for all patients  0.478 0.308 0.121 -0.126 1.082 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  0.445 0.194 0.022 0.064 0.827 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.087 0.180 0.629 -0.266 0.440 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
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Table A6.4 (A) Utility coefficients from covariate-adjusted univariate conditional logistic 
regression analysis (more educated (university, post-university) =1; less educated (primary 
school, secondary school) =0) using missing imputation. 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
-0.434 0.226 0.054 -0.876 0.008 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
2.358 0.135 <0.001 2.093 2.623 
Every 2-3 months for 5 years  1.931 0.170 <0.001 1.598 2.265 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.364 0.147 0.013 0.076 0.652 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.493 0.146 0.001 0.207 0.779 
Once or twice a year  1.594 0.131 <0.001 1.338 1.850 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.281 0.123 0.023 -0.523 -0.039 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.763 0.143 <0.001 0.482 1.044 
Yearly PET scan for all patients  0.918 0.164 <0.001 0.597 1.238 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  -0.111 0.097 0.255 -0.301 0.080 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.472 0.102 <0.001 0.272 0.671 
Interactions (Education)      
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
1.758 0.551 0.001 0.678 2.838 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
0.501 0.391 0.199 -0.264 1.267 
Every 2-3 months for 5 years  0.724 0.414 0.080 -0.088 1.536 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.309 0.289 0.285 -0.257 0.875 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
-0.069 0.285 0.809 -0.627 0.490 
Once or twice a year  0.985 0.364 0.007 0.272 1.698 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.810 0.279 0.004 0.262 1.358 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.507 0.266 0.057 -0.014 1.028 
Yearly PET scan for all patients  0.495 0.424 0.244 -0.337 1.326 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  0.458 0.256 0.073 -0.043 0.960 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.170 0.203 0.403 -0.228 0.568 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
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Table A6.4 (B) Utility coefficients from covariate-adjusted univariate conditional logistic 
regression analysis (more educated (university, post-university) =1; less educated (primary 
school, secondary school) =0) using complete case analysis. 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
-0.516 0.229 0.024 -0.966 -0.067 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
2.418 0.136 <0.001 2.151 2.685 
Every 2-3 months for 5 years  1.986 0.175 <0.001 1.642 2.330 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.404 0.151 0.007 0.108 0.699 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.522 0.149 <0.001 0.231 0.814 
Once or twice a year  1.599 0.134 <0.001 1.336 1.862 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.279 0.127 0.028 -0.527 -0.031 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.747 0.150 <0.001 0.453 1.040 
Yearly PET scan for all patients  0.883 0.169 <0.001 0.553 1.214 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  -0.094 0.101 0.353 -0.292 0.104 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.447 0.106 <0.001 0.240 0.655 
Interactions (Education)      
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
1.799 0.561 0.001 0.700 2.898 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
0.438 0.397 0.269 -0.339 1.216 
Every 2-3 months for 5 years  0.678 0.422 0.108 -0.150 1.505 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.314 0.294 0.286 -0.263 0.891 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
-0.063 0.291 0.829 -0.633 0.507 
Once or twice a year  1.006 0.370 0.007 0.281 1.732 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.878 0.280 0.002 0.328 1.427 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.530 0.273 0.052 -0.005 1.066 
Yearly PET scan for all patients  0.481 0.428 0.262 -0.359 1.320 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  0.451 0.263 0.087 -0.065 0.966 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.185 0.208 0.372 -0.222 0.593 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
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Table A6.5 (A) Utility coefficients from covariate-adjusted univariate conditional logistic 
regression analysis (living status: with family=1; alone =0) using missing imputation. 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
-0.161 0.730 0.825 -1.592 1.270 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
2.208 0.510 <0.001 1.207 3.208 
Every 2-3 months for 5 years  1.754 0.565 0.002 0.646 2.862 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.397 0.382 0.298 -0.351 1.146 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.085 0.302 0.778 -0.506 0.676 
Once or twice a year  1.763 0.477 <0.001 0.829 2.697 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.616 0.209 0.003 -1.026 -0.205 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.810 0.363 0.026 0.098 1.523 
Yearly PET scan for all patients  0.620 0.495 0.210 -0.350 1.591 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  ≈0.000 0.292 1.000 -0.573 0.573 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.286 0.189 0.130 -0.085 0.656 
Interactions (Living status)      
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
0.127 0.763 0.867 -1.367 1.622 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
0.258 0.526 0.623 -0.772 1.289 
Every 2-3 months for 5 years  0.353 0.586 0.547 -0.795 1.501 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.046 0.404 0.908 -0.746 0.839 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.439 0.330 0.184 -0.208 1.086 
Once or twice a year  0.041 0.493 0.934 -0.925 1.007 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.593 0.243 0.015 0.117 1.068 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.073 0.385 0.849 -0.681 0.828 
Yearly PET scan for all patients  0.451 0.520 0.385 -0.568 1.470 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  0.006 0.309 0.984 -0.599 0.611 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.255 0.212 0.229 -0.160 0.670 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
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Table A6.5 (B) Utility coefficients from covariate-adjusted univariate conditional logistic 
regression analysis (living status: with family=1; alone =0) using complete case analysis. 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
-0.161 0.730 0.825 -1.592 1.270 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
2.208 0.510 <0.001 1.207 3.208 
Every 2-3 months for 5 years  1.754 0.565 0.002 0.646 2.862 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.397 0.382 0.298 -0.351 1.146 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.085 0.302 0.778 -0.506 0.676 
Once or twice a year  1.763 0.477 <0.001 0.829 2.697 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.616 0.209 0.003 -1.026 -0.205 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.810 0.364 0.026 0.098 1.523 
Yearly PET scan for all patients  0.620 0.495 0.210 -0.350 1.591 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  ≈0.000 0.292 1.000 -0.573 0.573 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.286 0.189 0.131 -0.085 0.656 
Interactions (Living status)      
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
0.076 0.765 0.921 -1.423 1.575 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
0.300 0.527 0.569 -0.732 1.332 
Every 2-3 months for 5 years  0.403 0.586 0.492 -0.746 1.553 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.056 0.406 0.891 -0.740 0.851 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.461 0.331 0.164 -0.187 1.109 
Once or twice a year  0.053 0.494 0.915 -0.915 1.020 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.583 0.245 0.017 0.103 1.063 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.069 0.387 0.858 -0.689 0.827 
Yearly PET scan for all patients  0.443 0.521 0.396 -0.579 1.464 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  0.013 0.309 0.967 -0.593 0.619 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.265 0.213 0.215 -0.154 0.683 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
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Table A6.6 (A) Utility coefficients from covariate-adjusted univariate conditional logistic 
regression analysis (distance from home: ≥100 km =1; <100 km =0) using missing imputation. 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
-0.001 0.255 0.997 -0.501 0.499 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
2.347 0.167 <0.001 2.018 2.675 
Every 2-3 months for 5 years  2.022 0.187 <0.001 1.655 2.388 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.322 0.161 0.045 0.007 0.638 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.342 0.157 0.030 0.033 0.651 
Once or twice a year  1.857 0.157 <0.001 1.550 2.164 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.176 0.128 0.169 -0.427 0.075 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.866 0.152 <0.001 0.569 1.164 
Yearly PET scan for all patients  1.072 0.200 <0.001 0.680 1.463 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  -0.074 0.118 0.531 -0.306 0.158 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.465 0.113 <0.001 0.242 0.687 
Interactions (Distance)      
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
-0.133 0.457 0.772 -1.028 0.763 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
0.284 0.239 0.235 -0.185 0.753 
Every 2-3 months for 5 years  0.157 0.313 0.616 -0.457 0.772 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.349 0.248 0.160 -0.138 0.853 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.407 0.251 0.106 -0.086 0.900 
Once or twice a year  -0.162 0.248 0.515 -0.649 0.325 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.264 0.253 0.296 -0.231 0.760 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.033 0.247 0.894 -0.450 0.516 
Yearly PET scan for all patients  -0.134 0.299 0.655 -0.720 0.452 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  0.238 0.194 0.220 -0.142 0.619 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.149 0.176 0.398 -0.196 0.494 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
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Table A6.6 (B) Utility coefficients from covariate-adjusted univariate conditional logistic 
regression analysis (distance from home: ≥100 km =1; <100 km =0) using complete case 
analysis. 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
0.046 0.256 0.857 -0.456 0.548 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
2.353 0.172 <0.001 2.015 2.690 
Every 2-3 months for 5 years  2.014 0.193 <0.001 1.636 2.392 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.364 0.163 0.025 0.045 0.682 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.404 0.158 0.010 0.095 0.714 
Once or twice a year  1.900 0.159 <0.001 1.588 2.212 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.147 0.130 0.258 -0.402 0.108 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.869 0.155 <0.001 0.564 1.174 
Yearly PET scan for all patients  1.111 0.204 <0.001 0.711 1.510 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  -0.059 0.120 0.624 -0.295 0.177 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.476 0.116 <0.001 0.248 0.704 
Interactions (Distance)      
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
-0.180 0.458 0.695 -1.077 0.717 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
0.278 0.243 0.252 -0.197 0.754 
Every 2-3 months for 5 years  0.164 0.317 0.604 -0.457 0.786 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.307 0.249 0.218 -0.182 0.796 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.345 0.252 0.171 -0.149 0.838 
Once or twice a year  -0.205 0.250 0.413 -0.695 0.285 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.235 0.254 0.354 -0.262 0.733 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.031 0.249 0.902 -0.457 0.519 
Yearly PET scan for all patients  -0.172 0.302 0.567 -0.764 0.419 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  0.223 0.195 0.254 -0.160 0.606 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.137 0.178 0.440 -0.211 0.486 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
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Table A6.7 Utility coefficients from covariate-adjusted univariate conditional logistic 
regression analysis (number of treatments: ≥1 (2, 3 or 4) =1; one only =0). 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
0.540 0.371 0.145 -0.186 1.267 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
2.801 0.169 <0.001 2.469 3.133 
Every 2-3 months for 5 years  2.536 0.192 <0.001 2.160 2.911 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.763 0.200 <0.001 0.370 1.155 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.868 0.179 <0.001 0.516 1.219 
Once or twice a year  2.094 0.180 <0.001 1.742 2.447 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.197 0.174 0.258 -0.144 0.539 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
1.009 0.185 <0.001 0.646 1.372 
Yearly PET scan for all patients  1.381 0.234 <0.001 0.922 1.839 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  0.092 0.146 0.529 -0.194 0.377 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.520 0.139 <0.001 0.248 0.793 
Interactions (No. of treatments)      
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
-1.030 0.442 0.020 -1.896 -0.164 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
-0.622 0.243 0.010 -1.099 -0.146 
Every 2-3 months for 5 years  -0.823 0.290 0.005 -1.393 -0.254 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  -0.584 0.253 0.021 -1.080 -0.087 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
-0.701 0.246 0.004 -1.184 -0.218 
Once or twice a year  -0.507 0.244 0.038 -0.984 -0.029 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.523 0.225 0.020 -0.964 -0.083 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
-0.238 0.243 0.326 -0.715 0.237 
Yearly PET scan for all patients  -0.633 0.306 0.038 -1.233 -0.034 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  -0.165 0.189 0.383 -0.536 0.206 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  -0.016 0.177 0.926 -0.364 0.331 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
 
 
 
 
 
321 
 
Table A6.8 Utility coefficients from covariate-adjusted univariate conditional logistic 
regression analysis (time from treatment end: >2 years =1; ≤2 years=0). 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
0.461 0.321 0.150 -0.167 1.090 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
2.692 0.136 <0.001 2.426 2.959 
Every 2-3 months for 5 years  2.325 0.183 <0.001 1.965 2.684 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.553 0.161 0.001 0.236 0.869 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.566 0.158 <0.001 0.255 0.876 
Once or twice a year  2.109 0.156 <0.001 1.804 2.414 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.159 0.148 0.285 -0.132 0.450 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.997 0.158 <0.001 0.688 1.306 
Yearly PET scan for all patients  1.411 0.215 <0.001 0.989 1.833 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  0.177 0.116 0.125 -0.049 0.404 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.821 0.137 <0.001 0.552 1.090 
Interactions (Time from treatment end)      
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
-1.010 0.418 0.016 -1.829 -0.191 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
-0.494 0.249 0.047 -0.981 -0.007 
Every 2-3 months for 5 years  -0.498 0.299 0.096 -1.084 0.088 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  -0.238 0.252 0.344 -0.732 0.255 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
-0.185 0.251 0.462 -0.678 0.308 
Once or twice a year  -0.613 0.242 0.011 -1.086 -0.139 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.509 0.222 0.022 -0.945 -0.074 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
-0.249 0.240 0.300 -0.720 0.222 
Yearly PET scan for all patients  -0.782 0.298 0.009 -1.367 -0.197 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  -0.362 0.188 0.055 -0.731 0.007 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  -0.626 0.170 <0.001 -0.960 -0.293 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
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Table A6.9 (A) Utility coefficients from covariate-adjusted univariate conditional logistic 
regression analysis (difficulty level: equal to 1 (low)= 0; >1= 1) using missing imputation. 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
-0.108 0.330 0.744 -0.755 0.539 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
2.377 0.203 0.000 1.979 2.774 
Every 2-3 months for 5 years  2.092 0.223 0.000 1.656 2.528 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.427 0.190 0.025 0.054 0.800 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.634 0.189 0.001 0.263 1.005 
Once or twice a year  1.673 0.190 0.000 1.300 2.046 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.094 0.163 0.564 -0.413 0.225 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.785 0.193 0.000 0.407 1.163 
Yearly PET scan for all patients  0.771 0.236 0.001 0.309 1.234 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  -0.035 0.152 0.818 -0.332 0.262 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.345 0.124 0.005 0.102 0.588 
Interactions (Difficulty)      
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
0.118 0.429 0.784 -0.723 0.958 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
0.128 0.253 0.612 -0.367 0.624 
Every 2-3 months for 5 years  -0.036 0.301 0.906 -0.625 0.554 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.025 0.253 0.922 -0.470 0.520 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
-0.293 0.250 0.242 -0.784 0.197 
Once or twice a year  0.252 0.247 0.309 -0.233 0.736 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.011 0.226 0.961 -0.433 0.455 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.178 0.243 0.464 -0.298 0.653 
Yearly PET scan for all patients  0.487 0.303 0.108 -0.107 1.082 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  0.076 0.191 0.690 -0.299 0.452 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.327 0.175 0.062 -0.016 0.670 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
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Table A6.9 (B) Utility coefficients from covariate-adjusted univariate conditional logistic 
regression analysis (difficulty level: equal to 1 (low)= 0; >1= 1) using complete case analysis. 
Attribute-level Coeff. SE p-value 95% CI 
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
-0.280 0.330 0.396 -0.928 0.367 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
2.433 0.212 0.000 2.016 2.849 
Every 2-3 months for 5 years  2.129 0.235 0.000 1.669 2.590 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.404 0.198 0.042 0.015 0.793 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
0.624 0.197 0.002 0.237 1.011 
Once or twice a year  1.678 0.199 0.000 1.287 2.069 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  -0.106 0.172 0.536 -0.444 0.231 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.741 0.202 0.000 0.346 1.136 
Yearly PET scan for all patients  0.683 0.240 0.004 0.212 1.154 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  -0.037 0.159 0.815 -0.350 0.275 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.328 0.131 0.012 0.072 0.584 
Interactions (Difficulty)      
Frequency (and setting) of physical (and 
larynx/pharynx endoscopic) investigations 
     
Every 2-3 months for 3 years (primary care-based 
follow-up for 2 more years)  
0.290 0.429 0.498 -0.550 1.130 
Every 2-3 months for 2 years, every 5-6 months 
for 3 more years  
0.072 0.261 0.782 -0.439 0.583 
Every 2-3 months for 5 years  -0.073 0.310 0.814 -0.680 0.535 
Frequency of MRI/CT scans      
Only at the occurrence of new symptoms  0.047 0.259 0.855 -0.460 0.555 
One examination only at the beginning of follow-
up (later only at occurrence of new symptoms)  
-0.283 0.257 0.270 -0.786 0.220 
Once or twice a year  0.246 0.254 0.333 -0.252 0.745 
Frequency (and eligibility) of PET scans      
No PET scan during follow-up  0.024 0.233 0.919 -0.434 0.481 
Yearly PET scan only for high-risk patients (≥50 
years and heavy smokers)  
0.222 0.250 0.374 -0.267 0.711 
Yearly PET scan for all patients  0.575 0.306 0.060 -0.025 1.176 
Telephone calls to monitor occurrence of new 
symptoms  
     
No inter-visit calls from the hospital  0.079 0.198 0.690 -0.309 0.466 
Inter-visit calls by the nurse  - - - - - 
Inter-visit calls by the oncologist  0.344 0.180 0.056 -0.009 0.696 
CI: confidence interval; CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; SE: 
standard error. 
 
 
 
